



2026 Abstract Schedules

International Congress of Parkinson's Disease and Movement Disorders®

#	Abstract Title	Date	Session Time	Session	Station	Order	Abstract Subcategory	First Author
39	Exploring Usability and Feasibility of an Optimised Smartwatch to Monitor Medication Intake in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 1	1	Technology	Emma Packer
40	Objective Assessment of the Timed Up and Go Test in Parkinson's Disease Using AI-Based Markerless Video Analysis	Sunday, October 4	9:30 - 10:30	Session 1	Station 1	2	Technology	Claudia Ferraris
41	Real-World Digital Tracking of Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 1	3	Technology	Kinan Muhammed
42	Computer Vision for Quantitative Assessment of Posture and Instability in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 1	4	Technology	Gianluca Amprimo
43	Smartphone-Based Multilingual Application for Remote Screening and Monitoring of Motor Symptoms Associated with Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 1	5	Technology	Sandipan Pal
44	Advancing Regular Non-motor Symptom Reporting During Inpatient Parkinson's Disease Care Using a Self-Developed Digital Diary: A Three-Cohort Engagement Evaluation	Sunday, October 4	9:30 - 10:30	Session 1	Station 1	6	Technology	Alexander Wiederhold
86	Biomechanical Analysis of Gait Movement Disorders in Spinal Cord Injury and Its Implications for Rehabilitation Strategies	Sunday, October 4	9:30 - 10:30	Session 1	Station 2	1	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation	Manish Gupta
87	Repetitive Transcranial Magnetic Stimulation Improves Static Balance Control in Cerebellar Ataxia	Sunday, October 4	9:30 - 10:30	Session 1	Station 2	2	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation	Sumin Lee
88	Explainable Machine-Learning Risk Stratification to Identify High-Potential Physical Therapy Responders with Freezing of Gait in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 2	3	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation	Tsung-Lin Lee
89	Interventions in Friedreich's Ataxia and their Influence on Patient-centric Outcomes: A Systematic Review	Sunday, October 4	9:30 - 10:30	Session 1	Station 2	4	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation	Dorota Sarwinska
90	Rehabilitation Practices in Parkinson's Disease in Rome, Italy: Insights from Allied Health Professionals Prior to Implementation of the ParkinsonNet Model (ACTION-PD Project)	Sunday, October 4	9:30 - 10:30	Session 1	Station 2	5	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation	Danilo Genovese
91	Engage-Qatar PD (EQP): Pilot RCT of a Remote Coaching Intervention Using Online Platform to Promote Engagement in Physical Activity in People with Parkinson's Disease in Qatar.	Sunday, October 4	9:30 - 10:30	Session 1	Station 2	6	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation	Hanan Khalil

256	Identification of Alpha-synuclein Pathology in Dementia with Lewy Body Participants by Seed Amplification Assay	Sunday, October 4	9:30 - 10:30	Session 1	Station 3	1	Parkinsonism (Other)	Carly Farris
257	Manganese-induced neurotoxicity and Parkinsonian-like syndrome: potential protective role of Opuntia ficus-indica cladode extract in rats	Sunday, October 4	9:30 - 10:30	Session 1	Station 3	2	Parkinsonism (Other)	Hala Harifi
258	A highly specific skin α -synuclein seed amplification assay for screening of synucleinopathies	Sunday, October 4	9:30 - 10:30	Session 1	Station 3	3	Parkinsonism (Other)	Yihua Ma
259	Loss of NAA60-mediated N-terminal acetylation cause primary brain calcification with disturbed Golgi- and phosphate-maintenance functions	Sunday, October 4	9:30 - 10:30	Session 1	Station 3	4	Parkinsonism (Other)	Anette Siggervåg
260	SIRT3 upregulation in nigral dopaminergic neurons preserves motor circuit integrity for anti-sarcopenia	Sunday, October 4	9:30 - 10:30	Session 1	Station 3	5	Parkinsonism (Other)	Semin Park
261	PDGFB Mutations may Induce Primary Brain Calcification via the Gain-of-Function Mechanism	Sunday, October 4	9:30 - 10:30	Session 1	Station 3	6	Parkinsonism (Other)	Runlu Sun
237	A Novel Therapeutic Targeting the tPA-NMDAR Interaction for Multiple System Atrophy	Sunday, October 4	9:30 - 10:30	Session 1	Station 4	1	MSA, PSP, CBS: Pharmacology and Medical Management	Nathalie Delétage
238	Subcutaneous Levodopa Infusion in Multiple System Atrophy: a Case Series	Sunday, October 4	9:30 - 10:30	Session 1	Station 4	2	MSA, PSP, CBS: Pharmacology and Medical Management	Ana Aldaz Burgoa
239	Amyloid PET-Guided Anti-amyloid Therapy in Corticobasal Syndrome Associated with Clinical Improvement	Sunday, October 4	9:30 - 10:30	Session 1	Station 4	3	MSA, PSP, CBS: Pharmacology and Medical Management	Shinsuke Fujioka
240	Creutzfeldt Jakob Disease Miming a Cortico-basal syndrome: does it exist?	Sunday, October 4	9:30 - 10:30	Session 1	Station 4	4	MSA, PSP, CBS: Pharmacology and Medical Management	Yosr Memmich
241	Targeted IncobotulinumtoxinA Injections into the Muscle of Riolan: A Novel Rescue Strategy for Refractory Apraxia of Lid Opening in Neurodegenerative Disorders	Sunday, October 4	9:30 - 10:30	Session 1	Station 4	5	MSA, PSP, CBS: Pharmacology and Medical Management	Irina Miliukhina
242	Device-aided Therapies in Multiple System Atrophy: Long-term Follow-up Case Series	Sunday, October 4	9:30 - 10:30	Session 1	Station 4	6	MSA, PSP, CBS: Pharmacology and Medical Management	katarina rukavina
196	TMEM106B Amyloid Fibrils in the Choroid Plexus Mediate [18F]AV-1451 Retention: Cohort-Level Imaging and Cryo-EM Evidence	Sunday, October 4	9:30 - 10:30	Session 1	Station 5	1	MSA, PSP, CBS: Neuroimaging	Yun Fan
197	Coupling of Cholinergic and Dopaminergic Terminal Loss in Progressive Supranuclear Palsy: A Multimodal [18F]FEOBV and [11C]PE2I Study	Sunday, October 4	9:30 - 10:30	Session 1	Station 5	2	MSA, PSP, CBS: Neuroimaging	Prabesh Kanel
198	Cholinergic Systems Changes Associated with Freezing of Gait in Progressive Supranuclear Palsy	Sunday, October 4	9:30 - 10:30	Session 1	Station 5	3	MSA, PSP, CBS: Neuroimaging	Prabesh Kanel

199	Distinct FDG PET Metabolic Signatures and Dopaminergic Loss Across Multiple System Atrophy Subtypes	Sunday, October 4	9:30 - 10:30	Session 1	Station 5	4	MSA, PSP, CBS: Neuroimaging	Tiffany Carther-Krone
200	Microstructural cortical alterations are related to cognitive and disease severity in progressive supranuclear palsy	Sunday, October 4	9:30 - 10:30	Session 1	Station 5	5	MSA, PSP, CBS: Neuroimaging	Carla Garcia Vicente
201	Mapping Intrinsic Brain Network Connectivity Using Resting-State Functional MRI In Spinocerebellar Ataxia 12 In Comparison with Healthy Controls	Sunday, October 4	9:30 - 10:30	Session 1	Station 5	6	MSA, PSP, CBS: Neuroimaging	Pankaj pankaj
338	Cervical Dystonia: The Objective Evaluation Of Muscle Tone	Sunday, October 4	9:30 - 10:30	Session 1	Station 6	1	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Marco Falletti
339	The Clinical Profile and Management outcomes of Early-Onset Dystonia in a South African Population	Sunday, October 4	9:30 - 10:30	Session 1	Station 6	2	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Emmanuel Assey
340	Probable Corticobasal Syndrome Presenting as Writer's Cramp: A Case Report	Sunday, October 4	9:30 - 10:30	Session 1	Station 6	3	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Bárbara Dias
341	Impact of a Structured Patient Education Module on Knowledge of Botulinum Toxin Therapy, Goal Attainment, and Treatment Satisfaction in Cervical Dystonia	Sunday, October 4	9:30 - 10:30	Session 1	Station 6	4	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Kesineee Katawatee
342	A Novel paradigm for the recording of col-cap movements and muscle activity in Cervical Dystonia	Sunday, October 4	9:30 - 10:30	Session 1	Station 6	5	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Owen Killian
343	A Comparison of Video-Based and Sensor-Based Movement Measurements in Cervical Dystonia	Sunday, October 4	9:30 - 10:30	Session 1	Station 6	6	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Owen Killian
415	Genetic Disorders Presenting With Tremor at Onset: MDSGene systematic literature review	Sunday, October 4	9:30 - 10:30	Session 1	Station 7	1	Disparities	Vafa Alakbarzade
416	Analyzing Perceived Effectiveness of Implemented Recruitment and Retention Strategies for Underrepresented Racial and Ethnic Groups in Parkinson's Disease Clinical Trials	Sunday, October 4	9:30 - 10:30	Session 1	Station 7	2	Disparities	Pinky Agarwal
417	Representation of Women in Deep Brain Stimulation Trials in Movement Disorders: Protocol for a Systematic Review and Meta-analysis	Sunday, October 4	9:30 - 10:30	Session 1	Station 7	3	Disparities	Divyani Garg
418	Disparities for Tremor and Dystonia Patients Accessing Deep Brain Stimulation: An Explanatory Sequential Mixed Methods Study	Sunday, October 4	9:30 - 10:30	Session 1	Station 7	4	Disparities	Shaina Corrick
419	Equity in Access to Bilateral High Intensity MRI-Guided Focused Ultrasound for Essential Tremor	Sunday, October 4	9:30 - 10:30	Session 1	Station 7	5	Disparities	Jin Kyung Kim
420	The Impact of Insurance on Delivery of Huntington's Care at an HDSA Center of Excellence	Sunday, October 4	9:30 - 10:30	Session 1	Station 7	6	Disparities	Derrick Okine

466	In Silico Investigation of Dopamine Receptor–Calcium Channel Coupling in Subthalamic Nucleus Neurons: Implications for Parkinson’s Disease Therapy	Sunday, October 4	9:30 - 10:30	Session 1	Station 8	1	Drug-Induced Movement Disorders	Ashish Pradhan
467	Pulsatile Striatal Dopamine Dynamics Drive Levodopa Induced Dyskinesia In Advanced Parkinson Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 8	2	Drug-Induced Movement Disorders	Lu Su
468	Intranasal Delivery of Berberine-Loaded Solid Lipid Nanoparticles Ameliorates Neuropathological and Behavioral Deficits in a Preclinical Alzheimer’s Model	Sunday, October 4	9:30 - 10:30	Session 1	Station 8	3	Drug-Induced Movement Disorders	Rakesh Rajput
469	Ion Channel Modulation by Dopamine Receptors in Subthalamic Nucleus Neurons: Implications for Parkinson’s Disease Pathophysiology	Sunday, October 4	9:30 - 10:30	Session 1	Station 8	4	Drug-Induced Movement Disorders	Chitaranjan Mahapatra
470	Neuroprotective and Antiparkinsonian Effects of Green-Synthesized Silver Nanoparticles from Eclipta prostrata in a Haloperidol-Induced Murine Model	Sunday, October 4	9:30 - 10:30	Session 1	Station 8	5	Drug-Induced Movement Disorders	Sumit Rajput
471	The Long-Term Efficacy of Globus Pallidus Deep Brain Stimulation in Tardive Dystonia and Dyskinesia	Sunday, October 4	9:30 - 10:30	Session 1	Station 8	6	Drug-Induced Movement Disorders	Goun Je
608	DBS Evoked Cortical Potentials Can Predict Tremor Suppression	Sunday, October 4	9:30 - 10:30	Session 1	Station 9	1	Tremor	Till Dembek
609	Genetic analysis of the SLC38A6 gene in Chinese patients with essential tremor	Sunday, October 4	9:30 - 10:30	Session 1	Station 9	2	Tremor	Hongwei Wu
610	Cerebellar Non-Invasive Brain Stimulation for Tremor Reduction in Essential Tremor: Systematic Review and Meta-Analysis of Randomized Controlled Trials	Sunday, October 4	9:30 - 10:30	Session 1	Station 9	3	Tremor	Arunagiri Gunasekar
611	Differential Tremor Responses To Transcutaneous Spinal Cord Stimulation Across Tremor Syndromes	Sunday, October 4	9:30 - 10:30	Session 1	Station 9	4	Tremor	Razvan-Alexandru Steopoaie
612	Reduced Motor Unit Discharge Variability of Wrist Muscles 24 Hours After Closed-Loop Electrical Stimulation in Essential Tremor	Sunday, October 4	9:30 - 10:30	Session 1	Station 9	5	Tremor	Xin Yu
613	Cognitive Progression in Elderly Essential Tremor Patients: Evidence from an 18-Month Prospective Cohort	Sunday, October 4	9:30 - 10:30	Session 1	Station 9	6	Tremor	Elsayed Abed
603	RTN2 Variants Expand the ALS–Hereditary Spastic Paraplegia Disease Spectrum	Sunday, October 4	9:30 - 10:30	Session 1	Station 10	1	Spasticity	Antonio Orlacchio
604	Identification of Novel FA2H Mutations in Patients with Hereditary Spastic Paraplegia Type 35 (SPG35)	Sunday, October 4	9:30 - 10:30	Session 1	Station 10	2	Spasticity	Lebo Wang
605	Clinical Outcome Assessments for Spasticity and Functional Performance in Spastic Paresis: Which Scales Should Be Used?	Sunday, October 4	9:30 - 10:30	Session 1	Station 10	3	Spasticity	Robert Jech
606	Transcutaneous Spinal Cord Stimulation in Hereditary Spastic Paraplegias	Sunday, October 4	9:30 - 10:30	Session 1	Station 10	4	Spasticity	John Sanderson

607	Late-Onset Ataxia, Tremor and Spastic Paraparesis associated with the a Novel CCDC88C Variant: Expanding the Phenotypic Spectrum of mutation in the CCDC88C gene	Sunday, October 4	9:30 - 10:30	Session 1	Station 10	5	Spasticity	Iva Sarac
595	Sleep-related Falling Out of Bed in Elderly Patients: The Role of Obstructive Sleep Apnea	Sunday, October 4	9:30 - 10:30	Session 1	Station 10	6	Restless Legs Syndrome and Sleep Disorders	Ramy Alloush
1944	Calcification Foci Caused by Gene Defects in Primary Brain Calcification May Originate from Matrix Vesicle	Sunday, October 4	9:30 - 10:30	Session 1	Station 11	1	Rare Neurometabolic Movement Disorders	Xunuo Jin
1945	A Novel Homozygous Variant in MYORG is Associated with Primary Brain Calcification and Paroxysmal Dyskinesia	Sunday, October 4	9:30 - 10:30	Session 1	Station 11	2	Rare Neurometabolic Movement Disorders	Yuru Guo
1946	Clinical, Neuropathological, and Functional Analysis of the Most Prevalent CSF1R Pathogenic Variant, p. Ile794Thr.	Sunday, October 4	9:30 - 10:30	Session 1	Station 11	3	Rare Neurometabolic Movement Disorders	Lukasz Milanowski
1947	MT200605 for Huntington's Disease: Nonclinical finding and Phase I Clinical Result	Sunday, October 4	9:30 - 10:30	Session 1	Station 11	4	Rare Neurometabolic Movement Disorders	Liu Yongzhen
1948	The Clinical and Neuropathological Factors Associated with Brain Atrophy in CSF1R-RD.	Sunday, October 4	9:30 - 10:30	Session 1	Station 11	5	Rare Neurometabolic Movement Disorders	Lukasz Milanowski
1949	A Novel Hyperkinetic-Cerebellar Phenotype with Subependymal Nodules in Glutaric Acidemia Type 1	Sunday, October 4	9:30 - 10:30	Session 1	Station 11	6	Rare Neurometabolic Movement Disorders	Denise Avecilla-Bonilla
693	Prasinezumab in Early-Stage Parkinson's Disease: Additional Data from the PADOVA Study	Sunday, October 4	9:30 - 10:30	Session 1	Station 12	1	Parkinson's Disease: Clinical Trials	Tania Nikolcheva
694	NLRP3 Inhibition in Early-Stage Parkinson's disease: Results of a Phase Ib Study	Sunday, October 4	9:30 - 10:30	Session 1	Station 12	2	Parkinson's Disease: Clinical Trials	Gennaro Pagano
695	Modeling Parkinson's Disease Progression to Quantify Long-Term Treatment Effects via the Concept of 'Time Saved'	Sunday, October 4	9:30 - 10:30	Session 1	Station 12	3	Parkinson's Disease: Clinical Trials	Benjamin Ribba
696	Heterogeneous Responsiveness to Combined Motor-Cognitive Exercise in Parkinson's Disease: A Latent Class Analysis	Sunday, October 4	9:30 - 10:30	Session 1	Station 12	4	Parkinson's Disease: Clinical Trials	Juseon Hwang
697	Intranasal spray for nose-to-brain drug delivery: Emergency treatment of OFF episodes in Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 12	5	Parkinson's Disease: Clinical Trials	Yu Tang
698	Move-Brain-PD: a Randomized Multicenter Protocol of Remotely Monitored Home-based Aerobic Exercise for Parkinson's Disease Patients with Mild Cognitive Impairment	Sunday, October 4	9:30 - 10:30	Session 1	Station 12	6	Parkinson's Disease: Clinical Trials	Angelo Tiziano Cimmino
765	Clinical impact of local field potential sensing-guided deep brain stimulation: a real-world registry	Sunday, October 4	9:30 - 10:30	Session 1	Station 13	1	Parkinson's Disease: Clinical Trials	Jinyoung Youn

766	Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation on Gastrointestinal Function in Parkinson's Disease: A Preliminary Randomized Controlled Trial	Sunday, October 4	9:30 - 10:30	Session 1	Station 13	2	Parkinson's Disease: Clinical Trials	Zhuang Zhu
767	Discontinuation of Parkinson's Disease Clinical Studies: A Cross-Sectional Analysis	Sunday, October 4	9:30 - 10:30	Session 1	Station 13	3	Parkinson's Disease: Clinical Trials	Yousef Alnomani
768	The GLP-1 Agonist Paradox in Parkinson's Disease: A Comparative Analysis of Lixisenatide and Exenatide Phase III Trial Outcomes and Neuroprotective Mechanisms	Sunday, October 4	9:30 - 10:30	Session 1	Station 13	4	Parkinson's Disease: Clinical Trials	FOUAD AL-ZAIDI
769	Slow-SPEED UK: A Double-Blind Randomised Feasibility Trial of a Remote Gamified Physical Activity Programme in Adults with Hyposmia	Sunday, October 4	9:30 - 10:30	Session 1	Station 13	5	Parkinson's Disease: Clinical Trials	Viktoria Azoidou
770	The Emerging Landscape of Genotype-Stratified Clinical Trials in Parkinson's Disease and Atypical Parkinsonian Disorders	Sunday, October 4	9:30 - 10:30	Session 1	Station 13	6	Parkinson's Disease: Clinical Trials	Yuan Ye Beh
837	Improvement in Time Spent in OFF State and In the Functional Impact of Motor Fluctuations After Initiation with COMT Inhibitors in Parkinson's Disease Patients with Early Wearing-Off: Results from the REONPARK Study	Sunday, October 4	9:30 - 10:30	Session 1	Station 14	1	Parkinson's Disease: Pharmacology and Medical Management	Lydia López-Manzanares
838	Efficacy and Safety of Inhaled and Sublingual Apomorphine for On-Demand Treatment of OFF Episodes in Parkinson's Disease: A Meta-Analysis of Randomized Placebo-Controlled Trials	Sunday, October 4	9:30 - 10:30	Session 1	Station 14	2	Parkinson's Disease: Pharmacology and Medical Management	Juan Martinez-Lemus
839	Efficacy of botulinum toxin treatment for cervical dystonia associated with Parkinson's disease: A case series.	Sunday, October 4	9:30 - 10:30	Session 1	Station 14	3	Parkinson's Disease: Pharmacology and Medical Management	Seema Mian
840	A case of monotherapy with intracerebroventricular anaerobic dopamine allows complete control of Parkinson's disease symptoms	Sunday, October 4	9:30 - 10:30	Session 1	Station 14	4	Parkinson's Disease: Pharmacology and Medical Management	Caroline Moreau
841	Real-world database analysis of new-onset hypotension and medications for orthostatic hypotension prescribing patterns in patients with Parkinson's Disease receiving MAO-B Inhibitors and levodopa in Japan	Sunday, October 4	9:30 - 10:30	Session 1	Station 14	5	Parkinson's Disease: Pharmacology and Medical Management	Masahiro Nagai
842	Seven-Year Outcome of Focused Ultrasound Thalamotomy in Tremor Dominant Parkinson's Disease Patients	Sunday, October 4	9:30 - 10:30	Session 1	Station 14	6	Parkinson's Disease: Pharmacology and Medical Management	Maria Nassar
1815	Identifying Informative Speech Tasks for Detecting Clinically Relevant Changes in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 15	1	Parkinson's Disease (Other)	Tabea Thies

1816	Lactobacillus reuteri Y7 Improves Motor and Non-Motor Features Through Gut-Brain-Metabolic Modulation in a 6-OHDA Rat Model of Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 15	2	Parkinson's Disease (Other)	SHU PING TSAO
1817	Personal Views of Aging in Parkinson's Disease: How Do They Relate to Clinical, Cognitive and Behavioral Functioning?	Sunday, October 4	9:30 - 10:30	Session 1	Station 15	3	Parkinson's Disease (Other)	Maria Laura Nasi
1818	Speaking in Noise: Examination of Speech Motor Control in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 15	4	Parkinson's Disease (Other)	Anita Senthinathan
1819	Music as Therapy: A KAP Analysis of Music Therapy for Parkinson's Disease in India	Sunday, October 4	9:30 - 10:30	Session 1	Station 15	5	Parkinson's Disease (Other)	Mythili Udupa
1820	Baseline characteristics of fallers versus non-fallers in a remote, decentralized study of Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 15	6	Parkinson's Disease (Other)	Peggy Auinger
1887	Recruitment Strategies in a Diverse Parkinson's Disease Cohort: Lessons from the East London Parkinson's Disease Project	Sunday, October 4	9:30 - 10:30	Session 1	Station 16	1	Parkinson's Disease (Other)	Kamalesh Dey
1888	Immunological characteristics of Parkinson's disease by clinical form and stage	Sunday, October 4	9:30 - 10:30	Session 1	Station 16	2	Parkinson's Disease (Other)	Shakhzoda Jumanazarova
1889	Levels of IgA and IgG concentrations by stage of Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 16	3	Parkinson's Disease (Other)	Shodlik Jumaniyozov
1890	Global Trends in Parkinson's Disease Research: A Bibliometric Snapshot (2021-2024)	Sunday, October 4	9:30 - 10:30	Session 1	Station 16	4	Parkinson's Disease (Other)	Raghd Mansour
1891	Role and significance of C-reactive protein in stages of Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 16	5	Parkinson's Disease (Other)	Rustambek Matmurodov
1892	Characterising Consent and Engagement with Remote Blood Collection in PREDICT-PD	Sunday, October 4	9:30 - 10:30	Session 1	Station 16	6	Parkinson's Disease (Other)	Sophie Meyer
937	Impact of Symptom-Specific Odorants on the Diagnostic Accuracy of Brief Olfactory Tests in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 17	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Ting Chun Fang
938	The Syn-Q Study: Quantification of phosphorylated alpha-synuclein in patients with Parkinson's disease and REM sleep behavior disorder	Sunday, October 4	9:30 - 10:30	Session 1	Station 17	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Roy Freeman
939	Wearable assessment of levodopa-entacapone-carbidopa intestinal gel treatment characteristics at home: Pilot Protocol	Sunday, October 4	9:30 - 10:30	Session 1	Station 17	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Jakob Gerstl
940	Plasma Exosomal Cytokines as Longitudinal Biomarkers and Predictors of Parkinson's Disease Progression	Sunday, October 4	9:30 - 10:30	Session 1	Station 17	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Chien-Tai Hong

941	Peripheral Inflammatory Biomarkers as Predictive Indicator for Parkinson's Disease: a Systematic Review and Meta-Analysis	Sunday, October 4	9:30 - 10:30	Session 1	Station 17	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Hussien Hussien
942	Wearable-Derived Gait Biomarkers Predict Disease Severity and Quality of Life in Parkinson's Disease: A Machine Learning and Mediation Analysis	Sunday, October 4	9:30 - 10:30	Session 1	Station 17	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Qirui Jiang
1009	Biofluid Markers in Parkinson's Patients and Correlation with Cognitive Profile	Sunday, October 4	9:30 - 10:30	Session 1	Station 18	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Tritia Yamasaki
1010	Dual-Task Cost Assessment in Parkinson's Disease: A Literature Review of Clinical Applications and Measurement Approaches	Sunday, October 4	9:30 - 10:30	Session 1	Station 18	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Chitra Balasubramanian
1011	Cerebrospinal Fluid Markers are associated with Cognitive Decline in GBA1-associated Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 18	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Merle Bode
1082	The Protective role of Blood brain barrier-Vagal Interface in Parkinsonian pathology in mice	Sunday, October 4	9:30 - 10:30	Session 1	Station 18	4	Parkinson's Disease: Disease mechanisms	Jong Hun Ahn
1083	Dysregulation of lysosomal lipid microdomains impairs autophagic flux in GBA-associated Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 18	5	Parkinson's Disease: Disease mechanisms	Mingjia Chen
1084	Circadian Regulator REV-ERB α Drives Microglial Lipid Metabolic Reprogramming and Cognitive Impairment in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 18	6	Parkinson's Disease: Disease mechanisms	Tongtong Deng
1151	Pesticide Exposure and Motor Severity in Parkinson's Disease in a Mexican Population: A Retrospective Longitudinal Cohort Study	Sunday, October 4	9:30 - 10:30	Session 1	Station 19	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jose Espinoza-Solares
1152	Motor Frailty Index (MFI) as an Early Predictor of Functional Progression in Parkinson's Disease: A Longitudinal Analysis	Sunday, October 4	9:30 - 10:30	Session 1	Station 19	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Oscar Esquivel-Zapata
1153	Item – Level Drivers of Certification Failure in the MDS-UPDRS Motor Examination: A Five-Year Global Analysis	Sunday, October 4	9:30 - 10:30	Session 1	Station 19	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Cristian Falup-Pecurariu
1154	Global Performance Patterns in the MDS-UPDRS Motor Certification Program: A five-year Analysis	Sunday, October 4	9:30 - 10:30	Session 1	Station 19	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Cristian Falup-Pecurariu

1155	The association between Parkinson's Disease and Diabetes Mellitus.	Sunday, October 4	9:30 - 10:30	Session 1	Station 19	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Shi Jian Foo
1156	Military-related associations with Parkinson's disease (PD) in the Millenium Cohort Study	Sunday, October 4	9:30 - 10:30	Session 1	Station 19	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Samuel Goldman
1223	Implementation and Evaluation of a Pre-Clinic Questionnaire to Improve Data Capture and Consultation Efficiency in Parkinson's Disease Clinics: A Multi-Centre Pilot Study	Sunday, October 4	9:30 - 10:30	Session 1	Station 20	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Mubasher Qamar
1224	Weight and Body Mass Index Changes in Parkinson's Disease and Their Association with Disease Progression: A Two-Year Longitudinal Study	Sunday, October 4	9:30 - 10:30	Session 1	Station 20	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Nesya Fannia Rahmy
1225	Can Prayer Beads Quantify Bradykinesia? An Ultra-Low-Cost Approach to Motor Assessment in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 20	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Neila Raisa
1226	Detecting Parkinson's Disease with Postural Sway via Single IMU and Machine Learning	Sunday, October 4	9:30 - 10:30	Session 1	Station 20	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Farhan Rashid
1227	Deep brain stimulation improves levodopa-induced dyskinesias beyond medication reduction in Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 20	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Carlos Reyes
1228	Perceptions and knowledge about Parkinson's disease fluctuations among patients and caregivers: insights from a qualitative focus group	Sunday, October 4	9:30 - 10:30	Session 1	Station 20	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Juan Pablo Romero Muñoz

1295	Feasibility of the ActivPARK Study - Longitudinal Assessment of Physical Activity in People with Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 21	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Erika Franzén
1296	Levodopa dosing regimen influences repetitive tongue force maintenance in Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 21	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Sachi Hayasaka
1297	Knee Extensor Strength Is Associated with Torque Generation and Mobility in Parkinsonian Disorders	Sunday, October 4	9:30 - 10:30	Session 1	Station 21	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Shinya Komatsu
1298	A Novel Clinical Protocol for Monitoring Therapeutic Outcomes in Camptocormia in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 21	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Linda Lundh
1299	Characteristics of participants of the Australian National Disability Insurance Scheme with Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 21	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jennifer McGinley
1300	Grip strength and hand distress in de novo Parkinson's disease: support for early rehabilitation	Sunday, October 4	9:30 - 10:30	Session 1	Station 21	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Anna Szymanska
1367	Regulatory architecture of the SNCA locus in Parkinson's Disease: Characterization of reported functional mQTL variants in GP2	Sunday, October 4	9:30 - 10:30	Session 1	Station 22	1	Parkinson's Disease: Genetics	Diana Náfate Wences
1368	Expanded Parkinson's Disease GWAS in African Ancestry Populations Identifies Novel Risk Loci and Precision Medicine Targets	Sunday, October 4	9:30 - 10:30	Session 1	Station 22	2	Parkinson's Disease: Genetics	Njideka Okubadejo
1369	Integrative Analysis of GBA1 Mutations and GCase Deficiency in Parkinson's Disease using Long Read Nanopore Sequencing	Sunday, October 4	9:30 - 10:30	Session 1	Station 22	3	Parkinson's Disease: Genetics	Atif Shaikh
1370	Understanding the Earliest Phases of Parkinson's disease: An Update on the Prodromal Effort Within the Global Parkinson's Genetics Program	Sunday, October 4	9:30 - 10:30	Session 1	Station 22	4	Parkinson's Disease: Genetics	Manuela Tan
1371	Multi-ancestry analysis of POLG variants in Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 22	5	Parkinson's Disease: Genetics	Yi Wen Tay

1372	Genetic analysis of the X chromosome and Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 22	6	Parkinson's Disease: Genetics	Nicole Kuznetsov
1439	Strengthening Global Parkinson's Disease Research Capacity through the GP2 'Train the Trainer' Framework	Sunday, October 4	9:30 - 10:30	Session 1	Station 23	1	Parkinson's Disease: Genetics	Charlotte Andrews
1440	Clinical-Genealogical Analysis of Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 23	2	Parkinson's Disease: Genetics	Mumtozakho n Ibodullaeva
1441	SNCA Dysregulation Drives Oxidative Stress and Mitochondrial Dysfunction in Parkinson's Disease: Evidence from a Punjab Cohort	Sunday, October 4	9:30 - 10:30	Session 1	Station 23	3	Parkinson's Disease: Genetics	Mahalaxmi Iyer
1442	Evaluating Gene-Environment Interactions between Head Injury and Parkinson's Disease Risk Variants.	Sunday, October 4	9:30 - 10:30	Session 1	Station 23	4	Parkinson's Disease: Genetics	Ashvin Kuri
1443	Disease-specific Polygenic Risk Scores and Development of Incident Parkinson's Disease in a Large Cohort of Healthy Older Adults.	Sunday, October 4	9:30 - 10:30	Session 1	Station 23	5	Parkinson's Disease: Genetics	Ashvin Kuri
1444	Mutation screening of Miro1 and Miro2 in Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 23	6	Parkinson's Disease: Genetics	Junyu Lin
1511	Cortical Oscillatory Dynamics during Turning in Parkinson's Disease using OPM-MEG	Sunday, October 4	9:30 - 10:30	Session 1	Station 24	1	Parkinson's disease: Neuroimaging	Priya Sharma
1512	18F-FD4 PET Reveals α -Synuclein Deposition and Clinical Correlations in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 24	2	Parkinson's disease: Neuroimaging	Jian Wang
1513	Functional Connectivity Subtypes Predict Longitudinal Motor Progression and Gait Disturbance in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 24	3	Parkinson's disease: Neuroimaging	Shichan Wang
1514	Altered Degree Centrality and Its Association with Neurotransmitter Systems in Parkinson's Disease Patients with Impulse Control Disorders: A Resting-State fMRI Study	Sunday, October 4	9:30 - 10:30	Session 1	Station 24	4	Parkinson's disease: Neuroimaging	Xinping Wang
1515	Subregional Striatal Dopaminergic Deficits, Cerebral Hypoperfusion and Cognitive Impairment in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 24	5	Parkinson's disease: Neuroimaging	Xinyi Xie
1516	Quantitative Susceptibility Mapping Revealed Regional Iron Alteration and As a Biomarker for Dopaminergic Deficits in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 24	6	Parkinson's disease: Neuroimaging	Xinyi Xie
1583	Pain relief beyond motor cortex modulation: clinical-neurophysiological dissociation after M1-tDCS in Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 25	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Álvaro Megía- García
1584	Non-Motor Outcomes after STN-FUS for Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 25	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Elena Natera- Villalba

1585	Long-Term Effects of Repeated Home-Based tDCS on Language Production in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 25	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Nela Němcová Elfmarková
1586	Vitamin D and cognitive dysfunction in patients with Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 25	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Denis Novotnyi
1587	Evaluation of Sleep Parameters in Parkinson's Disease According to Disease Duration Using Ambulatory Circadian Monitoring	Sunday, October 4	9:30 - 10:30	Session 1	Station 25	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Lara Núñez Santos
1588	Clinical and Autonomic Correlates of Chronic Sialorrhea in Parkinson's Disease: A Questionnaire-Based Study with Cluster Analysis of Autonomic and Dysphagia Burden	Sunday, October 4	9:30 - 10:30	Session 1	Station 25	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Shohei Okusa
1717	Levodopa-Carbidopa Intestinal Gel Infusion Therapy in Advanced Parkinson's Disease: Extension Study of Long-term outcomes of Single Centre experience	Sunday, October 4	9:30 - 10:30	Session 1	Station 26	1	Parkinson's Disease: Surgical Therapy	Hend Alhodaif
1718	Clinical Features of DJ1 Gene Mutation Causing Parkinson's Disease from a Single Centre	Sunday, October 4	9:30 - 10:30	Session 1	Station 26	2	Parkinson's Disease: Surgical Therapy	Hend Alhodaif
1719	Challenging Traditional Paradigm: Clinical Outcomes of Early vs Late Subthalamic Deep Brain Stimulation in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 26	3	Parkinson's Disease: Surgical Therapy	BUSE CAGLA ARI
1720	A Structured Multidisciplinary Pathway for the Management of Complex Patients Following Deep Brain Stimulation	Sunday, October 4	9:30 - 10:30	Session 1	Station 26	4	Parkinson's Disease: Surgical Therapy	Carlota Ballester
1721	Deep Brain Stimulation (DBS) For Parkinson's Disease (PD) Patients Carrying The GBA Gene Variant: Greater-Than-Expected Benefits, Similar Cognitive Decline, But Caution Is Advised Regarding Anxiety And Depression.	Sunday, October 4	9:30 - 10:30	Session 1	Station 26	5	Parkinson's Disease: Surgical Therapy	OSCAR BERNAL-PACHECO
1722	Comparison of Non-Motor Outcomes after Subthalamic Nucleus versus Globus Pallidus Internus Deep Brain Stimulation in Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 26	6	Parkinson's Disease: Surgical Therapy	Paras Borse
1727	Quantitative Changes in Speech After Focused Ultrasound Thalamotomy in Parkinson's Disease and Essential Tremor	Sunday, October 4	9:30 - 10:30	Session 1	Station 27	1	Parkinson's Disease: Surgical Therapy	Pablo Cortadi La-Villa
1728	Longitudinal Evolution of Freezing of Gait after STN-DBS in Parkinson's disease: Insights from the GAIT-DBS multicenter Study	Sunday, October 4	9:30 - 10:30	Session 1	Station 27	2	Parkinson's Disease: Surgical Therapy	Lola Díaz-Feliz
1729	APOSTIM study: a prospective study on quality of life in Parkinsonian patients sequentially treated with apomorphine infusion and STN stimulation	Sunday, October 4	9:30 - 10:30	Session 1	Station 27	3	Parkinson's Disease: Surgical Therapy	Frederique Fluchere

1730	Anatomical and electrical field determinants of axial motor outcome after bilateral GPi-DBS in Parkinson's disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 27	4	Parkinson's Disease: Surgical Therapy	Manu Girija
1731	Determinants of Tremor Control Across Severity Levels Following GPi-Deep Brain Stimulation in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 27	5	Parkinson's Disease: Surgical Therapy	Manu Girija
1732	Set_my_DBS: Multicenter study for the development of quantitative methods to support the programming of deep brain stimulation systems in patients with Parkinson's disease.	Sunday, October 4	9:30 - 10:30	Session 1	Station 27	6	Parkinson's Disease: Surgical Therapy	Alejandro Gonzalez-Monzon
1798	When Surgical Candidates Become Ineligible: Loss of Deep Brain Stimulation Eligibility in Parkinson's Disease – A Descriptive Study from a Brazilian Referral Center	Sunday, October 4	9:30 - 10:30	Session 1	Station 28	1	Parkinson's Disease: Surgical Therapy	Juan Sánchez-León
1799	Should we really forget DBS in Parkinson's Patients with Dementia?	Sunday, October 4	9:30 - 10:30	Session 1	Station 28	2	Parkinson's Disease: Surgical Therapy	B Dhanushree Natarajan
1012	Longitudinal cognitive variability in isolated and probable REM sleep behaviour disorder using the Trail Making Test	Sunday, October 4	9:30 - 10:30	Session 1	Station 28	3	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Harneek Chohan
1013	Investigation of Sex-based Differences in the Utility of IgG Index as a Potential Predictor of Cognitive Impairment in Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 28	4	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Ruth Emily Edillor
1014	The Association Between Gastrointestinal Dysfunction and Psychological Health in Individuals with Parkinson's Disease	Sunday, October 4	9:30 - 10:30	Session 1	Station 28	5	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Makena Messing
1015	Dopamine depletion does not mitigate striatal reward prediction error signals	Sunday, October 4	9:30 - 10:30	Session 1	Station 28	6	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Jung Hwan Shin
45	Added Value of Wearable-Derived Gait Features Beyond Clinical Assessments in Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 1	1	Technology	Roel Weijer
46	Movement Neurophysiology Studies: Clinical Practice Patterns and Standardization	Sunday, October 4	12:00 - 13:00	Session 2	Station 1	2	Technology	Marcus Callister
47	Clinical feasibility of a semi-automated Olfactometry System in α -Synucleinopathies	Sunday, October 4	12:00 - 13:00	Session 2	Station 1	3	Technology	Alexander Jäck
48	Normative Dual-Task Gait Profiles Across the Adult Lifespan in Healthy Korean Adults	Sunday, October 4	12:00 - 13:00	Session 2	Station 1	4	Technology	Bora Jin
49	Digital acoustic assessment of alleviating maneuvers in laryngeal dystonia: a 2-patient case series	Sunday, October 4	12:00 - 13:00	Session 2	Station 1	5	Technology	Ildar Khasanov

50	Digital acoustic biomarkers of botulinum toxin response in laryngeal dystonia: a longitudinal case report	Sunday, October 4	12:00 - 13:00	Session 2	Station 1	6	Technology	Diana Khasanova
92	Spatiotemporal Biomarkers of Early Postural Instability in Parkinson's Disease: Implications for Early Intervention	Sunday, October 4	12:00 - 13:00	Session 2	Station 2	1	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation	Ryoma Taniuchi
93	Ante-Mortem Motor Speech Profiles in Postmortem Confirmed Atypical Parkinsonisms	Sunday, October 4	12:00 - 13:00	Session 2	Station 2	2	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation	Nicole Herndon
94	Effects of Dance for Parkinson's on Disease Severity, Functional Mobility, and Habitual Physical Activity: A Feasibility Study	Sunday, October 4	12:00 - 13:00	Session 2	Station 2	3	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation	Nadeesha Kalyani
95	Family Caregivers and eHealth in Parkinson's Disease: Insights From a Qualitative Study	Sunday, October 4	12:00 - 13:00	Session 2	Station 2	4	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation	Hanna Johansson
96	Allied Health Professionals in Movement Disorders: a survey of clinical practice and education needs across the world	Sunday, October 4	12:00 - 13:00	Session 2	Station 2	5	Allied Healthcare: Physical Therapy, Speech Therapy, Rehabilitation	Anjali Sivaramakrishnan
262	Normal Pressure Hydrocephalus Imaging Markers in Movement Disorders: Comparison of Parkinson's Disease, Essential Tremor, Dystonia, and Progressive Supranuclear Palsy	Sunday, October 4	12:00 - 13:00	Session 2	Station 3	1	Parkinsonism (Other)	BUSE CAGLAR
263	Genetic Architecture Of Intracranial Brain Calcification: A Systematic Review	Sunday, October 4	12:00 - 13:00	Session 2	Station 3	2	Parkinsonism (Other)	Solomiia Bandrivska
264	Parkinsonism Revealing a Late Form of Niemann-Pick Disease About a Case	Sunday, October 4	12:00 - 13:00	Session 2	Station 3	3	Parkinsonism (Other)	Chahrazad Boukadir
265	Variable Clinical and Neuroimaging Features in Spinocerebellar Ataxia Type 17	Sunday, October 4	12:00 - 13:00	Session 2	Station 3	4	Parkinsonism (Other)	Yuri Bronstein
266	Changes in CSF dynamics and regional brain activation following CSF drainage in normal pressure hydrocephalus: A combined 7T fMRI and 3T Cine MRI pilot study	Sunday, October 4	12:00 - 13:00	Session 2	Station 3	5	Parkinsonism (Other)	Hee Jin Chang
267	Motor Network Neurophysiological (TMS-EEG) Markers as Predictors of Long-Term Outcomes Following Ventriculoperitoneal Shunt in Normal Pressure Hydrocephalus	Sunday, October 4	12:00 - 13:00	Session 2	Station 3	6	Parkinsonism (Other)	Tal Davidy
243	Healthcare Resource Utilization and Costs of Multiple System Atrophy in the United States: An Observational Database Study	Sunday, October 4	12:00 - 13:00	Session 2	Station 4	1	MSA, PSP, CBS: Pharmacology and Medical Management	Sari Wald Grossman

244	Improvement of Pseudobulbar Affect in Progressive Supranuclear Palsy with Amantadine: A Case Report	Sunday, October 4	12:00 - 13:00	Session 2	Station 4	2	MSA, PSP, CBS: Pharmacology and Medical Management	Bashir Daud Shah
245	Heart Rate Variability as an Independent Predictive Biomarker for Fall Risk in Multiple System Atrophy	Sunday, October 4	12:00 - 13:00	Session 2	Station 4	3	MSA, PSP, CBS: Pharmacology and Medical Management	Rakesh Rajput
135	Exploratory Results From a Phase 1 Study of NIO752 in Progressive Supranuclear Palsy Supporting Further Clinical Studies	Sunday, October 4	12:00 - 13:00	Session 2	Station 4	4	MSA, PSP, CBS: Clinical Trials	Mirek Brys
136	Results from a Randomized, Double-Blind, Placebo-Controlled Study of ATH434 in MSA using CSF NfL as a Covariate	Sunday, October 4	12:00 - 13:00	Session 2	Station 4	5	MSA, PSP, CBS: Clinical Trials	Daniel Claassen
137	Home-based cerebellar transcranial stimulation for multiple system atrophy: A randomized trial	Sunday, October 4	12:00 - 13:00	Session 2	Station 4	6	MSA, PSP, CBS: Clinical Trials	Young Eun Huh
202	Emerging Roles for Imaging Techniques in Differentiating Underlying Pathologies in Corticobasal Syndrome	Sunday, October 4	12:00 - 13:00	Session 2	Station 5	1	MSA, PSP, CBS: Neuroimaging	Paro Bhaya
203	Role of florzolotau (18F) positron emission tomography in the diagnosis and clinical management of progressive supranuclear palsy: a real-world study	Sunday, October 4	12:00 - 13:00	Session 2	Station 5	2	MSA, PSP, CBS: Neuroimaging	Kun-Wang Chan
204	QSM-Based Substantia Nigra Volumetry Improves Differentiation of Progressive Supranuclear Palsy from Parkinson's Disease and Multiple System Atrophy	Sunday, October 4	12:00 - 13:00	Session 2	Station 5	3	MSA, PSP, CBS: Neuroimaging	Sun Ju Chung
205	Quanti-tau-PET Study of PI-2620 Tau-PET Quantification in Progressive Supranuclear Palsy	Sunday, October 4	12:00 - 13:00	Session 2	Station 5	4	MSA, PSP, CBS: Neuroimaging	Yaroslau Compta
206	Regional Distribution and Concordance of Structural MRI and 18F-FDG PET/MRI Findings in Parkinson-Plus Syndromes	Sunday, October 4	12:00 - 13:00	Session 2	Station 5	5	MSA, PSP, CBS: Neuroimaging	Aysegul Gunduz
207	Choroid Plexus Morphology and Enhancement as Imaging Markers for Early Differentiation of Multiple System Atrophy and Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 5	6	MSA, PSP, CBS: Neuroimaging	Sungyang Jo
344	Phenomenological Gaps in Rating Scales for Blepharospasm Motor Severity	Sunday, October 4	12:00 - 13:00	Session 2	Station 6	1	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Julianne Lee
345	Myoclonus-Dystonia as a Phenotype of HGPPS1: A Case Report	Sunday, October 4	12:00 - 13:00	Session 2	Station 6	2	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Sabina Munasipova
346	Treatment Patterns in Adults with Isolated Dystonia in the United States	Sunday, October 4	12:00 - 13:00	Session 2	Station 6	3	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Michael Oldham

347	Healthcare Resource Utilization and Associated Costs in Adults with Isolated Dystonia in the United States	Sunday, October 4	12:00 - 13:00	Session 2	Station 6	4	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Michael Oldham
348	An observational study of segmental and generalized isolated dystonia to inform development of new drug therapies	Sunday, October 4	12:00 - 13:00	Session 2	Station 6	5	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Michael Oldham
349	Auricular Symptoms in Cervical Dystonia: A Case Series	Sunday, October 4	12:00 - 13:00	Session 2	Station 6	6	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Hwai Yin Ooi
421	Built Environment and Accessibility to Parkinson's Disease Community Programs: A Preliminary Analysis	Sunday, October 4	12:00 - 13:00	Session 2	Station 7	1	Disparities	Chiamaka Onuigbo
422	Racial Disparities in End-of-Life Care among Patients with Advanced Movement Disorders in an Interdisciplinary Supportive Care Clinic	Sunday, October 4	12:00 - 13:00	Session 2	Station 7	2	Disparities	Kei Sugiura
423	Barriers and Enablers to Diversity and Inclusion in Movement Disorders Research (BIND-MD)	Sunday, October 4	12:00 - 13:00	Session 2	Station 7	3	Disparities	Hannah Collins
424	Disparities in Accessing MRI-Guided Focused Ultrasound (MRgFUS) and Gamma Knife for Tremor Treatment: A Retrospective Chart Review	Sunday, October 4	12:00 - 13:00	Session 2	Station 7	4	Disparities	Shaina Corrick
425	Cross-Continental Differences in Prodromal Symptoms of Lewy Body Dementia: A Comparative Analysis Across Asia, Europe, and North America	Sunday, October 4	12:00 - 13:00	Session 2	Station 7	5	Disparities	Connie Hu
426	Improving Community Access to Parkinson's Disease Clinical Trials: Protocol for a Regional Navigation Toolkit in Southern California	Sunday, October 4	12:00 - 13:00	Session 2	Station 7	6	Disparities	Alvin Singh
472	Methamphetamine: An Underrecognized Cause of Acute Chorea - A Case Report and Literature Review	Sunday, October 4	12:00 - 13:00	Session 2	Station 8	1	Drug-Induced Movement Disorders	Chatthong Kanchanawuttitham
473	Iatrogenic akathisia aggravating depressive and psychotic symptoms: a case report	Sunday, October 4	12:00 - 13:00	Session 2	Station 8	2	Drug-Induced Movement Disorders	Alena Katok
474	Comparison of Motor Severity in Individuals with Drug-Induced Parkinsonism and Idiopathic Parkinson's Disease A Systematic Review and Meta-Analysis	Sunday, October 4	12:00 - 13:00	Session 2	Station 8	3	Drug-Induced Movement Disorders	Eduardo Maciel
475	Methanol Intoxication Presenting as a Mixed Ataxic-Parkinsonian Syndrome With a Paradoxical Response to Levodopa: A Case Report	Sunday, October 4	12:00 - 13:00	Session 2	Station 8	4	Drug-Induced Movement Disorders	DIANA SOLORZAN O GOMEZ
476	Case of Head Drop as an Adverse Drug Reaction to Dopamine Agonists and Regulatory Evaluation	Sunday, October 4	12:00 - 13:00	Session 2	Station 8	5	Drug-Induced Movement Disorders	Anette Stark
477	Phenytoin Intoxication Masquerading as Generalized Chorea: A Case of Iatrogenic Double-Prescribing	Sunday, October 4	12:00 - 13:00	Session 2	Station 8	6	Drug-Induced Movement Disorders	Kamalesh Tayade
614	Beyond the Brain: Resting Tremor as a Presentation of Cervical Spinal Schwannoma	Sunday, October 4	12:00 - 13:00	Session 2	Station 9	1	Tremor	Tasneem Abu-Zahra

615	Objective profiling of parkinsonian and essential tremor using EMG and accelerometry	Sunday, October 4	12:00 - 13:00	Session 2	Station 9	2	Tremor	Fernando Alonso-Frech
616	Evaluation of neurosurgical treatment outcomes for tremor using dynamics of tract density and total entropy of the dentatorubrothalamic tract	Sunday, October 4	12:00 - 13:00	Session 2	Station 9	3	Tremor	Vitali Bayarchyk
617	Lingual tremor secondary to ischemic stroke of the left middle cerebral artery. Another movement disorder with cortical localization?	Sunday, October 4	12:00 - 13:00	Session 2	Station 9	4	Tremor	Alejandro Bonilla Tena
618	Disabling Holmes Tremor Following Pontine Hemorrhage Accompanied by a Unique Constellation of Movement Disorders	Sunday, October 4	12:00 - 13:00	Session 2	Station 9	5	Tremor	Paulo Cataniag
619	Rest Tremor does Not Predict Response to Focused Ultrasound Thalamotomy in Essential Tremor and Dystonic Tremor	Sunday, October 4	12:00 - 13:00	Session 2	Station 9	6	Tremor	Owen Chan
596	Efficacy of Vitamin C for Restless Legs Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials	Sunday, October 4	12:00 - 13:00	Session 2	Station 10	1	Restless Legs Syndrome and Sleep Disorders	Ana Fornari Caprara
597	A Real World Case Series of the Nidra Transcutaneous Afferent Patterned Stimulation Device in Moderate-to-Refractory Restless Legs Syndrome	Sunday, October 4	12:00 - 13:00	Session 2	Station 10	2	Restless Legs Syndrome and Sleep Disorders	Natalie Hellmers
598	A Meta-analysis of Tonic Motor Activation (TOMAC) Therapy for Restless Legs Syndrome	Sunday, October 4	12:00 - 13:00	Session 2	Station 10	3	Restless Legs Syndrome and Sleep Disorders	Jamir Pitton Rissardo
599	Stellate Ganglion Block for Restless Legs Syndrome in a Patient with Renal Failure a Case Report	Sunday, October 4	12:00 - 13:00	Session 2	Station 10	4	Restless Legs Syndrome and Sleep Disorders	weiwei Zhang
600	Efficacy of Mechanoacoustic Vibration Therapy on Motor Function, Bone Density, and Sleep Architecture in Elderly Women with Restless Legs Syndrome	Sunday, October 4	12:00 - 13:00	Session 2	Station 10	5	Restless Legs Syndrome and Sleep Disorders	Ekta -
601	The Impact of Insomnia and Sleep Fragmentation on Quality of Life and Neuropsychiatric Outcomes in Restless Legs Syndrome	Sunday, October 4	12:00 - 13:00	Session 2	Station 10	6	Restless Legs Syndrome and Sleep Disorders	Ankush Kumar
1950	Accelerated brain iron accumulation secondary to hypoxia in a patient with hereditary haemochromatosis with homozygous C282Y mutations.	Sunday, October 4	12:00 - 13:00	Session 2	Station 11	1	Rare Neurometabolic Movement Disorders	Arka Prava Chakraborty
1951	Spectrum of Wilson's Disease from a Tertiary care hospital	Sunday, October 4	12:00 - 13:00	Session 2	Station 11	2	Rare Neurometabolic Movement Disorders	Rashmi Devaraj
1952	Clinical and Functional Outcomes of Antiviral and Immunomodulatory Therapies in Subacute Sclerosing Panencephalitis	Sunday, October 4	12:00 - 13:00	Session 2	Station 11	3	Rare Neurometabolic Movement Disorders	Sidharth Rao Errabelly

1953	The Therapeutic Landscape of SSPE: A Systematic Review of Antiviral and Immunomodulatory Modalities	Sunday, October 4	12:00 - 13:00	Session 2	Station 11	4	Rare Neurometabolic Movement Disorders	Varad Jadhav
1954	Evaluation of Cardiac Markers and Clinical Metrics in Friedreich's Ataxia	Sunday, October 4	12:00 - 13:00	Session 2	Station 11	5	Rare Neurometabolic Movement Disorders	Thomas Keller
1955	Hyperkinetic Movement Disorder as the First Manifestation of Gaucher Disease Type 3	Sunday, October 4	12:00 - 13:00	Session 2	Station 11	6	Rare Neurometabolic Movement Disorders	Bilge Kocer
699	Comparative Effectiveness of Tavapadon Versus Real-world Oral Standard of Care Treatments in Parkinson's Disease With Motor Fluctuations: an Indirect Comparison Analysis	Sunday, October 4	12:00 - 13:00	Session 2	Station 12	1	Parkinson's Disease: Clinical Trials	Pinky Agarwal
700	Exploratory Efficacy Analysis of Tavapadon Versus MAO-B Inhibitors in People With Early Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 12	2	Parkinson's Disease: Clinical Trials	Eric Freire Alvarez
701	Systemic antioxidant response to bilateral anodal transcranial direct current stimulation in Parkinson's disease: findings from a pilot randomized controlled study	Sunday, October 4	12:00 - 13:00	Session 2	Station 12	3	Parkinson's Disease: Clinical Trials	Hikmat Hadoush
702	Changes in Continuous Good ON and Best ON Time During the Waking Day With Tavapadon in People With Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 12	4	Parkinson's Disease: Clinical Trials	Robert Hauser
703	Levodopa Initiation in Phase 3 Trials of Tavapadon, a Selective D1/D5 Agonist for Early Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 12	5	Parkinson's Disease: Clinical Trials	William Ondo
704	Identifying Peripheral Stimulation Sites to Treat Parkinson's Disease Gait Impairments	Sunday, October 4	12:00 - 13:00	Session 2	Station 12	6	Parkinson's Disease: Clinical Trials	Niamh Hennessy
771	The Clinical and Biological effects of a Whole Foods and Plant-Based Dietary Intervention in Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 13	1	Parkinson's Disease: Clinical Trials	Bram Boon
772	Randomized Controlled Trial Comparing Adaptive versus Continuous Subthalamic Nucleus Deep Brain Stimulation in Parkinson's Disease; Closed Loop Optimization of Deep Brain Stimulation Effect in Parkinson's Disease (CLOSE-PD study)	Sunday, October 4	12:00 - 13:00	Session 2	Station 13	2	Parkinson's Disease: Clinical Trials	Joost Genet
773	Patient-Defined Disease Progression in Parkinson Disease: Towards Patient-Relevant Outcome Measures	Sunday, October 4	12:00 - 13:00	Session 2	Station 13	3	Parkinson's Disease: Clinical Trials	Cristina Gonzalez-Robles
774	Foslevodopa-Foscarbidopa Continuous Subcutaneous Infusion Leads to Long-Term Reduction in Dyskinesia in Parkinson's Disease: Results from 5-Year Follow-Up	Sunday, October 4	12:00 - 13:00	Session 2	Station 13	4	Parkinson's Disease: Clinical Trials	Niroshan Jeyakumar

775	Cognitive and neuropsychiatric effects of home-based, remotely supervised strength exercise combined with guideline-based aerobic physical activity modification in Parkinson's Disease: a randomized controlled trial	Sunday, October 4	12:00 - 13:00	Session 2	Station 13	5	Parkinson's Disease: Clinical Trials	Ryul Kim
776	High-Frequency rTMS for Cognitive Impairment in Parkinson's Disease: A Randomized Sham-Controlled Trial in Veterans	Sunday, October 4	12:00 - 13:00	Session 2	Station 13	6	Parkinson's Disease: Clinical Trials	Yongsung Kim
843	Risk Factors and Etiologies for Emergency Visit among Parkinson's Disease Patients: a Narrative Review	Sunday, October 4	12:00 - 13:00	Session 2	Station 14	1	Parkinson's Disease: Pharmacology and Medical Management	Rajeev Ojha
844	Can a slogan poster featuring the patient's primary physician help improve gait and prevent falls at home in patients with Parkinson's disease?	Sunday, October 4	12:00 - 13:00	Session 2	Station 14	2	Parkinson's Disease: Pharmacology and Medical Management	Yasuyuki Okuma
845	Dopaminergic Medication Changes Following LFP-Guided Deep Brain Stimulation Programming in Parkinson's Disease: A Single-Centre Audit	Sunday, October 4	12:00 - 13:00	Session 2	Station 14	3	Parkinson's Disease: Pharmacology and Medical Management	Matthew Pagan
846	Impact of Vitamin D Supplementation on Cognitive Function, Quality of Life, and Dyskinesia in Parkinson's Disease: A Systematic Review and Meta-Analysis	Sunday, October 4	12:00 - 13:00	Session 2	Station 14	4	Parkinson's Disease: Pharmacology and Medical Management	Chamod Perera
847	Biochemical and Nutritional Changes During Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson's Disease: Findings from an Observational Cohort	Sunday, October 4	12:00 - 13:00	Session 2	Station 14	5	Parkinson's Disease: Pharmacology and Medical Management	Onanong Phokaewvara ngkul
848	Evaluating the Conversion of Immediate-Release and/or Extended-Release Levodopa to IPX203 in Patients with Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 14	6	Parkinson's Disease: Pharmacology and Medical Management	Linda Poon
1821	Nutritional Status as a Modifiable Determinant of Clinical Outcomes in Parkinson's Disease: A 12-Month Longitudinal Study in Patients Treated with DBS and L-Dopa	Sunday, October 4	12:00 - 13:00	Session 2	Station 15	1	Parkinson's Disease (Other)	Naia Ayo Mentxakatorre
1822	Multimodal Deep Learning for Parkinson's Disease Screening: Fusing Quantitative Gait Analysis and Clinical Features	Sunday, October 4	12:00 - 13:00	Session 2	Station 15	2	Parkinson's Disease (Other)	Xuerong Bai
1823	Five-Year Real-World Outcomes Of Botulinum Toxin Injections For Sialorrhoea In Parkinson's	Sunday, October 4	12:00 - 13:00	Session 2	Station 15	3	Parkinson's Disease (Other)	Raihaan Biju
1824	Sialorrhoea As An Indicator Of Palliative Phase In Advanced Parkinson's	Sunday, October 4	12:00 - 13:00	Session 2	Station 15	4	Parkinson's Disease (Other)	Raihaan Biju
1825	Scaling Evidence-based Community Rehabilitation for Parkinson's disease for Singapore: A Nationwide RE-AIM Implementation Study Protocol	Sunday, October 4	12:00 - 13:00	Session 2	Station 15	5	Parkinson's Disease (Other)	Chloe Lauha Chung
1826	The influence of Parkinson's disease duration on perceived quality of inpatient care	Sunday, October 4	12:00 - 13:00	Session 2	Station 15	6	Parkinson's Disease (Other)	Lynn Eickholt

1893	A Clinical Mapping Framework for Motor Balance Impairment in Welders Projected Against Parkinson Disease Severity Stages	Sunday, October 4	12:00 - 13:00	Session 2	Station 16	1	Parkinson's Disease (Other)	Sabarish Hariharan Narayanan
1894	Digital Assessment of Cognitive Function in Parkinson's Disease: Preliminary Feasibility and Validity Data	Sunday, October 4	12:00 - 13:00	Session 2	Station 16	2	Parkinson's Disease (Other)	Maria Laura Nasi
1895	How Parkinson's Disease Research Has Shifted from 2016 – 2025 at the MDS Congress: A Topic-Based Analysis	Sunday, October 4	12:00 - 13:00	Session 2	Station 16	3	Parkinson's Disease (Other)	Leonie Ramin
1896	Impact of Caffeine Consumption on Clinical Phenotype and Non-Motor Symptoms in Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 16	4	Parkinson's Disease (Other)	Arwa Rekik
1897	Early impairment in iTBS-induced cortical plasticity in drug-naïve Parkinson's disease: a rTMS pilot study	Sunday, October 4	12:00 - 13:00	Session 2	Station 16	5	Parkinson's Disease (Other)	Andrea Rizzardi
1898	Monitoring Levodopa Responsiveness in Parkinson's disease using wearable sensors: the digital levodopa challenge	Sunday, October 4	12:00 - 13:00	Session 2	Station 16	6	Parkinson's Disease (Other)	Andrea Rizzardi
943	Digital Respiratory Biomarkers as Early Indicators of Dysphagia and Aspiration Risk in Parkinson's Disease A Systematic Review	Sunday, October 4	12:00 - 13:00	Session 2	Station 17	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Meghnath Kakde
944	Real-Time Quaking-Induced Conversion Detection of Tear Fluid α -Synuclein as a Potential Biomarker for Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 17	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Asako Kakimoto
945	Risk stratification study of fluid biomarkers for alpha-synucleinopathy with dementia	Sunday, October 4	12:00 - 13:00	Session 2	Station 17	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Ryota Kamo
946	Large-Scale Shotgun Mass Spectrometry in Parkinson's Disease Plasma Identifies Novel Biomarker Candidates	Sunday, October 4	12:00 - 13:00	Session 2	Station 17	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Shervin Khosousi
947	PD Similarity Index: A Wearable Gait Biomarker Capturing the Continuum from iRBD to Parkinson Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 17	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Sang Jin Kim
948	Brain-Derived Neurotrophic Factor as a Biomarker of Depression in Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 17	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	In Hee Kwak
1085	Role of ApoE in α -Synuclein Pathology	Sunday, October 4	12:00 - 13:00	Session 2	Station 18	1	Parkinson's Disease: Disease mechanisms	Ali K. Jaafar
1086	DCN-PPN Pathway Activation Improves Motor Dysfunction via Synaptic Plasticity in Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 18	2	Parkinson's Disease: Disease mechanisms	Mengshi Liao
1087	LRRK2 G2019S Drives Lysosomal Lipid Remodeling and Inflammation in Human iPSC-Derived Microglia	Sunday, October 4	12:00 - 13:00	Session 2	Station 18	3	Parkinson's Disease: Disease mechanisms	Maria Tziortziou

1088	Modulatory effects of bacterial-derived serine protease on pathological α -synuclein fibrillation in vitro	Sunday, October 4	12:00 - 13:00	Session 2	Station 18	4	Parkinson's Disease: Disease mechanisms	Hui-Jun Yang
1089	The Influence of Glymphatic System Impairment on Cognitive Decline in Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 18	5	Parkinson's Disease: Disease mechanisms	Qin Zhang
1090	Electroacupuncture Restores Cortico-striatal Synaptic Plasticity by Promoting STEP61 against 6-OHDA Induced Extrasynaptic NMDAR/TRPM4 Complex	Sunday, October 4	12:00 - 13:00	Session 2	Station 18	6	Parkinson's Disease: Disease mechanisms	Yifan Zhang
1157	Normative Data for the IDEA Dementia Screen in Healthy Older Adults and People with Parkinson's Disease in Ethiopia: A Comparative Cross Sectional Study	Sunday, October 4	12:00 - 13:00	Session 2	Station 19	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Seid Gugssa
1158	Real-life accelerometer-based detection of DBS effects on tremor and dyskinesia in Parkinson's disease, trained with ecological momentary assessments	Sunday, October 4	12:00 - 13:00	Session 2	Station 19	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jeroen Habets
1159	The influence of probable rapid eye movement sleep behavior disorder on PD-related motor and non-motor symptoms and multiple functional outcomes among Chinese community-dwelling elderly population	Sunday, October 4	12:00 - 13:00	Session 2	Station 19	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Chao Han
1160	Remote Digital Deployment of a Validated Psychosis Screener in Parkinson's Disease: Real-World Feasibility and Screening Yield	Sunday, October 4	12:00 - 13:00	Session 2	Station 19	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Amanda Hare
1161	A Large-Scale Digital Parkinson Disease Platform Matches Clinician Identification of Dyskinesia and Uncovers Unmet Need Between Visits	Sunday, October 4	12:00 - 13:00	Session 2	Station 19	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Amanda Hare
1162	Association between probable RBD and reduced CSF 5-hydroxyindoleacetic acid levels in Parkinson's disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 19	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Keiko Hatano
1229	Three Years On: Outcomes of Subthalamic Nucleus Deep Brain Stimulation in Parkinson's disease from the Irish National DBS service	Sunday, October 4	12:00 - 13:00	Session 2	Station 20	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Federica Ruggieri

1230	Physical Activity is Associated with Attenuated Motor and Cognitive Progression in Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 20	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Dong-Woo Ryu
1231	Neurofilament Light Chain as a Prognostic Marker of Motor Progression in Parkinson's Disease: A Systematic Review	Sunday, October 4	12:00 - 13:00	Session 2	Station 20	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Maheeka Sabharwal
1232	Incidence and Outcomes of Hip Fractures in Parkinsonism vs Non-Parkinson Population: A Systematic Review of the Literature	Sunday, October 4	12:00 - 13:00	Session 2	Station 20	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Uttam Saini
1233	Longitudinal Weight/BMI Trajectories and Their Clinical Impact on Parkinson's Disease.	Sunday, October 4	12:00 - 13:00	Session 2	Station 20	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Karen Sánchez-Ramírez
1234	Sex Related Differences in Parkinsons Disease Motor and Non Motor Features Treatment Response and Quality of Life	Sunday, October 4	12:00 - 13:00	Session 2	Station 20	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Rodrigo Sanjinez
1301	Subtle Behavioral Changes Observed by Knowledgeable Informants Up to Decades Before Parkinson's Disease Diagnosis	Sunday, October 4	12:00 - 13:00	Session 2	Station 21	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Elizabeth Trinh
1302	Changes in ADL-Related Factors According to Disease Stage in Patients with Parkinson's Disease: Multiple Regression Analysis	Sunday, October 4	12:00 - 13:00	Session 2	Station 21	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Koji Watanabe
1303	Apparent Change Classification with Stage-Specific and Fixed Minimal Detectable Change Thresholds in Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 21	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ryo Yamasaki

1304	Speech And Gait In Newly Diagnosed Parkinson's Disease: Support For Early Rehabilitation	Sunday, October 4	12:00 - 13:00	Session 2	Station 21	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Tor Yhlen
1305	Multilingual Smartphone Application for Objective Motor Assessment in Parkinson Disease: Cross-Sectional Clinical Validation Study	Sunday, October 4	12:00 - 13:00	Session 2	Station 21	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Bikram Biswas
1306	A Brief Clinical Test Battery Predicting UPDRS II Disability in Parkinson Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 21	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Rebeka Dias
1373	Clinical Profile and Progression of Parkinson's Disease in Nigerians with the GBA1 African Ancestry-specific Risk Variant	Sunday, October 4	12:00 - 13:00	Session 2	Station 22	1	Parkinson's Disease: Genetics	Oluwadamilola Ojo
1374	Investigation of the Mendelian contribution of parkinsonism associated genes to Parkinson's disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 22	2	Parkinson's Disease: Genetics	Guillaume Cogan
1375	Detection of heterozygous ATP7B variants in Hawaii's Parkinson's Disease cohort: A case series of six patients	Sunday, October 4	12:00 - 13:00	Session 2	Station 22	3	Parkinson's Disease: Genetics	Malika Faouzi
1376	Genetic Variation in KCNJ6 Gene Increases Risk of Impulse Disorders in Parkinson's Disease: A Two-Cohort Study	Sunday, October 4	12:00 - 13:00	Session 2	Station 22	4	Parkinson's Disease: Genetics	Sergio García-Díaz
1377	Bridging Genetics and Precision Medicine in Parkinson's Disease through GP2: Translating Genetic Risk into Trial-Eligible GBA1 and LRRK2 Cohorts	Sunday, October 4	12:00 - 13:00	Session 2	Station 22	5	Parkinson's Disease: Genetics	Lara Lange
1378	A Genome-Wide Search for Common Variants Modifying Age at Onset in PRKN-Associated Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 22	6	Parkinson's Disease: Genetics	Poornima Jayadev Menon
1445	Smell Testing in The Global Parkinson's Genetics Program (GP2)	Sunday, October 4	12:00 - 13:00	Session 2	Station 23	1	Parkinson's Disease: Genetics	Sophie Meyer
1446	Investigating the role of ATP7B heterozygous variants in Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 23	2	Parkinson's Disease: Genetics	Pierfrancesco Mitrotti
1447	Genetic determinants of cognitive performance in Parkinson's disease: impact of distal regulatory variation at the SNCA locus in the gp2 cohort	Sunday, October 4	12:00 - 13:00	Session 2	Station 23	3	Parkinson's Disease: Genetics	Diana Náfate Wences
1448	Differential Effect of MAO-B Inhibitors in GBA1 Carriers with Parkinson's Disease Women vs Men	Sunday, October 4	12:00 - 13:00	Session 2	Station 23	4	Parkinson's Disease: Genetics	Hodaya Saragani
1449	Lysosomal polygenic risk score in Parkinson disease across populations.	Sunday, October 4	12:00 - 13:00	Session 2	Station 23	5	Parkinson's Disease: Genetics	Wenhua Sun

1450	Exploring the Causal Role of Mitochondria-related Genes in Parkinson's Disease through Multi-Omics Mendelian Randomization	Sunday, October 4	12:00 - 13:00	Session 2	Station 23	6	Parkinson's Disease: Genetics	Yichi Zhang
1517	White Matter Hyperintensity and the Spatial Subtypes in Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 24	1	Parkinson's disease: Neuroimaging	Xinyi Xie
1518	In Vivo 18F-Florzolotau Tau PET Imaging in Parkinson's Disease with and without Probable REM Sleep Behavior Disorder	Sunday, October 4	12:00 - 13:00	Session 2	Station 24	2	Parkinson's disease: Neuroimaging	Chenqin Xu
1519	Cerebellar peduncle microstructure and autonomic dysfunction in Parkinson's disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 24	3	Parkinson's disease: Neuroimaging	Rui Yang
1520	Distinct Cortical and Subcortical Network Mechanisms of High and Low Frequency Subthalamic Stimulation in Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 24	4	Parkinson's disease: Neuroimaging	Zhitong Zeng
1521	Cholinergic Pathway Degeneration Predicts Differential Phenoconversion to Synucleinopathies in Idiopathic REM Sleep Behavior Disorder	Sunday, October 4	12:00 - 13:00	Session 2	Station 24	5	Parkinson's disease: Neuroimaging	Dongling Zhang
1522	Dopaminergic reconfiguration of an inverted network hierarchy in Parkinson's disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 24	6	Parkinson's disease: Neuroimaging	Junjiao Zhang
1589	Sleep dysfunction and its clinical and video-polysomnographic correlates in patients with early Parkinson's disease in comparison with early Progressive supranuclear palsy	Sunday, October 4	12:00 - 13:00	Session 2	Station 25	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Nikhil Paul
1590	Exploring the Relationship Between Insomnia and Autonomic Dysfunction in Parkinson's Disease: A 1 Year SCOPA-AUT Analysis	Sunday, October 4	12:00 - 13:00	Session 2	Station 25	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Diana Petrosyan
1591	Effects of a Ballet-Based Intervention on Apathy and Non-Motor Symptoms in Parkinson's Disease: the PD-Ballet TM Randomised Controlled Trial	Sunday, October 4	12:00 - 13:00	Session 2	Station 25	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Aleksandra Podlowska
1592	Pain Assessment using Parkinson's Disease Pain Classification System (PD-PCS) and King's Parkinson Disease Pain Scale (KPPS) – a Comparative Study	Sunday, October 4	12:00 - 13:00	Session 2	Station 25	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Joao Welberthon Queiroz
1593	A Tiered Fecal Biomarker Approach to Identify Gut-Brain Axis Phenotypes in Young-Onset Parkinsonism in a Clinical Setting with Limited Resources	Sunday, October 4	12:00 - 13:00	Session 2	Station 25	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Neila Raisa
1594	International, multicenter validation study of the Shame in Parkinson's disease (SPARK) Scale	Sunday, October 4	12:00 - 13:00	Session 2	Station 25	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Carmen Rodriguez-Blazquez

1723	Electrode implantation outcome evaluation based on diffusion-tensor imaging math processing for PD patients with DBS	Sunday, October 4	12:00 - 13:00	Session 2	Station 26	1	Parkinson's Disease: Surgical Therapy	Anna Buniak
1724	A case of difficulty extubating after General Anesthesia Deep Brain Stimulation (DBS) surgery	Sunday, October 4	12:00 - 13:00	Session 2	Station 26	2	Parkinson's Disease: Surgical Therapy	Kuan Wen Chen
1725	Hybrid deep brain stimulation conversion using the S8 adaptor in Parkinson's disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 26	3	Parkinson's Disease: Surgical Therapy	Moongwan Choi
1726	Correlating Start Hesitation and Subthalamic Nucleus Activity in Parkinson's Disease Using Intraoperative Microelectrode Recordings and a Virtual Reality Task	Sunday, October 4	12:00 - 13:00	Session 2	Station 26	4	Parkinson's Disease: Surgical Therapy	Christopher Coppin
1646	Micro- and Nanoplastics in Parkinson's Disease Pathogenesis An Emerging Environmental Risk Factor	Sunday, October 4	12:00 - 13:00	Session 2	Station 26	5	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Assel Aralbayeva
1647	Substantia Nigra Free-Water, Metabolic Markers, and Motor Variability in Older Adults with Diabetes	Sunday, October 4	12:00 - 13:00	Session 2	Station 26	6	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Alexander Belnavis
1733	Oscillatory characterization of the STN beyond the resting state in patients with Parkinson's disease.	Sunday, October 4	12:00 - 13:00	Session 2	Station 27	1	Parkinson's Disease: Surgical Therapy	Alejandro González-Monzón
1734	Beta-motor state correspondence as a predictor of adaptive deep brain stimulation benefit in Parkinson's disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 27	2	Parkinson's Disease: Surgical Therapy	Takao Hashimoto
1735	Extended long-term follow-up of adaptive deep brain stimulation in Parkinson's disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 27	3	Parkinson's Disease: Surgical Therapy	Todd Herrington
1736	Clinical Outcomes and Safety of Ablative Surgery for Parkinson's Disease in Resource-Limited Settings: A Cohort from Indonesia	Sunday, October 4	12:00 - 13:00	Session 2	Station 27	4	Parkinson's Disease: Surgical Therapy	Rizka Ibonita
1737	Neuroimaging-guided automated optimization of deep brain stimulation in Parkinson's disease: preliminary results	Sunday, October 4	12:00 - 13:00	Session 2	Station 27	5	Parkinson's Disease: Surgical Therapy	Gabriele Imbalzano
1738	Towards intraoperative physiology-informed design of intermittent burst deep brain stimulation	Sunday, October 4	12:00 - 13:00	Session 2	Station 27	6	Parkinson's Disease: Surgical Therapy	Galymzhan Issabekov
1016	Adult hippocampal neurogenesis and cognitive and neuropsychiatric symptoms in Parkinson's disease: the MemHiN study	Sunday, October 4	12:00 - 13:00	Session 2	Station 28	1	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Lucia Batzu
1017	Data-driven Trajectories of Atrophy Explain Clinical Heterogeneity Across Lewy Body Diseases	Sunday, October 4	12:00 - 13:00	Session 2	Station 28	2	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Ajay Konuri

1018	Distinct Cognitive Profiles in Parkinson's and Alzheimer's Disease: Evidence from a Large Neurodegenerative Cohort	Sunday, October 4	12:00 - 13:00	Session 2	Station 28	3	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Irina Zhukova
1019	Increased Pre-Alpha EEG Functional Connectivity Forecasts Future Cognitive Decline in Parkinson's Disease	Sunday, October 4	12:00 - 13:00	Session 2	Station 28	4	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Alina Tetereva
1020	Neuropsychiatric Symptoms in Lewy Body Disease: Monoaminergic Activity and Resting State Networks	Sunday, October 4	12:00 - 13:00	Session 2	Station 28	5	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Laura Wright
1021	Cognitive Trajectories After STN DBS in Parkinson's Disease: 12-Month Outcomes	Sunday, October 4	12:00 - 13:00	Session 2	Station 28	6	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Neil Austin
51	Digital Facial Movement Analysis in Hemifacial Spasm: Potential and Limitations as a Clinical Biomarker	Sunday, October 4	13:00 - 14:00	Session 3	Station 1	1	Technology	Zuzana Kosutzka
52	Designing a virtual reality-based rehabilitation therapy for Parkinson disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 1	2	Technology	Ben Anthony Lopez
53	Automatic Segmentation of the Subthalamic Nucleus and Globus Pallidus Internus: Can it support planning and programming in Deep brain stimulation	Sunday, October 4	13:00 - 14:00	Session 3	Station 1	3	Technology	TANMOY MAITI
54	Identification of Digital Measures of Motor Progression from In-Clinic Assessments in Early Parkinson's Disease for Composite Digital Biomarkers: Results from WATCH-PD	Sunday, October 4	13:00 - 14:00	Session 3	Station 1	4	Technology	Jie Ren
55	Archimedes Spiral and Straight-Line Drawings as Digital Biomarkers in Cerebellar Ataxia: A Preliminary Study	Sunday, October 4	13:00 - 14:00	Session 3	Station 1	5	Technology	Kotaro Tsutsumi
56	Risk factors and management of postoperative infection following deep brain stimulation – A single center experience	Sunday, October 4	13:00 - 14:00	Session 3	Station 1	6	Technology	Khang Vo
121	Identification of Candidate Cerebrospinal Fluid Biomarkers in Multiple System Atrophy Using Mass Spectrometry-Based Proteomics in CSF Biobank Samples	Sunday, October 4	13:00 - 14:00	Session 3	Station 2	1	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Pekka Kallunki
122	Comprehensive Diagnostic Accuracy of α -Synuclein Seed Amplification Assays Across Non-Parkinsonian Synucleinopathies: A Systematic Review and Diagnostic Meta-analysis	Sunday, October 4	13:00 - 14:00	Session 3	Station 2	2	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Prashant Bhatele

123	Towards Biomarker-Driven Staging of Multiple System Atrophy Using Longitudinal Neurofilament Light Profiling	Sunday, October 4	13:00 - 14:00	Session 3	Station 2	3	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Linda Lei
124	Molecular Profiling of Brain-Derived Extracellular Vesicles and Fluid Biomarkers in Parkinsonism: Distinct Signatures and Clinical Correlates in Progressive Supranuclear Palsy	Sunday, October 4	13:00 - 14:00	Session 3	Station 2	4	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Akash Roy
125	Pharmacogenomic Analysis of KM-819-Related Hepatotoxicity in Patients with Multiple System Atrophy	Sunday, October 4	13:00 - 14:00	Session 3	Station 2	5	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Jeong-Hoon Han
126	Data-driven operational definition of square-wave jerks to optimize diagnostic discrimination of progressive supranuclear palsy	Sunday, October 4	13:00 - 14:00	Session 3	Station 2	6	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Duy Duan Nguyen
268	Identification of a Novel MYORG Mutation in Autosomal Recessive Idiopathic Basal Ganglia Calcification-7 (IBGC7): A Case Report	Sunday, October 4	13:00 - 14:00	Session 3	Station 3	1	Parkinsonism (Other)	Walaa Kamel
269	Quantitative susceptibility mapping with 7T MRI as a novel imaging biomarker for periventricular degeneration in normal pressure hydrocephalus: A pilot study	Sunday, October 4	13:00 - 14:00	Session 3	Station 3	2	Parkinsonism (Other)	Sangwoo Kim
270	Atypical vascular parkinsonism from a midbrain lesion with excellent dopaminergic response	Sunday, October 4	13:00 - 14:00	Session 3	Station 3	3	Parkinsonism (Other)	Woong-Woo Lee
271	Cerebral Small Vessel Disease Associated with Clinical Heterogeneity in Vascular Parkinsonism	Sunday, October 4	13:00 - 14:00	Session 3	Station 3	4	Parkinsonism (Other)	Yanyi Li
272	Very late-onset PKAN presenting with parkinsonism and lingual tremor at age 52	Sunday, October 4	13:00 - 14:00	Session 3	Station 3	5	Parkinsonism (Other)	Yong Luo
273	FUS R521S mutation causing levodopa responsive amyotrophic lateral sclerosis-Parkinson's disease (ALS-PD).	Sunday, October 4	13:00 - 14:00	Session 3	Station 3	6	Parkinsonism (Other)	Ray Peh
138	MobilityAPP: A randomized-controlled trial evaluating gait-focused physiotherapy in Parkinson's disease and atypical parkinsonian syndromes	Sunday, October 4	13:00 - 14:00	Session 3	Station 4	1	MSA, PSP, CBS: Clinical Trials	Victoria Sidoroff
139	Dysphagia and Oropharyngeal Freezing in Progressive Supranuclear Palsy	Sunday, October 4	13:00 - 14:00	Session 3	Station 4	2	MSA, PSP, CBS: Clinical Trials	Ping Wang
140	Abdominal Binders to treat Orthostatic Hypotension in Parkinsonian Syndromes	Sunday, October 4	13:00 - 14:00	Session 3	Station 4	3	MSA, PSP, CBS: Clinical Trials	Fabian Leys
194	Genomic analysis of an Argentinean PSP cohort	Sunday, October 4	13:00 - 14:00	Session 3	Station 4	4	MSA, PSP, CBS: Etiology	Nahuel Fonseca
195	Clinical Markers of Monogenic Mimics in Atypical Parkinsonism: Findings From a 150-Patient Series	Sunday, October 4	13:00 - 14:00	Session 3	Station 4	5	MSA, PSP, CBS: Etiology	Zhidong Cen
208	Computer-Assisted Morphometric Analysis of Midbrain and Pons for Differential Diagnosis of Parkinsonian Disorders	Sunday, October 4	13:00 - 14:00	Session 3	Station 5	1	MSA, PSP, CBS: Neuroimaging	Pan-Woo Ko

209	Reversible encephalitic Parkinsonism due to bilateral substantia nigra lesion showing preserved nigrostriatal dopaminergic activity	Sunday, October 4	13:00 - 14:00	Session 3	Station 5	2	MSA, PSP, CBS: Neuroimaging	Bon D. Ku
210	Comparison of Regional Perfusion Patterns in Clinical Subtypes of PSP and CBD: Dual Phase [¹⁸ F]FP CIT PET Study	Sunday, October 4	13:00 - 14:00	Session 3	Station 5	3	MSA, PSP, CBS: Neuroimaging	Chong Lee
211	Diagnostic Utility of [18F]FDG-PET in the Differential Diagnosis of Parkinsonian Syndromes: A Retrospective Study in an Indian Tertiary Care Cohort	Sunday, October 4	13:00 - 14:00	Session 3	Station 5	4	MSA, PSP, CBS: Neuroimaging	Arun Mani
212	Can Parkinson's Disease and Progressive Supranuclear Palsy be Distinguished Using Surgical Planning Image Analysis Software?	Sunday, October 4	13:00 - 14:00	Session 3	Station 5	5	MSA, PSP, CBS: Neuroimaging	Keita Matsuura
213	Diagnostic Utility of Routine 1.5T Brainstem Planimetry in Parkinsonism: Evidence from a Vietnamese Cohort	Sunday, October 4	13:00 - 14:00	Session 3	Station 5	6	MSA, PSP, CBS: Neuroimaging	Duy Duan Nguyen
350	Gender Differences in Cervical Dystonia Patients	Sunday, October 4	13:00 - 14:00	Session 3	Station 6	1	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Larisa Shperling
351	"Coder's Cramp": A Case Series of Task-Specific Typing Dystonia	Sunday, October 4	13:00 - 14:00	Session 3	Station 6	2	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Ralf Voshtina
352	Clinical Outcome Assessments for Psychiatric Manifestations in Dystonia: Systematic Review, Critique, and Recommendations	Sunday, October 4	13:00 - 14:00	Session 3	Station 6	3	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Aparna Wagle Shukla
353	Effects of Psychiatric Symptoms on Dystonia Risk: a Prospective Cohort and Mendelian Randomization Study	Sunday, October 4	13:00 - 14:00	Session 3	Station 6	4	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Xiaoting Zheng
354	Expanding the Spectrum of Non Motor Symptoms in Dystonia: Focus on Autonomic Signs and Pain	Sunday, October 4	13:00 - 14:00	Session 3	Station 6	5	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Pietro Antenucci
355	Early Manifestations of Cerebellar Ataxia with Neuropathy and Vestibular Areflexia Syndrome (CANVAS) Include Dystonic Laryngeal Phenomena	Sunday, October 4	13:00 - 14:00	Session 3	Station 6	6	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Owen Chan
427	GLP-1 Receptor Agonists in Movement Disorders: From Parkinson's Disease to the Broader Spectrum – Mechanisms, Evidence, and Future Directions	Sunday, October 4	13:00 - 14:00	Session 3	Station 7	1	Education in Movement Disorders	Ahmed Dahshan
428	Acrostic for the differential diagnosis of atypical Parkinsonian	Sunday, October 4	13:00 - 14:00	Session 3	Station 7	2	Education in Movement Disorders	Lucely Ortega-Bolaños
429	"Step-by-Step" in Movement Disorders: A Disease-Specific, Multi-Method Integrated Teaching Approach	Sunday, October 4	13:00 - 14:00	Session 3	Station 7	3	Education in Movement Disorders	Bo Wang

430	Podcast Based Learning in Movement Disorders: Educational Impact of the Podcast Movement Disorders Around the World	Sunday, October 4	13:00 - 14:00	Session 3	Station 7	4	Education in Movement Disorders	Nishitha bujala
431	Spectrum of Orthopaedic Problems in Patients with Movement Disorders: A Systematic Review of Clinical Manifestations	Sunday, October 4	13:00 - 14:00	Session 3	Station 7	5	Education in Movement Disorders	UTTAM SAINI
432	Evaluating YouTube as a source of health information on Parkinson's disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 7	6	Education in Movement Disorders	Kurt Joshua Baladjay
478	The Lentiform Fork Sign: Acute Parkinsonism in a Dialysis Patient with Metformin Misuse	Sunday, October 4	13:00 - 14:00	Session 3	Station 8	1	Drug-Induced Movement Disorders	Julia Haddad Labello
479	Rare Neurotoxicity of Cotrimoxazole A Movement Disorder Presentation In Elderly Patient	Sunday, October 4	13:00 - 14:00	Session 3	Station 8	2	Drug-Induced Movement Disorders	Mohamed KEITA Sr
498	Plasma Proteomics Reveals Altered Redox Balance And Protein Homeostasis In Spinocerebellar Ataxia Type 12	Sunday, October 4	13:00 - 14:00	Session 3	Station 8	3	Ataxia	Sabbir Ansari
499	Investigating Mitochondrial Integrity in Spinocerebellar Ataxia Type 12 via Patient-Derived iPSC Models	Sunday, October 4	13:00 - 14:00	Session 3	Station 8	4	Ataxia	Jyoti Rungta
500	Assessment of GCA repeat expansion in the GLS gene among Indian patients with Spinocerebellar Ataxia	Sunday, October 4	13:00 - 14:00	Session 3	Station 8	5	Ataxia	Varun Suroliya
501	Transcriptomic Profiling of Frataxin-Deficient Drosophila melanogaster to Identify Molecular Drivers and Pathway Disruptions in Friedreich's Ataxia	Sunday, October 4	13:00 - 14:00	Session 3	Station 8	6	Ataxia	Vishnu Swarup
620	Synchronous Unilateral Pendular Nystagmus and Palatal Myoclonus After Pontine Hemorrhage: A Case Report	Sunday, October 4	13:00 - 14:00	Session 3	Station 9	1	Tremor	John Paul Cruz
621	Prevalence of Pain and Effect of Scalp Block on Pain Scores During MRI Guided Focused Ultrasound Lesioning Procedure	Sunday, October 4	13:00 - 14:00	Session 3	Station 9	2	Tremor	Esther Davies
622	Stereotactic Neurosurgery for Holmes Tremor: a Retrospective Cohort Study	Sunday, October 4	13:00 - 14:00	Session 3	Station 9	3	Tremor	Dennis de Bont
623	Prospective International Registry Evaluating Real-World Clinical and Quality-of-Life Outcomes of Directional Deep Brain Stimulation in Essential Tremor	Sunday, October 4	13:00 - 14:00	Session 3	Station 9	4	Tremor	Günther Deuschl
624	Quantitative Changes in Speech After Unilateral and Bilateral VIM MRgFUS Thalamotomy in Essential Tremor	Sunday, October 4	13:00 - 14:00	Session 3	Station 9	5	Tremor	Graciela Diaz-Taveras
625	Olfactory Groove Meningioma Presenting with Recurrent Falls and Dystonic Head Tremor An Unusual Clinical Presentation	Sunday, October 4	13:00 - 14:00	Session 3	Station 9	6	Tremor	ISRA ELTAZI

602	Iron Dysregulation and Metabolic Inflammation in Restless Legs Syndrome: Clinical Correlates from a Tertiary hospital Cohort	Sunday, October 4	13:00 - 14:00	Session 3	Station 10	1	Restless Legs Syndrome and Sleep Disorders	Shraddha Shrivastava
680	Cerebellar-cortical-spinal information flow for motor kinematic control	Sunday, October 4	13:00 - 14:00	Session 3	Station 10	2	Non-Dystonia (Other)	Yi-Mei Wang
681	Behavioral Phenotype of a Mouse Model of Mixed Movement Disorders Linked to ADCY5	Sunday, October 4	13:00 - 14:00	Session 3	Station 10	3	Non-Dystonia (Other)	Jiyeon Baik
682	Transient Hemichorea Hemiballismus From A Punctate Centrum Semiovale Corona Radiata Infarct	Sunday, October 4	13:00 - 14:00	Session 3	Station 10	4	Non-Dystonia (Other)	Vida Alvarez
683	Real-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Tardive Dyskinesia	Sunday, October 4	13:00 - 14:00	Session 3	Station 10	5	Non-Dystonia (Other)	Qijing Bo
684	AI-driven quantification of oro-facial dyskinesia and kinetic entropy as a predictive biomarker for recovery in paediatric anti-NMDAR encephalitis	Sunday, October 4	13:00 - 14:00	Session 3	Station 10	6	Non-Dystonia (Other)	AMLAN DATTA
1956	An interesting case of progressive vision loss and unusual gait	Sunday, October 4	13:00 - 14:00	Session 3	Station 11	1	Rare Neurometabolic Movement Disorders	Ashok Kumar
1957	Establishing the Diagnosis of Wilson's Disease using the Leipzig Criteria in Patients with Neurological Manifestation: A Single-Center Observation	Sunday, October 4	13:00 - 14:00	Session 3	Station 11	2	Rare Neurometabolic Movement Disorders	Suneel Kumar
1958	THD (Tyrosine Hydroxylase Deficiency) in a 39-Year-Old Woman with Early-Onset Dystonia	Sunday, October 4	13:00 - 14:00	Session 3	Station 11	3	Rare Neurometabolic Movement Disorders	Tran Le
1959	Perrault Syndrome in a Young Adult with Co-existing HSD17B4 Variant and CNBP Mutation	Sunday, October 4	13:00 - 14:00	Session 3	Station 11	4	Rare Neurometabolic Movement Disorders	Isaiah Molina
1960	A Novel SPG11 Splice-Site Mutation in Hereditary Spastic Paraplegia: Clinical, Radiologic, and Genetic Insights from the First Philippine Case	Sunday, October 4	13:00 - 14:00	Session 3	Station 11	5	Rare Neurometabolic Movement Disorders	Ena Elizabeth Naoe
1961	Portosystemic Shunt Related Parkinsonism in Acquired Hepatocerebral Degeneration With Persistent Pallidal T1 Hyperintensity	Sunday, October 4	13:00 - 14:00	Session 3	Station 11	6	Rare Neurometabolic Movement Disorders	Anastasiya Pronina
705	Restoring the Axis: Efficacy of Fecal Microbiota Transplantation (FMT) on Motor and Non-Motor Symptoms in Parkinson's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (2023-2025)	Sunday, October 4	13:00 - 14:00	Session 3	Station 12	1	Parkinson's Disease: Clinical Trials	Zina Hussein
706	First-in-Human Single-Ascending-Dose Trial of ALN-SNCA, an Intrathecally Administered siRNA for Reducing α -synuclein, in Patients with Early-Stage Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 12	2	Parkinson's Disease: Clinical Trials	Mohsin Ahmed
707	Cannabis-based Oil for Pain and Other Non-motor Symptoms in Parkinson's Disease: a Randomized Controlled Trial	Sunday, October 4	13:00 - 14:00	Session 3	Station 12	3	Parkinson's Disease: Clinical Trials	Anna Alves

708	Opicapone for Management of Sleep Disturbances in Parkinson's Disease: Post-hoc Analysis of the OASIS trial in Patients With and Without Probable RBD	Sunday, October 4	13:00 - 14:00	Session 3	Station 12	4	Parkinson's Disease: Clinical Trials	Ghazal Banisadr
709	IncobotulinumtoxinA to Treat Sialorrhea in Parkinson's Disease: a Real-life Study: 7-year Interim Results	Sunday, October 4	13:00 - 14:00	Session 3	Station 12	5	Parkinson's Disease: Clinical Trials	Bruno Bergmans
710	Rehabilitation Following Initiation of Device Assisted Treatment in Parkinson's Disease - a Randomized Controlled Trial	Sunday, October 4	13:00 - 14:00	Session 3	Station 12	6	Parkinson's Disease: Clinical Trials	Ann Björkdahl
777	Acupuncture Combined with Anti-Parkinson Medication Improves Objective Balance Parameters in Patients with Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 13	1	Parkinson's Disease: Clinical Trials	Xin Liu
778	Can people with Parkinson's disease improve gait adaptation skills via upregulation of the posterior parietal cortex?	Sunday, October 4	13:00 - 14:00	Session 3	Station 13	2	Parkinson's Disease: Clinical Trials	Tomoha Ogawa
779	Development and initial feasibility of a Randomised Pilot Trial of Enhanced Tai Chi for Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 13	3	Parkinson's Disease: Clinical Trials	Mubasher Qamar
780	Baseline Characteristics of Participants Enrolled in a Randomised Pilot Study of Enhanced Tai Chi for Parkinson's disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 13	4	Parkinson's Disease: Clinical Trials	Mubasher Qamar
781	Trans-Spinal Theta Burst Stimulation for Axial Symptoms in Parkinson's Disease with Deep Brain Stimulation A Randomized Clinical Trial	Sunday, October 4	13:00 - 14:00	Session 3	Station 13	5	Parkinson's Disease: Clinical Trials	Augusto Rocha
782	A 6-month Pilot Study of Disease-Modifying Potential of Long-term Transcutaneous Auricular Vagus Nerve Stimulation in Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 13	6	Parkinson's Disease: Clinical Trials	Jiaxin Shi
849	Postural Disorders in Parkinson's Disease: The Role of Botulinum Toxin - A French prospective cohort	Sunday, October 4	13:00 - 14:00	Session 3	Station 14	1	Parkinson's Disease: Pharmacology and Medical Management	Mahe Poupon
850	Continuous subcutaneous levodopa infusion in advanced Parkinson's disease: a descriptive real-world cohort study	Sunday, October 4	13:00 - 14:00	Session 3	Station 14	2	Parkinson's Disease: Pharmacology and Medical Management	Patricia Prendes Fernandez
851	Reduction in Dopaminergic Medication in Patients with Parkinson's Disease Treated with Continuous Apomorphine Infusion versus Subthalamic Nucleus Deep Brain Stimulation: A Cohort Study	Sunday, October 4	13:00 - 14:00	Session 3	Station 14	3	Parkinson's Disease: Pharmacology and Medical Management	Lizeth Reyes
852	Dual device-aided therapy in advanced Parkinson's Disease: combining bilateral deep brain stimulation and continuous subcutaneous foslevodopa/foscarbidopa Infusion	Sunday, October 4	13:00 - 14:00	Session 3	Station 14	4	Parkinson's Disease: Pharmacology and Medical Management	Carmen Ribacoba Díaz
853	Sublingual apomorphine for parkinsonian tremor: Post-hoc analysis of pivotal trial data	Sunday, October 4	13:00 - 14:00	Session 3	Station 14	5	Parkinson's Disease: Pharmacology and Medical Management	Haidar S Dafsari

854	Device-aided Therapies are Associated with Significantly Greater Improvement in Quality of Life in Younger Patients Earlier Within Advanced Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 14	6	Parkinson's Disease: Pharmacology and Medical Management	Diego Santos García
1827	Perplexing Presentation of Myasthenia Gravis in an Elderly Patient with Essential Tremor and Parkinson's Disease Complex Case Report	Sunday, October 4	13:00 - 14:00	Session 3	Station 15	1	Parkinson's Disease (Other)	Isra Eltazi
1828	Telerehabilitation Versus Conventional Therapy in Parkinson's Disease: Evidence from Randomized Controlled Trials	Sunday, October 4	13:00 - 14:00	Session 3	Station 15	2	Parkinson's Disease (Other)	Ana Fornari Caprara
1829	Physical Proximity Influences Mobility in Advanced Parkinson's Disease Patient – Caregiver Dyads.	Sunday, October 4	13:00 - 14:00	Session 3	Station 15	3	Parkinson's Disease (Other)	Nesrine Harroum
1830	Knowledge, perception and access to care for Parkinson's disease in two selected local government areas in Lagos State, Southwestern Nigeria	Sunday, October 4	13:00 - 14:00	Session 3	Station 15	4	Parkinson's Disease (Other)	Olumide Ibode
1831	Gait Activation Improves Hypomimia in Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 15	5	Parkinson's Disease (Other)	Saikal Ismailova
1832	Long-term safety of deep brain stimulation (DBS): Real-world evidence	Sunday, October 4	13:00 - 14:00	Session 3	Station 15	6	Parkinson's Disease (Other)	Jennifer Joseph
1899	SNCA-Targeting RNAi Therapeutics Prevent Disease Progression in a Synucleinopathy Mouse Model and Enable Robust, Prolonged, and Safe Alpha-Synuclein Protein Reduction in the Cynomolgus Monkey Central Nervous System	Sunday, October 4	13:00 - 14:00	Session 3	Station 16	1	Parkinson's Disease (Other)	Pascaline Aimé-Wilson
1900	Novel Modeling Approach for Comparing Treatment-Naive and Post-Treatment Neuronal Synucleinopathy Progression Using Multi-Modal PPMI Data	Sunday, October 4	13:00 - 14:00	Session 3	Station 16	2	Parkinson's Disease (Other)	Ethan Brown
1901	The Impact of the Edmond J. Safra Nurse Educator Program at the Parkinson's Foundation on Nursing Education and Parkinson's Care	Sunday, October 4	13:00 - 14:00	Session 3	Station 16	3	Parkinson's Disease (Other)	Annie Li Wong
1902	TRACK-PD: Understanding Treatment Routines and Adherence in Care – Knowledge and Perspective of People Living with Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 16	4	Parkinson's Disease (Other)	Daniela Marinho
1903	A novel pro-drug overcomes short-half life and absorption challenges and increase brain penetration of dopamine as a potential therapy for Parkinson's disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 16	5	Parkinson's Disease (Other)	Charbel Moussa
1904	Development of a Clinical Decision Support System to Support Parkinson's Disease Management.	Sunday, October 4	13:00 - 14:00	Session 3	Station 16	6	Parkinson's Disease (Other)	Precious Onyeachu
949	Longitudinal Changes and Clinical utility of the Neurological Pupillary Index in De Novo Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 17	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Jun Seok Lee

950	Amyloid status as a moderator of the association between physical activity and progression of Parkinson's disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 17	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Myung Jun Lee
951	A Pilot Study of Phosphorylated Alpha-Synuclein Detection and Quantitation from Routine Colonic Biopsies in Patients with Parkinson's disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 17	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Todd Levine
952	Subthalamic Beta Sub-band Composition and Gamma Dynamics Across Medication and Stimulation States in Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 17	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	QINGHUA Li
953	Identification of Discriminative Odorants for Parkinson's Disease and Their Clinical Correlates: A Population-Specific Short-Form Approach	Sunday, October 4	13:00 - 14:00	Session 3	Station 17	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Yu Hsuan Lin
954	Upper Limb Coordination During Walking is Associated with Clinical Severity in Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 17	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Priya Sharma
1091	NIH Multicenter Consortium for Gut-Brain Communication in Parkinson's Disease: The Master Protocol and Timeline	Sunday, October 4	13:00 - 14:00	Session 3	Station 18	1	Parkinson's Disease: Disease mechanisms	Tao Xie
1092	Preserved Neuroplasticity in Patients Affected by Parkinson's Disease Responders to External Auditory Cueing Strategies	Sunday, October 4	13:00 - 14:00	Session 3	Station 18	2	Parkinson's Disease: Disease mechanisms	Alessandro Botta
1093	VPS13C Heterozygous Variant as a Potential Modifier in AARS1-Related Charcot-Marie-Tooth Disease with Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 18	3	Parkinson's Disease: Disease mechanisms	Chenxin Ying
1094	Multi-Target Neurobiological Mechanisms of Acupuncture in Levodopa-Induced Dyskinesia: From Dopamine Stabilization to Network Plasticity Modulation	Sunday, October 4	13:00 - 14:00	Session 3	Station 18	4	Parkinson's Disease: Disease mechanisms	Xin Liu
1095	Microglial Inflammatory Signaling Mediates Neuroimmune Dysregulation And Behavioral Dysfunction in A Parkinson's Disease Model	Sunday, October 4	13:00 - 14:00	Session 3	Station 18	5	Parkinson's Disease: Disease mechanisms	Mai M. Anwar
1096	Extracellular Neuromelanin Promotes Microglial Reactivity in Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 18	6	Parkinson's Disease: Disease mechanisms	Semra Smajic
1163	Are we overlooking wearing off? Evaluating the role of the WOQ-9 questionnaire in routine Parkinson's care	Sunday, October 4	13:00 - 14:00	Session 3	Station 19	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Grace Heery
1164	5-year Longitudinal Changes in Non-motor Symptoms and Their Association With Motor Progression in Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 19	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Sebastian Heinzel

1165	Driving Science to Address Early-Onset Parkinson's Disease in U.S. Military Service Members	Sunday, October 4	13:00 - 14:00	Session 3	Station 19	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	William Hoffman
1166	The Effects of War on Patients with Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 19	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Fatemeh Hojjatipour
1167	Early Use of a Conversational Assistant to Interpret Wearable and Patient-Reported Data in Parkinson Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 19	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Brianna Hood
1168	Prevalence of drooling in Parkinson's disease: a multi-center observational study	Sunday, October 4	13:00 - 14:00	Session 3	Station 19	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Mutsumi Iijima
1235	Integrated Digital Monitoring and Outpatient Clinical Care Management Program for Parkinson Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 20	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Shannon Shaffer
1236	Characteristics And Progression Of Non-Motor Symptoms In Parkinsons Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 20	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ali Shalash
1237	Predictors of Severity of Psychosis in Parkinson's Disease: A 3-year longitudinal cohort study	Sunday, October 4	13:00 - 14:00	Session 3	Station 20	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Rhea Sharma
1238	Nation-wide Slovak epidemiological study of movement disorders in Roma population: protocol and initial results	Sunday, October 4	13:00 - 14:00	Session 3	Station 20	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Matej Skorvanek

1239	Nationwide Prevalence of Parkinson's Disease in Slovakia: A Municipality-Level Analysis	Sunday, October 4	13:00 - 14:00	Session 3	Station 20	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Matej Skorvanek
1240	Clinical Gait Traits and Cerebellar-PPN Functional Connectivity Abnormalities in Early and Moderate-to-Advanced PD with Gait Disturbance via Perceptual Technology and MRI	Sunday, October 4	13:00 - 14:00	Session 3	Station 20	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jinghang Su
1307	The Effect of Scapular Dysfunction on Dynamic Balance in Patients with Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 21	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Gamze Polat
1308	Speech and Voice Changes after Intensive Therapy in Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 21	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Lyle Tadmor
1309	Assessment of Postural abnormalities in Early-stage Parkinson's Disease Using a Posture Analyzing and Virtual Reconstruction Device	Sunday, October 4	13:00 - 14:00	Session 3	Station 21	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Hui Woo Yang
1310	Early-Onset Parkinson's Disease Is Associated With Higher Utilization of Deep Brain Stimulation: Real-World Data From a Tertiary Movement Disorders Clinic	Sunday, October 4	13:00 - 14:00	Session 3	Station 21	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Marlene Arbeu Reyes
1311	Validation of Augmented Reality-Based Speech Biomarkers for Objective Detection and Monitoring of Parkinson's Disease and Atypical Parkinsonian Syndromes	Sunday, October 4	13:00 - 14:00	Session 3	Station 21	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Martyna Baran
1312	Metabolic Syndrome and Disease Severity in Parkinson's Disease: Association With Clinical Phenotype and Cerebral Small Vessel Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 21	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Nur Dilek Başpınar
1379	Rare Heterozygous SLC25A12 Variants Are Associated with Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 22	1	Parkinson's Disease: Genetics	Konstantin Senkevich
1380	Multi-omic, Multi-polygenic Score Prediction of Parkinson's disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 22	2	Parkinson's Disease: Genetics	Lachlan Gilchrist

1381	Exploring the Genetic Architecture of Parkinson's Disease in North Africa	Sunday, October 4	13:00 - 14:00	Session 3	Station 22	3	Parkinson's Disease: Genetics	Sana Hrir
1382	Limited Evidence for TPBG Variants in Parkinson's Disease Risk Across Global Ancestries	Sunday, October 4	13:00 - 14:00	Session 3	Station 22	4	Parkinson's Disease: Genetics	Rhiannon Laban
1383	Evaluation of Polygenic Risk Scores Derived from an Updated Cross-European GWAS for Parkinson's Disease Prediction in European and Ashkenazi Jewish Populations	Sunday, October 4	13:00 - 14:00	Session 3	Station 22	5	Parkinson's Disease: Genetics	Benjamín Pizarro-Galleguillos
1384	Gut Microbiome Metagenomics in Parkinson's Disease Stratified by the Asian-Prevalent LRRK2 Variants p.G2385R and p.R1628P	Sunday, October 4	13:00 - 14:00	Session 3	Station 22	6	Parkinson's Disease: Genetics	Tzi Shin Toh
1451	Analyzing the classification of 767 GBA1 variants to guide GBA1 PD risk prediction	Sunday, October 4	13:00 - 14:00	Session 3	Station 23	1	Parkinson's Disease: Genetics	Tobias Böttcher
1452	The Global Parkinsons Genetics Program: Expanding the Diversity of Neurological Disorder Data - 2026 Update	Sunday, October 4	13:00 - 14:00	Session 3	Station 23	2	Parkinson's Disease: Genetics	GP2 Global_Parkinsons Genetics_Program
1453	Genome-wide Discovery of GBA1 Modifiers in Parkinsons Disease Carriers across Populations from the Global Parkinsons Genetics Program	Sunday, October 4	13:00 - 14:00	Session 3	Station 23	3	Parkinson's Disease: Genetics	Mary Makarious
1454	fMRI Activity during Working Memory Manipulation is Associated with Caudate Integrity in Early Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 23	4	Parkinson's disease: Neuroimaging	Kathrin Giehl
1455	Mitochondrial Density Shapes Regional Vulnerability to Atrophy in Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 23	5	Parkinson's disease: Neuroimaging	Ajay Konuri
1456	Grey Matter Volume and White Matter Microstructural Alterations in PRKN-PD	Sunday, October 4	13:00 - 14:00	Session 3	Station 23	6	Parkinson's disease: Neuroimaging	Haotian Wang
1523	Neural Mechanisms of Motor Dysfunction in Idiopathic REM Sleep Behavior Disorder: An rs-fMRI Study Based on the Purdue Pegboard Test	Sunday, October 4	13:00 - 14:00	Session 3	Station 24	1	Parkinson's disease: Neuroimaging	Qihao Zhang
1524	Automated Differentiation for Early Parkinsonism Using Clinical Structural MRI: A Multicenter Study	Sunday, October 4	13:00 - 14:00	Session 3	Station 24	2	Parkinson's disease: Neuroimaging	Liche Zhou
1525	Neuromelanin-Sensitive MRI as a Marker of Clinical Severity and Disease Burden in Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 24	3	Parkinson's disease: Neuroimaging	Rayo Akande
1526	Peak Mean Skeletal Diffusivity as a Marker of Cognitive Impairment in Parkinson's disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 24	4	Parkinson's disease: Neuroimaging	William Aye
1527	Investigating Substantia Nigra Microstructural Integrity as a Potential Predictive Biomarker for Fall Burden in Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 24	5	Parkinson's disease: Neuroimaging	Isaac Bedoy
1528	Microstructural Correlates of Parkinson's Bradykinesia	Sunday, October 4	13:00 - 14:00	Session 3	Station 24	6	Parkinson's disease: Neuroimaging	Rita Benabderrazik

1595	Association of one-year group-based telerehabilitation with quality of life in Parkinson's disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 25	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Hiroki Saegusa
1596	Prevalence and characteristics of sleep disorders in Parkinson's disease: an Argentine cohort.	Sunday, October 4	13:00 - 14:00	Session 3	Station 25	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Florencia San Juan
1597	Global Parkinson's Symptoms Index Correlates with Changes in Quality of Life and Autonomy for Activities of Daily Living	Sunday, October 4	13:00 - 14:00	Session 3	Station 25	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Diego Santos García
1598	Smell as a Diagnostic Signature: Systematic Review and Meta-Analysis of UPSIT Accuracy in Distinguishing Parkinson's Disease from Essential Tremor	Sunday, October 4	13:00 - 14:00	Session 3	Station 25	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Mya Schiess
1599	Engage in Healthy Eating: A Community-Guided Approach to Culturally Sensitive Nutrition Support for People with Parkinson's Disease (PD)	Sunday, October 4	13:00 - 14:00	Session 3	Station 25	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Hiral Shah
1600	Reduced Slow Wave Sleep is Associated with Mobility Impairment in People with Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 25	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Madison Sleyster
1648	Effects of Chronic IEM-1460 Treatment on Perineuronal Net-Parvalbumin Interneuron Association in L-DOPA-Induced Dyskinesia	Sunday, October 4	13:00 - 14:00	Session 3	Station 26	1	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Nedime Bilbay
1649	Multi-Omics Analysis Reveals Brain and Biofluid Molecular Changes Induced by Chronic Sleep Fragmentation in a Prodromal Parkinson's Disease Mouse Model	Sunday, October 4	13:00 - 14:00	Session 3	Station 26	2	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Hiroko Bonkobara
1650	Targeting the NLRP3 Inflammasome by PD180970 Based on Differential Susceptibility to MPTP	Sunday, October 4	13:00 - 14:00	Session 3	Station 26	3	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Shatabdi Choudhury
1651	Patient-Derived α -Synuclein Kinetic Subtypes Drive Distinct Pathological Propagation Patterns and Brain Network Alterations in Parkinson's Disease Mouse Models	Sunday, October 4	13:00 - 14:00	Session 3	Station 26	4	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Wei Dai
1652	DDX17 Drives Astrocytic Mitochondrial Metabolic Reprogramming and Contributes to Parkinson's Disease Progression	Sunday, October 4	13:00 - 14:00	Session 3	Station 26	5	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Xiaolin Dong

1653	Macrophage Subtypes in Brainstem Catecholamine Regions in Healthy Ageing and Across Parkinson's Disease.	Sunday, October 4	13:00 - 14:00	Session 3	Station 26	6	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Anastasia Filimontseva
1739	Non-Motor Outcomes of Unilateral Magnetic Resonance-Guided Focused Ultrasound Surgery in Parkinson's Disease: A Meta-Analysis	Sunday, October 4	13:00 - 14:00	Session 3	Station 27	1	Parkinson's Disease: Surgical Therapy	Wajeeh Kashif
1740	Local Field Potential-Guided versus Clinically-Guided Electrode Identification For Continuous GPi-DBS in Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 27	2	Parkinson's Disease: Surgical Therapy	Asha Kishore
1741	Directional versus Omnidirectional GPi-DBS in Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 27	3	Parkinson's Disease: Surgical Therapy	Asha Kishore
1742	Complications Following Deep Brain Stimulation in Parkinson's Disease: Single-centre Experience (2009-2025)	Sunday, October 4	13:00 - 14:00	Session 3	Station 27	4	Parkinson's Disease: Surgical Therapy	Alice Kusnirova
1743	Adaptive Subthalamic Nucleus Deep Brain Stimulation (aDBS) for Refractory Dyskinesia in Parkinson's Disease: A Case Report of Two Patients	Sunday, October 4	13:00 - 14:00	Session 3	Station 27	5	Parkinson's Disease: Surgical Therapy	CLAIRE KAYEE LAU
1744	Automated Image-guided Programming for DBS Matches Expert Clinician Programming	Sunday, October 4	13:00 - 14:00	Session 3	Station 27	6	Parkinson's Disease: Surgical Therapy	Han Lee
1022	Sex-Specific Associations of APOE ε4 with Cognitive Decline in Parkinson's Disease: Insights from the Critical Path Institute GEM-PD Initiative	Sunday, October 4	13:00 - 14:00	Session 3	Station 28	1	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Ragasudha Botta
1023	Escitalopram for Depression and Motor Symptoms in Parkinson's Disease: A Systematic Review and Meta-analysis	Sunday, October 4	13:00 - 14:00	Session 3	Station 28	2	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Vishnu Byroju
1024	Dopaminergic Modulation Of Contextual Emotional Appraisal And Shame In Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 28	3	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Sabina Catalano Chiuve
1025	Impulse-compulsive disorders and non-motor symptom profiles in Parkinson's disease: findings from a Tunisian cohort	Sunday, October 4	13:00 - 14:00	Session 3	Station 28	4	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Elyes Cherif
1026	Association of Coffee Consumption and Smoking with Cognitive Function in Patients with Early Parkinson's Disease	Sunday, October 4	13:00 - 14:00	Session 3	Station 28	5	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Seong-Min Choi
1027	Neuropsychiatric Symptom Changes in Parkinson's Disease Patients Treated with Different Doses of Donepezil: A 24-Week Follow-up Study	Sunday, October 4	13:00 - 14:00	Session 3	Station 28	6	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	EUNJOO CHUNG

57	Beyond Parkinson's Disease, Impulse Control Dysregulation: The Psychosocial Correlates of Problematic Internet Use	Monday, October 5	9:30 - 10:30	Session 4	Station 1	1	Technology	Titilayo Adeoye
58	Real-World Clinical Outcomes of Adaptive versus Continuous Deep Brain Stimulation in Early-Stage Parkinson's Disease: A Systematic Review and Meta-Analysis of 2024-2025 Trials	Monday, October 5	9:30 - 10:30	Session 4	Station 1	2	Technology	FOUAD AL-ZAIDI
59	Sensor-based quantification of dyskinesia in Parkinson's Disease: supervised vs unsupervised settings	Monday, October 5	9:30 - 10:30	Session 4	Station 1	3	Technology	Luigi Borzi
60	From Clinic to Home: Transitioning a Reduced Wearable Sensor Monitoring Array in Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 1	4	Technology	Niall Conway
61	Reducing Cost and Operative Time in DBS with a Consolidated Workflow: A Time-Driven Activity-Based Costing Analysis	Monday, October 5	9:30 - 10:30	Session 4	Station 1	5	Technology	Aditya Goyal
62	Exploratory Quantitative Gait Analysis for Differentiating Parkinson's Disease from Atypical Parkinsonian Syndromes	Monday, October 5	9:30 - 10:30	Session 4	Station 1	6	Technology	Thansapol Jariyasethawong
127	An Elevation in the Serum Biomarker pTau-181 May Identify Progressive Supranuclear Palsy Pathology	Monday, October 5	9:30 - 10:30	Session 4	Station 2	1	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Kelly Ramirez
128	SCA27B and MSA-C with Positive Alpha-Synuclein Skin Biopsy - Case Report	Monday, October 5	9:30 - 10:30	Session 4	Station 2	2	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Ralf Voshtina
129	Fluid Biomarker Signatures in Atypical Parkinsonian Syndromes: Insights into Neurodegeneration and Clinical Heterogeneity	Monday, October 5	9:30 - 10:30	Session 4	Station 2	3	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Ravi yadav
130	Biomarker-Informed Survival Modelling Using Plasma Neurofilament Light and Clinical Predictors in a Prospective Multiple System Atrophy Cohort	Monday, October 5	9:30 - 10:30	Session 4	Station 2	4	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Viorica Chelban
131	Fluid Biomarkers and the 4R-Tauopathies	Monday, October 5	9:30 - 10:30	Session 4	Station 2	5	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Carmelo Fogliano
132	Automated Speech Analysis for the Differentiation of Multiple System Atrophy from Parkinson's Disease in an English-Speaking Cohort	Monday, October 5	9:30 - 10:30	Session 4	Station 2	6	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Éabha Ní Chonchúir
274	When Motion Ceases Twice: Delayed Post-Hypoxic Leukoencephalopathy with Parkinsonism, a Case Report.	Monday, October 5	9:30 - 10:30	Session 4	Station 3	1	Parkinsonism (Other)	Laia Peraferrer-Montesinos
275	Standardized Autonomic and Movement Assessment in Mexican Patients with Undetermined and Degenerative Progressive Parkinsonism: A Single-Center Experience	Monday, October 5	9:30 - 10:30	Session 4	Station 3	2	Parkinsonism (Other)	Daniel Rebolledo-Garcia

276	Juvenile-Onset Parkinsonism With Bilateral Striatal Necrosis Associated With a Pathogenic MT-ND3 Mitochondrial Variant	Monday, October 5	9:30 - 10:30	Session 4	Station 3	3	Parkinsonism (Other)	Tomás Rodríguez
277	Movement Disorders as an Atypical Presentation of Alzheimer's Disease: A Cerebrospinal Fluid Biomarker-Based Study	Monday, October 5	9:30 - 10:30	Session 4	Station 3	4	Parkinsonism (Other)	Flavia Rolim
278	Parkinsonism Induced By An Interpeduncular Cistern Epidermoid Cyst A Case Report And Literature Review	Monday, October 5	9:30 - 10:30	Session 4	Station 3	5	Parkinsonism (Other)	Mireille Salas-Crisostomo
279	Ventral Brainstem Syndrome Following Shunt Overdrainage and Underdrainage: A Rare and Reversible Complication of Ventriculoperitoneal Shunting	Monday, October 5	9:30 - 10:30	Session 4	Station 3	6	Parkinsonism (Other)	Rodrigo Sanjinez
410	Long-term utilization of onabotulinumtoxinA for the treatment of cervical dystonia	Monday, October 5	9:30 - 10:30	Session 4	Station 4	1	Dystonia (Other)	Richard Barbano
411	Genetically proven Juvenile-Onset Niemann–Pick Disease Type C Presenting with Dystonia- Ataxia syndrome.	Monday, October 5	9:30 - 10:30	Session 4	Station 4	2	Dystonia (Other)	Abhay Ranjan
412	Long-term dose-effect patterns with incobotulinumtoxinA, onabotulinumtoxinA, and abobotulinumtoxinA in cervical dystonia: multicenter real-world analysis	Monday, October 5	9:30 - 10:30	Session 4	Station 4	3	Dystonia (Other)	Benjamin Waeschle
413	Spiral Dx: Real-world Evaluation of an Artificial Intelligence algorithm for Tremor detection and classification from hand-drawn spirals [RE-AI-LTI]- Protocol of a randomised control trial	Monday, October 5	9:30 - 10:30	Session 4	Station 4	4	Dystonia (Other)	Shreya Xxxx
414	Acquired Hemidystonia as a Manifestation of Primary Antiphospholipid Syndrome in a Young Adult	Monday, October 5	9:30 - 10:30	Session 4	Station 4	5	Dystonia (Other)	Nasser Abdelall
214	Differential Cholinergic White Matter Microstructural Alterations in Multiple System Atrophy and Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 5	1	MSA, PSP, CBS: Neuroimaging	Siming Rong
215	Systemic Inflammation and Cerebral Small Vessel Disease in Progressive Supranuclear Palsy	Monday, October 5	9:30 - 10:30	Session 4	Station 5	2	MSA, PSP, CBS: Neuroimaging	Min Tian
216	18F-FD4 PET Reveals α -Synuclein Deposition and Clinical Correlations in Multiple System Atrophy	Monday, October 5	9:30 - 10:30	Session 4	Station 5	3	MSA, PSP, CBS: Neuroimaging	Jian Wang
217	Multi-Sequence MRI-Based Machine Learning Model for Differentiating Parkinson Disease (PD) from Multiple System Atrophy (MSA)	Monday, October 5	9:30 - 10:30	Session 4	Station 5	4	MSA, PSP, CBS: Neuroimaging	Yida Wang
218	Correlation Analysis of Cortical Activation and Aspiration Risk During Swallowing in Patients with Multiple System Atrophy	Monday, October 5	9:30 - 10:30	Session 4	Station 5	5	MSA, PSP, CBS: Neuroimaging	Yifei Xia
219	Beyond Diagnosis: Putaminal ADC Hyperintensity and Infratentorial Signs Reflect Motor Severity in MSA	Monday, October 5	9:30 - 10:30	Session 4	Station 5	6	MSA, PSP, CBS: Neuroimaging	Yang Zhao

356	Feasibility of home-based assessments using wearable sensors and videos in children with GNAO1-related movement disorders: A pilot study	Monday, October 5	9:30 - 10:30	Session 4	Station 6	1	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Larissa Heideman
357	Exploring the variability in spoken language comprehension, speech and functional communication in children with GNAO1-associated disorder: a case series	Monday, October 5	9:30 - 10:30	Session 4	Station 6	2	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Larissa Heideman
358	Tremor in Oromandibular Dystonia	Monday, October 5	9:30 - 10:30	Session 4	Station 6	3	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Akansha Jain
359	Nutritional Assessment in X-linked Dystonia Parkinsonism: Preliminary Results from a Pilot Study	Monday, October 5	9:30 - 10:30	Session 4	Station 6	4	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Pamela Danielle Lanuza
360	Sleep Quality Among Patients with X-linked Dystonia Parkinsonism	Monday, October 5	9:30 - 10:30	Session 4	Station 6	5	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Marie Elizabeth Magsombol
361	Phasic Hemidystonia Secondary to Cavernoma: A Case of Sustained Response to Botulinum Toxin	Monday, October 5	9:30 - 10:30	Session 4	Station 6	6	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Nusaibah Tahsin
433	Gauging The Applicability Of The Global Assessment Scale for Wilson's Disease in Brazil	Monday, October 5	9:30 - 10:30	Session 4	Station 7	1	Education in Movement Disorders	Anne Oliveira Santos
434	From Down Under to a Global Audience: Engaging 25,000 People Across 160 Countries to Improve Parkinson's Knowledge and Awareness	Monday, October 5	9:30 - 10:30	Session 4	Station 7	2	Education in Movement Disorders	Jane Alty
435	The Challenges for Diagnosis of Movement Disorders in Ukraine	Monday, October 5	9:30 - 10:30	Session 4	Station 7	3	Education in Movement Disorders	Yevgen Trufanov
436	Awareness about Movement Disorders among Ukrainian Neurologists	Monday, October 5	9:30 - 10:30	Session 4	Station 7	4	Education in Movement Disorders	Yevgen Trufanov
437	Partnering with Community Through Co-designed Education for People Living with Parkinson's	Monday, October 5	9:30 - 10:30	Session 4	Station 7	5	Education in Movement Disorders	Rachel Mouer
438	A National Interprofessional Model for Parkinson's Disease Education: Over 20 Years of Collaborative Learning Across the Veterans Health Administration	Monday, October 5	9:30 - 10:30	Session 4	Station 7	6	Education in Movement Disorders	Elizabeth Wong
502	Triplet repeat length determines the liquid-liquid phase separation propensity of single-stranded DNA	Monday, October 5	9:30 - 10:30	Session 4	Station 8	1	Ataxia	Hui-Jun Yang
503	Targeted Repeat-Expansion Screening Highlights Unmet Genomic Needs in Genetically Naïve Ataxia: A Ukrainian Single-Centre Pilot Study	Monday, October 5	9:30 - 10:30	Session 4	Station 8	2	Ataxia	Solomiia Bandrivska
504	PPP2R2B Splice Variant Dysregulation Promotes Mitochondrial Association and Neuronal Apoptosis in iPSC-Derived Neurons from Spinocerebellar Ataxia Type 12 Patient	Monday, October 5	9:30 - 10:30	Session 4	Station 8	3	Ataxia	Swarnava Sengupta

505	Pueraria tuberosa improves the locomotion defects in Drosophila model of FRDA	Monday, October 5	9:30 - 10:30	Session 4	Station 8	4	Ataxia	Ravi Kant Yadav
506	Blood glucose homeostasis is conserved in patients with mild to moderate Spinocerebellar Ataxia type 2	Monday, October 5	9:30 - 10:30	Session 4	Station 8	5	Ataxia	Raul Aguilera-Rodríguez
507	Genetic Landscape of Hereditary Ataxia in a Highly Consanguineous Population: A Nationwide Multicenter Study	Monday, October 5	9:30 - 10:30	Session 4	Station 8	6	Ataxia	Faisal Alqahtani
626	Dual-site rTMS for Essential Tremor	Monday, October 5	9:30 - 10:30	Session 4	Station 9	1	Tremor	ANANDA CAROLINA FALCONE
627	Factors Associated with Efficacy and Safety of Unilateral Thalamic MRgFUS in Essential Tremor: A Single-Center Cohort Study	Monday, October 5	9:30 - 10:30	Session 4	Station 9	2	Tremor	Mireia Gea
628	Passive smartphone-based tremor quantification in essential tremor	Monday, October 5	9:30 - 10:30	Session 4	Station 9	3	Tremor	Jakob Gerstl
629	Outcomes of a new electromyography-guided botulinum toxin injection clinic for medication-refractory upper limb tremor	Monday, October 5	9:30 - 10:30	Session 4	Station 9	4	Tremor	Rebecca Hoe
630	Life Changing Diagnoses; Distinguishing Holmes Tremor from Functional Tremor	Monday, October 5	9:30 - 10:30	Session 4	Station 9	5	Tremor	Audrey Hunt
631	Focused Ultrasound for Essential Tremor: Results After One Year	Monday, October 5	9:30 - 10:30	Session 4	Station 9	6	Tremor	Victor Hvingelby
685	A Case of NUS1 Spectrum Disorder with Adult-Onset Psychosis	Monday, October 5	9:30 - 10:30	Session 4	Station 10	1	Non-Dystonia (Other)	Daniela Fishbein
686	Tongue Fasciculations in Amyotrophic Lateral Sclerosis Compared Between Electromyography and Transoral Ultrasonography	Monday, October 5	9:30 - 10:30	Session 4	Station 10	2	Non-Dystonia (Other)	Naoki Iijima
687	Painful legs moving toes spectrum disorders – a systematic review	Monday, October 5	9:30 - 10:30	Session 4	Station 10	3	Non-Dystonia (Other)	Jaakko Kungshamn
688	Morvan Syndrome Associated with Malignant Thymoma and Double-Positive CASPR2/LGI1 Antibodies	Monday, October 5	9:30 - 10:30	Session 4	Station 10	4	Non-Dystonia (Other)	Kang-Po Lee
689	Rhythmic circular stump movements after traumatic amputation: jumping stump syndrome with rapid remission after botulinum toxin type A	Monday, October 5	9:30 - 10:30	Session 4	Station 10	5	Non-Dystonia (Other)	Pornpiroon Muangsiri
690	Non-Motor Symptoms in Hemifacial Spasm: A Cross-Sectional Study from a Brazilian Public Tertiary Center	Monday, October 5	9:30 - 10:30	Session 4	Station 10	6	Non-Dystonia (Other)	Miriam Soares
1962	The Landscape of Movement Disorders in Mitochondrial Aminoacyl t-RNA Synthetase Disorders: A Case Series	Monday, October 5	9:30 - 10:30	Session 4	Station 11	1	Rare Neurometabolic Movement Disorders	Sayoni Roy Chowdhury

1963	Diagnostic Odyssey in L-2-Hydroxyglutaric Aciduria: A Case with Progressive Cerebellar and Extrapyrimal Movement Disorder	Monday, October 5	9:30 - 10:30	Session 4	Station 11	2	Rare Neurometabolic Movement Disorders	Arushi Saini
1964	Positive Results from a Global Phase 3 Trial (IB1001-303) Evaluating Levacetylleucine in Ataxia-Telangiectasia	Monday, October 5	9:30 - 10:30	Session 4	Station 11	3	Rare Neurometabolic Movement Disorders	Bethany Zanrucha
1965	A Phase 3, Multinational, Randomized, Placebo-Controlled, Double-Blind, Crossover Trial (IB1001-304) Evaluating Levacetylleucine in CACNA1A Disorders	Monday, October 5	9:30 - 10:30	Session 4	Station 11	4	Rare Neurometabolic Movement Disorders	Bethany Zanrucha
1966	The utility of HbA1c in Predicting Neuroimaging Findings in Diabetic Striatopathy - A Systematic Review	Monday, October 5	9:30 - 10:30	Session 4	Station 11	5	Rare Neurometabolic Movement Disorders	Leroy D'Souza
1967	Exchangeable copper as a monitoring tool in Wilson disease: lessons from a 24-month prospective cohort	Monday, October 5	9:30 - 10:30	Session 4	Station 11	6	Rare Neurometabolic Movement Disorders	Clément Desjardins
711	Clinical Evaluation of TT-P34: Exploring Safety and CSF Exposure in Parkinson's Disease Patients	Monday, October 5	9:30 - 10:30	Session 4	Station 12	1	Parkinson's Disease: Clinical Trials	Andreas Borta
712	An Ongoing Phase 1/2, Multi-center, Open Label Study of NouvNeu001 for the Treatment of Advanced Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 12	2	Parkinson's Disease: Clinical Trials	Meng Cai
713	Relationship between automatic analysis of gait disorder and eye movement capture by AI and cognitive function in Parkinson's disease	Monday, October 5	9:30 - 10:30	Session 4	Station 12	3	Parkinson's Disease: Clinical Trials	Jing Cheng
714	Phase 1 Study of BT-409, a potent, selective, brain-penetrant, and oral small molecule inhibitor of NLRP3 in Healthy Volunteers and Adults with Parkinson's disease	Monday, October 5	9:30 - 10:30	Session 4	Station 12	4	Parkinson's Disease: Clinical Trials	Tien Dam
715	Phase 1 Study of BT-267, a potent, selective, brain-penetrant, and oral small molecule inhibitor of LRRK2	Monday, October 5	9:30 - 10:30	Session 4	Station 12	5	Parkinson's Disease: Clinical Trials	Tien Dam
716	Barriers to Disease-Modifying Clinical Trials in Parkinson's Disease: A Survey of Clinicians and Researchers Involved in Clinical Trials	Monday, October 5	9:30 - 10:30	Session 4	Station 12	6	Parkinson's Disease: Clinical Trials	J. Antonelle de Marcaida
783	Temporally Patterned Deep Brain Stimulation Improves Gait Metrics and Freezing of Gait in Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 13	1	Parkinson's Disease: Clinical Trials	Seongmi Song
784	Clustered Difference of Gut Microbiome in Helicobacter pylori-negative and positive Group Effect on Clinical Motor Symptoms in PD (Helicobacter pylori-Stool Microbiome or HP-SM Trial)	Monday, October 5	9:30 - 10:30	Session 4	Station 13	2	Parkinson's Disease: Clinical Trials	Wannisa Wongpipath pong
785	Effect of a Live-streaming Tele-exercise in Parkinson's Disease: a Multicenter, Controlled Trial in South Korea	Monday, October 5	9:30 - 10:30	Session 4	Station 13	3	Parkinson's Disease: Clinical Trials	Soyeon Yoon

786	High-Intensity Multimodal Training Through Group-Based Weighted Dance for Parkinson's Disease: A Feasibility Study	Monday, October 5	9:30 - 10:30	Session 4	Station 13	4	Parkinson's Disease: Clinical Trials	Yawen Chen
787	Frequency-Specific Effects of SMA-rTMS on Gait Initiation in Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 13	5	Parkinson's Disease: Clinical Trials	Yawen Chen
788	ALPHA-FIT: Slowing cognitive decline in alpha-synucleinopathies by enhancing physical activity	Monday, October 5	9:30 - 10:30	Session 4	Station 13	6	Parkinson's Disease: Clinical Trials	Emily Fitzgibbon
855	Nine-Year Outcome of MRI Guided Focused Ultrasound Thalamotomy in Essential Tremor Patients	Monday, October 5	9:30 - 10:30	Session 4	Station 14	1	Parkinson's Disease: Pharmacology and Medical Management	Ilana Schlesinger
856	Progression and disability in Parkinson's disease: what else can be done?	Monday, October 5	9:30 - 10:30	Session 4	Station 14	2	Parkinson's Disease: Pharmacology and Medical Management	Stanislav Shtaimets
857	Demographic And Clinical Characteristics Of Advanced Parkinson's Disease Patients Receiving Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) In The ELEGANCE Study: An Updated Interim Analysis	Monday, October 5	9:30 - 10:30	Session 4	Station 14	3	Parkinson's Disease: Pharmacology and Medical Management	Sukhdeep Singh
858	Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) Provides Sustained Improvement In Quality Of Life In Advanced Parkinson's For Up To Two Years	Monday, October 5	9:30 - 10:30	Session 4	Station 14	4	Parkinson's Disease: Pharmacology and Medical Management	Sukhdeep Singh
859	Intestinal Levodopa Infusion Therapies in Advanced Parkinson's Disease: A 6-Month Prospective Cohort Study	Monday, October 5	9:30 - 10:30	Session 4	Station 14	5	Parkinson's Disease: Pharmacology and Medical Management	Igor Straka
860	Assessing Concordance Between Clinical judgment And 5-2-1 Criteria In Advanced Parkinsons Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 14	6	Parkinson's Disease: Pharmacology and Medical Management	Adithya Subramaniam
1833	Effects of Repetitive Deep TMS on Motor Function and Cerebral Perfusion in Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 15	1	Parkinson's Disease (Other)	Byungseok Kim
1834	Development of a Nationwide Parkinson's Disease Cohort in Korea: Toward an Ethnicity-Specific Precision Medicine Platform	Monday, October 5	9:30 - 10:30	Session 4	Station 15	2	Parkinson's Disease (Other)	Joong-Seok Kim
1835	Treadmill-Based Backward Walking Training as a Rehabilitation Strategy in People with Parkinson's Disease: A Feasibility Study	Monday, October 5	9:30 - 10:30	Session 4	Station 15	3	Parkinson's Disease (Other)	Namathota Kumar
1836	RESET-DBS: An exploratory study on the safety and efficacy of personalized burst-patterned deep brain stimulation (DBS) in Parkinson's Disease (PD)	Monday, October 5	9:30 - 10:30	Session 4	Station 15	4	Parkinson's Disease (Other)	Florian Lange
1837	Healthcare Professionals' Perceptions of using eHealth in the Rehabilitation of Progressive Disease: A Qualitative Study	Monday, October 5	9:30 - 10:30	Session 4	Station 15	5	Parkinson's Disease (Other)	Breiffni Leavy
1838	Evaluating Generative AI Systems for Parkinsonism-related counseling: Bridging Accessibility Gaps through AI-Assisted Counseling	Monday, October 5	9:30 - 10:30	Session 4	Station 15	6	Parkinson's Disease (Other)	Chan Young Lee

1905	Caregiver Burden in Advanced versus Non-Advanced Parkinson's Disease: Strain and Health-Related Quality of Life	Monday, October 5	9:30 - 10:30	Session 4	Station 16	1	Parkinson's Disease (Other)	Suvi Ruohonen
1906	Clinician Guided Multimodal Kinematic AI System for Objective Assessment in Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 16	2	Parkinson's Disease (Other)	vivek tyagi
1907	Effects of Immersive Gamification Technology on the Physical Function of People with Parkinson's Disease: A Scoping Review	Monday, October 5	9:30 - 10:30	Session 4	Station 16	3	Parkinson's Disease (Other)	Khervin Ian Guitones
1908	Development of a Parkinson's Disease Dyadic Multidisciplinary Illness Management Program: Protocol for PATH Parkinson	Monday, October 5	9:30 - 10:30	Session 4	Station 16	4	Parkinson's Disease (Other)	Kiyeon Kim
1909	Outpatient Multidisciplinary Care for Parkinson's Disease: A Narrative Review of Care Models and Outcomes	Monday, October 5	9:30 - 10:30	Session 4	Station 16	5	Parkinson's Disease (Other)	Terri-Jeanne Liu
1910	Effects of Rhythmic Auditory Stimulation Combined with LSVT BIG based exercises and Task-Specific Training on Balance and Gait in Parkinson Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 16	6	Parkinson's Disease (Other)	Smati Sambyal
955	Associations of Accelerated Biological Aging With Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 17	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Ling Luo
956	Longitudinal Decline of Alanine Aminotransferase Activity in Parkinson's Disease and Its Association with Disease Duration	Monday, October 5	9:30 - 10:30	Session 4	Station 17	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Gadi Maayan Eshed
957	Identifying Parkinson's Disease Subtypes Using Fluid Biomarkers Clustering in the PPMI Cohort	Monday, October 5	9:30 - 10:30	Session 4	Station 17	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Caitlin McIntyre
958	Neuroinflammation and neurodegeneration biomarkers in Parkinson's disease: integration of neuroimaging and fluid markers	Monday, October 5	9:30 - 10:30	Session 4	Station 17	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Laura Melgarejo Martinez
959	Metabolic Frailty Shows Limited Predictive Insights into Motor Severity and Progression in Parkinson's Disease Beyond Lifestyle and Cardiometabolic Determinants	Monday, October 5	9:30 - 10:30	Session 4	Station 17	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Manon Mijnsbergen
960	Reduced Whole-blood Energy Metabolism in Parkinson's Disease.	Monday, October 5	9:30 - 10:30	Session 4	Station 17	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Yasuaki Mizutani
1097	Sleep Slow-Wave Activity Topography and Dynamics in PD: Relationships with Resting-State fMRI data and Glymphatic Clearance	Monday, October 5	9:30 - 10:30	Session 4	Station 18	1	Parkinson's Disease: Disease mechanisms	Olga Alenikova
1098	Multisite high-definition gamma-tACS combined with rhythmic auditory cued gait enhances network efficiency in patients with Parkinson's disease	Monday, October 5	9:30 - 10:30	Session 4	Station 18	2	Parkinson's Disease: Disease mechanisms	Laura Avanzino

1099	Modulated functional connectivity in patients with Parkinson's disease by transcutaneous auricular acupoint Vagus Nerve Stimulation (taVNS)	Monday, October 5	9:30 - 10:30	Session 4	Station 18	3	Parkinson's Disease: Disease mechanisms	Xiaojuan Dan
1100	Subthalamic low-frequency activity reflects engagement during live sports viewing	Monday, October 5	9:30 - 10:30	Session 4	Station 18	4	Parkinson's Disease: Disease mechanisms	Salvatore Falciglia
1101	Microstructural and functional abnormalities of Amygdala subregions in Parkinson's Disease with impulse control disorder	Monday, October 5	9:30 - 10:30	Session 4	Station 18	5	Parkinson's Disease: Disease mechanisms	Caiting Gan
1102	Frontal Cortical Reactivity Underlying Cue Responsiveness in Parkinson's Disease: a TMS-EEG Study	Monday, October 5	9:30 - 10:30	Session 4	Station 18	6	Parkinson's Disease: Disease mechanisms	Inbal Maidan
1169	Prevalence and associated factors of sarcopenia among Thai patients with ambulatory Parkinson's disease	Monday, October 5	9:30 - 10:30	Session 4	Station 19	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jirapath Intum
1170	Interpretable AI for Quantitative Video-Based UPDRS Assessment of Hand Movements in Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 19	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Atefeh Irani
1171	Mobility Impairment And Balance Perception Discrepancy In Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 19	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Eugenia Isadora
1172	Characterizing Gastrointestinal Dysfunction and its Psychosocial Associations in Idiopathic Parkinson's Disease: Findings from a Single centre Prospective Cross-sectional Indian study	Monday, October 5	9:30 - 10:30	Session 4	Station 19	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	APOORVA JANARDHAN
1173	Digital Prediagnostic Mobility and Autonomic Trajectories in a Large Parkinson Disease Network	Monday, October 5	9:30 - 10:30	Session 4	Station 19	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Tiffany Jansen
1174	Type 1 Diabetes and Risk of Parkinson's Disease: A Nationwide Nested Case-Control Study	Monday, October 5	9:30 - 10:30	Session 4	Station 19	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Seong Ho Jeong

1241	Early longitudinal changes in non-motor symptoms and routine health checkup parameters around the emergence of prodromal features of Lewy body disease	Monday, October 5	9:30 - 10:30	Session 4	Station 20	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Daigo Tamakoshi
1242	Urate Levels and Risk of Parkinson's Disease : A Two-Sample Mendelian Randomization Study	Monday, October 5	9:30 - 10:30	Session 4	Station 20	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Peng Tang
1243	Remote Longitudinal Follow-up of Participants in the Parkinson's Progression Markers Initiative (PPMI)	Monday, October 5	9:30 - 10:30	Session 4	Station 20	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	CAROLINE TANNER
1244	Early-Onset Parkinson's Disease with Early Peak-Dose Dyskinesia: A Case Report	Monday, October 5	9:30 - 10:30	Session 4	Station 20	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Vasilii Tkachenko
1245	Sharing Personal Research Data in The PPMI Study: Participant Impressions After Disclosure	Monday, October 5	9:30 - 10:30	Session 4	Station 20	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Thomas Tropea
1246	Dynamics of Motor Fluctuations and Medication Challenges in Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 20	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ornanong Udomsirithamrong
1313	Clinical instability and fluctuations as an early marker of accelerated progression	Monday, October 5	9:30 - 10:30	Session 4	Station 21	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ashley Beltrán-Torres
1314	The Use of Digital Tools for Parkinson's Phenotype Stratification to Improve Patients' Selection for Advanced Therapies	Monday, October 5	9:30 - 10:30	Session 4	Station 21	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Taylor Diven

1315	Defining a Population-Based Cohort of Individuals with Probable REM Sleep Behavior Disorder	Monday, October 5	9:30 - 10:30	Session 4	Station 21	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Karine Eid
1316	Burden and Geographic Distribution of Parkinson's Disease in Mexico: A GBD 2021 Analysis (1990-2023)	Monday, October 5	9:30 - 10:30	Session 4	Station 21	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Katia Farias-Moreno
1317	Spiral Dx Real World Evaluation Of An Artificial Intelligence Algorithm For Tremor Detection From Hand Drawn Spirals Community Study Protocol Of A Population Screening Study For Parkinson Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 21	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Md Afzal Hussain
1318	Pesticide Exposure and Smoking in Parkinson's Disease in Kyrgyzstan: A Case-Control Study	Monday, October 5	9:30 - 10:30	Session 4	Station 21	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Aruuke Kubanychbekova
1385	A Novel Genome Editing Strategy for Permanent and Precise Downregulation of α -Synuclein in Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 22	1	Parkinson's Disease: Genetics	Brigette Manohar
1386	Association of the GCH1 p.Ser80Asn variant with Parkinson's disease in East Asian populations	Monday, October 5	9:30 - 10:30	Session 4	Station 22	2	Parkinson's Disease: Genetics	Yi Wen Tay
1387	Nutritional status, clinical Features and lifestyle of Twins Discordant for Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 22	3	Parkinson's Disease: Genetics	Michela Barichella
1388	Dropped Head Syndrome From Combined MT-TE and MT-ND1 Mitochondrial Variants	Monday, October 5	9:30 - 10:30	Session 4	Station 22	4	Parkinson's Disease: Genetics	Jenny Chen
1389	A Rare Case of PLA2G6 Gene Related Early-Onset Dystonia-Parkinsonism; What Not to Miss Clinically and Radiologically	Monday, October 5	9:30 - 10:30	Session 4	Station 22	5	Parkinson's Disease: Genetics	Yildiz Degirmenci
1390	A Cumulative Genetic Risk Score Predicts Progression in Parkinson's Disease: 5-year longitudinal study from The Early Parkinson's disease Longitudinal Singapore (PALS) cohort	Monday, October 5	9:30 - 10:30	Session 4	Station 22	6	Parkinson's Disease: Genetics	XIAO DENG
1457	Prasinezumab's Impact on Neuromelanin- and Iron-Sensitive MRI Biomarkers in Parkinson's disease: Findings From the PADOVA Phase IIb Study	Monday, October 5	9:30 - 10:30	Session 4	Station 23	1	Parkinson's disease: Neuroimaging	Thomas Kustermann
1458	Altered local synchronization and functional connectivity in Patients with Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 23	2	Parkinson's disease: Neuroimaging	Dong Hyuk Lee
1459	Subthalamic Nucleus Deep Brain Stimulation Impact on Language Network Connectivity	Monday, October 5	9:30 - 10:30	Session 4	Station 23	3	Parkinson's disease: Neuroimaging	Daniel Lench

1460	Identification of Parkinson's Disease Tremor-Related Functional Network Topographies Using 3.0 T rs-fMRI	Monday, October 5	9:30 - 10:30	Session 4	Station 23	4	Parkinson's disease: Neuroimaging	Zhengyu Lin
1461	Deep learning-derived progression network in isolated REM sleep behavior disorder	Monday, October 5	9:30 - 10:30	Session 4	Station 23	5	Parkinson's disease: Neuroimaging	Nha Nguyen
1462	Therapeutic effects of intermittent theta-burst stimulation on motor, non-motor symptoms and functional connectivity in de novo Parkinson's disease	Monday, October 5	9:30 - 10:30	Session 4	Station 23	6	Parkinson's disease: Neuroimaging	Raúl Rashid-López
1529	Substantia nigra neuromelanin magnetic resonance imaging in LRRK2 asymptomatic carriers	Monday, October 5	9:30 - 10:30	Session 4	Station 24	1	Parkinson's disease: Neuroimaging	Vanessa Carvalho
1530	Microstructure predicts cognition after Neurostimulation in Parkinson's disease	Monday, October 5	9:30 - 10:30	Session 4	Station 24	2	Parkinson's disease: Neuroimaging	Lijiao Chen
1531	Locus Coeruleus-Thalamic Circuit Degeneration in Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 24	3	Parkinson's disease: Neuroimaging	Xilie Cui
1532	Distinct Local and Global Functional Network Reorganization Underlying STN versus GPi DBS in Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 24	4	Parkinson's disease: Neuroimaging	Hao Ding
1533	Phenoconversion from Rapid Eye Movement Sleep Behavior Disorder to Parkinson's Disease: A multimodal Imaging Study	Monday, October 5	9:30 - 10:30	Session 4	Station 24	5	Parkinson's disease: Neuroimaging	Junya Ebina
1534	Exploratory study of brain 5-HT4 receptor availability in early-stage Parkinson's disease	Monday, October 5	9:30 - 10:30	Session 4	Station 24	6	Parkinson's disease: Neuroimaging	Sirine HASSEN
1601	Developing a toolkit for the assessment and management of lower urinary tract symptoms in parkinsonism	Monday, October 5	9:30 - 10:30	Session 4	Station 25	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Matthew Smith
1602	Differential Effects of Digital Self-Monitoring and Multimodal Training in Adults with Sleep Difficulties on Sleep and Psychological Outcomes: Relevance to Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 25	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Tal Tamir
1603	The Registry for Sleep and Circadian Health Quality in Parkinson's Disease (ReSCQu-PD)	Monday, October 5	9:30 - 10:30	Session 4	Station 25	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Jade Thomas
1604	Impact of Continuous Subcutaneous Foslevodopa/Foscarbidopa (FLC/FCD) on Non-Motor Symptom Burden in Advanced Parkinson's Disease: Domain-Level Analysis	Monday, October 5	9:30 - 10:30	Session 4	Station 25	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Kiran Waqar
1605	Efficacy of High-Frequency Repetitive Transcranial Magnetic Stimulation (HF-rTMS) for Pain Management in Parkinson's Disease: A Systematic Review and Meta-Analysis	Monday, October 5	9:30 - 10:30	Session 4	Station 25	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Yi-Hong Wu

1606	The Unholy Marriage Between Ogilvie Syndrome and Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 25	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Yuliia Zashchypas
1654	Intestinal Dysbiosis in Parkinson's Disease: Mechanisms, Clinical Implications, and Therapeutic Perspectives (2015–2025)	Monday, October 5	9:30 - 10:30	Session 4	Station 26	1	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Hala Harifi
1655	Prosaposin differentially modulates lipid metabolism of striatal and non-striatal dopamine D1 receptor-expressing neurons and regulates L-DOPA-induced dyskinesia	Monday, October 5	9:30 - 10:30	Session 4	Station 26	2	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Yachao He
1656	Differential Microglial Activation and p-Ser129 Alpha-Synuclein Induction by Neurotropic and Non-Neurotropic Influenza A Virus Strains	Monday, October 5	9:30 - 10:30	Session 4	Station 26	3	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Thi Len Ho
1657	Study on the Mechanism of SIRT3 Protecting Parkinson's disease by Regulating Mitophagy	Monday, October 5	9:30 - 10:30	Session 4	Station 26	4	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Ningwei Hu
1658	Astrocyte Derived Extracellular Vesicle miR 210 Expression in Exenatide Treated Patients with Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 26	5	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Anagha Keshavaprasad
1659	Extracellular vesicle-based characterization of synaptic dysfunction in early Parkinson's disease	Monday, October 5	9:30 - 10:30	Session 4	Station 26	6	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Lille Kurvits
1745	Chinese Expert Consensus and Recommendations on Sensing-guided Deep Brain Stimulation for Parkinson's Disease: A Modified Delphi Study	Monday, October 5	9:30 - 10:30	Session 4	Station 27	1	Parkinson's Disease: Surgical Therapy	Feng-Tao LIU
1746	Cognitive Safety and Stability in DBS for Parkinson's Disease: Evidence for the Inclusion of Patients with Baseline Mild Cognitive Impairment.	Monday, October 5	9:30 - 10:30	Session 4	Station 27	2	Parkinson's Disease: Surgical Therapy	John Martin
1747	Cognitive Effects of Low-Frequency STN-DBS in Parkinson's Disease: A Systematic Review and Meta-Analysis	Monday, October 5	9:30 - 10:30	Session 4	Station 27	3	Parkinson's Disease: Surgical Therapy	Bruna Meira
1748	Therapeutic Efficacy of a Next-Generation 16-Contact Directional Deep Brain Stimulation System in Parkinson's Disease	Monday, October 5	9:30 - 10:30	Session 4	Station 27	4	Parkinson's Disease: Surgical Therapy	Francesca Morgante
1749	Unnecessary Ablative Surgery in an Untreated Parkinson's Disease Patient: Marked Clinical Improvement After Initiation of Dopaminergic Therapy	Monday, October 5	9:30 - 10:30	Session 4	Station 27	5	Parkinson's Disease: Surgical Therapy	Bakhtiyor Mukhammed aminov

1750	Beyond the “best contact”: correlation of ai-guided dbs contact distribution and subthalamic nucleus beta physiology in parkinson’s disease patients	Monday, October 5	9:30 - 10:30	Session 4	Station 27	6	Parkinson's Disease: Surgical Therapy	Shunsuke Obika
1028	Severity of Psychotic Symptoms Is Independently Associated with Caregiver Burden in Parkinson’s Disease: A Cross-Sectional Analysis	Monday, October 5	9:30 - 10:30	Session 4	Station 28	1	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Jose Espinoza-Solares
1029	Clinical study on acupuncture improving anxiety in Parkinson's disease by regulating the HPA axis	Monday, October 5	9:30 - 10:30	Session 4	Station 28	2	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Jingqi Fan
1030	Acute administration of methylphenidate modulates functional connectivity during the processing of irrelevant stimuli in Parkinson’s disease patients	Monday, October 5	9:30 - 10:30	Session 4	Station 28	3	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Noa Fogelson
1031	Proposed cognitive indices for the Parkinson’s Progression Markers Initiative	Monday, October 5	9:30 - 10:30	Session 4	Station 28	4	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	David González
1032	Optimal and invariant hierarchical cognitive indices in the Parkinson’s Progression Markers Initiative	Monday, October 5	9:30 - 10:30	Session 4	Station 28	5	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	David González
1033	Sex Differences for Primary Psychiatric Diagnoses and Associated Care Outcomes in Dementia with Lewy Bodies using Epic Cosmos	Monday, October 5	9:30 - 10:30	Session 4	Station 28	6	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Samantha Holden
63	Single-Camera AI Pose Estimation Predicts Clinician-Rated Gait Severity in Cerebellar Ataxia	Monday, October 5	12:00 - 13:00	Session 5	Station 1	1	Technology	Henry Keane
64	Modulation of Finely Tuned Gamma in the Globus Pallidus Internus with Deep Brain Stimulation and Levodopa	Monday, October 5	12:00 - 13:00	Session 5	Station 1	2	Technology	Zachary LaJoie
65	Evaluating Bradykinesia in Parkinson’s Disease: Added Value of Monitoring Passive Arm Movement with a Wrist-Worn Wearable Sensor	Monday, October 5	12:00 - 13:00	Session 5	Station 1	3	Technology	Manon Mijnsbergen
66	Digital Gait Biomarkers Reveal a Distinct Motor Prodrome Up to Five Years Before Parkinson’s Disease Diagnosis in the General Population	Monday, October 5	12:00 - 13:00	Session 5	Station 1	4	Technology	Paulo Pelicioni
67	Automated Identification of Freezing of Gait in Parkinson’s Disease Using Q-Learning Analysis during Virtual Reality-Based Gait Task	Monday, October 5	12:00 - 13:00	Session 5	Station 1	5	Technology	Kazuhide Seo
68	Sensor-based assessment of axial symptoms in Parkinson’s disease	Monday, October 5	12:00 - 13:00	Session 5	Station 1	6	Technology	Robjona Toska

133	Olfactory Function as a Biomarker of Disease Progression in Progressive Supranuclear Palsy	Monday, October 5	12:00 - 13:00	Session 5	Station 2	1	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Qi Shen
134	Proteome-Wide Association and Mendelian Randomization Analyses Identify Plasma GUSB as a Potential Biomarker for Multiple System Atrophy	Monday, October 5	12:00 - 13:00	Session 5	Station 2	2	MSA, PSP, CBS: Biomarkers (non-neuroimaging)	Xinchen` Wang
230	Evidence of Systemic and Neuro-Inflammation in Progressive Supranuclear Palsy: Insight from an Imaging-Inflammation Study	Monday, October 5	12:00 - 13:00	Session 5	Station 2	3	MSA, PSP, CBS: Pathophysiology / Molecular Mechanisms of Disease	Saikat Dey
231	Oligodendrocyte-Specific α -Synuclein Pathology is Linked to Severe Motor Phenotype in a Novel Mouse Model of Multiple System Atrophy	Monday, October 5	12:00 - 13:00	Session 5	Station 2	4	MSA, PSP, CBS: Pathophysiology / Molecular Mechanisms of Disease	Johanna Bergstrom
232	Age Related Susceptibility of Hippocampal Synaptic Ultrastructure and Spatial Cognition to Chronic Toluene Exposure: A Comparative Study of Immediate and Long Term Effects	Monday, October 5	12:00 - 13:00	Session 5	Station 2	5	MSA, PSP, CBS: Pathophysiology / Molecular Mechanisms of Disease	Nino Pochkhidze
233	Ferritin as a factor in the examination of Parkinson's disease and Progressive Supranuclear Palsy	Monday, October 5	12:00 - 13:00	Session 5	Station 2	6	MSA, PSP, CBS: Pathophysiology / Molecular Mechanisms of Disease	Piotr Alster
280	SLC20A2 Splice-Site Mutation (c.935-1G>A) Presenting as levodopa-responsive parkinsonism: Expanding the Phenotypic Spectrum of Primary Familial Brain Calcification	Monday, October 5	12:00 - 13:00	Session 5	Station 3	1	Parkinsonism (Other)	Hou-Ping Sytwu
281	Tablet-Based Quantitative Evaluation of Finger Movement in Essential Tremor: A Visual-Motor Task Study	Monday, October 5	12:00 - 13:00	Session 5	Station 3	2	Parkinsonism (Other)	Peng Tang
282	Mechanical Ventilation Modifies the Natural History of DCTN1 p.G71A Perry Disease: A 20-Year Longitudinal Study	Monday, October 5	12:00 - 13:00	Session 5	Station 3	3	Parkinsonism (Other)	Yoshio Tsuboi
283	Intrafamilial Phenotypic Diversity Associated with Coexisting LRRK2 G2385R and a Novel GCH1 Variant: A Case Report	Monday, October 5	12:00 - 13:00	Session 5	Station 3	4	Parkinsonism (Other)	Cheng-En Wang
284	Neurological Wilson's disease: another form of tauopathies?	Monday, October 5	12:00 - 13:00	Session 5	Station 3	5	Parkinsonism (Other)	XiaoPing Wang
285	Baclofen-Induced Worsening of Parkinsonism in a Patient with CADASIL and Brainstem Stroke	Monday, October 5	12:00 - 13:00	Session 5	Station 3	6	Parkinsonism (Other)	Yi-Hong Wu
146	Polygenic Risk Score-Based Phenome-Wide Association Study and Mendelian Randomization of Multiple System Atrophy in the UK	Monday, October 5	12:00 - 13:00	Session 5	Station 4	1	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Xinhui Chen

147	Mirrored-Self Misidentification Expands the Neuropsychiatric Spectrum of Corticobasal Syndrome	Monday, October 5	12:00 - 13:00	Session 5	Station 4	2	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Taina Gonçalves
148	Ultra-early Diagnosis of MSA-C Using Biological Biomarkers: A Two-Case Study Employing α -Synuclein PET and Fluid α -Synuclein Seeds Amplification Assay (SAA)	Monday, October 5	12:00 - 13:00	Session 5	Station 4	3	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Kento Aoshima
149	Psychometric Assessment of a Modified Version of the Unified Multiple System Atrophy Rating Scale Part I	Monday, October 5	12:00 - 13:00	Session 5	Station 4	4	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Anna-Karin Berger
150	Validation of the Chinese Version of the Unified Multiple System Atrophy Rating Scale	Monday, October 5	12:00 - 13:00	Session 5	Station 4	5	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Anna-Karin Berger
151	A Systematic Review and Meta-Analysis on Cognitive and Behavioral Impairments in Primary Tauopathies	Monday, October 5	12:00 - 13:00	Session 5	Station 4	6	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Karla Burgos
220	Distinct FDG-PET metabolic patterns and connectivity alterations in dopamine transporter-deficient versus -preserved MSA-C	Monday, October 5	12:00 - 13:00	Session 5	Station 5	1	MSA, PSP, CBS: Neuroimaging	Yixin Zhao
221	Volumetric Imaging Diagnostic Tool to Differentiate Progressive Supranuclear Palsy from Parkinson's Disease using Artificial Intelligence	Monday, October 5	12:00 - 13:00	Session 5	Station 5	2	MSA, PSP, CBS: Neuroimaging	Minsub Cho
222	Novel Structural MRI-Based Progression Subtypes and Prognostic Study in Multiple System Atrophy	Monday, October 5	12:00 - 13:00	Session 5	Station 5	3	MSA, PSP, CBS: Neuroimaging	Yixin Kang
223	Evaluating Magnetic Resonance Parkinsonism Index (MRPI) and MRPI 2.0 as Radiographic Metrics to Differentiate Progressive Supranuclear Palsy (PSP) from Normal Pressure Hydrocephalus (NPH)	Monday, October 5	12:00 - 13:00	Session 5	Station 5	4	MSA, PSP, CBS: Neuroimaging	Racheed Mani
224	Clinical Significance of Imaging Markers for Cerebellar Ataxia and Parkinsonism in Multiple System Atrophy	Monday, October 5	12:00 - 13:00	Session 5	Station 5	5	MSA, PSP, CBS: Neuroimaging	Yoshikazu Nakano
225	Associations Between FDG-PET Regional Metabolism and Clinical Severity in Progressive Supranuclear Palsy	Monday, October 5	12:00 - 13:00	Session 5	Station 5	6	MSA, PSP, CBS: Neuroimaging	Marcos Oliveira

362	The Role of Electrophysiology in Preventing Diagnostic Misclassification of a Craniocervical Dystonia	Monday, October 5	12:00 - 13:00	Session 5	Station 6	1	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Anthony Talaugon*
363	3D Markerless Video-Based Assessment of Lower Extremity Dystonia in X-linked Dystonia Parkinsonism and DYT-TOR1A	Monday, October 5	12:00 - 13:00	Session 5	Station 6	2	Dystonia: Epidemiology, phenomenology, clinical assessment, rating scales	Giulia Corniani
316	Regional Brain Volumes and Network Alterations During Task-Based fMRI in Writer's Cramp: A Comparison with Healthy Controls	Monday, October 5	12:00 - 13:00	Session 5	Station 6	3	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Deblina Biswas
317	Muscarinic receptor antagonism beyond M4 is required for efficacy in a preclinical model of dystonia and Parkinson's disease	Monday, October 5	12:00 - 13:00	Session 5	Station 6	4	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Mark Rogge
318	Plasma Extracellular Vesicle Protein Biomarker Discovery for Monogenic and Sporadic Dystonia	Monday, October 5	12:00 - 13:00	Session 5	Station 6	5	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Zachary Caffall
319	Frequency-Dependent Disruption of Head-Trunk Control in Cervical Dystonia	Monday, October 5	12:00 - 13:00	Session 5	Station 6	6	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Thomas Hart
448	Late onset chorea secondary to antiphospholipid syndrome with radiological correlation on brain FDG-PET: a case report.	Monday, October 5	12:00 - 13:00	Session 5	Station 7	1	Autoimmune Movement Disorders	Alejandro Bonilla Tena
449	Neurophysiologic Testing Aids Diagnosis of Stiff-person Spectrum Disorders	Monday, October 5	12:00 - 13:00	Session 5	Station 7	2	Autoimmune Movement Disorders	James Bower
450	Anti-IgLON5 testing in movement disorder clinical practice: Observational cohort study and systematic review	Monday, October 5	12:00 - 13:00	Session 5	Station 7	3	Autoimmune Movement Disorders	Manfredi Carta
451	Complex Tics in a Child with Communicating Hydrocephalus: A Diagnostic Challenge	Monday, October 5	12:00 - 13:00	Session 5	Station 7	4	Autoimmune Movement Disorders	SOMA MANI IMMANNI
452	Delayed Parkinsonism in Anti-NMDAR Encephalitis Following Immunotherapy – A Rare Clinical Manifestation	Monday, October 5	12:00 - 13:00	Session 5	Station 7	5	Autoimmune Movement Disorders	Claudia Irawan
453	Autoimmune Movement Disorders Presenting With Functional Phenotypes Diagnostic Pitfalls and Red Flags	Monday, October 5	12:00 - 13:00	Session 5	Station 7	6	Autoimmune Movement Disorders	Meghnath Kakde
508	Clinical and Genetic Characteristics of SACS-Related Ataxia: A Case Series of 13 Patients from a Consanguineous Arab Population	Monday, October 5	12:00 - 13:00	Session 5	Station 8	1	Ataxia	Hossam Alqahtani
509	SCA-2 Presenting as Isolated Progressive Spastic Paraparesis	Monday, October 5	12:00 - 13:00	Session 5	Station 8	2	Ataxia	Brandon Barton

510	Spinocerebellar Ataxia Type 27B: A Single-Center Experience	Monday, October 5	12:00 - 13:00	Session 5	Station 8	3	Ataxia	Sara Hooshmand
511	Clinical and genetic analysis of Kuwaiti and Saudi families exhibiting CLN5 adult-onset autosomal recessive spinocerebellar ataxia. A potential founder mutation	Monday, October 5	12:00 - 13:00	Session 5	Station 8	4	Ataxia	Walaa Kamel
512	Shunt-Responsive Normal Pressure Hydrocephalus in Spinocerebellar Ataxia Type 12: A Case Illustrating Treatable Neurodegenerative Overlap	Monday, October 5	12:00 - 13:00	Session 5	Station 8	5	Ataxia	Ranjot Kaur
513	Ataxia as the Primary Symptom of Leber Hereditary Optic Neuropathy: A Case Report of a Patient and Family Observation	Monday, October 5	12:00 - 13:00	Session 5	Station 8	6	Ataxia	Daria Korotkova
632	A retrospective Chart Review of Clinical and Demographic Patterns in Essential Tremor	Monday, October 5	12:00 - 13:00	Session 5	Station 9	1	Tremor	Somia Ibrahim
633	Does Fgatr Hypointensity Predict Outcomes After Deep Brain Stimulation For Action Tremors	Monday, October 5	12:00 - 13:00	Session 5	Station 9	2	Tremor	Nisa Kahn
634	Clinical Outcomes and Predictors of MR-Guided Focused Ultrasound Thalamotomy in Medically Refractory Essential Tremor: Initial Experience in Turkey	Monday, October 5	12:00 - 13:00	Session 5	Station 9	3	Tremor	Özgün Köksal
635	Clinical Features of Patients with an Essential Tremor-to-Parkinson's Disease Diagnostic Trajectory	Monday, October 5	12:00 - 13:00	Session 5	Station 9	4	Tremor	Aino Kuusela
636	Stimulation-Induced Laryngospasm During Awake Ventral Intermediate Nucleus Deep Brain Stimulation for Essential Tremor	Monday, October 5	12:00 - 13:00	Session 5	Station 9	5	Tremor	Marta Lamartine Monteiro
637	Setting research priorities for Essential Tremor: a James Lind Alliance Priority Setting Partnership	Monday, October 5	12:00 - 13:00	Session 5	Station 9	6	Tremor	Antonella Macerollo
691	An unusual case of cerebellar ischemic stroke initially presenting as isolated hemifacial spasm without other neurological symptoms and signs	Monday, October 5	12:00 - 13:00	Session 5	Station 10	1	Non-Dystonia (Other)	Won Tae Yoon
692	Movement Disorders Associated with Infections in Immunocompromised Non-HIV Patients: A Systematic Review	Monday, October 5	12:00 - 13:00	Session 5	Station 10	2	Non-Dystonia (Other)	Juan Sánchez-León
581	Efficacy and Safety of Ecopipam for Tourette Syndrome: A Meta analysis of Controlled Trials	Monday, October 5	12:00 - 13:00	Session 5	Station 10	3	Myoclonus/Tics/Stereotypies	Ashwin Achuthaprasad
582	Adult-Onset Stereotypies and Cortical Myoclonus: An Unusual Presentation of Cerebral Amyloid Angiopathy	Monday, October 5	12:00 - 13:00	Session 5	Station 10	4	Myoclonus/Tics/Stereotypies	Nghi Doan
583	STOP-TIC Updates: Strengthening Tourette Treatment Options using TMS to Improve CBIT: A randomized sham-controlled trial	Monday, October 5	12:00 - 13:00	Session 5	Station 10	5	Myoclonus/Tics/Stereotypies	Jessica Frey

584	Adult-Onset Alexander Disease with Paroxysmal Myoclonus-Like Episodes and a Novel GFAP Variant	Monday, October 5	12:00 - 13:00	Session 5	Station 10	6	Myoclonus/Tics/Stereotypies	Goeun Jung
1968	Natural History of Sialidosis Type I: A Prospective Longitudinal Follow-Up Study of Clinical and Electrophysiological Markers	Monday, October 5	12:00 - 13:00	Session 5	Station 11	1	Rare Neurometabolic Movement Disorders	Bo-Yun Gu
1969	Characterizing Movement Disorders in Niemann-Pick Disease Type C -A Registry-Based Analysis with Findings from the International Niemann-Pick-Disease Registry (INPDR)	Monday, October 5	12:00 - 13:00	Session 5	Station 11	2	Rare Neurometabolic Movement Disorders	Anika Menetrey
1970	Adolescent-onset Myoclonus Dystonia in MT-ND6 m.14487T>C-Associated Leigh Syndrome	Monday, October 5	12:00 - 13:00	Session 5	Station 11	3	Rare Neurometabolic Movement Disorders	Yulduz Nishonova
1971	Choreoathetosis revealing vitamin B12 deficiency : an unusual manifestation of subacute combined degeneration	Monday, October 5	12:00 - 13:00	Session 5	Station 11	4	Rare Neurometabolic Movement Disorders	Olfa Sakli
1916	Basal Ganglia Hypointensity Associated with Glucose Transporter Type 1 Deficiency Syndrome (GLUT1-DS)	Monday, October 5	12:00 - 13:00	Session 5	Station 11	5	Paroxysmal Movement Disorders	Cristina Jiménez Clopés
1917	Unmasking the Masquerader: Paroxysmal Kinesigenic Dyskinesia (PKD) Misdiagnosed as Epilepsy for Nearly a decade: Time to Act (Consecutive Cohort of 25 patients)	Monday, October 5	12:00 - 13:00	Session 5	Station 11	6	Paroxysmal Movement Disorders	RISHU BANSAL
717	The Allosteric Activator of Lysosomal Glucocerebrosidase VQ-101 Demonstrates Robust Evidence of Target and Pathway Engagement in People with Parkinson's Disease: Results from a 6-Month Open-Label Extension Study	Monday, October 5	12:00 - 13:00	Session 5	Station 12	1	Parkinson's Disease: Clinical Trials	Maurizio Facheris
718	Clinical Drug-Drug Interaction Profile Of BIA 28-6156: Results From Three Independent Phase I Studies	Monday, October 5	12:00 - 13:00	Session 5	Station 12	2	Parkinson's Disease: Clinical Trials	Tiago Fonseca
719	Noninvasive Electrosonic Brain Stimulation for Parkinson's Disease: Results from a Phase II Trial	Monday, October 5	12:00 - 13:00	Session 5	Station 12	3	Parkinson's Disease: Clinical Trials	Felipe Fregni
720	Evaluating a Decision Aid for Deep Brain Stimulation in Parkinson's Disease: Results of a Pre-Post Pilot Study	Monday, October 5	12:00 - 13:00	Session 5	Station 12	4	Parkinson's Disease: Clinical Trials	Michelle Fullard
721	Neuromodulation of Add-on Repetitive Transcranial Magnetic Stimulation improving Freezing of Gait in Parkinson's Disease: Integrated Cross-sectional and Interventional Evidence	Monday, October 5	12:00 - 13:00	Session 5	Station 12	5	Parkinson's Disease: Clinical Trials	Caiting Gan
722	Dual-Site Transcranial Magnetic Stimulation Ameliorates Freezing of Gait in Parkinson's Disease by Remodeling Cortical Excitatory-Inhibitory Balance and White Matter Microstructure: A Randomized Controlled Trial	Monday, October 5	12:00 - 13:00	Session 5	Station 12	6	Parkinson's Disease: Clinical Trials	Caiting Gan

789	Relationship Between Perceived and Actual Gluteal Muscle Activation in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 13	1	Parkinson's Disease: Clinical Trials	Kei Kakegawa
790	Effects of Targeted Memory Reactivation during Sleep on Motor Memory Consolidation in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 13	2	Parkinson's Disease: Clinical Trials	Letizia Micca
791	Decentralized Clinical Trial of a Phase 3 Light Therapy Device for Parkinson's Disease: Feasibility, Safety, and Efficacy	Monday, October 5	12:00 - 13:00	Session 5	Station 13	3	Parkinson's Disease: Clinical Trials	Sarrah Hussain
792	12-week Aerobic Interval Training Induces Hemisphere-Specific Neuroprotection in Parkinson's Disease: A Multimodal MRI, [18F]Fluorodopa PET/CT and BDNF Study	Monday, October 5	12:00 - 13:00	Session 5	Station 13	4	Parkinson's Disease: Clinical Trials	Karolina Lorek
793	Age-related characteristics of the clinical progression of Parkinson's disease	Monday, October 5	12:00 - 13:00	Session 5	Station 13	5	Parkinson's Disease: Clinical Trials	Bekzod Muminov
794	Identification of Phenotypes in a Prospective Parkinson's Disease Cohort Using Digital Wearable Monitoring	Monday, October 5	12:00 - 13:00	Session 5	Station 13	6	Parkinson's Disease: Clinical Trials	Angela Saenz
861	Opicapone Co-administration Allows Significant Flow Reduction in Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion: A Real-World Case Series	Monday, October 5	12:00 - 13:00	Session 5	Station 14	1	Parkinson's Disease: Pharmacology and Medical Management	Guillermo Tabar Comellas
862	Consistent Motor Benefit of Safinamide across Clinically Relevant Subgroups in Japanese Patients with Parkinson's Disease: A 24-Week Real-World Study	Monday, October 5	12:00 - 13:00	Session 5	Station 14	2	Parkinson's Disease: Pharmacology and Medical Management	Yoshio Tsuboi
863	Comparison Of Levodopa Dose Frequency And Parkinson's Kinetigraph Metrics For Screening Advanced Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 14	3	Parkinson's Disease: Pharmacology and Medical Management	Nazifa Ullah
864	Ambulatory PEMF stimulation using the DCcure device improves rest and postural tremor in patients with PD	Monday, October 5	12:00 - 13:00	Session 5	Station 14	4	Parkinson's Disease: Pharmacology and Medical Management	Ilia Urman
865	Safety of Opicapone After 10 Years of Post-Marketing experience Worldwide	Monday, October 5	12:00 - 13:00	Session 5	Station 14	5	Parkinson's Disease: Pharmacology and Medical Management	Margarida Vale
866	Real-World Experience with Continuous Subcutaneous Foslevodopa/Foscarbidopa (FLC/FCD) in Advanced Parkinson's Disease: A Single-Centre Cohort Study	Monday, October 5	12:00 - 13:00	Session 5	Station 14	6	Parkinson's Disease: Pharmacology and Medical Management	Kiran Waqar
1839	Current Landscape and Unmet Needs of Neuropalliative-Supportive Care for Parkinson's Disease in Korea: A Multicenter Survey of Patients, Caregiver, and Physicians	Monday, October 5	12:00 - 13:00	Session 5	Station 15	1	Parkinson's Disease (Other)	Chan Young Lee

1840	Wearable Sensors Identify Mobility Features Associated With Parkinson's Disease Years Before Clinical Diagnosis	Monday, October 5	12:00 - 13:00	Session 5	Station 15	2	Parkinson's Disease (Other)	Noa Levanon
1841	Hip fractures in Parkinson's Disease: A single-centre retrospective cohort study	Monday, October 5	12:00 - 13:00	Session 5	Station 15	3	Parkinson's Disease (Other)	Alistair Mackett Mackett
1842	Accelerating the Implementation of Network-based Care for Parkinson's Disease (ACTION-PD)	Monday, October 5	12:00 - 13:00	Session 5	Station 15	4	Parkinson's Disease (Other)	Marjan Meinders
1843	Patient Perspectives on Telemedicine and Remote Deep Brain Stimulation Programming in Parkinson's Disease: A Questionnaire Survey	Monday, October 5	12:00 - 13:00	Session 5	Station 15	5	Parkinson's Disease (Other)	Kei Okuba
1844	Restless leg syndrome in Parkinson's disease: A systematic review on the prevalence, demographic, clinical profile and diagnostic criteria	Monday, October 5	12:00 - 13:00	Session 5	Station 15	6	Parkinson's Disease (Other)	Alvin Payus
1911	Physiotherapists' Clinical Reasoning When Selecting Compensatory Strategies for Gait Impairments in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 16	1	Parkinson's Disease (Other)	Zhi Ying Wan
1912	The Role of Nurses in the Management of Parkinson's Disease : A Single-Center Study From Tunisia	Monday, October 5	12:00 - 13:00	Session 5	Station 16	2	Parkinson's Disease (Other)	Rania Zouari
1913	Patient-centered Parkinson's services and integrated primary care in southern Ghana: patient and caregiver perceptions from a cross-sectional survey	Monday, October 5	12:00 - 13:00	Session 5	Station 16	3	Parkinson's Disease (Other)	Mary Agoriwo
1914	About Data Missingness in Wearable Monitoring of Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 16	4	Parkinson's Disease (Other)	Emma Roveroni
1915	Predicting Parkinson's: Navigating Risk, Rights, and Regulation	Monday, October 5	12:00 - 13:00	Session 5	Station 16	5	Parkinson's Disease (Other)	Julia Braun
894	Fibrinogen and CFAH as putative biomarkers for Parkinson's disease	Monday, October 5	12:00 - 13:00	Session 5	Station 16	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Phalguni Alladi
961	Monitoring of Motor Complications with Wearable Technology in Parkinson's Patients Considered for Deep Brain Stimulation	Monday, October 5	12:00 - 13:00	Session 5	Station 17	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Juan Carlos Romero-Fábrega
962	High-dimensional proteomic profiling in plasma and CSF identifies molecular signatures in Parkinson's disease	Monday, October 5	12:00 - 13:00	Session 5	Station 17	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Silvia Rota
963	Vitamin D Status and Levodopa Responsiveness in Parkinson Disease and Association With Gastrointestinal Symptoms	Monday, October 5	12:00 - 13:00	Session 5	Station 17	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Gulnara Saidakhmetova
964	Automated differential diagnosis of Parkinson's disease and Parkinson-like disorders via motion capture analysis	Monday, October 5	12:00 - 13:00	Session 5	Station 17	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Wataru Sako
965	Enteric Alpha-Synuclein Pathology in Early-Onset Parkinson's Disease and an Incidental Case in Spinocerebellar Ataxia Type 6	Monday, October 5	12:00 - 13:00	Session 5	Station 17	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Chaewon Shin

966	Burst versus Conventional Deep Brain Stimulation Engage Distinct Cortico-Subthalamic Circuit Dynamics in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 17	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Tanmoy Sil
1103	Boosting cerebellum/M1 and PPC/M1 communication via tACS to improve cued gait in Parkinson's disease patients unresponsive to auditory cueing strategies.	Monday, October 5	12:00 - 13:00	Session 5	Station 18	1	Parkinson's Disease: Disease mechanisms	Elisa Pelosin
1104	Cortical Dynamics Underlying the Heterogeneous Dopamine Responsiveness of Rest Tremor in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 18	2	Parkinson's Disease: Disease mechanisms	Xitong Xu
1105	Latent Clinical States and Longitudinal Transitions in Prodromal Lewy Body Disease: A Data-Driven Analysis from the NaT-PROBE Study	Monday, October 5	12:00 - 13:00	Session 5	Station 18	3	Parkinson's Disease: Disease mechanisms	Kenshiro Fuse
1106	The Shape Of Sequence Effect In Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 18	4	Parkinson's Disease: Disease mechanisms	Anna Grandolfo
1107	Transcutaneous Auricular Vagus Nerve Stimulation as a Novel Therapy for Parkinson's Disease: Meta-Analytic Evidence of Motor and Gait Effects	Monday, October 5	12:00 - 13:00	Session 5	Station 18	5	Parkinson's Disease: Disease mechanisms	Khalid Sarhan
1108	Reduced Cholinergic Activity and Electrophysiological Slowing in Patients with GBA-PD	Monday, October 5	12:00 - 13:00	Session 5	Station 18	6	Parkinson's Disease: Disease mechanisms	Inbal Maidan
1175	Prosodic speech variability is associated with speech-related stigma in Parkinson's disease	Monday, October 5	12:00 - 13:00	Session 5	Station 19	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Hannah Jergas
1176	MLR-cerebellar network in body-first vs. brain-first PD: functional connectivity and clinical correlation with gait impairment	Monday, October 5	12:00 - 13:00	Session 5	Station 19	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Yao Jin
1177	The Alternating Finger Tapping Test Poorly Predicts Real-World Daily Activity Performance in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 19	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Pinvipa Kaewsom
1178	Differences in Lewy body dementia in people from ethnic minorities: a systematic review of epidemiology, diagnosis, clinical features and imaging	Monday, October 5	12:00 - 13:00	Session 5	Station 19	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Sabrina Kalam

1179	Variants in Cytochrome P450–encoding Genes Associated with Parkinson’s Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 19	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Naomi Kanzato
1180	Risk factors associated with Parkinson's disease in the DRC (Case of the Initiative Plus Hospital Center, Kinshasa)	Monday, October 5	12:00 - 13:00	Session 5	Station 19	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	PONTE KIATOKO
1247	Plasma Exchange and Reduced Parkinson’s Disease Diagnosis: A Nationwide Sequence Symmetry Analysis	Monday, October 5	12:00 - 13:00	Session 5	Station 20	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Shinichi Ueno
1248	Association Between Liver Function and Motor Symptoms in Parkinson’s Disease: A Cross-cohort Analysis of Chinese and PPMI patients	Monday, October 5	12:00 - 13:00	Session 5	Station 20	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Yuxi Wang
1249	Influence of disease stage upon real-world turning performance in people with Parkinson’s	Monday, October 5	12:00 - 13:00	Session 5	Station 20	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Claire Wilkinson
1250	Predicting Levodopa Responsiveness in Early Parkinson’s Disease Using Neural Perturbation Inference-Based Effective Connectivity	Monday, October 5	12:00 - 13:00	Session 5	Station 20	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Gao Xing
1251	Association of Benign Prostatic Hyperplasia With Incident Parkinson’s Disease in Men: A Prospective Cohort Study From the UK Biobank	Monday, October 5	12:00 - 13:00	Session 5	Station 20	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Yajiang Yu
1252	The Spectrum of Praxis Impairments in Patients with Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 20	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Zuleykha Zalyalova

1319	Antimicrobial Use and Risk of Parkinson's Disease: A Swedish National Case-control Study	Monday, October 5	12:00 - 13:00	Session 5	Station 21	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Sara Licaj
1320	The Green Parkinson's Belt: An Ecological Study of Agricultural Regions Linked to Increased Disease Burden in Mexico	Monday, October 5	12:00 - 13:00	Session 5	Station 21	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Francisco A. Luna-Rangel
1321	Acceptability and feasibility of digital mobility assessment for Parkinson's Disease: Perspectives from people with Parkinson's, carers and health and social care professionals in Ghana and Kenya	Monday, October 5	12:00 - 13:00	Session 5	Station 21	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Riona Mc Ardle
1322	Hip and Elbow Joint Angle Characteristics of Patients with Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 21	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Desy Rasmiyani
1323	Diagnostic Validity of PD Identification in a Neurologist-Certified National Drug Reimbursement Registry	Monday, October 5	12:00 - 13:00	Session 5	Station 21	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Valtteri Rätty
1324	Unveiling Oculomotor Phenotypes in Parkinson's Disease: A Multidimensional Clustering Analysis	Monday, October 5	12:00 - 13:00	Session 5	Station 21	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Arwa Rekik
1391	Evaluating the GBA1 Intronic rs3115534-G PD Risk Variant in the PD GENERation Cohort	Monday, October 5	12:00 - 13:00	Session 5	Station 22	1	Parkinson's Disease: Genetics	Allison Dilliot
1392	Novel associations of VPS13C with phenotype and conversion of idiopathic REM sleep behavior disorder	Monday, October 5	12:00 - 13:00	Session 5	Station 22	2	Parkinson's Disease: Genetics	Yanfei Ding
1393	CHCHD2 Exonic Deletion in a Chilean Parkinson's Disease Patient: First Latin American Report	Monday, October 5	12:00 - 13:00	Session 5	Station 22	3	Parkinson's Disease: Genetics	Elias Fernandez-Toledo
1394	Clinical and Genetic Profile of the ACTIVATE Population: A Phase 2 Trial of BIA 28-6156 in GBA-PD	Monday, October 5	12:00 - 13:00	Session 5	Station 22	4	Parkinson's Disease: Genetics	Joaquim Ferreira
1395	DJ-1 (PARK7) Heterozygous Mutation and Early-Onset Parkinson's Disease: A Chilean Case Report and Literature Review	Monday, October 5	12:00 - 13:00	Session 5	Station 22	5	Parkinson's Disease: Genetics	Katherin Guzmán

1396	Augmenting PD GENERation Genotyping with Continuous Digital Monitoring for Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 22	6	Parkinson's Disease: Genetics	Amanda Hare
1463	Midbrain Hypometabolism in Idiopathic REM Sleep Behavior Disorder Detected by [18F]-FDG PET as a Potential Biomarker of Nigral degeneration	Monday, October 5	12:00 - 13:00	Session 5	Station 23	1	Parkinson's disease: Neuroimaging	Anneke Below
1464	Investigating Hippocampal Subfield and Amygdala Volumes in Parkinson's Disease with Anxiety	Monday, October 5	12:00 - 13:00	Session 5	Station 23	2	Parkinson's disease: Neuroimaging	Yasmin Feuzi
1465	Glymphatic dysfunction in patients with Parkinson's disease is associated with regional amygdala and putamen degeneration	Monday, October 5	12:00 - 13:00	Session 5	Station 23	3	Parkinson's disease: Neuroimaging	Carla Garcia-Vicente
1466	Impaired Cortical Compensation in GBA1-Associated Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 23	4	Parkinson's disease: Neuroimaging	Kenan Steidel
1467	Cholinergic Dysconnectivity in Early Parkinson's Disease Aligns with the Basal Forebrain Functional Gradient	Monday, October 5	12:00 - 13:00	Session 5	Station 23	5	Parkinson's disease: Neuroimaging	Anna Ignatavicius
1468	Machine Learning-Based Brain Age Modeling Reveals Accelerated Structural Degeneration in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 23	6	Parkinson's disease: Neuroimaging	Zikun Liu
1535	Objective Characteristics and Brain Network Alterations in Early-Stage Parkinson's Disease with Gastric Motility Disorder	Monday, October 5	12:00 - 13:00	Session 5	Station 24	1	Parkinson's disease: Neuroimaging	Jia-Ying Jin
1536	Sequential neurodegenerative trajectories across the onset of mild parkinsonian signs in isolated REM sleep behavior disorder: a longitudinal multimodal imaging study	Monday, October 5	12:00 - 13:00	Session 5	Station 24	2	Parkinson's disease: Neuroimaging	Ryul Kim
1537	Basal Ganglia Lacunar Infarcts and Risk of Mortality and Dementia in Parkinsonism: A Population-Based Study	Monday, October 5	12:00 - 13:00	Session 5	Station 24	3	Parkinson's disease: Neuroimaging	Lorenzo Malfer
1538	Disease Endophenotyping through Graph and Adjacency Metrics (DEGAS): Network Biomarkers for Parkinson's Disease Prognosis	Monday, October 5	12:00 - 13:00	Session 5	Station 24	4	Parkinson's disease: Neuroimaging	A. Martinez-Nunez
1539	Examining the Impact of Fatigue on White Matter tracts in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 24	5	Parkinson's disease: Neuroimaging	Jae Young Park
1540	Electrocardiographic Indicators of Autonomic Dysfunction in Parkinson's Disease: A Scoping Review and Meta-analysis	Monday, October 5	12:00 - 13:00	Session 5	Station 24	6	Parkinson's disease: Neuroimaging	Ibrahim Serag
1607	Electroencephalographic and Functional Magnetic Resonance Imaging Analysis of Daytime Sleepiness in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 25	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Jinru Zhang

1608	Integrating Olink Proteomics and Multimodal MRI to Reveal a Multimodal Signature of Parkinson's Disease with REM Sleep Behavior Disorder	Monday, October 5	12:00 - 13:00	Session 5	Station 25	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Liuhui Zhu
1609	Two-year Outcomes of Rapid Eye Movement Behavior Disorder Following Globus Pallidus Interna Deep Brain Stimulation for Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 25	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Jose Rafael Zuzuarregui
1610	Two-year Outcomes of Restless Legs Syndrome Following Globus Pallidus Interna Deep Brain Stimulation for Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 25	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Jose Rafael Zuzuarregui
1611	Clinical and Psychophysiological Characteristics of Chronic Pain in Parkinson's Disease: Pain Phenotypes, Central Sensitization, and Quality of Life	Monday, October 5	12:00 - 13:00	Session 5	Station 25	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Bella Alieva
1612	Perceived Consequences and Catastrophising Help Explain Health-Related Quality of Life in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 25	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Viktoria Azoidou
1660	Impact of Alpha-Synuclein Burden and Cellular Stress on GBA-PD Macrophage	Monday, October 5	12:00 - 13:00	Session 5	Station 26	1	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Veronica Lentini
1661	Cerebellar α -Synucleinopathy Contributes to Gait and Balance Impairment in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 26	2	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Tianbai Li
1662	Mechanistic study of PARP9-mediated mitochondrial transfer in regulating dopaminergic neuronal injury and neuroinflammation in Parkinson's disease	Monday, October 5	12:00 - 13:00	Session 5	Station 26	3	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Mengshi Liao
1663	Non-Motor Phenotypes and Intestinal Microbiome Alterations in GBA1-Associated Parkinson's Disease: Evidence for a Body-First Subtype	Monday, October 5	12:00 - 13:00	Session 5	Station 26	4	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Irina Miliukhina
1664	The Effect of Levodopa on Calpain Activity in Patients with Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 26	5	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Zamira Muruzheva
1665	Neurofilament Light Chain Triggers Protein Aggregation, Neurotoxicity and Gliosis in Parkinson's Disease through p38/MK2/NF- κ B/CREB1 and Nrf2/HO-1 Signalling	Monday, October 5	12:00 - 13:00	Session 5	Station 26	6	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Anjuman Nanda

1751	Real-World Outcomes with Directional Deep Brain Stimulation Systems Featuring Multiple Independent Current Control: U.S. Experience	Monday, October 5	12:00 - 13:00	Session 5	Station 27	1	Parkinson's Disease: Surgical Therapy	Michael Okun
1752	Clinical and Programming Parameter Comparison of STN and GPi Deep Brain Stimulation Targets in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 27	2	Parkinson's Disease: Surgical Therapy	Hatice Ömercikoğlu Özden
1753	DBS withdrawal syndrome in Parkinson's disease: Clinical features and outcomes of two new cases	Monday, October 5	12:00 - 13:00	Session 5	Station 27	3	Parkinson's Disease: Surgical Therapy	Emma Ottela
1754	LFP-Based Deep Brain Stimulation Programming and Transition to Adaptive Deep Brain Stimulation in a Patient with Parkinson's Disease: A Case Report from Thailand	Monday, October 5	12:00 - 13:00	Session 5	Station 27	4	Parkinson's Disease: Surgical Therapy	Onanong Phokaewvara ngkul
1755	Dorsal STN and Zona Incerta Stimulation as a Strategy to Reduce Dyskinesia after STN-DBS: A Case Series with Literature Reviews	Monday, October 5	12:00 - 13:00	Session 5	Station 27	5	Parkinson's Disease: Surgical Therapy	Onanong Phokaewvara ngkul
1756	Comparative Motor Response to Bilateral STN-DBS in LRRK2-Related and Idiopathic Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 27	6	Parkinson's Disease: Surgical Therapy	Jamir Pitton Rissardo
1034	Cardiovascular Autonomic Dysfunction and Cognitive Impairment in Parkinson's Disease: A Systematic Review	Monday, October 5	12:00 - 13:00	Session 5	Station 28	1	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Meghnath Kakde
1035	Multivariate Cognitive Markers of Dementia Progression in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 28	2	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Suk Yun Kang
1036	Social Cognition in Patients with Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 28	3	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Aryun Kim
1037	Evaluating the Relationship between Depression and Other Non-Motor Symptoms in Parkinson's Disease	Monday, October 5	12:00 - 13:00	Session 5	Station 28	4	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Matthew Leung
1038	Strategies for Harmonising Clinical Data for Multi-Centre, Large Scale Genome-Wide Association Studies	Monday, October 5	12:00 - 13:00	Session 5	Station 28	5	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Miguel Martín-Bórnez
1039	Preservation of Cognition Following Intravenous Mesenchymal Stem Cell Therapy in Parkinson's Disease: Secondary Analysis of a Randomized Trial	Monday, October 5	12:00 - 13:00	Session 5	Station 28	6	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Juan Martinez-Lemus
69	An artificial intelligence-based model to predict Parkinson's disease risk: the AI-PRA study protocol.	Monday, October 5	13:00 - 14:00	Session 6	Station 1	1	Technology	Sasivimol Virameteekul

70	Tailoring Exergame-Based Training to Parkinson's Disease: Qualitative insights from Clinicians, Relatives, and Technology Experts	Monday, October 5	13:00 - 14:00	Session 6	Station 1	2	Technology	Nadejda Baraznenok
71	A Digital Toolkit for Movement Disorders Clinicians	Monday, October 5	13:00 - 14:00	Session 6	Station 1	3	Technology	Amanda Lin
72	Advancing Mobility-Related Activities of Daily Living Monitoring in Parkinson's Disease: A Systematic Review of Wearable Sensor Technologies	Monday, October 5	13:00 - 14:00	Session 6	Station 1	4	Technology	Suppakorn Yamutai
73	Assessing the Feasibility of a Multimodal Control Model for Deep Brain Stimulation in Parkinson's Disease: A Structured Literature Review	Monday, October 5	13:00 - 14:00	Session 6	Station 1	5	Technology	Jodi Dubuclet
74	Development of a Web Based Neuro Recovery Roadmap Prototype for Visualizing and Tracking Multidisciplinary Rehabilitation in Movement Disorders	Monday, October 5	13:00 - 14:00	Session 6	Station 1	6	Technology	Nyoman Artha Megayasa
234	Caudate-Predominant Striatal Dopaminergic Deficits in bvFTD with Parkinsonism	Monday, October 5	13:00 - 14:00	Session 6	Station 2	1	MSA, PSP, CBS: Pathophysiology / Molecular Mechanisms of Disease	Lu Feng
235	Plasma Proteomics in PSP	Monday, October 5	13:00 - 14:00	Session 6	Station 2	2	MSA, PSP, CBS: Pathophysiology / Molecular Mechanisms of Disease	Shermyn Neo
236	Phenotypic Evolution from Nonfluent PPA to PSP	Monday, October 5	13:00 - 14:00	Session 6	Station 2	3	MSA, PSP, CBS: Pathophysiology / Molecular Mechanisms of Disease	Sangmin Park
1	Differences in Sleep and Activity Digital Phenotypes from Wrist Accelerometry in Parkinson's Disease, At-Risk Individuals, and Healthy Controls	Monday, October 5	13:00 - 14:00	Session 6	Station 2	4	Artificial Intelligence (AI) and Machine Learning	Ioannis Gerasimou
2	Digital Health, Telemedicine, and Artificial Intelligence in Parkinson's Disease Management During COVID-19: A Narrative Review	Monday, October 5	13:00 - 14:00	Session 6	Station 2	5	Artificial Intelligence (AI) and Machine Learning	Hala Harifi
286	Severe Gastroparesis and Atypical Parkinsonism as Presenting Features of Neuronal Intranuclear Inclusion Disease (NIID)	Monday, October 5	13:00 - 14:00	Session 6	Station 3	1	Parkinsonism (Other)	Yi-Hong Wu
287	Delayed-Onset Rapidly Progressive Parkinsonism After BCMA×CD3 Bispecific Antibody Therapy: A Case Report	Monday, October 5	13:00 - 14:00	Session 6	Station 3	2	Parkinsonism (Other)	I-Fang Yang
288	Diagnostic Accuracy of NPH by Radiographic Suspicion and Effect on Patient Outcomes	Monday, October 5	13:00 - 14:00	Session 6	Station 3	3	Parkinsonism (Other)	Sydney Yee
289	Predictors of Shunt Placement for Patients with Normal Pressure Hydrocephalus following a Multidisciplinary Evaluation	Monday, October 5	13:00 - 14:00	Session 6	Station 3	4	Parkinsonism (Other)	Gina Yu

290	Delayed Parkinsonism Following Japanese Encephalitis: A Case Report with Dopamine Transporter Imaging and L-dopa/DCI treatment	Monday, October 5	13:00 - 14:00	Session 6	Station 3	5	Parkinsonism (Other)	Ryotaro Yui
291	Parkinsonism in B-Cell Maturation Antigen-Targeting CAR-T Cell Cancer Therapies	Monday, October 5	13:00 - 14:00	Session 6	Station 3	6	Parkinsonism (Other)	Aryeh Zolin
152	Levodopa-induced peak-dyskinesia and motor fluctuations in corticobasal syndrome	Monday, October 5	13:00 - 14:00	Session 6	Station 4	1	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Nuria Caballol
153	Pain in Multiple System Atrophy: a healthcare professionals' survey	Monday, October 5	13:00 - 14:00	Session 6	Station 4	2	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Nicole Campese
154	Sex Differences in Disease Severity and Impact for Progressive Supranuclear Palsy and Corticobasal Syndrome	Monday, October 5	13:00 - 14:00	Session 6	Station 4	3	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Danelle Carter
155	A Novel Case of Persistent Singing in Progressive Supranuclear Palsy	Monday, October 5	13:00 - 14:00	Session 6	Station 4	4	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Francesca China
156	Clinical Features of Multiple System Atrophy Across Diverse Populations: A Systematic Review of Subtypes and Diagnostic Frameworks	Monday, October 5	13:00 - 14:00	Session 6	Station 4	5	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Mario Cornejo-Olivas
157	Sleep symptoms in people with Progressive Supranuclear Palsy in Argentina	Monday, October 5	13:00 - 14:00	Session 6	Station 4	6	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Blas Couto
226	Central Autonomic Network Alterations in MSA: From Subcortical Degeneration to Prefrontal Reorganization	Monday, October 5	13:00 - 14:00	Session 6	Station 5	1	MSA, PSP, CBS: Neuroimaging	Yuke Wang
227	Prospective Comparison of Volumetric and Diffusion MRI Biomarkers for Multiple System Atrophy	Monday, October 5	13:00 - 14:00	Session 6	Station 5	2	MSA, PSP, CBS: Neuroimaging	Félix MARCHAND
228	Local Glymphatic Dysfunction in Multiple System Atrophy: Insights from Multimodal MRI	Monday, October 5	13:00 - 14:00	Session 6	Station 5	3	MSA, PSP, CBS: Neuroimaging	Jèssica Pardo

229	Cortical Mean Diffusivity as a Measure of Microstructural Neurodegeneration in Multiple System Atrophy	Monday, October 5	13:00 - 14:00	Session 6	Station 5	4	MSA, PSP, CBS: Neuroimaging	Jèssica Pardo
378	Bilateral GPi Deep Brain Stimulation for Severe Speech-Induced Dystonic Dysfluency: A Novel Phenotype at the Stuttering-Dystonia Interface	Monday, October 5	13:00 - 14:00	Session 6	Station 5	5	Dystonia: Medical Therapy / Surgical Therapy	Yasmin Abdelmajid
379	Predictors of Secondary Non-Response to Botulinum Neurotoxin Type-A in Cervical Dystonia: A Multi-Center Egyptian Study	Monday, October 5	13:00 - 14:00	Session 6	Station 5	6	Dystonia: Medical Therapy / Surgical Therapy	Elsayed Abed
320	Voxel-Based Morphometry Reveals Gray Matter Volume Reductions in Sporadic Dystonia	Monday, October 5	13:00 - 14:00	Session 6	Station 6	1	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Oluwatosin Omilabu
321	Power Spectral Density Increases Covary with Clinical Overstimulation During Dystonia Deep Brain Stimulation Programming	Monday, October 5	13:00 - 14:00	Session 6	Station 6	2	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Madelyn Pascual
322	Characterizing Local Field Potentials in Early-Onset Dystonia	Monday, October 5	13:00 - 14:00	Session 6	Station 6	3	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Pritha Bisarad
323	Rethinking the Divide: Are Cervical Dystonia and Myofascial Pain Two Sides of the Same Coin?	Monday, October 5	13:00 - 14:00	Session 6	Station 6	4	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Maie Abdel-Wahab
324	Point-of-Care Neuromuscular Ultrasound With Fractal Biomarkers for Stratification of Neuropathic and Myogenic Drivers of Motor Decline	Monday, October 5	13:00 - 14:00	Session 6	Station 6	5	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Rostyslav Bubnov
325	Re-emerging and Emerging Tremor with Postural Changes in Tremor in Dystonia	Monday, October 5	13:00 - 14:00	Session 6	Station 6	6	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Russell Anne Carandang
454	Anti-IgLON5 Encephalitis Presenting as Chronic Progressive Asymmetrical Ataxia and Chorea	Monday, October 5	13:00 - 14:00	Session 6	Station 7	1	Autoimmune Movement Disorders	Punchika Kosiyakul
455	Incidence and movement disorders associated with Steroid-Responsive Encephalopathy Associated with Autoimmune Thyroiditis (SREAT) in the Princess Maha Chakri Sirindhorn Medical Center (MSMC)	Monday, October 5	13:00 - 14:00	Session 6	Station 7	2	Autoimmune Movement Disorders	Kulthida Methawasin
456	Unveiling the unusual: PNMA2 paraneoplastic syndrome	Monday, October 5	13:00 - 14:00	Session 6	Station 7	3	Autoimmune Movement Disorders	Mansi Shah
457	Too Weak to Stand, Too Stiff to Fall: Overlap Syndrome of Stiff-Person-Syndrome and Anti-HMGCR Necrotizing Myopathy. Case report.	Monday, October 5	13:00 - 14:00	Session 6	Station 7	4	Autoimmune Movement Disorders	WOLFGANG TRILLO ALVAREZ

458	Clinical Profile, Therapeutic Interventions, and Outcome Predictors of Paraneoplastic Movement Disorders – A Tertiary Care Centre Experience	Monday, October 5	13:00 - 14:00	Session 6	Station 7	5	Autoimmune Movement Disorders	ASISH VIJAYARAGHAVAN
459	A Case of Anti-NMDA Receptor Encephalitis Presenting with Refractory Myoclonus and Perioral Dyskinesia during the First Trimester of Pregnancy	Monday, October 5	13:00 - 14:00	Session 6	Station 7	6	Autoimmune Movement Disorders	TAEKYUN YOON
514	Progressive Spastic Ataxia Associated with a GRM1 Variant in a Young Female	Monday, October 5	13:00 - 14:00	Session 6	Station 8	1	Ataxia	Wen Zhen Lin
515	Disease Burden Profile of Patients with Spinocerebellar Ataxia in China: A Real-World Registry Study (2025)	Monday, October 5	13:00 - 14:00	Session 6	Station 8	2	Ataxia	Li-Yuan Lu
516	A Case of Progressive Cerebellar Syndrome with Ataxia as a First Sign	Monday, October 5	13:00 - 14:00	Session 6	Station 8	3	Ataxia	Jessica Mateo
517	A Case of Rapidly Evolving Ataxic Syndrom in a Young Adult	Monday, October 5	13:00 - 14:00	Session 6	Station 8	4	Ataxia	Jessica Mateo
518	Omaveloxolone in a real-world setting: implications in Friedreich Ataxia beyond the classic study population	Monday, October 5	13:00 - 14:00	Session 6	Station 8	5	Ataxia	Wolfgang Nachbauer
519	A case series of Spinocerebellar ataxia subtype 15 from Chile	Monday, October 5	13:00 - 14:00	Session 6	Station 8	6	Ataxia	Matias Niedbalski
638	Cognitive Impairment and Agent Orange Exposure in Veterans with Essential Tremor.	Monday, October 5	13:00 - 14:00	Session 6	Station 9	1	Tremor	Roald Menodiado
639	One-Year Outcomes of Radiofrequency Thalamotomy Versus MR-Guided Focused Ultrasound: A Prospective Single-Centre Comparative Study	Monday, October 5	13:00 - 14:00	Session 6	Station 9	2	Tremor	Masyitah Mohamad
640	Phenotype - lesion correlation in post-stroke movement disorders: Lessons learnt from two cases	Monday, October 5	13:00 - 14:00	Session 6	Station 9	3	Tremor	Adreesh Mukherjee
641	Determinant factor of tremor recurrence after Vim-FUS in ET and tremor-dominant PD	Monday, October 5	13:00 - 14:00	Session 6	Station 9	4	Tremor	Elena Natera-Villalba
642	Motion-Capture features associated with Outcome after MRgFUS Vim thalamotomy for Essential Tremor	Monday, October 5	13:00 - 14:00	Session 6	Station 9	5	Tremor	Yosuke Osakada
643	Ulixacaltamide Demonstrates Broad Functional Improvement Across Individual Domains of Activities of Daily Living in Essential Tremor	Monday, October 5	13:00 - 14:00	Session 6	Station 9	6	Tremor	Steven Petrou
585	Post-COVID Movement Disorders: Clinical Spectrum and Mechanisms A Systematic Review	Monday, October 5	13:00 - 14:00	Session 6	Station 10	1	Myoclonus/Tics/Stereotypies	Shradha Kakde
586	Thalamic Hub Dysregulation in FCMT1: Multimodal MRI and Gene-Imaging Evidence	Monday, October 5	13:00 - 14:00	Session 6	Station 10	2	Myoclonus/Tics/Stereotypies	Jiaxiang Li
587	Bilateral Globus Pallidus Internus Deep Brain Stimulation for Myoclonus-Dystonia in Variant Ataxia-Telangiectasia: A Case Report	Monday, October 5	13:00 - 14:00	Session 6	Station 10	3	Myoclonus/Tics/Stereotypies	Siquan Liang
588	Bilateral Hemifacial Spasm Caused by In-Ear Hearing Aids	Monday, October 5	13:00 - 14:00	Session 6	Station 10	4	Myoclonus/Tics/Stereotypies	Jade Thomas

589	Redefining Anatomical Boundaries, An Atypical Case of MV-PLUS with Supratentorial extension.	Monday, October 5	13:00 - 14:00	Session 6	Station 10	5	Myoclonus/Tics/Stereotypies	WOLFGANG TRILLO ALVAREZ
590	Ntng2 Associated Neurodevelopmental Disorder A Recognisable Syndrome With Stereotypies	Monday, October 5	13:00 - 14:00	Session 6	Station 10	6	Myoclonus/Tics/Stereotypies	Dilek Türkmen
1918	Novel Presentation of Spinocerebellar Ataxia 27B (SCA27B): Episodic, Exercise-induced Truncal Dystonia Responsive to Dalfampridine	Monday, October 5	13:00 - 14:00	Session 6	Station 11	1	Paroxysmal Movement Disorders	Caroline Donahue
1919	Expanding the Phenotypic Spectrum of PRRT2 Channelopathy: A Homozygous Mutation With Early Epilepsy, Autism And Dysmorphism In A Consanguineous Family	Monday, October 5	13:00 - 14:00	Session 6	Station 11	2	Paroxysmal Movement Disorders	Neha Mishra
1920	A Methodological Framework for Selecting Digital Gait Outcomes in Clinical Trials	Monday, October 5	13:00 - 14:00	Session 6	Station 11	3	Paroxysmal Movement Disorders	Vrutangkumar Shah
1921	Homozygous PRRT2 Frameshift Mutation Presenting with Infantile Onset Seizures and Childhood Episodic Ataxia	Monday, October 5	13:00 - 14:00	Session 6	Station 11	4	Paroxysmal Movement Disorders	Prashant Bhatele
1922	Expanding the phenotypic spectrum of FGF14 GAA repeat expansion to paroxysmal kinesigenic dyskinesia	Monday, October 5	13:00 - 14:00	Session 6	Station 11	5	Paroxysmal Movement Disorders	Clément Desjardins
723	Robot-Assisted Transplantation of Hypoimmune iPSC-Derived Dopaminergic Progenitor Cells for PRKN-EOPD	Monday, October 5	13:00 - 14:00	Session 6	Station 12	1	Parkinson's Disease: Clinical Trials	Jifeng Guo
724	Reframing Treatment Paradigms: The Rise of Cell and Gene Therapies in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 12	2	Parkinson's Disease: Clinical Trials	Laurentiu Gutiu
725	Global Momentum in Parkinson's Disease Therapeutics: Ten-Year Trends in Mechanisms, Modalities, and Clinical Endpoints	Monday, October 5	13:00 - 14:00	Session 6	Station 12	3	Parkinson's Disease: Clinical Trials	Laurentiu Gutiu
726	Complete Resolution of Troublesome Dyskinesia in People With Advanced Parkinson's Disease Treated With Foslevodopa/Foscarbidopa: Post Hoc Analysis From a 52-Week Phase 3 Trial	Monday, October 5	13:00 - 14:00	Session 6	Station 12	4	Parkinson's Disease: Clinical Trials	Robert Hauser
727	IPX203 Achieves High Responder Rates Independent of Fluctuation Severity: Insights From RISE-PD	Monday, October 5	13:00 - 14:00	Session 6	Station 12	5	Parkinson's Disease: Clinical Trials	Robert Hauser
728	Improved "Good On" Time and Reduced Motor Fluctuations After Switching to IPX203: Interim Real-World Results from the First 111 Patients in ELEVATE PD	Monday, October 5	13:00 - 14:00	Session 6	Station 12	6	Parkinson's Disease: Clinical Trials	Robert Hauser
795	Demystifying the Delivery of Multi-arm Multi-stage Platform Trials for Parkinson's Disease – Framework and Recommendations from EJS ACT-PD	Monday, October 5	13:00 - 14:00	Session 6	Station 13	1	Parkinson's Disease: Clinical Trials	Christine Girges
796	Effectiveness of Proprioceptive Neuromuscular Facilitation (PNF)-based exercise in people with Pisa syndrome from Parkinson's disease: a case report	Monday, October 5	13:00 - 14:00	Session 6	Station 13	2	Parkinson's Disease: Clinical Trials	Irene Wong-Yu

797	Screening the Neuroprotective Potential of Mushroom Extracts in In Vitro Models of Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 13	3	Parkinson's Disease: Pharmacology and Medical Management	Fazliddin Dustov
798	Low-dose ketamine reduces dopamine 2 receptor-like agonist-induced dyskinesia in a preclinical model	Monday, October 5	13:00 - 14:00	Session 6	Station 13	4	Parkinson's Disease: Pharmacology and Medical Management	Torsten Falk
799	L-DOPA Metabolism as a Function Related to the Potency of iPSC-Derived Dopaminergic Progenitor cells	Monday, October 5	13:00 - 14:00	Session 6	Station 13	5	Parkinson's Disease: Pharmacology and Medical Management	Satoe Hiramatsu
800	The Potential of Mobile Applications to Enhance Self-Management in Parkinson's Disease: A Systematic Review	Monday, October 5	13:00 - 14:00	Session 6	Station 13	6	Parkinson's Disease: Pharmacology and Medical Management	Foivos Kanellos
867	The ORCHESTRA Study Year 2: Practical Experiences With Foslevodopa/Foscarbidopa Treatment in Advanced Parkinson's Disease in a Real-World Setting	Monday, October 5	13:00 - 14:00	Session 6	Station 14	1	Parkinson's Disease: Pharmacology and Medical Management	Tobias Warneck
868	Clinical Underestimation of Wearing-Off in Parkinson's Disease: Patient-Reported Outcomes Versus Clinical Assessment and Impact on Quality of Life	Monday, October 5	13:00 - 14:00	Session 6	Station 14	2	Parkinson's Disease: Pharmacology and Medical Management	Mrinal Acharya
869	Real-World Clinical Experience With Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion In Advanced Parkinson's Disease Patients With Mild Cognitive Impairment And History Of Psychosis	Monday, October 5	13:00 - 14:00	Session 6	Station 14	3	Parkinson's Disease: Pharmacology and Medical Management	Mariam Nadia Afkir Ortega
870	Beyond Motor Outcomes: Health Literacy, Medication Adherence, and Quality of Life in Parkinson's Disease Patients Undergoing the Levodopa Challenge Test	Monday, October 5	13:00 - 14:00	Session 6	Station 14	4	Parkinson's Disease: Pharmacology and Medical Management	Matheus da Silva
871	Effects of Modafinil on Motor and Non-Motor Outcomes in Parkinson's Disease: A Meta-Analysis of Randomized, Placebo-Controlled Trials	Monday, October 5	13:00 - 14:00	Session 6	Station 14	5	Parkinson's Disease: Pharmacology and Medical Management	Amanda Lin
872	Various Levodopa Formulation effects on Local Field Potentials in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 14	6	Parkinson's Disease: Pharmacology and Medical Management	Achyutha Madamangalam
1845	Virtual Reality-Based Rehabilitation for Freezing of Gait in Parkinson's Disease: Implications for Cognitive-Motor Integration: A Systematic Review	Monday, October 5	13:00 - 14:00	Session 6	Station 15	1	Parkinson's Disease (Other)	Warongporn Phuenpathom
1846	Bridging the Gap: Physical Activity and Rehabilitation Patterns in Patients with Parkinsonism	Monday, October 5	13:00 - 14:00	Session 6	Station 15	2	Parkinson's Disease (Other)	Joana Pona-Ferreira
1847	Benefit of Telemedicine Usage in Parkinson's Disease Patients in Appalachia	Monday, October 5	13:00 - 14:00	Session 6	Station 15	3	Parkinson's Disease (Other)	Sydney Rashid
1848	Health-Related Quality of Life in patients with Parkinson's disease based on the ICF model	Monday, October 5	13:00 - 14:00	Session 6	Station 15	4	Parkinson's Disease (Other)	Stanislav Shtaimets

1849	Transforming Acute Parkinson's Care: Impact of a Proactive, Specialist-led Front-Door Rapid Response Parkinson's Service (RRPD)	Monday, October 5	13:00 - 14:00	Session 6	Station 15	5	Parkinson's Disease (Other)	Nishantha Silva
1850	Toward a Standardized Measure of Parkinson's Disease Psychosis: Preliminary Inter-Rater Reliability of the MDS Parkinson's Disease Psychosis Rating Scale (MDS-PDPRS)	Monday, October 5	13:00 - 14:00	Session 6	Station 15	6	Parkinson's Disease (Other)	Michelle Tosin
895	Motor variability in isolated and probable REM sleep behaviour disorder using remote finger tapping	Monday, October 5	13:00 - 14:00	Session 6	Station 16	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Harneek Chohan
896	Identification of Alpha-synuclein Pathology in Idiopathic Rapid Eye Movement Sleep Disorder Participants by Seed Amplification Assay	Monday, October 5	13:00 - 14:00	Session 6	Station 16	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Carly Farris
897	Multimodal Immune Biomarkers of Parkinson's Disease Progression	Monday, October 5	13:00 - 14:00	Session 6	Station 16	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Alex Friend
898	Alpha-synuclein Seed Amplification Assay Set Up: Quality Control Using Standards and Controls	Monday, October 5	13:00 - 14:00	Session 6	Station 16	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Brook Huxford
899	Age-Dependent Peripheral Dissemination of α -Synuclein Seeds: Mechanistic Basis for Blood-Based Early Detection of Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 16	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	yaoyun kuang
900	Real-World Turning Impairments in Fallers with Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 16	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Vrutangkumar Shah
967	Synuclein and dopamine transporter biomarkers among phenoconverters to parkinsonian disorders	Monday, October 5	13:00 - 14:00	Session 6	Station 17	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Cristina Simonet
968	Standardised Home-Based Walk Tests Can Capture Gait Differences in Parkinson's Disease Using Wearable Sensors	Monday, October 5	13:00 - 14:00	Session 6	Station 17	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Charalampos Sotirakis
969	Microsaccade Alterations and Clinical Correlates in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 17	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Theodora Soumala
970	Speech Impairment Severity and Motor Symptom Lateralisation in Advanced Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 17	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Thomas Tienkamp
971	Plasma Fibrinogen Associates with Dopaminergic Neurodegeneration Independent of Peripheral Inflammation in drug-naïve Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 17	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Tadashi Umehara
972	Association of Serum Linoleic Acid-containing Plasmalogens With Parkinson's Disease: the PPMI Study	Monday, October 5	13:00 - 14:00	Session 6	Station 17	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Danlei Wang

1109	Digital Kinematic Measures of Finger Tapping Detect Dose-Dependent Effects of Deep Brain Stimulation in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 18	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Gabriela Acevedo
1110	Investigating the Causal Relationship Between Tofu Intake and Parkinson's Disease in the Asian Population Using Mendelian Randomization	Monday, October 5	13:00 - 14:00	Session 6	Station 18	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Xingzhi Guo
1111	Impact of Variants in ADH1B and ALDH2 on Parkinson's Disease in Japan	Monday, October 5	13:00 - 14:00	Session 6	Station 18	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Masako Kinoshita
1112	Validation of an Objective Parkinson's Disease Digital Assessment Tool in Individuals with PD and Healthy Controls	Monday, October 5	13:00 - 14:00	Session 6	Station 18	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Nathan Meier
1113	Epidemiology of Parkinson's Disease and Parkinsonism in Kazakhstan from 2015 to 2024 based on National Health Data	Monday, October 5	13:00 - 14:00	Session 6	Station 18	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Zhanybek Myrzayev
1114	Towards the detection of troublesome dyskinesia in Parkinson's disease using wearable sensors	Monday, October 5	13:00 - 14:00	Session 6	Station 18	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Masseng Ruben
1181	Dyskinesia-Hyperpyrexia Syndrome Mimicking a Generalized Seizure in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 19	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Byungseok Kim
1182	Dopamine Agonist-Associated Dropped Head Syndrome in Parkinson's Disease: A Case Series	Monday, October 5	13:00 - 14:00	Session 6	Station 19	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Laurel Kovalchick

1183	Comorbid Diabetes Exacerbates Motor and Nonmotor Dysfunction in Parkinson's disease- a Cross-sectional Study	Monday, October 5	13:00 - 14:00	Session 6	Station 19	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Syam Krishnan
1184	Parkinson's Disease Duration at Total Knee Arthroplasty and 5-Year Vascular and Periprosthetic Outcomes: A Nationwide Matched Cohort Study	Monday, October 5	13:00 - 14:00	Session 6	Station 19	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Do-Young Kwon
1185	Sex Differences in Motor and Nonmotor Symptoms of De Novo Parkinson Disease by Age Group	Monday, October 5	13:00 - 14:00	Session 6	Station 19	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Kyum-Yil Kwon
1186	Characterizing Longitudinal Motor Progression in Parkinson's Disease leveraging Digital Health Technologies in L-DOPA ON and OFF States	Monday, October 5	13:00 - 14:00	Session 6	Station 19	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Stefan Lambrecht
1253	Effects of LSVT BIG on Balance Dysfunction in Parkinson's Disease and Its Underlying Cortical Regulatory Mechanisms Using fNIRS	Monday, October 5	13:00 - 14:00	Session 6	Station 20	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Xiaohua Zha
1254	Multimodal Elastography-Assisted Quantitative Evaluation Tool for Diagnosing Rigidity in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 20	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jing Zhao
1255	Association between Sleep Behaviors and Age at Onset of Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 20	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ning Zhou
1256	Association of IL-6 and Lp(a) with Incidental Parkinson's Disease Risk and Motor Severity After Stroke: A Prospective Cohort Study	Monday, October 5	13:00 - 14:00	Session 6	Station 20	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Zhuang Zhu

1257	Treatment Patterns in Parkinson's Disease in Kyrgyzstan: Evidence from a Kyrgyz PD Cohort	Monday, October 5	13:00 - 14:00	Session 6	Station 20	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Eliza Zhunusova
1258	Passive Lumbar Accelerometry Reveals Motor and Behavioral Signatures Associated with High Risk for Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 20	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Aviv Ziv
1325	Parkinson's Disease and Osteoporosis Comorbidity: A Bibliometric Analysis and Exploration of Mechanistic Pathways and Key Genes	Monday, October 5	13:00 - 14:00	Session 6	Station 21	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Liangman Xiao
1326	Lifestyle Factors as Predictors of Progression in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 21	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Xinyuan Zhang
1327	Occupational Pesticide Exposure, Personal Protective Equipment, and Parkinson's Disease: An Observational Study from the PPMI Cohort	Monday, October 5	13:00 - 14:00	Session 6	Station 21	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Brenda Gonzalez-Bedolla
1328	Treatment Patterns and Time Between Therapies Among People with Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 21	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Michal Lubomski
1329	A Patient-Directed AI-Enabled Platform for Continuous Personalised Parkinson's Management	Monday, October 5	13:00 - 14:00	Session 6	Station 21	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Edward Meinert
1330	Long-term exposure to fine particulate matter (PM2.5) is associated with earlier onset of Parkinson's disease: a retrospective population-based cohort study	Monday, October 5	13:00 - 14:00	Session 6	Station 21	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Carlo Santoro
1397	Early-Onset Parkinson's Disease Associated with a Recurrent 16p11.2 Microdeletion Involving PRRT2	Monday, October 5	13:00 - 14:00	Session 6	Station 22	1	Parkinson's Disease: Genetics	Nan Jin
1398	Intra-familial phenotypic variability in a novel Autosomal dominant GCH1 variant	Monday, October 5	13:00 - 14:00	Session 6	Station 22	2	Parkinson's Disease: Genetics	Walaa Kamel

1399	Rare Variant Analysis in Parkinson's Disease Patients Stratified by Polygenic Risk	Monday, October 5	13:00 - 14:00	Session 6	Station 22	3	Parkinson's Disease: Genetics	Sajanth Kanagasingham
1400	Young onset Parkinson's disease patient who has GBA1 pathogenic variant exhibiting progressive supranuclear palsy phenotype	Monday, October 5	13:00 - 14:00	Session 6	Station 22	4	Parkinson's Disease: Genetics	Ryeong Tae Kim
1401	Early-Onset and Familial Parkinson's Disease in Kyrgyzstan: A PD Cohort Subset for Family-Based Genetic Studies	Monday, October 5	13:00 - 14:00	Session 6	Station 22	5	Parkinson's Disease: Genetics	Suium Kyialbekova
1402	ITSN1 Loss-of-Function variants and Parkinson's disease risk in a Chinese cohort	Monday, October 5	13:00 - 14:00	Session 6	Station 22	6	Parkinson's Disease: Genetics	Chunyu Li
1469	Attention-Enhanced Deep Learning for Midbrain MRI Segmentation in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 23	1	Parkinson's disease: Neuroimaging	Chitaranjan Mahapatra
1470	Regional Basal Ganglia Hypoperfusion in Early Parkinson's Disease: Evidence from CT Perfusion Imaging	Monday, October 5	13:00 - 14:00	Session 6	Station 23	2	Parkinson's disease: Neuroimaging	Fayzullo Mallaev
1471	Data-driven Longitudinal Trajectories of Hippocampal Volume in Parkinson's Disease and Across the Neurodegenerative Disease Spectrum	Monday, October 5	13:00 - 14:00	Session 6	Station 23	3	Parkinson's disease: Neuroimaging	Usman Saeed
1472	Dynamic Neural States underlying Freezing of Gait in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 23	4	Parkinson's disease: Neuroimaging	Yanqiu Tian
1473	Automated MRI Biomarker Extraction for Parkinson's Disease Using Attention-Based U-Net Segmentation	Monday, October 5	13:00 - 14:00	Session 6	Station 23	5	Parkinson's disease: Neuroimaging	G Kuanar
1474	Resting-state network reorganization following multimodal lifestyle intervention in Parkinson's disease	Monday, October 5	13:00 - 14:00	Session 6	Station 23	6	Parkinson's disease: Neuroimaging	Amirali Aali
1541	Amyloid Burden in the Precuneus and Posterior Cingulate Gyrus Is Associated With Cognitive Function and White Matter Microstructure in Lewy Body Dementia	Monday, October 5	13:00 - 14:00	Session 6	Station 24	1	Parkinson's disease: Neuroimaging	Haruka Takeshige-Amano
1542	The Transcriptomic, Neurotransmitter, and Cell Type Signatures Underlying Pure Fatigue in Early-stage Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 24	2	Parkinson's disease: Neuroimaging	Yi Xiao
1543	DTI-ALPS Insights into Glymphatic Dynamics and Neurovascular Changes in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 24	3	Parkinson's disease: Neuroimaging	Gülce Coşku Yılmaz Çakan
1544	Multimodal Quantitative MRI Improves Parkinson's Disease Classification	Monday, October 5	13:00 - 14:00	Session 6	Station 24	4	Parkinson's disease: Neuroimaging	Pamela González-Méndez
1545	Drivers of Navigated Walking Performance in Aging and Parkinson's Disease: Insights From Behavioral Clustering, Clinical and Neuroimaging Data	Monday, October 5	13:00 - 14:00	Session 6	Station 24	5	Parkinson's disease: Neuroimaging	Alexander Kvist

1546	Regional Homogeneity in the Visual Network Mediates between Microbiota and Cognition in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 24	6	Parkinson's disease: Neuroimaging	Sara Monti
1613	Bidirectional associations between seizures and parkinsonism: a retrospective case series	Monday, October 5	13:00 - 14:00	Session 6	Station 25	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Yuqing Chen
1614	Prevalence of sarcopenic obesity and its association with non-motor symptoms in early Parkinson's disease	Monday, October 5	13:00 - 14:00	Session 6	Station 25	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Seohee Choi
1615	Cardiac Pacing Strategies for Cardiovascular Autonomic Dysfunction in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 25	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Yann Cordes
1616	Sex-Specific Associations Between Orthostatic Hypotension and Cerebral Hypoperfusion Injury in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 25	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Zihao Li
1617	REM Sleep Behaviour Disorder and early non-motor symptoms in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 25	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Hui Ting Lim
1618	Posterior tibial nerve Stimulation in the management of Urinary Disorders in Parkinson's Disease Experience of the National Hospital Center of Pikine	Monday, October 5	13:00 - 14:00	Session 6	Station 25	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Falonne NIAKAM M.
1666	Integrating Transcriptomics and Morphological Profiling to Characterize GBA-Associated Parkinson's Disease in Midbrain Organoids	Monday, October 5	13:00 - 14:00	Session 6	Station 26	1	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Francesco Nasta
1667	Targeting the Immunoproteasome PSMB8: A dual strategy to enhance α -synuclein clearance and mitigate CD8+ T-Cell neurotoxicity in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 26	2	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Huu Dat Nguyen
1668	The "Sequestration" hypothesis: Longitudinal systemic priming and CNS infiltration of Neutrophil Extracellular Traps in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 26	3	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Huu Dat Nguyen
1669	Raman Spectroscopic Identification of Biochemical Alterations in Post Mortem Brain Tissue Microarrays from Parkinsons and Alzheimers Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 26	4	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	ABDULQUDUS OLUWASHOLA OMIRUDE

1670	GBA1 deficiency promotes tau and TDP-43 co-pathology	Monday, October 5	13:00 - 14:00	Session 6	Station 26	5	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Anna Park
1671	Activation of the MT1 Receptor Ameliorates Mitochondrial Dysfunction in MPP+/MPTP-Induced Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 26	6	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Lili Qi
1757	Interleaving Deep Brain Stimulation: Achieving Optimal Clinical Outcomes at Lower Per-contact Voltages and Energy Consumption	Monday, October 5	13:00 - 14:00	Session 6	Station 27	1	Parkinson's Disease: Surgical Therapy	Chia Yin Por
1758	Axonal-demyelinating polyneuropathy after subcutaneous foslevodopa/foscarbidopa infusion - case report.	Monday, October 5	13:00 - 14:00	Session 6	Station 27	2	Parkinson's Disease: Surgical Therapy	Dominika Przewodowska
1759	Longitudinal gait change after unilateral MRgFUS thalamotomy or subthalamotomy in Parkinson's disease	Monday, October 5	13:00 - 14:00	Session 6	Station 27	3	Parkinson's Disease: Surgical Therapy	Eduardo Salinas Jaime
1760	Deep brain stimulation effects on Parkinson's disease patients with orthostatic hypotension	Monday, October 5	13:00 - 14:00	Session 6	Station 27	4	Parkinson's Disease: Surgical Therapy	Dylan Samayoa
1761	Subthalamic Deep Brain Stimulation Produces Consistent Improvements in Sleep Quality and Daytime Sleepiness in Parkinson's Disease: A Systematic Review and Meta-analysis	Monday, October 5	13:00 - 14:00	Session 6	Station 27	5	Parkinson's Disease: Surgical Therapy	Mya Schiess
1762	Does Subthalamic Nucleus DBS Produce Sustained Improvement in Postural Abnormalities? A 5 Year Prospective Study	Monday, October 5	13:00 - 14:00	Session 6	Station 27	6	Parkinson's Disease: Surgical Therapy	Mustafa Siddiqui
1040	Cholinergic Basal Forebrain Atrophy Associates with Short-Latency Afferent Inhibition and Cognitive Impairment in Parkinson's Disease	Monday, October 5	13:00 - 14:00	Session 6	Station 28	1	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Juan Francisco Martín-Rodríguez
1041	The Lewy Body Dementia Domain Rating Scale (LBD-DRS): Patient and Care Partner Perspectives	Monday, October 5	13:00 - 14:00	Session 6	Station 28	2	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Elie Matar
1042	Temporal Ordering of Biomarker Abnormality Events Leading to Cognitive Impairment in Parkinson's Disease: A Disease Event-Based Model Analysis of the PPMI Cohort	Monday, October 5	13:00 - 14:00	Session 6	Station 28	3	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Ahmed Negida
1043	Impact of Amyloid-beta co-pathology on future hallucination in Parkinson's disease	Monday, October 5	13:00 - 14:00	Session 6	Station 28	4	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Mincheol Park

1044	Electrophysiological Evaluation of Visual Hallucination in Parkinson's Disease Psychosis	Monday, October 5	13:00 - 14:00	Session 6	Station 28	5	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Zachary Piazza
1045	Verbal Communication After Subthalamic Nucleus Deep Brain Stimulation	Monday, October 5	13:00 - 14:00	Session 6	Station 28	6	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Federico Rodriguez-Porcel
75	The PD Diary by MDS: Development and Early Usability Testing of a Patient-Centered Digital Tool for Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 1	1	Technology	Pablo Rábano-Suárez
76	Digital Biomarkers of Spinocerebellar Ataxia Type 3: Wearable Sensor Metrics during Turning and Postural Adjustments	Tuesday, October 6	9:30 - 10:30	Session 7	Station 1	2	Technology	Rchel Guimarães
77	Digital Innovation in Parkinson's Disease – Governing Care and Managing Autonomy	Tuesday, October 6	9:30 - 10:30	Session 7	Station 1	3	Technology	Bjoern Schmitz-Luhn
78	Personalized Factors Influencing Technological Solutions for Mobility - Insights from A Wearable Device in Parkinsons Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 1	4	Technology	Amey Desai
84	Neurotwin: Extended-reality based virtual brain imaging for one-stop-shop diagnosis and progression of Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 1	5	AI, Technology, Telemedicine (Other)	Natalie Hellmers
85	Implementation of a Hindi REDCap Instrument for the Unified Parkinson's Disease Rating Scale (UPDRS)	Tuesday, October 6	9:30 - 10:30	Session 7	Station 1	6	AI, Technology, Telemedicine (Other)	Arunmozhimaran Elavarasi
3	Linear-Time RWKV Multimodal Fusion of Smartphone Audio and Wearable Signals for Mild Cognitive Impairment Screening	Tuesday, October 6	9:30 - 10:30	Session 7	Station 2	1	Artificial Intelligence (AI) and Machine Learning	Daria Hemmerling
4	A biomarker of Huntington's disease progression derived from deep neural speech representations	Tuesday, October 6	9:30 - 10:30	Session 7	Station 2	2	Artificial Intelligence (AI) and Machine Learning	Clément Le Moine
5	Machine Learning for Early Detection of Huntington's Disease: Integrating Non-Motor Symptoms and Gender-Specific Differences	Tuesday, October 6	9:30 - 10:30	Session 7	Station 2	3	Artificial Intelligence (AI) and Machine Learning	Sumit Rajput
6	Voice-Based Screening of Parkinsonian Disorders Using Acoustic Feature Analysis and Machine Learning	Tuesday, October 6	9:30 - 10:30	Session 7	Station 2	4	Artificial Intelligence (AI) and Machine Learning	Luis Cruz-Mondragon
7	Machine Learning-Driven Analysis of Epigenetic Signatures in Juvenile Huntington's Disease: Investigating Histone Modification Dynamics	Tuesday, October 6	9:30 - 10:30	Session 7	Station 2	5	Artificial Intelligence (AI) and Machine Learning	Rohit Kumar
8	Machine Learning-Based Frequency-Domain Analysis of Gait Acceleration for Huntington's Disease Detection	Tuesday, October 6	9:30 - 10:30	Session 7	Station 2	6	Artificial Intelligence (AI) and Machine Learning	Rohit Kumar

292	Safety and Feasibility of Repetitive Transcranial Magnetic Stimulation in Dementia with Lewy Bodies: An Ongoing Proof-of-Concept Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 3	1	Parkinsonism (Other)	Kyoungwon Baik
293	Contribution of blood lipid profile to long-term outcome in idiopathic normal pressure hydrocephalus	Tuesday, October 6	9:30 - 10:30	Session 7	Station 3	2	Parkinsonism (Other)	Jacopo Bissacco
294	Quantifying longitudinal clinical trajectories of disease progression and prognosis in Primary Brain Calcification, the Padua PBC-cohort experience	Tuesday, October 6	9:30 - 10:30	Session 7	Station 3	3	Parkinsonism (Other)	Giulia Bonato
295	Response to symptomatic therapy in Primary Brain Calcification: a cohort survey	Tuesday, October 6	9:30 - 10:30	Session 7	Station 3	4	Parkinsonism (Other)	Giulia Bonato
296	Postural Stability After CSF Drainage in Idiopathic Normal Pressure Hydrocephalus: Association with Gait Response	Tuesday, October 6	9:30 - 10:30	Session 7	Station 3	5	Parkinsonism (Other)	Hee Jin Chang
297	A Longitudinal Case of Adult-Onset Progressive Ataxia in a Patient with a Pathogenic Variant of IRF2BPL	Tuesday, October 6	9:30 - 10:30	Session 7	Station 3	6	Parkinsonism (Other)	Samantha De Groot
158	Sleep disorder Clustering and Clinical Impact in Multiple System Atrophy	Tuesday, October 6	9:30 - 10:30	Session 7	Station 4	1	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jiawen Dong
159	Real-World Survival, Healthcare Access, and Medication Patterns in Atypical Parkinsonian Disorders: A Multi-System EHR Analysis	Tuesday, October 6	9:30 - 10:30	Session 7	Station 4	2	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	J Daniel Fenn
160	A Case report of Progressive Supranuclear Palsy with Cerebellar Ataxia and Chorea	Tuesday, October 6	9:30 - 10:30	Session 7	Station 4	3	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Daniela Fishbein
161	Micrographia in Parkinson's Disease and Multiple System Atrophy: A Quantitative Tablet-Based Handwriting Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 4	4	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Yuki Hagiwara
162	Diagnostic Delay in Multiple System Atrophy: Sociodemographic and Clinical Predictors in a Single-Center Cohort	Tuesday, October 6	9:30 - 10:30	Session 7	Station 4	5	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Taryn Kaneko

163	Task-Dependent Modulation of Reflexive and Voluntary Saccades in Parkinson Disease and Multiple System Atrophy	Tuesday, October 6	9:30 - 10:30	Session 7	Station 4	6	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Hyunji Kim
380	A Therapeutic Approach to Writer's Cramp-Type Focal Dystonia Using Botulinum Toxin: Experience of the Neurology/Movement Disorders Department of the Hospital do Servidor Público de São Paulo	Tuesday, October 6	9:30 - 10:30	Session 7	Station 5	1	Dystonia: Medical Therapy / Surgical Therapy	Kaísy Alves
381	Efficacy of Dysport in the treatment of late onset-lingal dystonia secondary to neuroleptics	Tuesday, October 6	9:30 - 10:30	Session 7	Station 5	2	Dystonia: Medical Therapy / Surgical Therapy	Chahrazad Boukadir
382	Local Field Potentials (LFP) Insights in the Treatment of X-linked Dystonia-Parkinsonism with Deep Brain Stimulation of the Subthalamic Nucleus	Tuesday, October 6	9:30 - 10:30	Session 7	Station 5	3	Dystonia: Medical Therapy / Surgical Therapy	Jenny Chen
383	Efficacy and safety of single-photon emission computed tomography (SPECT) aided botulinum toxin injection in writers' cramp: A PROBE Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 5	4	Dystonia: Medical Therapy / Surgical Therapy	Animesh Das
384	Are All Toxins Created Equal? Real-world analysis of Abo-, Inco- and Ona- BoNT-A from prospective LIVEchart over 7 years	Tuesday, October 6	9:30 - 10:30	Session 7	Station 5	5	Dystonia: Medical Therapy / Surgical Therapy	Richard Ellis
385	Botulinum toxin treatment patterns and outcomes in head and neck dystonia: experience from a tertiary, multidisciplinary clinical service	Tuesday, October 6	9:30 - 10:30	Session 7	Station 5	6	Dystonia: Medical Therapy / Surgical Therapy	Rebecca Everitt
326	Evaluation of Electromyographic Measures of Cervical Dystonia Using a 12-Muscle Recording Paradigm	Tuesday, October 6	9:30 - 10:30	Session 7	Station 6	1	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Owen Killian
327	Multimodal Imaging in Cervical Dystonia with Botulinum Toxin Treatment: A Pilot 5.0T MRI and 99mTc-MIBI SPECT/CT Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 6	2	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Jing Li
328	Long-term therapeutic effects of repetitive transcranial magnetic stimulation combined with lidocaine injection (rTMS-LI) in dystonia	Tuesday, October 6	9:30 - 10:30	Session 7	Station 6	3	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Nagako Muraser
329	Investigating Cerebellar Network Alterations in Musician's Dystonia	Tuesday, October 6	9:30 - 10:30	Session 7	Station 6	4	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Negar Nasrkhani
330	Trancranial Sonography Reveals Striatal Neurodegeneration in the Prodromal Phase of X-linked Dystonia-Parkinsonism	Tuesday, October 6	9:30 - 10:30	Session 7	Station 6	5	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Martje Pauly

331	An Unusual Cause Of Opisthotonus In A Young Female With Complete Recovery	Tuesday, October 6	9:30 - 10:30	Session 7	Station 6	6	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Alex Rebello
460	A Severe Parkinsonism Revealing Neurosarcoidosis : A Case Report	Tuesday, October 6	9:30 - 10:30	Session 7	Station 7	1	Autoimmune Movement Disorders	Rania Zouari
461	“Unexplained” Chorea Explained by Neuronal Antibodies: A Dutch Cohort Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 7	2	Autoimmune Movement Disorders	Jeroen Kerstens
462	Anti-Amphiphysin Stiff-Person Spectrum Disorders: A Case Series Highlighting an Unusual Isolated Upper-limb Presentation and Systematic Review	Tuesday, October 6	9:30 - 10:30	Session 7	Station 7	3	Autoimmune Movement Disorders	Andrew Lee
463	Movement Disorder Phenotypes in Neuronal Antibody-Mediated Autoimmune Encephalitis	Tuesday, October 6	9:30 - 10:30	Session 7	Station 7	4	Autoimmune Movement Disorders	Negar Nasrkhani*
464	Clinical Features and Treatment Response in Stiff Person Spectrum Disorder: A Case Series from a Tertiary Neurology Centre	Tuesday, October 6	9:30 - 10:30	Session 7	Station 7	5	Autoimmune Movement Disorders	Abel Oommen
465	Dystonia parkinsonism revealing CV2 positive autoimmune encephalitis	Tuesday, October 6	9:30 - 10:30	Session 7	Station 7	6	Autoimmune Movement Disorders	Olfa Sakli
520	Ambulatory prognosis in spinocerebellar ataxia type 6: a single-center cohort study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 8	1	Ataxia	JINICHI NUNOMURA
521	Effects of a Six-Week Neurorehabilitation Program on Ataxia, Balance and Gait in a Patient with CANVAS Syndrome: A Case Report	Tuesday, October 6	9:30 - 10:30	Session 7	Station 8	2	Ataxia	Mustafacan Salamci
522	Late-Onset Bulbar-Predominant Neurodegeneration Associated With a Truncating AFG3L2 Variant: Expanding the Clinical Spectrum of AFG3L2-Related Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 8	3	Ataxia	Rhea Sharma
523	Cross-Sectional and Longitudinal MRI Biomarkers of Neurodegeneration in Friedreich’s Ataxia	Tuesday, October 6	9:30 - 10:30	Session 7	Station 8	4	Ataxia	Rodrigo Sutil Berjón
524	Clinical Spectrum of Cerebellar Fits in Adults and Children: A Systematic Review	Tuesday, October 6	9:30 - 10:30	Session 7	Station 8	5	Ataxia	Prashant Bhatele
525	Genotype-Specific Risk Factors for Falls in Spinocerebellar Ataxia: A Cross-Sectional Analysis of SCA1, SCA2, SCA3, and SCA6	Tuesday, October 6	9:30 - 10:30	Session 7	Station 8	6	Ataxia	Shriya Kakde
644	Holmes Tremor Secondary to Structural Brain Lesions: A Case Series from a Tertiary National Referral Hospital	Tuesday, October 6	9:30 - 10:30	Session 7	Station 9	1	Tremor	Dyandra Prameswari
645	Efficacy of Bilateral Ventral Intermediate Nucleus Deep Brain Stimulation in Patients with Neuronal Intranuclear Inclusion Disease-Related Tremor: A Longitudinal Case Series	Tuesday, October 6	9:30 - 10:30	Session 7	Station 9	2	Tremor	Zhiyuan Qi
646	Proposal of Anatomico-Functional Tremor Patterns for Ultrasound-Guided Botulinum Toxin Infiltration	Tuesday, October 6	9:30 - 10:30	Session 7	Station 9	3	Tremor	Gabriel Salazar

647	Longitudinal gait changes after unilateral and bilateral MRgFUS thalamotomy in Essential Tremor	Tuesday, October 6	9:30 - 10:30	Session 7	Station 9	4	Tremor	Eduardo Salinas Jaime
648	Framework for Future Neurology Trials: Enhanced Scientific Rigor Through Innovative Decentralized Trial Methodology	Tuesday, October 6	9:30 - 10:30	Session 7	Station 9	5	Tremor	Marcia Souza
649	Ulixacaltamide Demonstrates Superiority Over Placebo as Monotherapy and as Add-on to Propranolol in Essential Tremor: Phase 3 ESSENTIAL3 Study 1	Tuesday, October 6	9:30 - 10:30	Session 7	Station 9	6	Tremor	Marcio Souza
591	Efficacy of Deutetrabenazine in Patients with Tourette Syndrome: A Meta-Analysis of Randomized Controlled Trials	Tuesday, October 6	9:30 - 10:30	Session 7	Station 10	1	Myoclonus/Tics/Stereotypies	Mohamed Zanaty
592	Opsoclonus-Myoclonus-Ataxia Syndrome in Adults: Case Series in Vietnam	Tuesday, October 6	9:30 - 10:30	Session 7	Station 10	2	Myoclonus/Tics/Stereotypies	Nga Bui
594	Longitudinal shifts in goal-directed and habitual control relate to tic severity and cortico-striatal connectivity in adolescents with Tourette syndrome	Tuesday, October 6	9:30 - 10:30	Session 7	Station 10	3	Myoclonus/Tics/Stereotypies	Charly Lecomte
549	Intrinsic Suppression of the NRF2-Ferroptosis Defense Axis Defines Selective Vulnerability of D2-Striosome Neurons in Huntington's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 10	4	Huntington's Disease	liyuan lu
550	Anticipatory Language Prediction ERPs Detect Early Neurophysiological Changes in Asymptomatic Huntington's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 10	5	Huntington's Disease	Arnau Puig-Davi
1923	Receptor Selectivity Profile and Clinical Significance of Ecopipam and Its Metabolites as a Potential Therapy for Tourette Syndrome	Tuesday, October 6	9:30 - 10:30	Session 7	Station 11	1	Pediatric Movement Disorders	Stephen Wanaski
1924	Multi-Omics Biomarker Discovery in Friedreich's Ataxia Cardiomyopathy	Tuesday, October 6	9:30 - 10:30	Session 7	Station 11	2	Pediatric Movement Disorders	Faiza Siddiqui
1925	From Clinical Patterns to Symptom-specific Functional Networks in Dyskinetic Cerebral Palsy	Tuesday, October 6	9:30 - 10:30	Session 7	Station 11	3	Pediatric Movement Disorders	Ana Luisa Almeida Marcelino
1926	Paroxysmal Torticollis Revealing Cervical disc Calcifications in a Child About a Case	Tuesday, October 6	9:30 - 10:30	Session 7	Station 11	4	Pediatric Movement Disorders	Chahrazad Boukadir
1927	Neurological disease progression in adults with ataxia telangiectasia - a longitudinal study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 11	5	Pediatric Movement Disorders	Anke Hensiek
1928	Plasma Phospho-Tau217 and Neuromelanin-Sensitive MRI as Candidate Biomarkers in Beta-Propeller Protein-Associated Neurodegeneration	Tuesday, October 6	9:30 - 10:30	Session 7	Station 11	6	Pediatric Movement Disorders	Jae-Hyeok Lee
729	Switching to IPX203 from IPX066 Significantly Improves "Good On" Time and Reduces Motor Fluctuations Under Real-World Conditions	Tuesday, October 6	9:30 - 10:30	Session 7	Station 12	1	Parkinson's Disease: Clinical Trials	Robert Hauser
730	Continued Evaluation of Clinical Outcomes in Participants With Parkinson's Disease Through 4 Years After Bemdaneprocel Administration	Tuesday, October 6	9:30 - 10:30	Session 7	Station 12	2	Parkinson's Disease: Clinical Trials	Claire Henschcliffe

731	A Retrospective Comparison of Multiple Approaches to LFP-guided and Imaging Guided Contact Selection in Subthalamic Deep Brain Stimulation for Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 12	3	Parkinson's Disease: Clinical Trials	Simon Herstell
732	Lu AF28996, a Novel Oral D1-like/D2-like Receptor Agonist, May Improve Motor Complications in People with Parkinson's Disease: Results from an 18-week open-label, Phase 1b Trial	Tuesday, October 6	9:30 - 10:30	Session 7	Station 12	4	Parkinson's Disease: Clinical Trials	Astrid-Maria Højer
733	A Phase 1b Study to Investigate Safety, Tolerability and Biomarker Responses of Repeated Subcutaneous Doses of HER-096 in Subjects with Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 12	5	Parkinson's Disease: Clinical Trials	Kira Holmström
734	Switching to IPX203 Significantly Increases the Duration of "Good On" Intervals: Interim Real-World Results from the First 111 Patients in ELEVATE-PD	Tuesday, October 6	9:30 - 10:30	Session 7	Station 12	6	Parkinson's Disease: Clinical Trials	Stuart Isaacson
801	Brain-targeted dual-loaded extracellular vesicles enable PROTAC-mediated LRRK2 degradation in Parkinson's disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 13	1	Parkinson's Disease: Pharmacology and Medical Management	Ji-Eun Kim
802	Deciphering the NLRP3-Driven Olfactory-Brain Axis in Parkinson's disease: Neuroprotective Role of Betulin	Tuesday, October 6	9:30 - 10:30	Session 7	Station 13	2	Parkinson's Disease: Pharmacology and Medical Management	Abhishek Kumar
803	Oral D1-like/D2-like Receptor Agonist, Lu AF28996, Provides Robust Antiparkinsonian Efficacy with Reduced Dyskinesia in the MPTP-Macaque Model	Tuesday, October 6	9:30 - 10:30	Session 7	Station 13	3	Parkinson's Disease: Pharmacology and Medical Management	Hanna Lindgren
804	Translational evaluation of CSF as a relevant compartment for assessing target engagement of therapeutic anti- α -syn antibodies.	Tuesday, October 6	9:30 - 10:30	Session 7	Station 13	4	Parkinson's Disease: Pharmacology and Medical Management	Marta Ramos Vega
805	Therapeutic Potential of Probiotics for Clinical Management in Parkinson's Disease: A Systematic Review	Tuesday, October 6	9:30 - 10:30	Session 7	Station 13	5	Parkinson's Disease: Pharmacology and Medical Management	Amelia Suhendro
806	Probiotic Y7 Intervention Is Associated with Improved Motor, Gut-Related, and L-DOPA-Related Outcomes in a Rat Model of Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 13	6	Parkinson's Disease: Pharmacology and Medical Management	HUI YU Huang
873	Impact of Helicobacter pylori Eradication on MDS-UPDRS Part III Motor Score in Patients With Parkinson's Disease A Prospective Cohort Study in Northern Mexico	Tuesday, October 6	9:30 - 10:30	Session 7	Station 14	1	Parkinson's Disease: Pharmacology and Medical Management	Samuel Murillo Quintana
874	Single centre experience with subcutaneous foslevodopa/foscarbidopa for GBA Parkinson's disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 14	2	Parkinson's Disease: Pharmacology and Medical Management	Inés Muro
875	Polypharmacy and its Impact in Individuals with Parkinson's Disease: Theory- and Data-Driven Approaches	Tuesday, October 6	9:30 - 10:30	Session 7	Station 14	3	Parkinson's Disease: Pharmacology and Medical Management	Emma Nguyen

876	Continuous Subcutaneous Foslevodopa/Foscarbidopa Infusion in Advanced Parkinson's Disease: Results from a Prospective Real-world Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 14	4	Parkinson's Disease: Pharmacology and Medical Management	Giulia Pinola
877	The Impact of Dopamine-Induced Impulse Control Disorders on Quality of Life in Young-Onset Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 14	5	Parkinson's Disease: Pharmacology and Medical Management	Samanyu Pokhriyal
878	Efficacy and Safety of GLP-1 Receptor Agonists in Parkinson's Disease: A Meta-Analysis Integrating the 96-Week Phase 3 Exenatide Trial Results	Tuesday, October 6	9:30 - 10:30	Session 7	Station 14	6	Parkinson's Disease: Pharmacology and Medical Management	Khalid Sarhan
1851	Oral Frailty in Patients with Parkinson's Disease: A Cross-Sectional Study Using the OF-5 Checklist	Tuesday, October 6	9:30 - 10:30	Session 7	Station 15	1	Parkinson's Disease (Other)	Shinta Ueno
1852	Data Driven Clinical Insights from Longitudinal Cloud-Aggregated Neural Data to Inform a Real-World Adaptive DBS Programming	Tuesday, October 6	9:30 - 10:30	Session 7	Station 15	2	Parkinson's Disease (Other)	Okeanis Vaou
1853	Integrated and Multidisciplinary Care for Older Adults with Parkinson's Disease: A value-driven approach	Tuesday, October 6	9:30 - 10:30	Session 7	Station 15	3	Parkinson's Disease (Other)	Preetha Venugopalan Menon
1854	Discontinuation Patterns and Predictive Factors in Continuous Subcutaneous Foslevodopa/Foscarbidopa (FLC/FCD) Therapy: Insights from Early Clinical Experience	Tuesday, October 6	9:30 - 10:30	Session 7	Station 15	4	Parkinson's Disease (Other)	Kiran Waqar
1855	The Impact of Delaying Subcutaneous Device-Aided Therapy for Patients with Advanced Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 15	5	Parkinson's Disease (Other)	Robert Wiggins
1856	Two Voices, One Disease: Patient and Care Partner Decision Dynamics on Advanced Therapies for Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 15	6	Parkinson's Disease (Other)	Wei Zhang
901	smSAA: developing a quantitative seed amplification assay with single molecule spectroscopy	Tuesday, October 6	9:30 - 10:30	Session 7	Station 16	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Emma Sierecki
902	Quantitative Assessment of Rigidity in Parkinson's Disease Using Wearable Inertial Sensors and Electromyography During Daily-Life Monitoring	Tuesday, October 6	9:30 - 10:30	Session 7	Station 16	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Carolina Travassos Valdez
903	Paired cerebrospinal fluid and serum analysis of irisin and associated LC3B levels in Parkinson's disease and atypical Parkinsonism	Tuesday, October 6	9:30 - 10:30	Session 7	Station 16	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Steffen Witte
904	Gut Barrier Failure In Parkinson Disease: Reduced Colonic Resilience In Moderate Disease And Spontaneous Pan-Intestinal Leak In Severe Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 16	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Mohamed Abdel-Mohsen
905	The enteric footprint of de novo parkinson's disease cohort: constipation, inflammation, and nulis biomarker profiling.	Tuesday, October 6	9:30 - 10:30	Session 7	Station 16	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Silvia Enriquez Calzada

906	Translational Target Engagement of HER-096 Demonstrates Concordant Proteostasis and Mitochondrial Modulation in Preclinical Models and Patients with Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 16	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Kira Holmström
973	Long-term outcomes and real-world implementation of adaptive deep brain stimulation in Parkinson's disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 17	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Victoria Witzig
974	A composite oculomotor biomarker for differentiating Parkinson's disease from multiple system atrophy	Tuesday, October 6	9:30 - 10:30	Session 7	Station 17	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Magdalena Wójcik-Pędziwiatr
975	Serum Nutritional Biomarkers Associated with Isolated REM Sleep Behavior Disorder and α -synucleinopathy Phenoconversion	Tuesday, October 6	9:30 - 10:30	Session 7	Station 17	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Hui Zhang
976	Decoding Parkinson's Disease Metabolic Landscape: Targeted 4D-Metabolomics of Urinary Amine-Phenol Submetabolomes for Specific Signature Identification and Biomarker Discovery	Tuesday, October 6	9:30 - 10:30	Session 7	Station 17	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Yu Zhang
977	Beyond the Spinal Tap: Diagnostic Accuracy of Alpha-Synuclein Seeding Amplification Assays (SAA) in Cutaneous and Ocular Biofluids – A Comparative Diagnostic Accuracy Review	Tuesday, October 6	9:30 - 10:30	Session 7	Station 17	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	FOUAD AL-ZAIDI
978	Digital Mobility Outcomes for Modelling Self-Perceived Gait Security in People with Parkinsonian Disorders	Tuesday, October 6	9:30 - 10:30	Session 7	Station 17	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Francesca Boschi
1115	Longitudinal cognitive trajectories and predictors of dementia conversion in Parkinson's disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 18	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Nora Sánchez-Lorenzo
1116	Sex Differences in Prodromal Features of Parkinson's Disease: Evidence from Large Multi-Centre Cohorts	Tuesday, October 6	9:30 - 10:30	Session 7	Station 18	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Manuela Tan
1117	Challenges of Translating the MDS-UPDRS into Ukrainian During Wartime	Tuesday, October 6	9:30 - 10:30	Session 7	Station 18	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	TARAS VOLOSHYN
1118	Digitizing PD Rating Scales Increases Reliability and Accessibility	Tuesday, October 6	9:30 - 10:30	Session 7	Station 18	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ziv Yekutieli

1119	Smartphone Video Derived Digital Motor Phenotypes of MDS UPDRS-Related Tasks via a Comprehensive Motor Function Test	Tuesday, October 6	9:30 - 10:30	Session 7	Station 18	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Nikos Grammalidis
1120	Segment-Level Gait Dynamics Reveal Parkinsonian Motor Signatures in Fall-Prone Older Adults Using Multi-Channel Time-Frequency Deep Learning	Tuesday, October 6	9:30 - 10:30	Session 7	Station 18	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Bohyun Kim
1187	Probable RBD and Anxiety in Early Parkinson's Disease Predict Subsequent Functionally Disabling Medication-Refractory Tremor	Tuesday, October 6	9:30 - 10:30	Session 7	Station 19	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	David Ledingham
1188	Head Trauma History and Motor Phenotype in Early Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 19	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Hak-Loh Lee
1189	Clinical Characteristics of Fracture Injury by Falling in Parkinson's Disease, a Prospective Cohort Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 19	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jae-Jung Lee
1190	Continuous Subcutaneous Apomorphine Infusion in Parkinson Disease: Final Data from the Multi-Year InfusON Open-Label Extension Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 19	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Peter LeWitt
1191	Sleep Circadian Rhythms and Brain Disorders: A Large Prospective Cohort and Mendelian randomization Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 19	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Yuanyuan Li
1192	The 360° Turn Test as a Single and Dual Task in people with Parkinson's disease and cognitively unimpaired controls	Tuesday, October 6	9:30 - 10:30	Session 7	Station 19	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Magnus Lindh-Rengifo

1259	Sex Differences in the Reported Prodromal Symptoms of Parkinson's Disease (PD) in the Fox Insight Cohort	Tuesday, October 6	9:30 - 10:30	Session 7	Station 20	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Zainab Zullali
1260	Global and Turkish Comorbidity Profiles in Parkinson's Disease: The ANPAR Cohort and a Systematic Review	Tuesday, October 6	9:30 - 10:30	Session 7	Station 20	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Talha Abali
1261	Clinical Profile of Early-Onset Parkinson's Disease in a Tertiary Hospital in Oman	Tuesday, October 6	9:30 - 10:30	Session 7	Station 20	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jawaher Al Balushi
1262	Sleep Disturbances and Dyskinesia Burden in Parkinson's Disease: Relevance for Motor Complication Management	Tuesday, October 6	9:30 - 10:30	Session 7	Station 20	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Viktoria Azoidou
1263	Exploring Demographic Correlates of Diagnostic Interval of Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 20	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Monique Bienen
1264	Impact of Multi-day Wearable Monitoring on Neurologists' Assessment of Motor Fluctuations and Treatment Strategies in Parkinson's Disease: A Real-World Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 20	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Maria Borrell-Pichot
1331	Wearable-Derived Cardiac Features and Cardiac-Motor Interconnection Across Parkinson's Disease Severities	Tuesday, October 6	9:30 - 10:30	Session 7	Station 21	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Patricio Arrue
1332	Dual-Task Gait Costs do not Increase Across Stages of Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 21	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Heloyza Bernini

1333	How Common Is Central Pain in Parkinson's Disease? A Systematic Review and Meta-Analysis	Tuesday, October 6	9:30 - 10:30	Session 7	Station 21	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Leonardo Gomes Pereira
1334	Dual-Task Gait Costs are not Reduced by Immediate Repetition in Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 21	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Gabriela Koitla
1335	Interaction Between Physical and Cognitive Function That Determines ADL Improvement in Hospitalized Patients with Parkinson's Disease: Implications for Individualized Rehabilitation Strategies	Tuesday, October 6	9:30 - 10:30	Session 7	Station 21	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ryo Nakagawa
1336	Exploring "sense of muscle contraction" during gluteus maximus training in Parkinson's disease: a preliminary EMG perception study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 21	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Junya Ogawa
1403	Metabolic Brain Pattern and Longitudinal Progression in GBA-Associated Parkinson's Disease Revealed by 18F-FDG PET/CT	Tuesday, October 6	9:30 - 10:30	Session 7	Station 22	1	Parkinson's Disease: Genetics	Pei Hong Li
1404	Prevalence and neuroimaging presentations of Parkinsonism patients with p.R544C NOTCH3 mutation in Taiwan	Tuesday, October 6	9:30 - 10:30	Session 7	Station 22	2	Parkinson's Disease: Genetics	Juei-Jueng Lin
1405	Parkinson's Disease Genetics: From Monogenic Causes to Polygenic Risk and Clinical Translation	Tuesday, October 6	9:30 - 10:30	Session 7	Station 22	3	Parkinson's Disease: Genetics	Xiaodie Liu
1406	Harmonized Analysis of Parkinson's Disease-Associated Variants in the AfrAbia PD Genomic Consortium Cohort	Tuesday, October 6	9:30 - 10:30	Session 7	Station 22	4	Parkinson's Disease: Genetics	Wael Mohamed
1407	Preliminary Genetic Spectrum of Parkinson's Disease in the Israeli PD GENERation Cohort	Tuesday, October 6	9:30 - 10:30	Session 7	Station 22	5	Parkinson's Disease: Genetics	Nurit Omer
1408	SAA Positivity Rate Amongst Dual LRRK2-GBA1, GBA1 and LRRK2 Carriers with Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 22	6	Parkinson's Disease: Genetics	Penina Ponger
1475	Cerebellar-Basal Ganglia Circuitry in the Pathogenesis of Parkinsonian Postural Instability	Tuesday, October 6	9:30 - 10:30	Session 7	Station 23	1	Parkinson's disease: Neuroimaging	Olga Alenikova
1476	Distinct Patterns of Perivascular Diffusivity and Choroid Plexus Volume in De Novo Parkinson's Disease and Type 2 Diabetes	Tuesday, October 6	9:30 - 10:30	Session 7	Station 23	2	Parkinson's disease: Neuroimaging	Yun Jung Bae
1477	Correlations Between Clinical Variables And Cerebral Perfusion in Parkinson's Disease With Mild Cognitive Impairment: A Multi-Delay pcASL Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 23	3	Parkinson's disease: Neuroimaging	Narayan Chaurasiya

1478	Beyond Motor Symptoms: Utilizing the FreeSurfer Brainstem Substructures Module to Characterize a Complex Parkinsonian Phenotype with Profound Dysautonomia	Tuesday, October 6	9:30 - 10:30	Session 7	Station 23	4	Parkinson's disease: Neuroimaging	Mann Leon Chin
1479	Default Mode Network Co-Activation Pattern Dynamics and Their Relationship to Cognition in Parkinson's Disease with and without Mild Cognitive Impairment	Tuesday, October 6	9:30 - 10:30	Session 7	Station 23	5	Parkinson's disease: Neuroimaging	Praneeth Sai Chunchu
1480	Association of Glymphatic Flow at Diffusion Tensor Image with Motor Symptoms and Striatal Dopamine Degeneration in Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 23	6	Parkinson's disease: Neuroimaging	Seok Jong Chung
1547	Posterior Cortical Hypometabolism in GBA1 Variant Carriers with and without Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 24	1	Parkinson's disease: Neuroimaging	Micol Avenali
1548	Resting-state functional network alterations in early Parkinson's disease anxiety: a 7T MRI study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 24	2	Parkinson's disease: Neuroimaging	Guillaume Carey
1549	Genotype Matters: Vagus Nerve Atrophy in GBA-Associated Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 24	3	Parkinson's disease: Neuroimaging	Jacopo Di Giovanni
1550	Active Contact Localization in the Subthalamic Nucleus Predicts Phonemic Fluency Decline After Bilateral STN-DBS	Tuesday, October 6	9:30 - 10:30	Session 7	Station 24	4	Parkinson's disease: Neuroimaging	Šimon Janovič
1551	Neuromelanin Loss Is Associated with Increased Substantia Nigra Free-Water: a Longitudinal Study of Controls, RBD, and PD	Tuesday, October 6	9:30 - 10:30	Session 7	Station 24	5	Parkinson's disease: Neuroimaging	Victoria Madge
1552	Clinical Utility of DaT-SPECT as a Predictive Tool for the Development of Parkinson's Disease and Related α -synucleinopathies in REM-Behavior Disorder	Tuesday, October 6	9:30 - 10:30	Session 7	Station 24	6	Parkinson's disease: Neuroimaging	Maggie Markgraf
1619	Testing the body vs brain-first hypothesis in early PD: a cross-sectional study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 25	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Agustín Querejeta-Coma
1620	Impact of foslevodopa/foscarbidopa infusion on autonomic symptoms in advanced Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 25	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Domiziana Rinaldi
1621	Safindream Safinamide as First Add On to Levodopa Improves Nonmotor Symptoms in Parkinson disease A Prospective Real World Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 25	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Francisco José Salazar Hernández
1622	Affective Symptom Burden in Individuals with Olfactory Dysfunction in the PREDICT-PD Cohort	Tuesday, October 6	9:30 - 10:30	Session 7	Station 25	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Anisa Shahid

1623	Logopenic Aphasia After Thalamotomy in Parkinson's Disease: A Case Report	Tuesday, October 6	9:30 - 10:30	Session 7	Station 25	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Irem Sibel Sipahi
1624	Video-Nystagmographic Biomarkers of Oculomotor Dysfunction in Parkinson's Disease: Correlation With Motor Severity and Cognition	Tuesday, October 6	9:30 - 10:30	Session 7	Station 25	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Kamalesh Tayade
1672	Midbrain Organoid Modeling and Transcriptomic Characterization of NOTCH2NLC GGC Repeat Expansion-Associated Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 26	1	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Hengrong Qian
1673	Gelsolin and Secretogranin-3 induce Parkinsonian features in rodent models.	Tuesday, October 6	9:30 - 10:30	Session 7	Station 26	2	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Ragini Raghu
1674	Skin Tau Quantification as a Potential Degeneration Biomarker in Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 26	3	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Jon Rodriguez-Antiguedad
1675	Single-Neuron Analysis of Mitochondrial DNA Alterations and Respiratory Chain Dysfunction in Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 26	4	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Anna Rubiolo
1676	Baicalein Attenuates Rotenone-Induced Neurodegeneration by Regulating BDNF/CREB/Akt Signaling in Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 26	5	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Amit Singh
1677	Traumatic Brain Injury Exacerbates Parkinsonian Neurodegeneration Through Alpha Synuclein Dysregulation	Tuesday, October 6	9:30 - 10:30	Session 7	Station 26	6	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Ankit Satyaprakash Singh
1763	Application of the MDS Nonmotor-Symptom Questionnaire in Evaluation of Deep Brain Stimulation Candidates.	Tuesday, October 6	9:30 - 10:30	Session 7	Station 27	1	Parkinson's Disease: Surgical Therapy	Travis Turner
1764	Evaluating pseudo-monopolar LFP recordings from the STN for optimized DBS contact selection in Parkinson's disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 27	2	Parkinson's Disease: Surgical Therapy	Annabel vander Weide
1765	Effect of deep brain stimulation on quality of life in Parkinson's disease: a longitudinal analysis of clinical improvement and response probability using mixed-effects models and GEE	Tuesday, October 6	9:30 - 10:30	Session 7	Station 27	3	Parkinson's Disease: Surgical Therapy	María Fernanda Velasco-Delgado

1766	Real-World Clinical Outcomes and Patient Experience Following Hybrid DBS Conversion to a Neurostimulator with Advanced Current Steering	Tuesday, October 6	9:30 - 10:30	Session 7	Station 27	4	Parkinson's Disease: Surgical Therapy	Jan Vesper
1767	Lead Asymmetry and Axial Symptom Response to Deep Brain Stimulation in Parkinson's Disease: A Synthetic Pilot Modeling Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 27	5	Parkinson's Disease: Surgical Therapy	Emirhan Yildirim
1768	Structural Brain Measures Predict Cognitive Performance After Deep Brain Stimulation for Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 27	6	Parkinson's Disease: Surgical Therapy	John Younce
1046	Cerebral Small Vessel Disease-Related Degeneration of Cholinergic Pathways Contributes to Cognitive Impairment in Parkinson's Disease	Tuesday, October 6	9:30 - 10:30	Session 7	Station 28	1	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Siming Rong
1047	Depression and Psychosis in military Veterans with Parkinson's Disease (PD)	Tuesday, October 6	9:30 - 10:30	Session 7	Station 28	2	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Aliya Sarwar
1048	Categorization and Characterization of Cognitive Phenotypes in Parkinson's Disease Using Machine Learning.	Tuesday, October 6	9:30 - 10:30	Session 7	Station 28	3	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Harold Trujillo-Guerra
1049	Comprehensive Cognitive Assessment Scales and APOE Gene Impact on Cognitive Function in Parkinson's Disease: A Beijing Population Study	Tuesday, October 6	9:30 - 10:30	Session 7	Station 28	4	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Zhiyue Wu
1050	A Retrospective Cohort-Based Construction of a Risk Prediction Model for Anxiety or Depression in Parkinson's Disease and Analysis of Acupuncture Exposure Effects	Tuesday, October 6	9:30 - 10:30	Session 7	Station 28	5	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Wu YiXuan
1051	Prevalence and Clinical Determinants of Cognitive Impairment in a Diverse Parkinson's Disease Cohort	Tuesday, October 6	9:30 - 10:30	Session 7	Station 28	6	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Alexandra Zirra
79	Remotely acquired speech-based biomarkers and their relation to motor and cognitive functions in Parkinson's disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 1	1	Telemedicine	Alexander Jäck
80	Telemedicine in Parkinson's Disease Management: Lessons from Resource-Limited Settings Like Nepal	Tuesday, October 6	12:30 - 13:30	Session 8	Station 1	2	Telemedicine	AYUSH CHANDRA
81	The OxQUIP At-Home Study: Protocol and Preliminary Findings	Tuesday, October 6	12:30 - 13:30	Session 8	Station 1	3	Telemedicine	Niall Conway
82	Evaluating Parkinson's Disease Telehealth in Residential Aged Care	Tuesday, October 6	12:30 - 13:30	Session 8	Station 1	4	Telemedicine	Jo-Anne Ponce

83	Holistic Sensor-Based Profiling of Parkinson's Disease via Mixed Reality: Implementation and Multimodal Feasibility	Tuesday, October 6	12:30 - 13:30	Session 8	Station 1	5	Telemedicine	Wojciech Szecowka
9	An International Consensus Framework for Computer Vision-ready acquisition and reporting: Toward Measurement-grade video in Neurology	Tuesday, October 6	12:30 - 13:30	Session 8	Station 2	1	Artificial Intelligence (AI) and Machine Learning	Jane Alty
10	Objective detection of morning bradykinesia in Parkinson's Disease using a wearable inertial sensor	Tuesday, October 6	12:30 - 13:30	Session 8	Station 2	2	Artificial Intelligence (AI) and Machine Learning	Nuria Caballo
11	Detecting Early and Prodromal Parkinson's Disease in the Elderly Using Multimodality Digital Biomarkers: A Pilot Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 2	3	Artificial Intelligence (AI) and Machine Learning	Sung-Pin Fan
12	Deep Learning-Enhanced Multimodal MRI for Real-World Differentiation of Parkinsonian Disorders	Tuesday, October 6	12:30 - 13:30	Session 8	Station 2	4	Artificial Intelligence (AI) and Machine Learning	Septian Hartono
13	Prediction of Cognitive Decline After STN-DBS in Parkinson's Disease Using Preoperative Electroencephalography and a Deep Learning Model	Tuesday, October 6	12:30 - 13:30	Session 8	Station 2	5	Artificial Intelligence (AI) and Machine Learning	Kosuke Iwami
14	Uncovering Sleep Neural Signatures of Parkinson's Disease and REM Sleep Behavior Disorder from Polysomnography through Interpretable Deep Learning	Tuesday, October 6	12:30 - 13:30	Session 8	Station 2	6	Artificial Intelligence (AI) and Machine Learning	Sunil Kim
298	Nigrostriatal Dopaminergic Impairment Patterns in Idiopathic Normal Pressure Hydrocephalus Identified by 18F-FP-DTBZ PET: a 5-Year Longitudinal Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 3	1	Parkinsonism (Other)	Chong Dong
299	Gait parameters, Imaging features, and CSF tap test in idiopathic Normal Pressure Hydrocephalus (iNPH) Is composite testing the way to go	Tuesday, October 6	12:30 - 13:30	Session 8	Station 3	2	Parkinsonism (Other)	Arunmozhi aran Elavarasi
300	Cognitive profiles in idiopathic normal pressure hydrocephalus: clinical patterns and the impact of coexisting neurodegeneration	Tuesday, October 6	12:30 - 13:30	Session 8	Station 3	3	Parkinsonism (Other)	Christian Espinoza-Vinces
301	Homozygous ATP13A2 Mutation Associated Kufor-Rakeb Syndrome Expanding The Spectrum Of Juvenile Parkinsonism	Tuesday, October 6	12:30 - 13:30	Session 8	Station 3	4	Parkinsonism (Other)	Antonio Guechi
302	Sudomotor Dysfunction in Patients With Normal and Abnormal Cardiac MIBG	Tuesday, October 6	12:30 - 13:30	Session 8	Station 3	5	Parkinsonism (Other)	Zhilin Jiang
303	Pattern and progression of sudomotor dysfunction in alpha synucleinopathies	Tuesday, October 6	12:30 - 13:30	Session 8	Station 3	6	Parkinsonism (Other)	Zhilin Jiang
164	Evaluation of Semantic Space Search Metrics in Phonemic Fluency: Comparison among Basal Ganglia Disorders and Healthy Controls	Tuesday, October 6	12:30 - 13:30	Session 8	Station 4	1	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Shunsuke Kobayashi

165	Corticobasal Syndrome: A Single-Center Retrospective Review	Tuesday, October 6	12:30 - 13:30	Session 8	Station 4	2	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Emma Krening
166	Multiple System Atrophy-India (MSA-IND) Registry	Tuesday, October 6	12:30 - 13:30	Session 8	Station 4	3	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Niraj Kumar
167	Clinical progression of PSP-Richardson's syndrome and other PSP variants in an East Asian cohort	Tuesday, October 6	12:30 - 13:30	Session 8	Station 4	4	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Seungmin Lee
168	The epidemiological study of multiple system atrophy beginning in Hokkaido, Japan 2014-2026	Tuesday, October 6	12:30 - 13:30	Session 8	Station 4	5	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Masaaki Matsushima
169	Latin American (LatAM) Progressive Supranuclear Palsy Consortium	Tuesday, October 6	12:30 - 13:30	Session 8	Station 4	6	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jacy Parmera
386	Deep Brain Stimulation for Focal Abdominal Dystonia	Tuesday, October 6	12:30 - 13:30	Session 8	Station 5	1	Dystonia: Medical Therapy / Surgical Therapy	Carina França
387	Circuit Malfunctions Undetectable by DBS Programmers: Role of Intraoperative Direct Measurement of Impedance	Tuesday, October 6	12:30 - 13:30	Session 8	Station 5	2	Dystonia: Medical Therapy / Surgical Therapy	Jun Ikezawa
388	Clinical Outcomes of Deep Brain Stimulation in Malaysian Children with Pharmacoresistant Dystonia	Tuesday, October 6	12:30 - 13:30	Session 8	Station 5	3	Dystonia: Medical Therapy / Surgical Therapy	Wei Kang Lim
389	Single stage Dual target Deep Brain Stimulation for Dystonic Tremor	Tuesday, October 6	12:30 - 13:30	Session 8	Station 5	4	Dystonia: Medical Therapy / Surgical Therapy	TANMOY MAITI
390	Dystonia 3x3: A training framework for beginners in botulinum neurotoxin treatment of cervical dystonia	Tuesday, October 6	12:30 - 13:30	Session 8	Station 5	5	Dystonia: Medical Therapy / Surgical Therapy	Sebastian Paus
391	Phenotypic Spectrum, Neuroimaging Findings, Genotypic Correlates, and Treatment Outcomes in KMT2B-Related Disorder: A Multicenter Retrospective Cohort Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 5	6	Dystonia: Medical Therapy / Surgical Therapy	Sayoni RoyChowdhury

332	Basal ganglia and cerebellum involvement in Myelin Oligodendrocyte antibody associated disease (MOGAD) presenting with facial Dystonia and limb Tremor	Tuesday, October 6	12:30 - 13:30	Session 8	Station 6	1	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Neetu Sinha
333	Adult Onset Isolated Lower Limb Dystonia: Clinical Phenomenology and Dopaminergic Imaging Correlates	Tuesday, October 6	12:30 - 13:30	Session 8	Station 6	2	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Paloma Becker
334	Pallidal Local Field Potentials modulation by Deep Brain Stimulation in Acquired Dystonia due to Kernicterus	Tuesday, October 6	12:30 - 13:30	Session 8	Station 6	3	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Francesca Antonio Cammarota
335	Hemidystonia Beyond the Basal Ganglia: Etiological Heterogeneity in an 11 Patient Case Series	Tuesday, October 6	12:30 - 13:30	Session 8	Station 6	4	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Hector Canfield Medina
336	Longitudinal motor network responses to pallidal DBS in cervical dystonia: an ongoing DBS-fMRI study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 6	5	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Eric Cito
337	Serum Biomarker Profiles in Adolescents with Type 1 Diabetes-Associated Dystonia: The Role of Neurofilament Light Chain and Metabolic Indices	Tuesday, October 6	12:30 - 13:30	Session 8	Station 6	6	Dystonia: Disease Mechanisms / Neuroimaging / Neurophysiology	Ankush Kumar
480	Effect Of Low Frequency rTMS on Functional Tremor - Objective Evidence From A Single-Session And Longitudinal Observations	Tuesday, October 6	12:30 - 13:30	Session 8	Station 7	1	Functional Movement Disorders / Psychogenic Movement Disorders	Dipanwita Santra
481	Neuroprotective Effects of Emodin Against Rotenone-Induced Parkinsonism Through Regulation of SIRT1-Mediated Inflammasome and Nrf2 Pathways	Tuesday, October 6	12:30 - 13:30	Session 8	Station 7	2	Functional Movement Disorders / Psychogenic Movement Disorders	Abhishek Kumar
482	Dual Task Effect in Posturography Enhances Diagnosis of Functional Ataxia	Tuesday, October 6	12:30 - 13:30	Session 8	Station 7	3	Functional Movement Disorders / Psychogenic Movement Disorders	Anastasia Mezenchuk
483	Prevalence of Functional Neurological Signs in Parkinson's Disease: A Multicenter Cross-Sectional Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 7	4	Functional Movement Disorders / Psychogenic Movement Disorders	Ava baghaei
484	Functional Movement Disorders in Older Adults in Latin America: A Narrative Literature Review	Tuesday, October 6	12:30 - 13:30	Session 8	Station 7	5	Functional Movement Disorders / Psychogenic Movement Disorders	Maria Bonilla-Arbeláez
485	A Novel Bedside Clinical Test ("Vibration" Sign) Improves Diagnostic Differentiation of Functional Movement Disorders: A Prospective Pilot Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 7	6	Functional Movement Disorders / Psychogenic Movement Disorders	Divyani Garg

526	Home-Based Targeted tDCS for Cerebellar Ataxia: Results of a Randomized Double-Blind Crossover Study with Remote Functional Assessment	Tuesday, October 6	12:30 - 13:30	Session 8	Station 8	1	Ataxia	Nikole Rozenberg
527	Clinicogenetic Characterization of Sporadic Adult-Onset Ataxias in Austria	Tuesday, October 6	12:30 - 13:30	Session 8	Station 8	2	Ataxia	Lina Schwaighofer
528	The Non-Motor and Extra-Cerebellar Motor Spectrum of Adult-Onset Genetic and Sporadic Cerebellar Ataxias	Tuesday, October 6	12:30 - 13:30	Session 8	Station 8	3	Ataxia	Emma Woo
529	Genetic spectrum of spinocerebellar ataxia type 27b (atx-fgf14-gaa): a single-center study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 8	4	Ataxia	Arina Protsenko
530	Progressive Lifelong Chorea with Spastic Paraparesis and Cerebellar Ataxia Associated with Two Heterozygous Variants in the SYNE1 Gene: A Case Report	Tuesday, October 6	12:30 - 13:30	Session 8	Station 8	5	Ataxia	Iva Sarac
531	Expanding the clinical and genetic spectrum of SCA15: a rare case report	Tuesday, October 6	12:30 - 13:30	Session 8	Station 8	6	Ataxia	Mansi Shah
650	Tremor on Smiling but Not Laughing: An Electrophysiological Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 9	1	Tremor	Yi-Cheng Tai
651	Development of Motor Complications in Rubral Tremor treated with Levodopa	Tuesday, October 6	12:30 - 13:30	Session 8	Station 9	2	Tremor	Tara Torabi
652	Kinetic–rest tremor polarity for differentiating dystonic tremor and Parkinson’s disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 9	3	Tremor	Takashi Tsuboi
653	Clinical Effectiveness of Radiofrequency Thermal Ablative Lesioning for the Management of Motor Symptoms in Movement Disorders: Real-World Evidence	Tuesday, October 6	12:30 - 13:30	Session 8	Station 9	4	Tremor	Jan Vesper
654	Comparing Deep Brain Stimulation and MRI-Guided Focused Ultrasound Thalamotomy for Essential Tremor: A Single-Center, 1-Year Observational Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 9	5	Tremor	Emma Woo
655	Local Brain Structural Changes After Transcranial Magnetic Stimulation for Essential Tremor: An Exploratory MRI Analysis	Tuesday, October 6	12:30 - 13:30	Session 8	Station 9	6	Tremor	Jing Xu
551	Extracellular Small RNAs in Huntington’s disease: from Brain to CSF Analysis	Tuesday, October 6	12:30 - 13:30	Session 8	Station 10	1	Huntington's Disease	Gonzalo Olmedo-Saura
552	PPAR-γ-dependent Neuroprotection by Ferulic acid improves Motor deficits in 3-nitropropionic acid model of Huntington’s disease in rats	Tuesday, October 6	12:30 - 13:30	Session 8	Station 10	2	Huntington's Disease	Nishandeep Singh
553	Effectiveness and Safety of Deutetrabenazine in Chinese Patients with Huntington’s Disease-associated Chorea: A Multicenter Phase 4 Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 10	3	Huntington's Disease	Yangfan Cheng

554	Patient and Caregiver Perspectives on Patient Burden of Huntington Disease Chorea and the Real-World Impact of Deutetrabenazine Treatment	Tuesday, October 6	12:30 - 13:30	Session 8	Station 10	4	Huntington's Disease	Daniel Claassen
555	Depressive Symptoms and Functional Impairment in Huntington's Disease A Brazilian Cohort Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 10	5	Huntington's Disease	Débora Corrêa
556	Psychiatric Symptoms and Quality of Life in Huntington's Disease Evidence from a Brazilian Cohort	Tuesday, October 6	12:30 - 13:30	Session 8	Station 10	6	Huntington's Disease	Débora Corrêa
1929	IncobotulinumtoxinA for the Treatment of Lower Limb Spasticity in Children and Adolescents with Cerebral Palsy Evaluation of Lower Limb IncobotulinumtoxinA Efficacy (ELLIE)	Tuesday, October 6	12:30 - 13:30	Session 8	Station 11	1	Pediatric Movement Disorders	Iryna Makedonska
1930	Presence of Common Psychiatric Diagnoses Did Not Impact the Efficacy or Safety of Ecopipam in Individuals With Tourette Syndrome	Tuesday, October 6	12:30 - 13:30	Session 8	Station 11	2	Pediatric Movement Disorders	Joseph McGuire
1931	Childhood-Onset Parkinsonism with Prominent Pyramidal Signs: A Complex Neurogenetic Phenotype	Tuesday, October 6	12:30 - 13:30	Session 8	Station 11	3	Pediatric Movement Disorders	Daniela Munoz-Chesta
1932	Basal Ganglia Germinoma (BGG) Presenting as Hemidystonia	Tuesday, October 6	12:30 - 13:30	Session 8	Station 11	4	Pediatric Movement Disorders	Casey Ryan
1933	Movement Disorder Spectrum and Neurological Outcomes in Children with Neuronal Ceroid Lipofuscinosis	Tuesday, October 6	12:30 - 13:30	Session 8	Station 11	5	Pediatric Movement Disorders	Arushi Saini
1934	Functional Improvement Following Early GPi-DBS for Moderate-Stage Atypical KMT2B Dystonia: A Case Report in a 13-Year-Old Girl	Tuesday, October 6	12:30 - 13:30	Session 8	Station 11	6	Pediatric Movement Disorders	Zoé Sclavont
735	Real-World Impact of "Off" Time Reduction with Foslevodopa/Foscarbidopa in Advanced Parkinson's Disease: Post Hoc Analysis of the ROSSINI Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 12	1	Parkinson's Disease: Clinical Trials	Wolfgang Jost
736	Pulse-Width Dependent Motor Performance in Deep Brain Stimulation of Subthalamic Nucleus in Parkinson's Disease: Evidence for a Kinematic Optimum Near 50 μ s in Hand Movement	Tuesday, October 6	12:30 - 13:30	Session 8	Station 12	2	Parkinson's Disease: Clinical Trials	Philipp Köberle
737	Efficacy of Repetitive Transcranial Magnetic Stimulation for Improving Motor Function in Parkinson's disease; A Prospective, Multicenter, Crossover Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 12	3	Parkinson's Disease: Clinical Trials	Sang jin Lee
738	Effectiveness of Acupuncture for Parkinson's Disease with Mild Cognitive Impairment A Randomized Clinical Trial	Tuesday, October 6	12:30 - 13:30	Session 8	Station 12	4	Parkinson's Disease: Clinical Trials	Ian I. Leong
739	Effects of Bright Light Therapy On Sleep And Functional Brain Networks In Parkinson's Disease-A Pilot Trial	Tuesday, October 6	12:30 - 13:30	Session 8	Station 12	5	Parkinson's Disease: Clinical Trials	Hanxing Li

740	Can Voice Therapy Improve Swallowing in Advanced Parkinson's Disease? A Comparison of SPEAK OUT!® Outcomes in Patients With Deep Brain Stimulation and Medical Therapy	Tuesday, October 6	12:30 - 13:30	Session 8	Station 12	6	Parkinson's Disease: Clinical Trials	Nontakorn Likhitwitaya wuid
807	Levodopa-Induced Dyskinesias in Patients with Parkinson's Disease in the Uzbek Population	Tuesday, October 6	12:30 - 13:30	Session 8	Station 13	1	Parkinson's Disease: Pharmacology and Medical Management	Gullola Isroilova
808	Clinical Impact of Nicotine in Parkinson's Disease: Evidence from Randomized Controlled Studies	Tuesday, October 6	12:30 - 13:30	Session 8	Station 13	2	Parkinson's Disease: Pharmacology and Medical Management	Jamir Pitton Rissardo
809	Harnessing the Local Wisdom of Central Kalimantan's Eleutherine palmifolia (Dayak Onion) in Parkinson's Disease Therapy: A Molecular Docking and Ethnopharmacological Study"	Tuesday, October 6	12:30 - 13:30	Session 8	Station 13	3	Parkinson's Disease: Pharmacology and Medical Management	Ranintha Surbakti
810	Aerva Lanata Decoction Alleviates Neuroinflammation And Locomotor Dysfunction In Parkinson Model	Tuesday, October 6	12:30 - 13:30	Session 8	Station 13	4	Parkinson's Disease: Pharmacology and Medical Management	GIRISH CHANDRAN
811	Repurposing Rifabutin for Neuro-Metabolic Disorders: AMPK-PGC-1 α -Driven Mitochondrial Protection in Diabetes Associated Parkinsonism	Tuesday, October 6	12:30 - 13:30	Session 8	Station 13	5	Parkinson's Disease: Pharmacology and Medical Management	MOHD IBRAHIM KHAN
812	Icariin, a Flavonoid from Epimedium, Confers Dopaminergic Neuroprotection and Neuromodulation in MPTP-Induced Parkinsonian Rats	Tuesday, October 6	12:30 - 13:30	Session 8	Station 13	6	Parkinson's Disease: Pharmacology and Medical Management	Amit Singh
879	Continuous Subcutaneous Levodopa Therapy Improves Motor Fluctuations and Quality of Life in Parkinson's Disease: Evidence from Meta-analysis of Clinical Trials	Tuesday, October 6	12:30 - 13:30	Session 8	Station 14	1	Parkinson's Disease: Pharmacology and Medical Management	Khalid Sarhan
880	From Roots to Relief: A Systematic Review of Herbal Medicines in Parkinson's Management	Tuesday, October 6	12:30 - 13:30	Session 8	Station 14	2	Parkinson's Disease: Pharmacology and Medical Management	Narumol Sukmueng
881	A Case Report: Optimising Motor and Non-Motor Control in Advanced Parkinson's Disease: The Role of Foslevodopa/Foscarbidopa After Deep Brain Stimulation	Tuesday, October 6	12:30 - 13:30	Session 8	Station 14	3	Parkinson's Disease: Pharmacology and Medical Management	Jacinta Wong
882	Medical Management of Late-stage Parkinson's Disease – a Cross-sectional, Multinational Survey	Tuesday, October 6	12:30 - 13:30	Session 8	Station 14	4	Parkinson's Disease: Pharmacology and Medical Management	Christine Pallauf
883	Modulation of Excitatory/Inhibitory Neurotransmission via Targeting GABAA-Gephyrin Signaling: Integrated In-Silico, In-Vitro, and In-Vivo Evidence in Parkinson's Disease Models	Tuesday, October 6	12:30 - 13:30	Session 8	Station 14	5	Parkinson's Disease: Pharmacology and Medical Management	Shivani Chib

884	Predictors of Levodopa-Induced Dyskinesia in Parkinson's Disease: A Systematic Review and Meta-Analysis	Tuesday, October 6	12:30 - 13:30	Session 8	Station 14	6	Parkinson's Disease: Pharmacology and Medical Management	Ahmed Elsaid
1857	Clinical Predictors of Cognitive Decline in Parkinson's Disease: A Longitudinal Cohort Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 15	1	Parkinson's Disease (Other)	Irina Zhukova
1858	Pelvic periosteal stimulation for Axial Rigidity in Parkinson's Disease: A Retrospective Case Series	Tuesday, October 6	12:30 - 13:30	Session 8	Station 15	2	Parkinson's Disease (Other)	Aerisa Ahn
1859	Menstrual Cycle Influence on Parkinson's Disease Symptoms in Women with Early-Onset	Tuesday, October 6	12:30 - 13:30	Session 8	Station 15	3	Parkinson's Disease (Other)	Elina Bagdasarova
1860	The Care Assessment Need Score Underestimates 90-Day Mortality in Veterans with Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 15	4	Parkinson's Disease (Other)	Abigail Bossart
1861	Nutritional Status Assessment in Patients with Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 15	5	Parkinson's Disease (Other)	María Belén Charra Castellani
1862	Prodromal Parkinson's Disease in Singapore: Motor and Non-Motor Symptom Patterns	Tuesday, October 6	12:30 - 13:30	Session 8	Station 15	6	Parkinson's Disease (Other)	Regina Chen
907	Seed Amplification Assay Is More Sensitive To Detecting α -Synuclein In Gut Biopsies Than Immunohistochemistry	Tuesday, October 6	12:30 - 13:30	Session 8	Station 16	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Bryan Killinger
908	Mild Motor Impairments in Rapid Eye Movement Behavior Disorder: Tremor and Bradykinesia	Tuesday, October 6	12:30 - 13:30	Session 8	Station 16	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Joonho Lee
909	Clinical Relevance of Oral Health Assessment in Parkinson's Disease Monitoring	Tuesday, October 6	12:30 - 13:30	Session 8	Station 16	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Raza Naqvi
910	Delineating Therapeutic and Non-therapeutic Neural Signatures of Deep Brain Stimulation	Tuesday, October 6	12:30 - 13:30	Session 8	Station 16	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Tanmoy Sil
911	Unraveling Kinase-Phosphatase Dysregulation in Parkinson's disease Peripheral Blood Mononuclear Cells Through Targeted Transcript Analysis	Tuesday, October 6	12:30 - 13:30	Session 8	Station 16	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Esha Basu
912	Beyond Freezing of Gait Episodes in Parkinson's Disease: Intercritical Kinematic Gait Pattern Matters.	Tuesday, October 6	12:30 - 13:30	Session 8	Station 16	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Giuseppe De Biasi
979	EEG-based Functional Connectivity Reveals a Genotype-Specific Network Signature in GBA-Associated Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 17	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Matteo Conti
980	Olfactory Dysfunction Across Neurodegenerative Disorders: A Prospective Cross-Sectional Comparison of Parkinson's Disease, Alzheimer's Disease and Idiopathic REM Sleep Behavior Disorder	Tuesday, October 6	12:30 - 13:30	Session 8	Station 17	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Johanna Einhaus
981	Associations Between Saccadic and Motoric Symptoms in Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 17	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Melissa Gibbs

982	Underestimation of Nighttime Sleep Symptoms in Isolated RBD is Associated with Increased Risk of Phenoconversion to Synucleinopathy: A North American Prodromal Synucleinopathy Consortium Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 17	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Jongmok Ha
983	Event-Locked Characterization of Movement-Related Beta Modulation using Synchronized Local Field Potentials and Video-Based Kinematics	Tuesday, October 6	12:30 - 13:30	Session 8	Station 17	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Deborah Hubers
984	Longitudinal Association Between Baseline CSF GFAP Levels and Clinical Progression in Parkinson's Disease A PPMI Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 17	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Zahra Huseynli
1121	Sensor-Derived Gait Patterns Predict Motor Progression in Parkinson's Disease Beyond Baseline Dopamine Transporter Imaging	Tuesday, October 6	12:30 - 13:30	Session 8	Station 18	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Hwayoung Park
1122	Rates Of Phenoconversion And Progression To Functionally Meaningful Impairment In NSD Stage 2B Participants: PPMI cohort	Tuesday, October 6	12:30 - 13:30	Session 8	Station 18	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Tanya Simuni
1123	Diet Quality and Nutrient Intake in Parkinson's Disease: A Multicenter Study in Egypt	Tuesday, October 6	12:30 - 13:30	Session 8	Station 18	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Elsayed Abed
1124	The "Guarda" (Tower) Drawing Test: A Novel Bedside Tool to Quantify Bradykinesia in Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 18	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Santiago Celi Aguilar
1125	Multimodal Gait Analysis Using Video Pose Estimation Deep Learning and Walkway Parameters: Parkinsonism Detection and Phenotyping	Tuesday, October 6	12:30 - 13:30	Session 8	Station 18	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Yoon Seob Kim
1126	Electronic Health Record Integration Improves Markerless 3D Gait-Based Prediction of Parkinson's Disease Motor Symptom Severity	Tuesday, October 6	12:30 - 13:30	Session 8	Station 18	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Lauren Lim

1193	Does Fall-Related Activity Avoidance Differ between people with Parkinson's disease versus Cognitively Unimpaired Controls?	Tuesday, October 6	12:30 - 13:30	Session 8	Station 19	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Magnus Lindh-Rengifo
1194	Multidimensional Motor Dysfunction in Early Parkinsons Disease With Turning Velocity as a Sensitive Staging Biomarker	Tuesday, October 6	12:30 - 13:30	Session 8	Station 19	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Peipei Liu
1195	Determinants of Quality of Life According to Brain-first and Body-first in Patients with Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 19	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Xi-ning Liu
1196	Quantitative Analysis of Oculomotor Abnormalities in Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 19	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Yue Liu
1197	Differential Oculomotor Patterns in Parkinson's Disease and Multiple System Atrophy With Predominant Parkinsonism	Tuesday, October 6	12:30 - 13:30	Session 8	Station 19	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Yue Liu
1198	Cross-Cultural Validation of the Hebrew version of The International Parkinson and Movement Disorder Society Non-Motor Rating Scale	Tuesday, October 6	12:30 - 13:30	Session 8	Station 19	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Vered Livneh
1265	Clinical Outcome Assessments for Parkinson's Disease Psychosis: A Systematic Review	Tuesday, October 6	12:30 - 13:30	Session 8	Station 20	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ellen Camboe
1266	Investigating Smiling Asymmetries in Parkinson's Disease through the Whistle-Smile Reflex	Tuesday, October 6	12:30 - 13:30	Session 8	Station 20	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Martina De Riggi

1267	Metabolic Syndrome is not Associated with Parkinson's Disease Severity, but Individual Metabolic Components May Be	Tuesday, October 6	12:30 - 13:30	Session 8	Station 20	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Taís Denicol
1268	Revisiting the Association between Estrogen Exposure and Parkinson's Disease: A Fox Insight Analysis	Tuesday, October 6	12:30 - 13:30	Session 8	Station 20	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Surabhi Dharmadhikari
1269	Evaluating Environmental, Cognitive and Psychiatric Factors in Pakistani PD patients: London Pakistan Parkinson's Project (LP-3) Pilot Findings	Tuesday, October 6	12:30 - 13:30	Session 8	Station 20	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Faiza Durrani
1270	Clinical and Sociodemographic Characteristics of Rural and Urban Individuals Living with Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 20	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Kalyn Dyer
1337	Considering Oral Health to Optimise the Potential for Current and Future Treatments in Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 21	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jane Price
1338	Characteristics and Outcomes of Hospitalisation Episodes for Australians living with Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 21	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Sze-Ee Soh
1339	Association Between Step Count Change Rate During Dual Task Timed Up and Go and Balance Components in Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 21	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Yuta Yamazaki
1351	Bridging the Genomic Gap: Ancestry-Aware Polygenic Risk and Variant Discovery in African Parkinson's Disease Cohorts	Tuesday, October 6	12:30 - 13:30	Session 8	Station 21	4	Parkinson's Disease: Genetics	Benjamin Adebisi
1352	Differential expression of nucleotide excision repair genes in Parkinson's disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 21	5	Parkinson's Disease: Genetics	Pavel Francisco Bermúdez Ramírez

1353	SMR Combined with Multi Omics to Investigate the Mechanism of Action of the Cell Senescence Associated Gene (CDK2AP1) in Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 21	6	Parkinson's Disease: Genetics	Jianzhun Chen
1409	Identification of DAGLB Variants in Chinese Patients With Early-Onset Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 22	1	Parkinson's Disease: Genetics	Wen Ren
1410	The Effect of LRRK2 and GBA1 Mutations on Survival in Early- and Late-onset Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 22	2	Parkinson's Disease: Genetics	Raz Rubin
1411	Lack of Association Between Polygenic Risk Scores for Parkinson's Disease and Age at Onset, Freezing of Gait, or Psychosis	Tuesday, October 6	12:30 - 13:30	Session 8	Station 22	3	Parkinson's Disease: Genetics	Roni Shisgal
1412	Monogenic Parkinson's Disease Australia (MonoPDAus) Project Update	Tuesday, October 6	12:30 - 13:30	Session 8	Station 22	4	Parkinson's Disease: Genetics	Sue-Faye Siow
1413	Complex FGF14 Repeat Expansion in Early-Onset Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 22	5	Parkinson's Disease: Genetics	Dejin Song
1414	Genetic analysis of Mongolian patients with Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 22	6	Parkinson's Disease: Genetics	Bayasgalan Tserensodnom
1481	Clinical Significance of Automatically Assessed Perivascular Space Count in Subcortical White Matter of Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 23	1	Parkinson's disease: Neuroimaging	Seok Jong Chung
1482	R1 from 18PR04.MZ as a Proxy for Cerebral Blood Flow in Degenerative Parkinsonism: Comparison with 15O-H2O PET/CT.	Tuesday, October 6	12:30 - 13:30	Session 8	Station 23	2	Parkinson's disease: Neuroimaging	Andres Damian
1483	Baseline MRI Predictors of Phenoconversion and Prodromal Progression in Non-Manifesting PD Mutation Carriers: A Longitudinal Retrospective Analysis	Tuesday, October 6	12:30 - 13:30	Session 8	Station 23	3	Parkinson's disease: Neuroimaging	Amgad Droby
1484	Topographic Heterogeneity of Dopaminergic Denervation and Iron Deposition in Functional Subregions of Nigrostriatal System in Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 23	4	Parkinson's disease: Neuroimaging	YuJie Duan
1485	Does PET Imaging Modality Influence Artificial Intelligence Performance in Diagnosing Parkinson's Disease? Diagnostic Test Accuracy Meta-analysis	Tuesday, October 6	12:30 - 13:30	Session 8	Station 23	5	Parkinson's disease: Neuroimaging	Mohamed Hamouda Elkasaby
1486	Toward Objective Monitoring of Motor Fluctuations in Parkinson's Disease: TMS-EEG Biomarkers	Tuesday, October 6	12:30 - 13:30	Session 8	Station 23	6	Parkinson's disease: Neuroimaging	Tsvia Fay-Karmon
1553	Semiquantitative [¹²³ I]FP-CIT SPECT metrics combined with machine learning improve clinical differentiation of parkinson's disease and atypical parkinsonian syndrome	Tuesday, October 6	12:30 - 13:30	Session 8	Station 24	1	Parkinson's disease: Neuroimaging	Paula Fernandez-Rodriguez
1554	The Anxiolytic Effect of Cannabidiol and Tetrahydrocannabinol in a Reserpine Model of Parkinson's Disease in Mice	Tuesday, October 6	12:30 - 13:30	Session 8	Station 24	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Halima Tanko

1555	The Effects of Bright Light Therapy on Improving Sleep Disorders in Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 24	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Wei-Ye Xie
1556	Association of Triglycerides, LDL, and IL-6 with Non-Motor Symptoms in Parkinson's Disease: A Cross-Sectional Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 24	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Fortune de Amor
1557	Cerebral Small Vessel Disease Burden and Motor Phenotype Expression in Parkinsonian Syndromes: A Quantitative Neuroimaging Analysis	Tuesday, October 6	12:30 - 13:30	Session 8	Station 24	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Fayzullo Mallaev
1558	Hula as an Integrative Movement-Based Therapy: Baseline Cohort Characteristics	Tuesday, October 6	12:30 - 13:30	Session 8	Station 24	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Ruby Shuman
1625	Wearable IMU-Based Gait Analysis Reveals Pharmacological Freezing-of-Gait Phenotypes in Parkinson Disease: A Longitudinal Two-Visit Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 25	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	FURKAN TOKDEMİR
1626	Subthalamic Nucleus Oscillatory Coupling During Sleep is Impaired in Parkinson's Disease and Associated with Memory Consolidation	Tuesday, October 6	12:30 - 13:30	Session 8	Station 25	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Zixiao Yin
1627	Baseline auditory-perceptual speech ratings predict improvement in voice intensity after group-based speech intervention in Parkinson's disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 25	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Hanna Steurer
1628	Feasibility and Preliminary Outcomes of an Online Fatigue Self Management Programme for People With Parkinsons Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 25	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	sarah Alageel
1629	Pain Inverts the Relationship Between Beta-band Power and Fatigue Severity in PD: an EEG Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 25	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Alfonso Hurtado-Martínez
1630	The association of low back pain-related disability with functional mobility among individuals with Parkinson disease in Sri Lanka.	Tuesday, October 6	12:30 - 13:30	Session 8	Station 25	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Sanduni Thakshila
1678	Lipid Alterations in Central Nervous System and Plasma During Early Stages of Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 26	1	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Poonam Thakur

1679	Single-Cell Transcriptomics and Experimental Models Implicate Functional Hypoxia in Microglial DAM Polarization and α -Synuclein Accumulation, with Involvement of HIF-1 α , in Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 26	2	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Hualin Wang
1680	Altered Glia Limitans Structure and Function in Parkinson's Disease and Multiple System Atrophy	Tuesday, October 6	12:30 - 13:30	Session 8	Station 26	3	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Lingbing Wang
1681	GBA1 L444P mutation increases susceptibility to neuroinflammation and promotes pro-inflammatory immune responses	Tuesday, October 6	12:30 - 13:30	Session 8	Station 26	4	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Ruochen Wang
1682	TMEM106B Fibrils Potentiate Pathological α -Synuclein Aggregation in Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 26	5	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Wanbing Zhao
1683	Association of MT-ATP6 Polymorphisms with Increased Reactive Oxygen Species and Biomarker Alterations in Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 26	6	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Bala Chandar
1769	Protocol for Rapidly Adaptive Deep Brain Stimulation to improve Freezing of Gait in Patients with Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 27	1	Parkinson's Disease: Surgical Therapy	Jamal Al Ali
1770	Risk of Ischemic Cerebrovascular Events in Patients with Deep Brain Stimulation for Parkinson's Disease: A Cohort Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 27	2	Parkinson's Disease: Surgical Therapy	Pietro Antenucci
1771	Adaptive Deep Brain Stimulation in Parkinson Disease: Preliminary Single-Center Results	Tuesday, October 6	12:30 - 13:30	Session 8	Station 27	3	Parkinson's Disease: Surgical Therapy	Cristina Gonzalez-Robles
1772	All Left: A Case of Ipsilateral Stimulation Induced Dyskinesia	Tuesday, October 6	12:30 - 13:30	Session 8	Station 27	4	Parkinson's Disease: Surgical Therapy	Pooja Gupta
1773	Deep Brain Stimulation Outcomes in Parkinson's Disease Patients With GBA1 Variants: A Systematic Review and Meta-analysis	Tuesday, October 6	12:30 - 13:30	Session 8	Station 27	5	Parkinson's Disease: Surgical Therapy	Amir Hegazi
1774	Tremorography as an objective marker of the response after MRgFUS VIM in essential tremor and Parkinson's disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 27	6	Parkinson's Disease: Surgical Therapy	Anna Krasilnikova
1052	Executive Dysfunction as a Determinant of Functional Impairment in Parkinson's Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 28	1	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Nanda Adhitama

1053	Improving Equitable Access to Parkinson's Disease Exercise Programs Through a Student-Led Transportation Model	Tuesday, October 6	12:30 - 13:30	Session 8	Station 28	2	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Sanaea Bhagwagar
1054	Impact of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion on Neuropsychiatric Symptoms in Clinical Practice: A Multicenter Study	Tuesday, October 6	12:30 - 13:30	Session 8	Station 28	3	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	D Campo-Caballero
1055	Differentiation of Parkinsonian Syndromes Using Cognitive Strategies and Associations with Non-tremor Motor Progression	Tuesday, October 6	12:30 - 13:30	Session 8	Station 28	4	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Aminette D'Souza
1056	Parkinson disease psychosis: A systematic review and meta-analysis	Tuesday, October 6	12:30 - 13:30	Session 8	Station 28	5	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Jared Hinkle
1057	Synergistic Impact of Plasma Neurofilament Light Chain and Neuroimaging Deficits on Cognitive Decline in Prodromal Lewy Body Disease	Tuesday, October 6	12:30 - 13:30	Session 8	Station 28	6	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Keita Hiraga
106	Compassion Focussed Therapy Groups for People with Parkinson's and their care-partners	Tuesday, October 6	13:30 - 14:30	Session 9	Station 1	1	Quality Of Life/Caregiver Burden in Movement Disorders	Olivia Batterbee
107	Association of Riverine Heavy Metal Contamination with Parkinson's Disease Risk in Rural Pune: A Population-Based Case-Control Study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 1	2	Quality Of Life/Caregiver Burden in Movement Disorders	Anita Gangadhar
108	Beyond Symptom Relief: Physician Empathy Outperforms Clinical Severity in Predicting Quality of Life for Patients Undergoing Botulinum Toxin Therapy	Tuesday, October 6	13:30 - 14:30	Session 9	Station 1	3	Quality Of Life/Caregiver Burden in Movement Disorders	Tristan Kölsche
109	A Switching from Oral Donepezil to a Twice-Weekly Korean Transdermal Donepezil Patch in Patients with Dementia with PD	Tuesday, October 6	13:30 - 14:30	Session 9	Station 1	4	Quality Of Life/Caregiver Burden in Movement Disorders	Mee Park
110	Association of Quality of Life with Risk Markers and Prodromal Signs of Parkinson's Disease in the Population-Based Healthy Brain Ageing Study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 1	5	Quality Of Life/Caregiver Burden in Movement Disorders	Noelia Peña Arauzo
111	Self-Efficacy in Lewy Body Dementia Family Caregivers Is Associated with Better Sleep Quality and Social Support, and Lower Depression, Loneliness, and Strain	Tuesday, October 6	13:30 - 14:30	Session 9	Station 1	6	Quality Of Life/Caregiver Burden in Movement Disorders	Marla Tharp
15	Real-World Mobile Voice Classification for Parkinson's Disease Using Convolutional Neural Networks and Mel-Spectrogram Features	Tuesday, October 6	13:30 - 14:30	Session 9	Station 2	1	Artificial Intelligence (AI) and Machine Learning	Natthaphat Leabthong

16	Large Language Models for Clinical Feature Suggestion from Parkinson's Disease Clinical Notes	Tuesday, October 6	13:30 - 14:30	Session 9	Station 2	2	Artificial Intelligence (AI) and Machine Learning	Grace Yoojin Lee
17	Video-Based Gait Analysis for Objective Assessment of Motor Severity and Surgical Outcome in Parkinson's Disease: A Scalable Alternative to Subjective Rating	Tuesday, October 6	13:30 - 14:30	Session 9	Station 2	3	Artificial Intelligence (AI) and Machine Learning	Yavuz Samanci
18	External Validation of a Machine Learning Classifier for Motor Progression in Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 2	4	Artificial Intelligence (AI) and Machine Learning	Anupa Vijayakumari
19	Smartphone Video-Based Finger Tapping Analysis Using Machine Learning for Parkinson's Disease Classification	Tuesday, October 6	13:30 - 14:30	Session 9	Station 2	5	Artificial Intelligence (AI) and Machine Learning	Mrinal Acharya
20	Frequency and Phenotypic Characterization of Genetic Causes of Sporadic Late-Onset Cerebellar Ataxia: insights from a Cohort of 315 patients	Tuesday, October 6	13:30 - 14:30	Session 9	Station 2	6	Artificial Intelligence (AI) and Machine Learning	Marie Barrat
304	Phenotypic and Genotypic Spectrum of MAPT-associated Parkinsonism in a Multi-ethnic Malaysian Cohort	Tuesday, October 6	13:30 - 14:30	Session 9	Station 3	1	Parkinsonism (Other)	Jie Ping Schee
305	[18F]-FDG-PET metabolic phenotyping in idiopathic normal pressure hydrocephalus: visual and voxel-wise evidence across neurodegenerative phenotypes	Tuesday, October 6	13:30 - 14:30	Session 9	Station 3	2	Parkinsonism (Other)	Christian Espinoza-Vinces
306	DCTN1 Gene: A p.(Gly59Ser) Family Report	Tuesday, October 6	13:30 - 14:30	Session 9	Station 3	3	Parkinsonism (Other)	Giulia Fabris
307	Clinical features of vascular parkinsonism	Tuesday, October 6	13:30 - 14:30	Session 9	Station 3	4	Parkinsonism (Other)	Rasulberdi Juraev
308	Clinical-Radiological Correlation in Patients with brain calcifications: a case series	Tuesday, October 6	13:30 - 14:30	Session 9	Station 3	5	Parkinsonism (Other)	ADRIANA ORTIZ CARDENAS
309	Cognitive Profile In Indian Patients with Spinocerebellar Ataxia (SCA) - Prospective Cross-sectional Study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 3	6	Parkinsonism (Other)	Amira Patel
170	Clinical Characterization and Functional Correlates of Multiple System Atrophy in Sri Lanka: Preliminary Results from a Cross-Sectional Collaborative Study with Global Parkinson's Genetic Program (GP2)	Tuesday, October 6	13:30 - 14:30	Session 9	Station 4	1	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Amasha Pathirage
171	Prognostic Factors for Survival in Multiple System Atrophy: A Retrospective Cohort Study with Focus on Surgical Interventions	Tuesday, October 6	13:30 - 14:30	Session 9	Station 4	2	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Hideyuki Shimizu

172	A prospective single-center study investigating the utility of supportive features in the diagnosis of multiple system atrophy with predominant cerebellar ataxia	Tuesday, October 6	13:30 - 14:30	Session 9	Station 4	3	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Atsuhiko Sugiyama
173	Clinical Correlates of Dysphagia in Multiple System Atrophy: A Multicenter Retrospective Study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 4	4	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Nobutaka Takahashi
174	Quantitative Assessment of Finger Movement Profile in a Visual-Motor Task Using a Tablet Computer: Application in Multiple System Atrophy	Tuesday, October 6	13:30 - 14:30	Session 9	Station 4	5	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Peng Tang
175	Clinicodemographic characterization of Multiple System Atrophy in a multi-ethnic Malaysian cohort	Tuesday, October 6	13:30 - 14:30	Session 9	Station 4	6	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jeffrey Wei-Yang Tee
392	Motor and Non-motor Outcomes of Globus Pallidus internus Deep Brain Stimulation for Dystonia	Tuesday, October 6	13:30 - 14:30	Session 9	Station 5	1	Dystonia: Medical Therapy / Surgical Therapy	Vasundhara S Rangan
393	Dual Globus Pallidus Internus and Pallidothalamic Tract Deep Brain Stimulation for Hemichoreodystonia Secondary to Severe COVID-19 Infection: A Case Report	Tuesday, October 6	13:30 - 14:30	Session 9	Station 5	2	Dystonia: Medical Therapy / Surgical Therapy	Weerawat Saengphatrachai
394	Multi-target Deep Brain Stimulation for Dystonia and Complex tremor syndromes: A Single-Centre Case Series and Literature Review	Tuesday, October 6	13:30 - 14:30	Session 9	Station 5	3	Dystonia: Medical Therapy / Surgical Therapy	Alyssa Shiramba
395	When Muscles Relax but Symptoms Persist: A Case of Dysfunctional Sensory-Motor Cortical Integration in Botulinum Toxin-Resistant Blepharospasm	Tuesday, October 6	13:30 - 14:30	Session 9	Station 5	4	Dystonia: Medical Therapy / Surgical Therapy	Vasilii Tkachenko
396	Complete and sustained remission of cervical dystonia after repeated dual-target low-frequency rTMS (right M1 + left cerebellum): a 2-year follow-up case report	Tuesday, October 6	13:30 - 14:30	Session 9	Station 5	5	Dystonia: Medical Therapy / Surgical Therapy	Ying Wu
397	Simultaneous EEG and Pallidal Local Field Potential Recording in the Diagnosis of Paroxysmal Movements in a Patient with PDE2A Mutation	Tuesday, October 6	13:30 - 14:30	Session 9	Station 5	6	Dystonia: Medical Therapy / Surgical Therapy	Sushuma Yarlagadda
439	Determinants of depression severity in patients of Spinocerebellar ataxia 12	Tuesday, October 6	13:30 - 14:30	Session 9	Station 6	1	Education, History, Disparities (Other)	Janvi Bilga
440	Assessment of dysautonomia in patients with sporadic adult-onset ataxia	Tuesday, October 6	13:30 - 14:30	Session 9	Station 6	2	Education, History, Disparities (Other)	Natalija Joksimović

441	Effect of clonazepam on restless legs syndrome in a multiparous pregnant woman	Tuesday, October 6	13:30 - 14:30	Session 9	Station 6	3	Education, History, Disparities (Other)	Srđana Telarović
442	Poststroke Movement Disorders: Clinical, Neuroimaging and Electrophysiological correlates	Tuesday, October 6	13:30 - 14:30	Session 9	Station 6	4	Education, History, Disparities (Other)	SIVA ROJA YELLATURI
443	Global Roles of Nurses and Advanced Practice Providers in Parkinson's Disease Care: Findings from an International Workforce Survey	Tuesday, October 6	13:30 - 14:30	Session 9	Station 6	5	Education, History, Disparities (Other)	Kelly Papesch
486	Multidisciplinary Day-Clinic Treatment for Functional Movement Disorders Embedded in a Movement Disorders Center	Tuesday, October 6	13:30 - 14:30	Session 9	Station 7	1	Functional Movement Disorders / Psychogenic Movement Disorders	Patricia Krause
487	Diagnosis and Treatment of Occult Psychogenic Movement Disorder Without Mood Disorder: A Case Report	Tuesday, October 6	13:30 - 14:30	Session 9	Station 7	2	Functional Movement Disorders / Psychogenic Movement Disorders	Hai Liang
488	Polymyographic Features Suggestive of Functional Etiology in Patients with Cervical Dystonia	Tuesday, October 6	13:30 - 14:30	Session 9	Station 7	3	Functional Movement Disorders / Psychogenic Movement Disorders	Michal Minar
489	Skin Biopsy for Phosphorylated Alpha-Synuclein and DAT Imaging in Patients Diagnosed with Psychogenic Parkinsonism	Tuesday, October 6	13:30 - 14:30	Session 9	Station 7	4	Functional Movement Disorders / Psychogenic Movement Disorders	Julia Phillips
490	Functional Movement Disorders in a Public Health System: Misdiagnosis, Diagnostic Delay, and Healthcare Utilization in 61 Patients	Tuesday, October 6	13:30 - 14:30	Session 9	Station 7	5	Functional Movement Disorders / Psychogenic Movement Disorders	Lucia Tesolin
491	Diagnostic Sensitivity of a Shortened Accelerometry-Based Functional Tremor Battery	Tuesday, October 6	13:30 - 14:30	Session 9	Station 7	6	Functional Movement Disorders / Psychogenic Movement Disorders	Marko Cibula
532	Genetic modifiers of the clinical phenotype in Spinocerebellar Ataxia type 2. 25 years of candidate genes studies and the forthcoming GWAS era	Tuesday, October 6	13:30 - 14:30	Session 9	Station 8	1	Ataxia	Luis Almaguer-Mederos
533	GSTM1 and GSTT1 null genotypes as candidate modifiers of clinical severity and genomic instability in Cuban patients with Spinocerebellar Ataxia type 2	Tuesday, October 6	13:30 - 14:30	Session 9	Station 8	2	Ataxia	Dany Cuello-Almarales
593	Adult-Onset Opsoclonus-Myoclonus-Ataxia Syndrome Associated with West Nile Virus Mimicking a Functional Movement Disorder	Tuesday, October 6	13:30 - 14:30	Session 9	Station 8	3	Myoclonus/Tics/Stereotypies	Samantha De Groot
656	Temporal Interference Stimulation of Dentate Nucleus Suppressed Essential Tremor	Tuesday, October 6	13:30 - 14:30	Session 9	Station 9	1	Tremor	Shaoyi Zhang
657	Comparative Efficacy of Wrist-Worn Non-Invasive Peripheral Nerve Stimulation for Essential Tremor: A Systematic Review and Meta-Analysis of Randomized Controlled Trials	Tuesday, October 6	13:30 - 14:30	Session 9	Station 9	2	Tremor	Yehia Abdalla
658	Myoclonic Tremor and Cervical Dystonia as an Atypical Presentation of Ataxia-Telangiectasia	Tuesday, October 6	13:30 - 14:30	Session 9	Station 9	3	Tremor	Mariam Nadia Afkir Ortega

659	Plasma and CSF Autoimmune Markers in Orthostatic Tremor Insights from a Prospective Tertiary Centre Cohort	Tuesday, October 6	13:30 - 14:30	Session 9	Station 9	4	Tremor	Paloma Becker
660	High Frequency of Neurological Soft Signs in Prospectively Evaluated Essential Tremor Patients	Tuesday, October 6	13:30 - 14:30	Session 9	Station 9	5	Tremor	Lukas Gattermeyer-Kell
661	Congenital Portosystemic Shunting: A Wilson's Disease Mimic	Tuesday, October 6	13:30 - 14:30	Session 9	Station 9	6	Tremor	Linda Lei
557	Sleep Architecture and Cognitive Performance in Early Huntington's Disease: A Pilot Study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 10	1	Huntington's Disease	Emily Forbes
558	FuRST 2.0, A Patient Reported Outcome (PRO) Measure of Functional Ability in Huntington's Disease (HD): Getting Response Options Right	Tuesday, October 6	13:30 - 14:30	Session 9	Station 10	2	Huntington's Disease	Rebecca Fuller
559	Sleep Disturbances in Huntington's Disease A Cross-Sectional Study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 10	3	Huntington's Disease	Greta Hemicker
560	Real-World Evaluation of Deutetrabenazine for Huntington Disease-Associated Chorea in South Korea: Study Design and Baseline Characteristics	Tuesday, October 6	13:30 - 14:30	Session 9	Station 10	4	Huntington's Disease	Mira Jung
561	Late-Onset Huntington's Disease Misdiagnosed as Post-Stroke Chorea: A Case Report	Tuesday, October 6	13:30 - 14:30	Session 9	Station 10	5	Huntington's Disease	Jun Seok Lee
562	Clinical and Phenotypic Features of Concurrent Huntington's Disease and Amyotrophic Lateral Sclerosis: A Case Series	Tuesday, October 6	13:30 - 14:30	Session 9	Station 10	6	Huntington's Disease	Jackson Mitzner
1935	Pelizaeus Merzbacher like disease (PMLD): Neuroradiological Phenotyping	Tuesday, October 6	13:30 - 14:30	Session 9	Station 11	1	Pediatric Movement Disorders	Khushali Shah
1936	Safety and Effect of Ecopipam During the First 8 Weeks of Treatment for Tourette Syndrome: A Post Hoc Analysis	Tuesday, October 6	13:30 - 14:30	Session 9	Station 11	2	Pediatric Movement Disorders	Kinga Tomczak
1937	Effects of Manual Therapy on Hand Dexterity in Children Aged 4-8 Years: A Prospective Interventional Study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 11	3	Pediatric Movement Disorders	Taras Voloshyn
1938	SCN8A-Related Disorders: Expanding the Movement Disorder Phenotype Through a Case Report and Literature Review	Tuesday, October 6	13:30 - 14:30	Session 9	Station 11	4	Pediatric Movement Disorders	Reem Alkhodair
1939	Movement Disorder Phenotypes and Etiological Associations in Genetic Early-Onset Ataxias: A Pediatric Cohort Study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 11	5	Pediatric Movement Disorders	Fawez Dridi
1940	Feasibility of Remote Identification of Catatonia Across Different Motor Presentations	Tuesday, October 6	13:30 - 14:30	Session 9	Station 11	6	Pediatric Movement Disorders	Neeraj Kadubandi
741	Responsiveness of Sensor-Derived Measures From a Smartphone-Based Active Typing Test in the Phase 2b LUMA Study of Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 12	1	Parkinson's Disease: Clinical Trials	Roy Llorens Arenas

742	Responsiveness of a Smartphone-Based Sensor-Derived Composite Endpoint in a Phase 2b Study in Parkinson's Disease (PD)	Tuesday, October 6	13:30 - 14:30	Session 9	Station 12	2	Parkinson's Disease: Clinical Trials	Roy Llorens Arenas
743	Mass balance and metabolism of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase, in humans	Tuesday, October 6	13:30 - 14:30	Session 9	Station 12	3	Parkinson's Disease: Clinical Trials	Ana Loureiro
744	Phase 2 Trial for the Treatment of Early-stage Parkinson's Disease with TJ0113, a Small Molecule Mitophagy Activator	Tuesday, October 6	13:30 - 14:30	Session 9	Station 12	4	Parkinson's Disease: Clinical Trials	Wei Luo
745	Sensory-Motor Discrepancy of Arm Swing During Gait in Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 12	5	Parkinson's Disease: Clinical Trials	Tadamitsu Matsuda
746	Exposure-Response Analysis of Glovadalen in the ATLANTIS Phase II Study: Trial Simulation Explains Dose-Response for OFF Time in Parkinson's	Tuesday, October 6	13:30 - 14:30	Session 9	Station 12	6	Parkinson's Disease: Clinical Trials	Denis Menshykau
813	Differences in Levodopa Equivalent Daily Dose (LEDD) Based on Disease Duration in Parkinson's Disease Patients at RSCM - A Tertiary National Referral Hospital	Tuesday, October 6	13:30 - 14:30	Session 9	Station 13	1	Parkinson's Disease: Pharmacology and Medical Management	Fitri Abdat
814	Continuous Subcutaneous Foslevodopa/Foscarbidopa After Deep Brain Stimulation or Levodopa-Carbidopa Intestinal Gel: A Case Series in Advanced Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 13	2	Parkinson's Disease: Pharmacology and Medical Management	Yasmin Abdelmajid
815	Inpatient Titration Protocol and Practical Implementation of Continuous Subcutaneous Foslevodopa/Foscarbidopa: Lessons from 28 Consecutive Cases	Tuesday, October 6	13:30 - 14:30	Session 9	Station 13	3	Parkinson's Disease: Pharmacology and Medical Management	Yasmin Abdelmajid
816	Efficacy and Safety of Mesdopetam (IRL790) for Levodopa Induced Dyskinesia in Parkinson's Disease: A Meta analysis of Randomized Controlled Trials	Tuesday, October 6	13:30 - 14:30	Session 9	Station 13	4	Parkinson's Disease: Pharmacology and Medical Management	Ashwin Achuthaprasad
817	Switch from LCIG to LECIG in advanced Parkinson's Disease: Real World Outcomes from a Single Centre	Tuesday, October 6	13:30 - 14:30	Session 9	Station 13	5	Parkinson's Disease: Pharmacology and Medical Management	Ana Aldaz Burgoa
818	When Presynaptic Stimulation is Not Enough: Severe Biphasic Dyskinesia on LECIG Reversed by Postsynaptic Apomorphine Rescue	Tuesday, October 6	13:30 - 14:30	Session 9	Station 13	6	Parkinson's Disease: Pharmacology and Medical Management	Araceli Alonso Cánovas
885	Clinical Features and Trajectories Related to Entacapone Use in Parkinson's Disease: insights from the French NS Park Cohort	Tuesday, October 6	13:30 - 14:30	Session 9	Station 14	1	Parkinson's Disease: Pharmacology and Medical Management	Silvia Gallo
886	"Most of us are improvising with the work we are doing": Perspectives of health and social care professionals in Ghana and Kenya on mobility management for Parkinson's disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 14	2	Parkinson's Disease: Pharmacology and Medical Management	Riona Mc Ardle

887	Real-world variability in dosing of continuous subcutaneous foslevodopa/foscarbidopa infusion in advanced Parkinson's disease: evidence from a single-center cohort	Tuesday, October 6	13:30 - 14:30	Session 9	Station 14	3	Parkinson's Disease: Pharmacology and Medical Management	Iulia Murasan
888	Immunological principles of levodopa therapy in Parkinson's disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 14	4	Parkinson's Disease: Pharmacology and Medical Management	Olim Naimov
889	Beyond Motor Fluctuations: Non-Motor and Quality-Of-Life Outcomes with Subcutaneous Foslevodopa/Foscarbidopa Infusion in Real-World Practice	Tuesday, October 6	13:30 - 14:30	Session 9	Station 14	5	Parkinson's Disease: Pharmacology and Medical Management	Valle Pérez-del-Olmo
890	Serum Zinc Reduction During Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 14	6	Parkinson's Disease: Pharmacology and Medical Management	Takaya Utsunomiya
1863	Access to rehabilitation therapy for people with Parkinson's disease in Rome, Italy	Tuesday, October 6	13:30 - 14:30	Session 9	Station 15	1	Parkinson's Disease (Other)	Giulia Di Lazzaro
1864	A Specialized 3D-Printed Device for Gait Rehabilitation in Parkinson's: Development and Application.	Tuesday, October 6	13:30 - 14:30	Session 9	Station 15	2	Parkinson's Disease (Other)	Saikal Ismailova
1865	Pilot Study of Vibrotactile Gait Cueing with the NUSHU X Sneaker in Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 15	3	Parkinson's Disease (Other)	Divya Kashyap
1866	Sequential Multi-Target tDCS Improves Gait in Parkinson's Disease: A Randomized Controlled Study Using IMU-Based Gait Analysis	Tuesday, October 6	13:30 - 14:30	Session 9	Station 15	4	Parkinson's Disease (Other)	Dongwon Lee
1867	Experiences of Patients with Parkinson's Disease regarding Pharmacological Treatment in three Peruvian Regions	Tuesday, October 6	13:30 - 14:30	Session 9	Station 15	5	Parkinson's Disease (Other)	Jeel Moya-Salazar
1868	Mild Parkinsonian Signs in Prodromal Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 15	6	Parkinson's Disease (Other)	Yi Hao Nah
913	Uncovering Parkinson Disease Progression Biomarkers with Plasma Proteomics and Functional Genomics	Tuesday, October 6	13:30 - 14:30	Session 9	Station 16	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Chanhee Jeong
914	Isolated REM Sleep Behavior Disorder is Associated with Altered Nocturnal Skin Temperature Dynamics	Tuesday, October 6	13:30 - 14:30	Session 9	Station 16	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Ignacio Roura
915	Characterising immune changes in the nose in Parkinson's disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 16	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Clotilde Tournier
916	α -Synuclein biomarkers in prodromal synucleinopathies: a systematic review and meta-analysis.	Tuesday, October 6	13:30 - 14:30	Session 9	Station 16	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Sasivimol Virameteekul
917	Untangling the Web of Fall Risk in Parkinson's Disease Through Machine Learning	Tuesday, October 6	13:30 - 14:30	Session 9	Station 16	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Maeve Bradley

918	Baseline plasma neurofilament light and phosphorylated tau 181 levels predict longitudinal cognitive decline in APOE4 and long SNCA Rep1 carriers in Parkinson's disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 16	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Samuel Ng
985	Elevated Myeloperoxidase Levels and Activity as Potential Biomarkers for Parkinson's Disease: A Systematic Review and Meta-Analysis	Tuesday, October 6	13:30 - 14:30	Session 9	Station 17	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Susmin Karki
986	Multiplexed Serum Biomarkers for Differentiating the Parkinson's Disease Continuum and Disease Severity	Tuesday, October 6	13:30 - 14:30	Session 9	Station 17	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Min Seung Kim
987	Why Context Matters: The Influence of Medication and Environment on Real-World Gait in People with Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 17	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Charlotte Lang
988	Wearable Gait Metrics as Potential Digital Biomarkers in GBA1 Non-Manifesting Carriers	Tuesday, October 6	13:30 - 14:30	Session 9	Station 17	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Nadine Loefflad
989	Reduced Glucocerebrosidase Activity Is Associated with Cognitive Decline in Severe GBA1-Associated Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 17	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Daniel Macias-Garcia
990	Gait Kinematics as Biomarkers of Preclinical Parkinson's Disease: A Systematic Review of Sensor-Based Studies	Tuesday, October 6	13:30 - 14:30	Session 9	Station 17	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Karim Makhoul
1127	Quantitative Assessment of Turning Kinematics and its Association with Parkinson's Disease Severity	Tuesday, October 6	13:30 - 14:30	Session 9	Station 18	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Gabrielle Reinking
1128	Fracture Burden and Health-Related Quality of Life in Older Adults with Parkinson's Disease in Rural India: A Community-Based Study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 18	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Bibhu Kuanar
1129	MDS-UPDRS Part III Cannot Be Reliably Reduced for Prognostic Modeling in Early Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 18	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Mohammad Alam
1130	Influence of Disease Duration on Motor Progression in Parkinson's Disease: A Longitudinal Cohort Study with Age at Onset Stratification and Sensitivity Analysis	Tuesday, October 6	13:30 - 14:30	Session 9	Station 18	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Naresh Babu

1131	Use of Mucuna Pruriens (M. Pruriens) in People with Parkinson's Disease (PwPD)	Tuesday, October 6	13:30 - 14:30	Session 9	Station 18	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	María Bacigalupe
1132	Does Balance Mediate the Relationship Between Aerobic Capacity and Walking Endurance in Parkinson's Disease?	Tuesday, October 6	13:30 - 14:30	Session 9	Station 18	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Chitra Balasubramaniam
1199	Mapping the Temporal Evolution of Non-Motor Symptoms in Parkinson's Disease: Findings from 100 Outpatient Cases Using a Single-Page Temporal Template	Tuesday, October 6	13:30 - 14:30	Session 9	Station 19	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Farsana Madathum Kuzhiyil
1200	Disrupted Sleep and Daytime Sleepiness are Associated With Poorer Quality of Life in Advanced Parkinson's Disease: ROSSINI Interim Results	Tuesday, October 6	13:30 - 14:30	Session 9	Station 19	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Irene Malaty
1201	Olfactory Dysfunction in Parkinson's Disease: A Single-Center Study Using the Alcohol Sniff Test	Tuesday, October 6	13:30 - 14:30	Session 9	Station 19	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Selly Marisdina
1202	Environmental Risk Factor Co-Exposure as Drivers of Parkinson's Disease Development: A Scoping Review	Tuesday, October 6	13:30 - 14:30	Session 9	Station 19	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Angus McNamara
1203	Effect of Random Training- Test Splits on Radiomic Classification of Parkinson's Disease from T1-Weighted MRI in Machine Learning	Tuesday, October 6	13:30 - 14:30	Session 9	Station 19	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Shyamal Mehta
1204	Videonystagmography findings, Postural Balance, and Falls in Parkinson's disease patients	Tuesday, October 6	13:30 - 14:30	Session 9	Station 19	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Isabel Monteiro

1271	Quadriceps Femoris and Gastrocnemius Muscle Activation Patterns during Gait in Patients with Parkinsons Disease Using Surface Electromyography	Tuesday, October 6	13:30 - 14:30	Session 9	Station 20	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Fadhilla Fianurrachm ania
1272	Exploring a Milestone-Based Approach as an Outcome Measure for Disease-Modifying Parkinson Disease Trials	Tuesday, October 6	13:30 - 14:30	Session 9	Station 20	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Cristina Gonzalez-Robles
1273	Pilot feasibility study of home-based assessment of aspiration risk among people with Parkinson's disease in rural northern Tanzania	Tuesday, October 6	13:30 - 14:30	Session 9	Station 20	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Rebecca Haggie
1274	Objective Parkinson's Diagnosis Using a Novel Accelerometer Assessment and Machine Learning	Tuesday, October 6	13:30 - 14:30	Session 9	Station 20	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Lukas Jurcaga
1275	The Parkinson's Impact Project: A Multimodal Longitudinal Study of Disease Development and Progression at the 23andMe Research Institute	Tuesday, October 6	13:30 - 14:30	Session 9	Station 20	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Matthew Kmiecik
1276	The Parkinson's Clinical Cohorts Collaborative (PC3) - A Novel Research Database for Parkinson's Disease Research	Tuesday, October 6	13:30 - 14:30	Session 9	Station 20	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ashvin Kuri
1354	Analysis of Genetic Variants Associated with Parkinson's Disease and Depression	Tuesday, October 6	13:30 - 14:30	Session 9	Station 21	1	Parkinson's Disease: Genetics	Diana Delgado-Gutiérrez
1355	Cross-Family Analysis of Rare Deleterious Variants Segregating in Families with Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 21	2	Parkinson's Disease: Genetics	Carolín Gabbert
1356	Investigating the Genetic Effect of GALC in Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 21	3	Parkinson's Disease: Genetics	Morvarid Ghamgosar Shahkhali
1357	Cross-trait and Multi-polytranscriptomic Score Prediction of Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 21	4	Parkinson's Disease: Genetics	Lachlan Gilchrist
1358	Fine-Mapping Genetic Risk and Age at Onset Loci in Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 21	5	Parkinson's Disease: Genetics	Simona Jasaitytė

1359	Exploring Genetic Contributions to Disease Progression on Hoehn and Yahr Scales in Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 21	6	Parkinson's Disease: Genetics	Lietzel Jones
1415	Association between Smoking and LRRK2 Variants on Parkinson's Disease Risk	Tuesday, October 6	13:30 - 14:30	Session 9	Station 22	1	Parkinson's Disease: Genetics	Jia-Dong James Wang
1416	Young-Onset Parkinson's Disease with Coexisting GBA1 Mutation and ATXN3 Repeat Expansion: A Double Hit?	Tuesday, October 6	13:30 - 14:30	Session 9	Station 22	2	Parkinson's Disease: Genetics	Dallah Yoo
1417	Kufor-Rakeb Syndrome With a Novel Splice-Site Variant in the ATP13A2 Gene	Tuesday, October 6	13:30 - 14:30	Session 9	Station 22	3	Parkinson's Disease: Genetics	Liliya Zaripova
1418	Investigating the Link Between Alzheimer's Disease Genetic Risk Variants and Parkinson's Disease Cognitive Impairment: An Exploration of Genetic Overlap	Tuesday, October 6	13:30 - 14:30	Session 9	Station 22	4	Parkinson's Disease: Genetics	Alexandra Zirra
1419	Motor Fluctuations and Dyskinesias in LRRK2-Associated Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 22	5	Parkinson's Disease: Genetics	Asma Agrebaoui
1420	Clinical and Kinematic Assessment of Parkinsonian Features in Young Adults with 22q11.2 Deletion Syndrome	Tuesday, October 6	13:30 - 14:30	Session 9	Station 22	6	Parkinson's Disease: Genetics	Luca Angelini
1487	Specific thalamic subnuclei volumes associate with autonomic dysfunction in Parkinson's disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 23	1	Parkinson's disease: Neuroimaging	Shotaro Haji
1488	Baseline assessment of nigrostriatal integrity via VMAT2 PET in participants with Parkinson's disease from the BIIB122/DNL151 LUMA Phase 2b study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 23	2	Parkinson's disease: Neuroimaging	Antoine Hone-Blanchet
1489	The Relationship Between Substantia Nigra Hyperchogenicity and Clinical Features and Disease Progression in Parkinson's Disease Patients	Tuesday, October 6	13:30 - 14:30	Session 9	Station 23	3	Parkinson's disease: Neuroimaging	Wanjing Hu
1490	Predictors of cognitive trajectories in Parkinson's disease with mild cognitive impairment after STN-DBS: a diffusion MRI study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 23	4	Parkinson's disease: Neuroimaging	Eriko Igami
1491	Comparison of Subcortical Brain Volumes in Different At-risk Cohorts of Parkinson's Disease - Preliminary Data from the MUMFORD Study.	Tuesday, October 6	13:30 - 14:30	Session 9	Station 23	5	Parkinson's disease: Neuroimaging	Frank Jagusch
1492	The Diagnostic Value of Dopaminergic-Glucose United PET Imaging in Parkinson's disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 23	6	Parkinson's disease: Neuroimaging	Xin-Yi Li
1559	Pain Management in Parkinson's Disease: The Role of TRPV1 as a Therapeutic Target	Tuesday, October 6	13:30 - 14:30	Session 9	Station 24	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	SukJun Song
1560	Impact of TRPV4 Deletion on Nociception in an Experimental Model of Parkinson's Disease Non-Motor Symptoms	Tuesday, October 6	13:30 - 14:30	Session 9	Station 24	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Leonardo Gomes Pereira

1561	Three Different Behavioral Trajectories in L-DOPA-Treated Parkinson's Disease Patients	Tuesday, October 6	13:30 - 14:30	Session 9	Station 24	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Giovanni Albani
1562	Motor Trajectory in Parkinson's Disease With Excessive Daytime Sleepiness: A Longitudinal Cohort Study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 24	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Kento Aoshima
1563	Restless Limbs Syndrome (RLS) is More Likely a Premotor Symptom of Parkinson's Disease than a Predisposing Condition.	Tuesday, October 6	13:30 - 14:30	Session 9	Station 24	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	David Dickoff
1564	One-Year Trajectories of Non-Motor Symptoms in Parkinson's Disease: A Longitudinal Cohort Study Using the MDS-NMS with Age at Onset Stratification	Tuesday, October 6	13:30 - 14:30	Session 9	Station 24	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Deep Faldu
1631	Early integrated Dysphagia and Nutritional Management in Parkinsonism: a prospective Feasibility Study to prevent Malnutrition and Complications	Tuesday, October 6	13:30 - 14:30	Session 9	Station 25	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Yuliia Zashchypas
1632	Parkinson's disease patients with sleep disturbances: Motor and non-motor profiling	Tuesday, October 6	13:30 - 14:30	Session 9	Station 25	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Rihab Guizani
1633	Hemoglobin Levels and Non Motor Symptoms in Parkinsons Disease Patients with Modified Hoehn and Yahr Scores	Tuesday, October 6	13:30 - 14:30	Session 9	Station 25	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Fadillatul Hukmiyya
1634	Odor-specific olfactory dysfunction in early-onset Parkinson's disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 25	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Dariya Larina
1635	Evaluating the Stability of a Short Smell Test in the PREDICT-PD Cohort	Tuesday, October 6	13:30 - 14:30	Session 9	Station 25	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Sophie Meyer
1636	Sleep habits and lifestyle factors in people with Parkinson's disease compared with healthy controls	Tuesday, October 6	13:30 - 14:30	Session 9	Station 25	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Iulia Murasan
1684	Cerebrovascular reactivity in Parkinson's disease: acute effects of Levodopa assessed by transcranial doppler	Tuesday, October 6	13:30 - 14:30	Session 9	Station 26	1	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Francesco Garramone

1685	Regional α -Synuclein Seeding Activity in Parkinson's disease and Multiple System Atrophy	Tuesday, October 6	13:30 - 14:30	Session 9	Station 26	2	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Danyeong Kim
1686	Cerebrospinal Fluid Metabolic Alterations Reveal a Central Energy Metabolism Shift in Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 26	3	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Ryunosuke Nagao
1687	An Optimized Workflow for High-Throughput RNA-Seq from Human Deep Brain Tissue Using DBS Microelectrodes	Tuesday, October 6	13:30 - 14:30	Session 9	Station 26	4	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Sandeep Xxx
1688	Monocyte and T-cell Immunological Profiles of Asian LRRK2 Variants G2385R And R1628P in Parkinson's Disease: Associations with Clinical Measures	Tuesday, October 6	13:30 - 14:30	Session 9	Station 26	5	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Nur Jannah Zulkefli
1689	Irisin as a Molecular Mediator of Exercise Induced Neuroprotection and Disease Modification in Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 26	6	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Nikhil Choudhary
1775	Rescue Electrode Implantation after Deep Brain Stimulation in Parkinson's disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 27	1	Parkinson's Disease: Surgical Therapy	Carlos Lazaro-Hernandez
1776	Movement decoding from subthalamic nucleus during deep brain stimulation surgery	Tuesday, October 6	13:30 - 14:30	Session 9	Station 27	2	Parkinson's Disease: Surgical Therapy	Joshua Li
1777	The UF Adaptive Deep Brain Stimulation Experience	Tuesday, October 6	13:30 - 14:30	Session 9	Station 27	3	Parkinson's Disease: Surgical Therapy	Achyutha Madamangalam
1778	Simulation Artifact in Complex Deep Brain Stimulation Patients	Tuesday, October 6	13:30 - 14:30	Session 9	Station 27	4	Parkinson's Disease: Surgical Therapy	Achyutha Madamangalam
1779	Differential effects of levodopa and subthalamic nucleus deep brain stimulation on the bradykinesia components in Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 27	5	Parkinson's Disease: Surgical Therapy	Daniel Marín-Medina
1780	Clinical outcomes of deep brain stimulation for Parkinson's disease in the Dominican Republic: results from a newly established single-center DBS program	Tuesday, October 6	13:30 - 14:30	Session 9	Station 27	6	Parkinson's Disease: Surgical Therapy	Wendy Massih Montero
1058	Changing the 'Game': The Impact of 'Serious Games'-based Cognitive Training on Cognitive Function in Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 28	1	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Madeleine Homes-Vickers

1059	The Evolutionary Pathway of Cognitive Impairment in Parkinson's Disease: A SuStaln Study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 28	2	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Anqi Huang
1060	Functional Dyskinesia in a Patient with Parkinson's Disease: A Diagnostic and Therapeutic Challenge	Tuesday, October 6	13:30 - 14:30	Session 9	Station 28	3	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Vladimir Kotenev
1061	Prevalence and Treatment Patterns of Anxiety Symptoms in Parkinson's Disease	Tuesday, October 6	13:30 - 14:30	Session 9	Station 28	4	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Joyce Lam
1062	The Burden of Cognitive Impairment in People with Parkinson's across Outpatients and Prevalent Patients in Coastal Kenya: A Transforming Parkinson's Care in Africa (TraPCAf) Study	Tuesday, October 6	13:30 - 14:30	Session 9	Station 28	5	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Richard Morton
1063	Cognition and Dementia in a Kenyan Parkinson's Disease Cohort: A Sub-study of the TraPCAf Consortium	Tuesday, October 6	13:30 - 14:30	Session 9	Station 28	6	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Jamila Nambafu
112	Creative Engagement as a Unique Lens on Quality of Care in Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 1	1	Quality Of Life/Caregiver Burden in Movement Disorders	Sara Zeggio
113	Assessing an inclusive online lifestyle-based intervention program that supports British Columbians living with chronic neurological conditions, their care partners and healthy agers	Wednesday, October 7	9:30 - 10:30	Session 10	Station 1	2	Quality Of Life/Caregiver Burden in Movement Disorders	Alisa Hashimoto
114	Lived Experience of Parkinson's Disease in Six African Countries: A Qualitative, Multi-site Transforming Parkinson's Care in Africa (TraPCAf) Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 1	3	Quality Of Life/Caregiver Burden in Movement Disorders	Natasha Fothergill-Misbah
115	Optimizing Institutional Long-Term Care in Advanced Parkinson's and Other Neurodegenerative Disease: The OPTICARE Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 1	4	Quality Of Life/Caregiver Burden in Movement Disorders	Johanne Stuempel
116	The Barcelona PSP Registry Therapeutic Education Program: a Longitudinal Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 1	5	Quality Of Life/Caregiver Burden in Movement Disorders	Ana Camara
117	myParkinson's Wellbeing Programme for people newly diagnosed and their care-partners	Wednesday, October 7	9:30 - 10:30	Session 10	Station 1	6	Quality Of Life/Caregiver Burden in Movement Disorders	Ruth Lewis-Morton
21	A Diffusion MRI Neurodegeneration Index for Lewy Body Dementia & Alzheimer's disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 2	1	Artificial Intelligence (AI) and Machine Learning	Shannon Chiu

22	Classification of Fallers in Parkinson's Disease Through Machine Learning Based Feature Analysis	Wednesday, October 7	9:30 - 10:30	Session 10	Station 2	2	Artificial Intelligence (AI) and Machine Learning	Sumin Kim
23	Fusion Learning with Attention-VAE Imputation for Mixed-Reality Multisensor Screening of Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 2	3	Artificial Intelligence (AI) and Machine Learning	Justyna Krzywdziak
24	Enhancing Neurology Resident Communication of Functional Movement Disorder Using an Artificial Intelligence (AI)-Based Patient Actor	Wednesday, October 7	9:30 - 10:30	Session 10	Station 2	4	Artificial Intelligence (AI) and Machine Learning	Sarala Sharma
25	A Deep Learning Model-based Screening System for Nystagmus in Central Vertigo	Wednesday, October 7	9:30 - 10:30	Session 10	Station 2	5	Artificial Intelligence (AI) and Machine Learning	Hideaki Takeda
26	Artificial Intelligence-Based Voice Analysis for Early Detection of Parkinson's Disease: A Systematic Review	Wednesday, October 7	9:30 - 10:30	Session 10	Station 2	6	Artificial Intelligence (AI) and Machine Learning	Olivier UWISHEMA
310	Childhood-Onset Spastic Paraparesis Followed by Early-Onset Parkinsonism: A Genetically Unresolved Case of Complicated Hereditary Spastic Paraplegia	Wednesday, October 7	9:30 - 10:30	Session 10	Station 3	1	Parkinsonism (Other)	Iva Sarac
311	Utility of DaTscan in Children with suspected Juvenile Parkinsonism: A Single-Centre Cohort Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 3	2	Parkinsonism (Other)	Antonio Spagarino
312	Late Diagnosed Kufor Rakeb Syndrome Presenting as Drug Induced Parkinsonism	Wednesday, October 7	9:30 - 10:30	Session 10	Station 3	3	Parkinsonism (Other)	Murat Gultekin
246	App-Based Speech Assessment Differentiates PD and PSP: A Feasibility Study in Italian Speakers	Wednesday, October 7	9:30 - 10:30	Session 10	Station 3	4	MSA, PSP, CBS (Other)	Tabea Thies
247	The Feasibility and Safety of Rehabilitation Program in Patients with Multiple System Atrophy	Wednesday, October 7	9:30 - 10:30	Session 10	Station 3	5	MSA, PSP, CBS (Other)	Grace Yoojin Lee
248	Cognitive & Clinical Correlates of Quality of Life in Probable Progressive Supranuclear Palsy	Wednesday, October 7	9:30 - 10:30	Session 10	Station 3	6	MSA, PSP, CBS (Other)	Teresa Leong
176	Early Clinical Characteristics of Pathologically Confirmed Progressive Supranuclear Palsy and Corticobasal Degeneration	Wednesday, October 7	9:30 - 10:30	Session 10	Station 4	1	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Simon KS Ting
177	Clinical Spectrum of Atypical Parkinsonian Disorders in Sri Lanka: Preliminary Results from a Global Parkinson's Genetic Programme (GP2) Collaborative Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 4	2	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Velummylum Vithudsha
178	Quality of Life in Atypical Parkinsonian Disorders: Preliminary Results from a Multicentre Cross-Sectional Study in Sri Lanka (GP2 Collaboration)	Wednesday, October 7	9:30 - 10:30	Session 10	Station 4	3	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Velummylum Vithudsha

179	Dynamic and Multimodal Prediction of Phenoconversion to Cerebellar Multiple System Atrophy among Sporadic Late-Onset Cerebellar Ataxia	Wednesday, October 7	9:30 - 10:30	Session 10	Station 4	4	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Thomas Wirth
180	Cerebellar Variant of Progressive Supranuclear Palsy: First Case Report from Peru	Wednesday, October 7	9:30 - 10:30	Session 10	Station 4	5	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Fitzgerald Arroyo-Ramirez
181	REM Sleep Behaviour Disorder (RBD) and its relation to Non-motor Symptoms in Progressive Supranuclear Palsy(PSP).	Wednesday, October 7	9:30 - 10:30	Session 10	Station 4	6	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Neeraj Balaini
398	Long-Term Efficacy and Determinants of Motor and Quality-of-Life Outcomes Following Bilateral GPi-DBS in Dystonia	Wednesday, October 7	9:30 - 10:30	Session 10	Station 5	1	Dystonia: Medical Therapy / Surgical Therapy	Gülce Coşku Yılmaz Çakan
399	Axial parkinsonism after 15 years of pallidal stimulation in generalized dystonia	Wednesday, October 7	9:30 - 10:30	Session 10	Station 5	2	Dystonia: Medical Therapy / Surgical Therapy	Clément Desjardins
400	Short Term Effects of Wearable Vibrotactile Stimulation in Laryngeal Dystonia	Wednesday, October 7	9:30 - 10:30	Session 10	Station 5	3	Dystonia: Medical Therapy / Surgical Therapy	Nghi Doan
401	Levodopa-Responsive Dystonia in Adenylosuccinate Lyase (ADSL) Deficiency Treated With Bilateral GPi Deep Brain Stimulation	Wednesday, October 7	9:30 - 10:30	Session 10	Station 5	4	Dystonia: Medical Therapy / Surgical Therapy	Karen Ibarra
402	Dystonias in a Nigerian Tertiary Hospital: A Case Series Highlighting Diagnostic and Therapeutic Challenges and a Five-Year Retrospective Review	Wednesday, October 7	9:30 - 10:30	Session 10	Station 5	5	Dystonia: Medical Therapy / Surgical Therapy	Ijeoma NDIONUKA
403	Rare Observations of Sustained Symptomatic Improvement with Botulinum Toxin Type A Injections in Facial and Cervical Dystonia: Case Series	Wednesday, October 7	9:30 - 10:30	Session 10	Station 5	6	Dystonia: Medical Therapy / Surgical Therapy	Nikole Rozenberg
444	From Hysteria to Functional Movement Disorders: The Evolution of a Concept	Wednesday, October 7	9:30 - 10:30	Session 10	Station 6	1	History of Movement Disorders	Leila Ali
445	Early Descriptions of Sensorimotor Control and Movement Disorders in the Medieval Islamic Golden Age: Insights from Rhazes (Al Razi) and Avicenna (Ibn Sina)	Wednesday, October 7	9:30 - 10:30	Session 10	Station 6	2	History of Movement Disorders	Leila Ali
446	The Historical Role of Sex and Gender in the History of Access to Movement Disorder Care: A Literature Review	Wednesday, October 7	9:30 - 10:30	Session 10	Station 6	3	History of Movement Disorders	Shaina Corrick

447	What two Versions of Parkinson's „The Budget of the People“ might tell us about the Historical Background	Wednesday, October 7	9:30 - 10:30	Session 10	Station 6	4	History of Movement Disorders	Stefan Lorenzl
364	Uncovering novel genomic alterations in dystonia using gene burden analysis	Wednesday, October 7	9:30 - 10:30	Session 10	Station 6	5	Dystonia: Genetics	Arti Saini
365	High Frequency of Pathogenic Variants in Neurodevelopmental Genes in Patients with Dystonia	Wednesday, October 7	9:30 - 10:30	Session 10	Station 6	6	Dystonia: Genetics	Linn Welzel
492	Closed-Loop Acoustic Neuromodulation for Functional Movement Disorder	Wednesday, October 7	9:30 - 10:30	Session 10	Station 7	1	Functional Movement Disorders / Psychogenic Movement Disorders	Brendan Dukes
493	Functional Belly Dancer Dyskinesia Associated with Abdominal Pain: A Case Series	Wednesday, October 7	9:30 - 10:30	Session 10	Station 7	2	Functional Movement Disorders / Psychogenic Movement Disorders	Margareth Hildaria
494	Phenotypic Overlap Between Essential Tremor and Dystonic Tremor: Diagnostic Features, Misclassification, and Clinical Implications: A Systematic Review	Wednesday, October 7	9:30 - 10:30	Session 10	Station 7	3	Functional Movement Disorders / Psychogenic Movement Disorders	Shradha Kakde
495	“Shaky Eyes”: an Unusual Case of Ocular Movement Disorder	Wednesday, October 7	9:30 - 10:30	Session 10	Station 7	4	Functional Movement Disorders / Psychogenic Movement Disorders	Alessandro Mechelli
496	A Retrospective Video Review Of Functional Movement Disorders (FMD)	Wednesday, October 7	9:30 - 10:30	Session 10	Station 7	5	Functional Movement Disorders / Psychogenic Movement Disorders	Ishu Goyal
497	Functional Neurological Disorder And Anti-GAD65-Associated Autoimmune Neurological Disease: Diagnostic Overlap In A Retrospective Case Series	Wednesday, October 7	9:30 - 10:30	Session 10	Station 7	6	Functional Movement Disorders / Psychogenic Movement Disorders	Blanca Talavera
534	A Specific Neuronal Subpopulation in Globus Pallidus External Segment Mediates the Pathogenesis of Dyskinesia in Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 8	1	Choreas (Non-Huntington's Disease)	Cong Shen
535	Acute Hemichorea as a Rare Presentation of Right Temporoparietal Infarction: A Case Report	Wednesday, October 7	9:30 - 10:30	Session 10	Station 8	2	Choreas (Non-Huntington's Disease)	Sungjae AHN
536	Caffeine and Tobacco Exposure and the Presence of Levodopa-Induced Dyskinesia (LID) in the STAT-PD Trial	Wednesday, October 7	9:30 - 10:30	Session 10	Station 8	3	Choreas (Non-Huntington's Disease)	A Dakota Clarke
537	Binge-eating as an Initial Presentation for the Diagnosis of Chorea-acanthocytosis	Wednesday, October 7	9:30 - 10:30	Session 10	Station 8	4	Choreas (Non-Huntington's Disease)	Keng Ming Lau
538	VPS13A Disease: 15 Years of Illness Awaiting a Diagnosis	Wednesday, October 7	9:30 - 10:30	Session 10	Station 8	5	Choreas (Non-Huntington's Disease)	Kseniia Manyшева
539	Anti-mGluR5 Antibody-Mediated Chorea Secondary to Gastric Cancer: A case report	Wednesday, October 7	9:30 - 10:30	Session 10	Station 8	6	Choreas (Non-Huntington's Disease)	Matías Niedbalski
662	Micrographia is an Early Abnormality in CAR-T Cell Therapy-Associated ICANS	Wednesday, October 7	9:30 - 10:30	Session 10	Station 9	1	Tremor	Jorge Patino

663	Treatment-Responsive Holmes Tremor in a Patient with HIV-Associated Hydrocephalus: An Experience from Tertiary Care Hospital	Wednesday, October 7	9:30 - 10:30	Session 10	Station 9	2	Tremor	Ardine Cahya Pratiwi
664	Tremor and Gait Worsening in Angelman Syndrome: Phenotypic Variability in Two Adult Sisters With Possible Valproate-Related Exacerbation	Wednesday, October 7	9:30 - 10:30	Session 10	Station 9	3	Tremor	Leonardo Salinas-Yañez
665	Clinical Utility of Neurophysiological Tremor Study Within a Joint Neurology-Neurophysiology Movement Disorders Clinic: One-Year Retrospective Two-Center Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 9	4	Tremor	Laura Santos
666	Clinical and Kinematic Evaluation of a Tremor-Damping Glove in Essential Tremor	Wednesday, October 7	9:30 - 10:30	Session 10	Station 9	5	Tremor	Runjie Bill Shi
667	Kinematic Characterization of Upper Limb Tremor Distribution in Essential Tremor	Wednesday, October 7	9:30 - 10:30	Session 10	Station 9	6	Tremor	Runjie Bill Shi
563	HD-RAC (Huntington's Disease Research at Convention) Series: Novel approach to pilot data collection for outcome measures in Huntington's disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 10	1	Huntington's Disease	Swati Sathe
564	Perception of Early-Intervention Therapies and Clinically Meaningful Delays in Huntington's Disease Onset and Progression: The Pre-HDBOI Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 10	2	Huntington's Disease	Ali Toumadj
565	Non-motor symptoms in Huntington's disease: Results from the Validation of the Non-motor Symptoms Scale (MDS-NMS)	Wednesday, October 7	9:30 - 10:30	Session 10	Station 10	3	Huntington's Disease	Jose Valera-Bermejo
566	Early Reduction in Cerebral Histamine 3 Receptor Expression in People with Huntington's Disease: Results from the iMarkHD Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 10	4	Huntington's Disease	Daniel van Wamelen
567	Stimulation-Level Sweet-Spot and Connectivity Analysis of Pallidal DBS in Huntington's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 10	5	Huntington's Disease	Maria Borrell-Pichot
568	Psychotic Symptoms and Cognitive Impairment in Huntington's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 10	6	Huntington's Disease	Débora Corrêa
1941	Genotype-Phenotype Correlations in KCNMA1 Channelopathy: A Comparative Analysis of Gain-of-Function and Loss-of-Function Variants in a Korean Cohort and Literature Review	Wednesday, October 7	9:30 - 10:30	Session 10	Station 11	1	Pediatric Movement Disorders	Jee Min Kim
1942	Expanding the Childhood Spectrum of Dentatorubral-pallidoluysian Atrophy: Neuropsychiatric and Motor Phenotypes in Four Siblings	Wednesday, October 7	9:30 - 10:30	Session 10	Station 11	2	Pediatric Movement Disorders	Michael Siegel
1943	Integrating Multidisciplinary, Family-Centered Care to Optimize Functional Outcomes in Children with Cerebral Palsy.	Wednesday, October 7	9:30 - 10:30	Session 10	Station 11	3	Pediatric Movement Disorders	Taras Voloshyn

747	Evaluation of Swallowing and Cough Function in older Patients with Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 12	1	Parkinson's Disease: Clinical Trials	Masahiro Nakamori
748	Comparative efficacy and safety of Safinamide versus Opicapone in Japanese patients with Parkinson's Disease and wearing-off: A matching-adjusted indirect comparison	Wednesday, October 7	9:30 - 10:30	Session 10	Station 12	2	Parkinson's Disease: Clinical Trials	Noriko Nishikawa
749	A Phase I Multicenter Trial of a Novel Gene Therapy BBM-P002 for Parkinsons Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 12	3	Parkinson's Disease: Clinical Trials	Mengyue Niu
750	EAGLE: Protocol for a Phase 3 Study to Evaluate the Efficacy and Safety of Two Mobile Applications Combined with Immediate-Release CD/LD for the Management of Idiopathic Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 12	4	Parkinson's Disease: Clinical Trials	Sheila Oren
751	Pharmacoscintigraphic Evaluation and Safety of a Novel, Dual-pulse, Delayed-release carbidopa/levodopa Tablet for Bedtime Dosing	Wednesday, October 7	9:30 - 10:30	Session 10	Station 12	5	Parkinson's Disease: Clinical Trials	Anne Østerskov
752	Qihuang Needle Therapy for Motor Symptoms in Parkinson's Disease: A Randomized Controlled Trial	Wednesday, October 7	9:30 - 10:30	Session 10	Station 12	6	Parkinson's Disease: Clinical Trials	Wanqing Peng
819	Psychosis in Parkinson's Disease Patients Treated with Continuous Subcutaneous Foslevodopa/Foscarbidopa: A Real-World Observational Study.	Wednesday, October 7	9:30 - 10:30	Session 10	Station 13	1	Parkinson's Disease: Pharmacology and Medical Management	Mireia Angerri Nadal
820	First Reported Experience of Dual Therapy With Deep Brain Stimulation and Foslevodopa/Foscarbidopa Subcutaneous Infusion	Wednesday, October 7	9:30 - 10:30	Session 10	Station 13	2	Parkinson's Disease: Pharmacology and Medical Management	Elena Casas
821	Hot and Fast but Still Parkinson's Disease: A Case of Dyskinesia-Hyperpyrexia Syndrome	Wednesday, October 7	9:30 - 10:30	Session 10	Station 13	3	Parkinson's Disease: Pharmacology and Medical Management	Tacio Coradine
822	Personalised Selection Of Device-Aided Infusion Therapies In Advanced Parkinson's Disease: A European Expert Delphi Consensus	Wednesday, October 7	9:30 - 10:30	Session 10	Station 13	4	Parkinson's Disease: Pharmacology and Medical Management	Valentina Correa-Gallego
823	Does Knowing More Mean Tolerating More? Satisfaction with Medication Information and Levodopa Dosage in Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 13	5	Parkinson's Disease: Pharmacology and Medical Management	Matheus da Silva
824	Efficacy of Opicapone in Early Motor Fluctuations in Parkinson's Disease: A Comparison of Early versus Later Initiation	Wednesday, October 7	9:30 - 10:30	Session 10	Station 13	6	Parkinson's Disease: Pharmacology and Medical Management	Joaquim Ferreira
891	Levodopa-Entacapone-Carbidopa Intestinal Gel in Advanced Parkinson's Disease: a Four-Year Real-Life Experience	Wednesday, October 7	9:30 - 10:30	Session 10	Station 14	1	Parkinson's Disease: Pharmacology and Medical Management	JOZSEF SZASZ
892	From Vision to Reality: Nursing Driven Implementation, Policy, and Safety Framework for Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion in a Tertiary Movement Disorder Centre	Wednesday, October 7	9:30 - 10:30	Session 10	Station 14	2	Parkinson's Disease: Pharmacology and Medical Management	Emma de Freitas

893	Toward Global Best Practices for Managing Skin Complications in Subcutaneous Infusion Therapy for Parkinson's Disease: A Nursing and Advanced Practice Perspective	Wednesday, October 7	9:30 - 10:30	Session 10	Station 14	3	Parkinson's Disease: Pharmacology and Medical Management	Clarisse Goas
1800	Robust Location-Agnostic Turn Speed Estimation to Ensure Consistent Remote Monitoring of Gait Impairment in Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 14	4	Parkinson's Disease (Other)	Lorenza Angelini
1801	Dopamine and Na,K-ATPase: Mechanisms of Direct Enzyme Modulation in the Hippocampus	Wednesday, October 7	9:30 - 10:30	Session 10	Station 14	5	Parkinson's Disease (Other)	Gvantsa Chkadua
1802	Neuroprotective Effects of Curcumin on Hippocampal-PPN Circuitry in a Rotenone-Induced Rat Model of Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 14	6	Parkinson's Disease (Other)	Lilit Darbinyan
1869	Correlation between handwriting and cognitive function in patients with Parkinson's disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 15	1	Parkinson's Disease (Other)	Shunsuke Obika
1870	Functional Intramuscular Stimulation for Pain in Parkinson's Disease and Sporadic Amyotrophic Lateral Sclerosis: A Retrospective Case Series	Wednesday, October 7	9:30 - 10:30	Session 10	Station 15	2	Parkinson's Disease (Other)	Claire Peterson
1871	Overactive Bladder in Parkinson's Disease: A Frequent but Underrecognized Non-Motor Symptom	Wednesday, October 7	9:30 - 10:30	Session 10	Station 15	3	Parkinson's Disease (Other)	Annisa Rahma
1872	Longitudinal evolution of impulsive-compulsive behaviors and their prognostic value in Parkinson's disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 15	4	Parkinson's Disease (Other)	Mariana Rocha-de-León
1873	Neuropsychiatric Symptoms in Parkinson's Disease in Low- and Middle-Income Countries: A Systematic Review	Wednesday, October 7	9:30 - 10:30	Session 10	Station 15	5	Parkinson's Disease (Other)	Olivier UWISHEMA
1874	Exercise and SUTT: A 9-week randomized, double-blinded, controlled intervention on Parkinsonian Gait.	Wednesday, October 7	9:30 - 10:30	Session 10	Station 15	6	Parkinson's Disease (Other)	Elizabeth Atterbury
919	Urine-derived neuronal extracellular vesicle α -synuclein seed amplification assay for synucleinopathies: a non-invasive biomarker study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 16	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Hoang-Bao-Tram Tran
920	Serum Based biomarkers in Parkinson's disease with and without cognitive deficits.	Wednesday, October 7	9:30 - 10:30	Session 10	Station 16	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	R Bhavani
921	Dietary and Environmental Risk Factors of Parkinson's Disease: An Integrated Network Pharmacology Approach	Wednesday, October 7	9:30 - 10:30	Session 10	Station 16	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Debosmita Ghosh
922	Dysregulation of the Intestinal Macrophage CXCL8/CXCR2 Axis and Its Role in α -Synuclein Clearance	Wednesday, October 7	9:30 - 10:30	Session 10	Station 16	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Tianyu Hu
923	Urine and Plasma Bis(monoacylglycero)phosphate (BMP) in Asian LRRK2 p.G2385R and p.R1628P Variant Carriers with Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 16	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Anis Nadhirah Khairul Anuar

924	Quantitative Neurodegenerative Risk Modelling and Clinical Score Prediction Using Mixed Reality	Wednesday, October 7	9:30 - 10:30	Session 10	Station 16	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Joanna Stępień
991	Hepatic Biomarker Profile Across Parkinson's Disease Severity Stages in a Peruvian Cohort	Wednesday, October 7	9:30 - 10:30	Session 10	Station 17	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Jeel Moya-Salazar
992	Distinct HD-EEG Functional Connectivity Patterns in Early-Onset Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 17	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Clara Simonetta
993	Do Digital Mobility Outcomes Differ Across Clinically Defined NSD-ISS Stages in Parkinson's Disease?	Wednesday, October 7	9:30 - 10:30	Session 10	Station 17	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Patrick Tait
994	Beta and Gamma Local Field Potentials in Chronic Deep Brain Stimulation for Parkinson's Disease: Programming Implications from a Systematic Review	Wednesday, October 7	9:30 - 10:30	Session 10	Station 17	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Khaing Seaint Thu Aung
995	Platelet Lipidomic and Alpha-Synuclein as Peripheral Biomarkers of Disease Progression and Risk in GBA1-Associated Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 17	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Giuseppe Uras
996	Clinical and Patient-Reported Outcomes in Patients With and Without Severe Bradykinesia According to Sensor Measurements	Wednesday, October 7	9:30 - 10:30	Session 10	Station 17	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Daniel von Below
1133	Establishing the Ukrainian Parkinson's Disease Cohort within GP2: Early Results from the UPGRADE-PD Initiative	Wednesday, October 7	9:30 - 10:30	Session 10	Station 18	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Solomiia Bandrivska
1134	Saccadic Hypometria as a Biomarker of Longitudinal Change in MDS-UPDRS Part II and Axial Motor Subscores: Results from the Multicenter PALOMA Trial	Wednesday, October 7	9:30 - 10:30	Session 10	Station 18	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Assaf Benesh
1135	Lifestyle Changes After Parkinson's Disease Diagnosis: Associations with Age, Sex, Disease Duration, and Self-Perceived Quality of Life	Wednesday, October 7	9:30 - 10:30	Session 10	Station 18	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jose Bestoso
1136	Age-Modulated Gait Adaptations to Progressive Fatigue in Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 18	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Thomas Bowman

1137	Online Assessments Measure Motor and Cognitive Progression in People with and without Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 18	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ethan Brown
1138	Bidirectional Association Between Gout and Parkinson's Disease: A Systematic Review and Meta-Analysis	Wednesday, October 7	9:30 - 10:30	Session 10	Station 18	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Vishnu Byroju
1205	Clinical Factors Associated with the Hospitalization of Patients with Parkinson's Disease: A 3-year Prospective Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 19	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Remi Morimoto
1206	Clinical Stage According to Hoehn & Yahr Scale as a Predictor of Non-Motor Symptom Severity in Parkinson's Disease: A Cross-Sectional in Peru	Wednesday, October 7	9:30 - 10:30	Session 10	Station 19	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jeel Moya-Salazar
1207	Magnitude of Non-Motor Symptoms Among People with Parkinson's Disease in Rural and Urban Tanzania	Wednesday, October 7	9:30 - 10:30	Session 10	Station 19	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Brighton Mushengezi
1208	Validation of Instrumented Finger Tapping Metrics for Bradykinesia in Parkinson's disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 19	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Sai Nagaratnam
1209	Utility of Telephone Follow-up of PD Patients with Medication Adjustment	Wednesday, October 7	9:30 - 10:30	Session 10	Station 19	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Shermyn Neo
1210	Retrieval-Augmented Generation (RAG) Chatbot for Parkinson's Disease Patient Education and AI-Assisted Clinical Pre-Assessment	Wednesday, October 7	9:30 - 10:30	Session 10	Station 19	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Him Wai Ng

1277	What Non-Genetic Parkinson's Disease Risk Factors are Africans Exposed To? A Scoping Review	Wednesday, October 7	9:30 - 10:30	Session 10	Station 20	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jim Lee
1278	Regional landscape of Parkinson's disease: An update from the NeuRA Natural History of Parkinson's Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 20	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Weber Liu
1279	Mood Motor Interactions in Parkinson Disease Clinical Associations and Neurobiological Mechanisms	Wednesday, October 7	9:30 - 10:30	Session 10	Station 20	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Gabrielle Mathew
1280	Predictors of Parkinson's Disease Phenoconversion in Non-manifesting LRRK2 Carriers	Wednesday, October 7	9:30 - 10:30	Session 10	Station 20	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jing Han Ng
1281	Causes of Death and Clinical Predictors of Mortality in Parkinson's Disease and Parkinsonism: A 30-Year Population-Based Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 20	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Francesco Onorati
1282	Levodopa-Induced Dyskinesia Predicts Falls, Fall-Related Injuries, and Their Consequences in Parkinson's Disease: A Prospective PPMI Cohort Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 20	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Paulo Pelicioni
1360	NPC2 is an Allele-Specific Modifier of GBA1-Associated Parkinson's Disease Risk	Wednesday, October 7	9:30 - 10:30	Session 10	Station 21	1	Parkinson's Disease: Genetics	Jonggeol Kim
1361	Sex-Stratified Multi-Omic Integration Identifies Sexually Dimorphic Molecular Targets in Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 21	2	Parkinson's Disease: Genetics	Joo-Yeon Lee
1362	Shared and Sex-Specific Genetic Risk for Parkinson's Disease Across European Populations	Wednesday, October 7	9:30 - 10:30	Session 10	Station 21	3	Parkinson's Disease: Genetics	Hampton Leonard
1363	Genome-wide Discovery of Genetic Modifiers of LRRK2 risk in Parkinson's Disease Carriers across European Populations	Wednesday, October 7	9:30 - 10:30	Session 10	Station 21	4	Parkinson's Disease: Genetics	Hampton Leonard
1364	LRRK2 Mutation Spectrum and Association Study in a Multi-ethnic Cohort of Malaysian Parkinson's Disease Patients	Wednesday, October 7	9:30 - 10:30	Session 10	Station 21	5	Parkinson's Disease: Genetics	Kai Shi Lim

1365	Expanding Parkinson's Disease Genomics in East Africa	Wednesday, October 7	9:30 - 10:30	Session 10	Station 21	6	Parkinson's Disease: Genetics	Rahema Mohammad
1421	Prognostic Impact of GBA Variants on Mortality in Parkinson's Disease: A Systematic Review and Meta-Analysis	Wednesday, October 7	9:30 - 10:30	Session 10	Station 22	1	Parkinson's Disease: Genetics	Nathan Chan
1422	Discordant Siblings Reveal Determinants of Clinical Penetrance in GBA-Associated Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 22	2	Parkinson's Disease: Genetics	Tommaso Filidei
1423	Intersectin-1 (ITSN1) Loss-of-Function Variants in Parkinson's Disease: Clinical Phenotypes and Neuropathological Insights	Wednesday, October 7	9:30 - 10:30	Session 10	Station 22	3	Parkinson's Disease: Genetics	Joshua Frost
1424	Handwriting in PRKN-PD: A Study of Movement Control	Wednesday, October 7	9:30 - 10:30	Session 10	Station 22	4	Parkinson's Disease: Genetics	Amy Gallagher
1425	How large must a Parkinson's disease trial be to detect pharmacogenomic interactions? Power benchmarks derived from the Exenatide PD3 clinical trial	Wednesday, October 7	9:30 - 10:30	Session 10	Station 22	5	Parkinson's Disease: Genetics	Rowan Gurney
1426	PPP2R5D Variants in Patients Diagnosed With Parkinson's Disease. A Large-Scale Multi-Cohort Analysis	Wednesday, October 7	9:30 - 10:30	Session 10	Station 22	6	Parkinson's Disease: Genetics	Ignacio Keller Sarmiento
1493	Structural-Functional Coupling Supporting Motor Reserve in Early-Stage Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 23	1	Parkinson's disease: Neuroimaging	Yanyi Li
1494	Reconfiguration of Structural-Functional Coupling Associated with Clinical Features and 5-Year Progression in Parkinson's Disease: A Cross-sectional and Longitudinal Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 23	2	Parkinson's disease: Neuroimaging	Yanyi Li
1495	Cerebellar Network Compensation in Parkinson's Disease: Functional Connectivity Across Motor and Cognitive Circuits	Wednesday, October 7	9:30 - 10:30	Session 10	Station 23	3	Parkinson's disease: Neuroimaging	Chi-Ying (Roy) Lin
1496	DTI-Based Comparative Analysis of Microstructural Alterations in Parkinson Disease and Atypical Parkinsonism	Wednesday, October 7	9:30 - 10:30	Session 10	Station 23	4	Parkinson's disease: Neuroimaging	Hao Lin
1497	Basal Ganglia Pathway Recruitment Determines Bidirectional Bradykinesia Modulation by DBS in Humans	Wednesday, October 7	9:30 - 10:30	Session 10	Station 23	5	Parkinson's disease: Neuroimaging	Pavel Navratil
1498	Resting-state pupil fluctuations reflect monoaminergic brainstem dysfunction associated with non-motor symptoms in early Parkinson's disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 23	6	Parkinson's disease: Neuroimaging	Lucas Negri
1565	Diagnosis and therapeutic approaches for sialorrhea in patients with Parkinson's disease.	Wednesday, October 7	9:30 - 10:30	Session 10	Station 24	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Natalia Fedotova

1566	The Sweet Smell of ON: Phantosmia During Motor Fluctuations After Initiation of Foslevodopa/Foscarbidopa Infusion Therapy	Wednesday, October 7	9:30 - 10:30	Session 10	Station 24	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Suganya Giri Ravindran
1567	Structural validity, reliability, and minimally important differences for the SCOPA-AUT	Wednesday, October 7	9:30 - 10:30	Session 10	Station 24	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	David González
1568	Effect of Poor Sleep Quality on Fatigue Severity in Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 24	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Nesrin Helvacı Yılmaz
1569	A Pragmatic Phenotype-Guided Algorithm for Constipation in Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 24	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Grace Hey
1570	Diagnostic Test Utilization and Timing in a Multidisciplinary Gastrointestinal Symptom Clinic: Insights from the Parkinson's Research and Integrated Support Model (PRISM) Clinic	Wednesday, October 7	9:30 - 10:30	Session 10	Station 24	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Grace Hey
1637	Nocturnal hypokinesia in Parkinson's disease: impact on sleep and quality of life	Wednesday, October 7	9:30 - 10:30	Session 10	Station 25	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Iulia Murasan
1638	Sleep Patterns and Cognitive Function in Parkinson's Disease: a Longitudinal Pilot Study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 25	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Maria Laura Nasi
1639	Non-Motor Symptom Burden as a Key Determinant of Disease Clustering in Parkinson's Disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 25	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Arwa Rekik
1640	Supine Graded Exercise and Orthostatic Blood Pressure in Alpha-Synucleinopathies	Wednesday, October 7	9:30 - 10:30	Session 10	Station 25	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Amber van.der Stam
1641	Impulse Control in Parkinson's: β - and Muscle Burst Dynamics Reveal Distinct Effects of Pathology and Dopamine Medication	Wednesday, October 7	9:30 - 10:30	Session 10	Station 25	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Aliya Warden
1642	Boxing-Based Exercise Programs for Parkinson's Disease: A Review of Motor and Quality-of-Life Outcomes	Wednesday, October 7	9:30 - 10:30	Session 10	Station 25	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Connie Hu

1690	Insight into α -synuclein pathogenicity by a human cell model with suppressed NatB-mediated N-terminal acetylation	Wednesday, October 7	9:30 - 10:30	Session 10	Station 26	1	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Alessia Caiella
1691	Human Snca Knock-In Mouse as a Model for Synucleinopathy Research	Wednesday, October 7	9:30 - 10:30	Session 10	Station 26	2	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Elif Cinar
1692	Disrupted Lipid Homeostasis and Mitochondrial Remodeling in A53T α -Synuclein Astrocytes	Wednesday, October 7	9:30 - 10:30	Session 10	Station 26	3	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Ilaria Goglia
1693	STN Neuronal Activity Shows Complex and Patient-Dependent Differences in Akinetic-Rigid Parkinson's Disease With and Without Dystonia	Wednesday, October 7	9:30 - 10:30	Session 10	Station 26	4	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Anna Golik
1694	Targeting c-Abl/Drp1-Dependent Mitochondrial Fission: Neuroprotective Effects of Berberine Chloride in Parkinson's Disease Models	Wednesday, October 7	9:30 - 10:30	Session 10	Station 26	5	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Dharmendra Khatri
1695	Analysis of Sphingolipid Metabolism Gene Expression in the Parkinson's Disease Postmortem Brain Dataset	Wednesday, October 7	9:30 - 10:30	Session 10	Station 26	6	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Jeng-Lin Li
1781	Perioperative outcomes for patients with Parkinson's disease - a scoping review	Wednesday, October 7	9:30 - 10:30	Session 10	Station 27	1	Parkinson's Disease: Surgical Therapy	Amelia Paveley
1782	Electrode localization in STN deep brain stimulation using image reconstruction from an emerging DBS program in the Dominican Republic	Wednesday, October 7	9:30 - 10:30	Session 10	Station 27	2	Parkinson's Disease: Surgical Therapy	Laura Reyes Lagarde
1783	Neuropsychiatric profile and its evolution in patients with Parkinson's disease undergoing bilateral Subthalamic Deep Brain Stimulation - a retrospective study	Wednesday, October 7	9:30 - 10:30	Session 10	Station 27	3	Parkinson's Disease: Surgical Therapy	Harishma S
1784	Effect of subthalamic nucleus deep brain stimulation on heart rate variability in Parkinson's disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 27	4	Parkinson's Disease: Surgical Therapy	Cheewapon Sawanon
1785	Network determinants of stimulation-induced speech impairment after subthalamic DBS in Parkinson's disease	Wednesday, October 7	9:30 - 10:30	Session 10	Station 27	5	Parkinson's Disease: Surgical Therapy	Mario Sousa
1786	The Impact of Demographic Factors on Skull Density Ratios in a Hawaii Cohort	Wednesday, October 7	9:30 - 10:30	Session 10	Station 27	6	Parkinson's Disease: Surgical Therapy	Kenny Thai
1064	Cognitive Impairment and Neuropsychiatric Manifestations in Parkinson's disease in Africa: A Systematic Review of Evidence	Wednesday, October 7	9:30 - 10:30	Session 10	Station 28	1	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Mundih Njohjam

1065	Digital cognitive training and promoting a healthy lifestyle as a booster for cognitive reserve in prodromal Parkinson's disease?	Wednesday, October 7	9:30 - 10:30	Session 10	Station 28	2	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Anja Ophey
1066	Nigrostriatal Dopaminergic Patterns in Dementia with Lewy Bodies and Parkinson's Disease Subtypes: A DAT-SPECT Study within the SOC Framework	Wednesday, October 7	9:30 - 10:30	Session 10	Station 28	3	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Giovanni Palermo
1067	Early Caudate Dopaminergic Loss as an Imaging Biomarker of Cognitive Impairment in Parkinson's Disease: A Longitudinal Analysis	Wednesday, October 7	9:30 - 10:30	Session 10	Station 28	4	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Baikuntha Panigrahi
1068	Efficacy of Aripiprazole on Cognitive Functions in Parkinson's Disease: A Systematic Review and Meta-analysis	Wednesday, October 7	9:30 - 10:30	Session 10	Station 28	5	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Ibrahim Serag
1069	Psychiatric Profiles in Parkinson: A Cluster Analysis of Cognitive Performance	Wednesday, October 7	9:30 - 10:30	Session 10	Station 28	6	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Roberto Trejo-Ayala
118	Integrating Psychology into a Parkinson's Disease Service - Evaluating Need	Wednesday, October 7	12:00 - 13:00	Session 11	Station 1	1		Ruth Lewis-Morton
119	Parkinson's Disease and Parkinsonism Family Center Psychoeducational Program for Patients and Caregivers	Wednesday, October 7	12:00 - 13:00	Session 11	Station 1	2	Quality Of Life/Caregiver Burden in Movement Disorders	Matilde Serini
120	Lived Experiences and the Weight of Parkinson's Caregiving in Kenya	Wednesday, October 7	12:00 - 13:00	Session 11	Station 1	3	Quality Of Life/Caregiver Burden in Movement Disorders	Brenda Mghendi
100	Suicidal Ideation and Behavior in Parkinson's Disease: A Systematic Review and Meta-Analysis	Wednesday, October 7	12:00 - 13:00	Session 11	Station 1	4	Patient Perspectives	Sonali Priyadarsine e Kuanar
101	Nutrition and Dietary Assessment as a Wellness Factor in Parkinson's Disease and Related Disorders	Wednesday, October 7	12:00 - 13:00	Session 11	Station 1	5	Patient Perspectives	Natalie Hellmers
102	Healthcare Utilization and Economic Burden in Patients with Friedreich's Ataxia: Baseline Results of the PROFA Study	Wednesday, October 7	12:00 - 13:00	Session 11	Station 1	6	Patient Perspectives	Dorota Sarwinska
27	Safer AI Dosing Recommendations in Parkinson's Disease Through Uncertainty-Adaptive Prediction	Wednesday, October 7	12:00 - 13:00	Session 11	Station 2	1	Artificial Intelligence (AI) and Machine Learning	Ricardo Diaz-Rincon
28	Prospective Evaluation of a Video-Based Motor Assessment Workflow: Feasibility, Usability, and Data Quality	Wednesday, October 7	12:00 - 13:00	Session 11	Station 2	2	Artificial Intelligence (AI) and Machine Learning	Bronwyn Bridges

29	Retrospective Video-Based Motor Assessment: Feasibility and Inter-Rater Variability in Remote Scoring	Wednesday, October 7	12:00 - 13:00	Session 11	Station 2	3	Artificial Intelligence (AI) and Machine Learning	Orla Hares
30	Kinematic Discriminative Component (KDC) a New Biomarker to Measure Parkinson's Disease Severity	Wednesday, October 7	12:00 - 13:00	Session 11	Station 2	4	Artificial Intelligence (AI) and Machine Learning	Mario Perales
31	Inter-Rater Variability in Motor Assessment Scoring: Measurement Implications for Understanding Movement Disorders in Aging	Wednesday, October 7	12:00 - 13:00	Session 11	Station 2	5	Artificial Intelligence (AI) and Machine Learning	Ravideep Singh
32	An AI-Based Wearable Device Application To Assess Motor Skills Anomalies Associated with Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 2	6	Artificial Intelligence (AI) and Machine Learning	Anika Ganu
249	Freezing of Gait in Atypical Parkinsonism improves with Transcranial Direct Current Stimulation	Wednesday, October 7	12:00 - 13:00	Session 11	Station 3	1	MSA, PSP, CBS (Other)	Somdattaa Ray
250	Revisiting Prodromal Diagnostic Criteria in MSA: The Need for Early MRI-Based Diagnosis	Wednesday, October 7	12:00 - 13:00	Session 11	Station 3	2	MSA, PSP, CBS (Other)	Jehyun Ahn
251	A Distinct Genetic Landscape of Progressive Supranuclear Palsy in Asians: Beyond the MAPT-Dominant Paradigm	Wednesday, October 7	12:00 - 13:00	Session 11	Station 3	3	MSA, PSP, CBS (Other)	Pin-Shiuan Chen
252	Social Determinants of Health and MSA survival	Wednesday, October 7	12:00 - 13:00	Session 11	Station 3	4	MSA, PSP, CBS (Other)	Yee Yen Goh
253	POLG-Related Disease Mimicking Progressive Supranuclear Palsy with Selective Vertical Gaze Restriction	Wednesday, October 7	12:00 - 13:00	Session 11	Station 3	5	MSA, PSP, CBS (Other)	Emma Orozco
254	Atypical Parkinson: what can an outpatient Voice and Swallowing Clinic offer to patients	Wednesday, October 7	12:00 - 13:00	Session 11	Station 3	6	MSA, PSP, CBS (Other)	Eleftheria Iliadou
182	Utility of the Short Cognitive and Neuropsychiatric Assessment Scale (ShoCo) in a Multiethnic Asian Cohort of Patients with Progressive Supranuclear Palsy	Wednesday, October 7	12:00 - 13:00	Session 11	Station 4	1	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Kelly Chen
183	Exploring Swallowing Dysfunction, Quality of Life, and Caregiver Burden in Multiple System Atrophy	Wednesday, October 7	12:00 - 13:00	Session 11	Station 4	2	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Irem Karagoz
184	Clinical and Cognitive Profile in Patients with Atypical Parkinsonian Syndromes: A Longitudinal Study from a Tertiary Care Center	Wednesday, October 7	12:00 - 13:00	Session 11	Station 4	3	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ravichandiran Kumar

185	Insights on the Groaning Phenomenon from a Large Asian Progressive Supranuclear Palsy Cohort	Wednesday, October 7	12:00 - 13:00	Session 11	Station 4	4	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ting Qing Lim
186	Metabolic-Structural Patterns Across Progressive Supranuclear Palsy Clinical Variants: a Multimodal PET-MRI Study	Wednesday, October 7	12:00 - 13:00	Session 11	Station 4	5	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Victor Maciel
187	Clinical Analysis of Progressive Supranuclear Palsy in Sri Lanka: Preliminary Results from a Cross-Sectional Collaborative Study with Global Parkinson's Genetic Program (GP2)	Wednesday, October 7	12:00 - 13:00	Session 11	Station 4	6	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Amasha Pathirage
404	Safety and Effectiveness of DaxibotulinumtoxinA in Cervical Dystonia: A Systematic Review and Meta-Analysis of Different Doses	Wednesday, October 7	12:00 - 13:00	Session 11	Station 5	1	Dystonia: Medical Therapy / Surgical Therapy	Haneen Sabet
405	Image-Guided DBS Programming in Dystonia: Experience from a Tertiary Public Brazilian Center	Wednesday, October 7	12:00 - 13:00	Session 11	Station 5	2	Dystonia: Medical Therapy / Surgical Therapy	Miriam Soares
406	Clinical Outcomes of Globus Pallidus Interna Deep Brain Stimulation in Primary and Secondary Dystonia: A Single-Center Experience	Wednesday, October 7	12:00 - 13:00	Session 11	Station 5	3	Dystonia: Medical Therapy / Surgical Therapy	ümmü reyyan toklu çetinkaya
407	Treatment of Bilateral Centromedian-Parafascicular (CM-Pf) Deep Brain Stimulation in a Pediatric Case of Rapid-Onset Dystonia-Parkinsonism	Wednesday, October 7	12:00 - 13:00	Session 11	Station 5	4	Dystonia: Medical Therapy / Surgical Therapy	Yang Zhao
408	Effects of Botulinum Toxin Therapy on Depression, Anxiety, Pain, and Quality of Life in Patients with Dystonia	Wednesday, October 7	12:00 - 13:00	Session 11	Station 5	5	Dystonia: Medical Therapy / Surgical Therapy	Nur Dilek Başpınar
409	Central Nervous System Lesioning Procedures For Dystonia In The Deep Brain Stimulation Era: A Systematic Review	Wednesday, October 7	12:00 - 13:00	Session 11	Station 5	6	Dystonia: Medical Therapy / Surgical Therapy	Laura Santos
366	ANK2 Mutations Associated with a Myoclonus-Dystonia Phenotype: Expanding the Neurological Spectrum of Ankyrin-B Dysfunction	Wednesday, October 7	12:00 - 13:00	Session 11	Station 6	1	Dystonia: Genetics	Alexandra Lackova
367	Modifiers of Intergenerational Repeat Changes in X-linked Dystonia-Parkinsonism	Wednesday, October 7	12:00 - 13:00	Session 11	Station 6	2	Dystonia: Genetics	Nadine Endaya
368	From Cerebral Palsy to GNAO1-Related Movement Disorder: An Adult Diagnosis with Marked Response to Pallidal Deep Brain Stimulation	Wednesday, October 7	12:00 - 13:00	Session 11	Station 6	3	Dystonia: Genetics	Sandra Antigua-Jimenez
369	Genetic Predictors in Dystonia: A Phenotypic Analysis.	Wednesday, October 7	12:00 - 13:00	Session 11	Station 6	4	Dystonia: Genetics	Nishanth Gowda

370	Childhood-onset Dystonia Linked to KIF5A:p.Arg422Cys: Case Report and Functional Characterization	Wednesday, October 7	12:00 - 13:00	Session 11	Station 6	5	Dystonia: Genetics	Pablo Lorenzo-Barreto
371	Late-onset THAP-1 with SCA8 expansion mimicking functional movement disorder, case report.	Wednesday, October 7	12:00 - 13:00	Session 11	Station 6	6	Dystonia: Genetics	Zhanybek Myrzayev
540	Reversible Uremic Striatopathy Presenting as Acute Generalized Myoclonus and Chorea in a Patient with End Stage Renal Disease: A video-case report	Wednesday, October 7	12:00 - 13:00	Session 11	Station 8	1	Choreas (Non-Huntington's Disease)	Lakhan Parajiya
541	Ipsilateral chorea due to thalamic hemorrhage: insights into network mechanisms of post-stroke hyperkinetic disorders	Wednesday, October 7	12:00 - 13:00	Session 11	Station 8	2	Choreas (Non-Huntington's Disease)	Lina Quintero-Giraldo
542	Clinical and genetic profiles of patients with Huntington's disease and other hereditary choreas: Experience from an Indian Movement Disorder Clinic.	Wednesday, October 7	12:00 - 13:00	Session 11	Station 8	3	Choreas (Non-Huntington's Disease)	Divya Radhakrishnan
543	Marked intrafamilial phenotypic variability in VPS13A disease: a case series of three siblings	Wednesday, October 7	12:00 - 13:00	Session 11	Station 8	4	Choreas (Non-Huntington's Disease)	Sanketh Rampes
544	Cryptococcal Meningitis Presenting with Lower Body Parkinsonism and Generalized Chorea: A Case Report	Wednesday, October 7	12:00 - 13:00	Session 11	Station 8	5	Choreas (Non-Huntington's Disease)	Sakdipat Songwisit
545	Clinical Outcomes Of Globus Pallidus Internus Deep Brain Stimulation In ADCY5-Related Dyskinesia: A Case Series From A Tertiary Movement Disorders Center	Wednesday, October 7	12:00 - 13:00	Session 11	Station 8	6	Choreas (Non-Huntington's Disease)	Tahani Alhawsawi
668	Association study of genetic variants with Essential Tremor	Wednesday, October 7	12:00 - 13:00	Session 11	Station 9	1	Tremor	Brendan Tan
669	Electrophysiological Signatures of Peak Tremor Frequency Differentiate Parkinson's Disease, Essential Tremor, and Dystonic Tremor: A Three-Way Comparative Study	Wednesday, October 7	12:00 - 13:00	Session 11	Station 9	2	Tremor	VU THI HINH
670	Genetic Architecture of Essential Tremor: Clinical Misdiagnosis and Structural Variant Contributions to Neurobiological Pathways	Wednesday, October 7	12:00 - 13:00	Session 11	Station 9	3	Tremor	Xiaosheng Zheng
671	Outcomes of Bilateral Deep Brain Stimulation Following Prior MR-guided Focused Ultrasound Thalamotomy	Wednesday, October 7	12:00 - 13:00	Session 11	Station 9	4	Tremor	Andrea Zoana
672	Relationship Between Psychosocial Factors and Tremor Severity in Essential Tremor	Wednesday, October 7	12:00 - 13:00	Session 11	Station 9	5	Tremor	Nur Dilek Başpınar
673	Clinical Characteristics and Functional Impact of Tremor in Patients with Multiple Sclerosis in Nepal: A Cross-Sectional Observational Study	Wednesday, October 7	12:00 - 13:00	Session 11	Station 9	6	Tremor	AYUSH CHANDRA
569	Suicidal Ideation and the Hippocampal Histaminergic System in Huntington's Disease: A PET Study	Wednesday, October 7	12:00 - 13:00	Session 11	Station 10	1	Huntington's Disease	Peace Eze

570	Strategies for Participant Retainment in Large Observational Studies in Movement Disorders: a Single Centre Experience	Wednesday, October 7	12:00 - 13:00	Session 11	Station 10	2	Huntington's Disease	Monika Hartmann
571	Processing Speed across Huntington's Disease Stages and its association with Striatal PDE10A Density	Wednesday, October 7	12:00 - 13:00	Session 11	Station 10	3	Huntington's Disease	Claudia Madrigal Esquivel
572	Speech Changes as Biomarkers in Huntington's Disease: a Meta-Analysis	Wednesday, October 7	12:00 - 13:00	Session 11	Station 10	4	Huntington's Disease	Dorothy Nguyen
573	Antidepressants in Huntington's Disease: A Meta Analysis of Mood and Motor Outcomes with Placebo-controlled Trials	Wednesday, October 7	12:00 - 13:00	Session 11	Station 10	5	Huntington's Disease	Jorge Patino
574	Efficacy and Adverse Events of Tetrabenazine, Deutetrabenazine, and Valbenazine in Huntington's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 10	6	Huntington's Disease	Jorge Patino
753	Long-Term Open-Label Data on the GCase Modulator GT-02287 in People with Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 12	1	Parkinson's Disease: Clinical Trials	Raffaella Pozzi
754	Clinical and Mobility Outcome with Ring versus Directional Globus Pallidus Stimulation in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 12	2	Parkinson's Disease: Clinical Trials	Anjanibhargavi Ragothaman
755	A Randomized Controlled Trial Evaluating Ankle Pump Combined with Compression Abdominal Belts on Orthostatic Hypotension in Patients with Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 12	3	Parkinson's Disease: Clinical Trials	Zheng Ruan
756	Effects of Auricular Vagus Nerve Stimulation Combined with Neurorehabilitation on Motor Symptoms, Balance, and Gait in People with Parkinson's Disease: Preliminary Results of a Prospective Study	Wednesday, October 7	12:00 - 13:00	Session 11	Station 12	4	Parkinson's Disease: Clinical Trials	Mustafacan Salamci
757	Disease-Modifying Outcomes Following High Intensity Boxing and Sensory Exercise in Parkinson's Disease: Results From a Double-blinded Randomized Controlled Trial	Wednesday, October 7	12:00 - 13:00	Session 11	Station 12	5	Parkinson's Disease: Clinical Trials	Kishorree Sangarapillai-Patel
758	Outcomes from Unilateral MR-Guided Focused Ultrasound Pallidothalamic Tractotomy for Advanced Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 12	6	Parkinson's Disease: Clinical Trials	Harini Sarva
825	Long-term Safety of Opicapone in Parkinson's Disease Patients with First Signs of Wearing-off	Wednesday, October 7	12:00 - 13:00	Session 11	Station 13	1	Parkinson's Disease: Pharmacology and Medical Management	Joaquim Ferreira
826	Ketogenic Diet and Motor Outcomes in Parkinson's Disease: A Meta-analysis of Randomized Trials	Wednesday, October 7	12:00 - 13:00	Session 11	Station 13	2	Parkinson's Disease: Pharmacology and Medical Management	Ana Fornari Caprara

827	Effectiveness of Switching from Levodopa-Carbidopa Intestinal Gel to Levodopa-Carbidopa-Entacapone Intestinal Gel in Patients with Refractory Biphase and Peak-of-Dose Dyskinesia	Wednesday, October 7	12:00 - 13:00	Session 11	Station 13	3	Parkinson's Disease: Pharmacology and Medical Management	Rocio Garcia-Ramos Garcia
828	Efficacy and Safety of Muscle Afferent Block for Camptocormia in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 13	4	Parkinson's Disease: Pharmacology and Medical Management	Shotaro Horie
829	Medication Burden and Associated Challenges for People with Parkinson's: A Survey of 359 UK Patients	Wednesday, October 7	12:00 - 13:00	Session 11	Station 13	5	Parkinson's Disease: Pharmacology and Medical Management	Shelley Jones
830	Remaining unmet needs in Essential Tremor and Parkinson's Disease: European Neurologists' Assessments of Pharmacologic Response and Advanced Therapy Use	Wednesday, October 7	12:00 - 13:00	Session 11	Station 13	6	Parkinson's Disease: Pharmacology and Medical Management	Natalie Kaempff
1803	Proximity Ligation Assay Reveals Early Tractopathy in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 14	1	Parkinson's Disease (Other)	YuHong Fu
1804	Restoring Dopaminergic Function: iPSC-derived MSCs Show Therapeutic Promise in Parkinson's Disease Rat Model	Wednesday, October 7	12:00 - 13:00	Session 11	Station 14	2	Parkinson's Disease (Other)	Ujaswini Gogoi
1805	Impaired Retention of Goal-Directed Movements in Parkinson's Disease: A 2-Year Longitudinal Analysis	Wednesday, October 7	12:00 - 13:00	Session 11	Station 14	3	Parkinson's Disease (Other)	Joongsuk Kim
1806	Festinating Speech in Parkinson's Disease: Effects of Deep-Brain Stimulation and Interspeaker Variability	Wednesday, October 7	12:00 - 13:00	Session 11	Station 14	4	Parkinson's Disease (Other)	Yunjung Kim
1807	Bisphenol S: A Potential Environmental Modifier of LRRK2-Associated Parkinson's disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 14	5	Parkinson's Disease (Other)	Begoña Talavera Andújar
1808	Comparability of Smartphone App and Booth Recordings for Robust Acoustic Speech Monitoring in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 14	6	Parkinson's Disease (Other)	Tabea Thies
1875	Taekwondo Training with External Focus of Attention as a Complex Motor Intervention in Parkinson's Disease: A Pilot Study	Wednesday, October 7	12:00 - 13:00	Session 11	Station 15	1	Parkinson's Disease (Other)	Bokkyu Kim
1876	Community Gym Exercise Therapy for People Living with Early Onset Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 15	2	Parkinson's Disease (Other)	Claire Thwaites
1877	Device-Assisted Therapies in Parkinson Disease: Patient Preference Following Nurse-Led Education	Wednesday, October 7	12:00 - 13:00	Session 11	Station 15	3	Parkinson's Disease (Other)	David Tsui
1878	Beyond Relaxation: Can Self-Initiated Therapeutic Tremors Improve Functional Gait and ADL in Parkinson's Disease?	Wednesday, October 7	12:00 - 13:00	Session 11	Station 15	4	Parkinson's Disease (Other)	Elizabeth Atterbury
1879	Fear Across the Disease Course: How Age, Sex, and Disease Duration Influence Different Types of Fear in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 15	5	Parkinson's Disease (Other)	Adetayo Babarinde

1880	How Remote Coaching Enables Engagement in Physical Activity for People with Parkinson's Disease in Qatar: A Qualitative Study of Participant and Therapist Perspectives	Wednesday, October 7	12:00 - 13:00	Session 11	Station 15	6	Parkinson's Disease (Other)	Maal Elamin
925	Characteristics of Cortical Beta Bursts in Parkinson's disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 16	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Laura Witt
926	Retrospective Evaluation of microRNA-7-5p and Neuron-Derived α -Synuclein in Prodromal Parkinson's Disease as Phenoconversion Biomarkers	Wednesday, October 7	12:00 - 13:00	Session 11	Station 16	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Christopher Adams
927	Metabolomic profile as a biomarker of non-motor symptoms severity in patients with Parkinson's disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 16	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Kriscila Aguiar
928	Disentangling Disease- and Medication-Associated Gut Microbiome Signatures in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 16	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	moongwan Choi
929	Heart Rate Variability in Early Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 16	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Seok Jong Chung
930	Title: Association of Neurofilament Light Chain and Peripheral Inflammatory Biomarkers with Clinical Progression in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 16	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Doniyorbek Daminov
997	Kinetic Features of Alpha-synuclein Positivity in CSF Seed Amplification in Parkinson's Disease: an Exploratory Cross-cohort Analysis	Wednesday, October 7	12:00 - 13:00	Session 11	Station 17	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	April Wen
998	Association of Neurofilament Light Chain with Substantia Nigra Degeneration in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 17	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Wenjuan WU
999	Markerless Kinematics of Levodopa Response During Activities of Daily Living in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 17	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Juyoung Yun
1000	Sensitivity of AI-Derived Video-Based Digital Biomarkers to Motor Progression in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 17	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Tahereh Zarrat Ehsan
1001	AI-based Progression and Medication Response Prediction in Parkinson's Disease: the AI-PMP Study Protocol	Wednesday, October 7	12:00 - 13:00	Session 11	Station 17	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Natalia del Campo
1002	SEMG for Dyskinesia Detection in Parkinson's Disease Using Machine Learning	Wednesday, October 7	12:00 - 13:00	Session 11	Station 17	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Ester Muñoz-delCampo

1139	Risk of Deep Venous Thrombosis in Patients With Parkinson's Disease: A Meta-Analysis of Observational Studies	Wednesday, October 7	12:00 - 13:00	Session 11	Station 18	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Vishnu Byroju
1140	Patient self-rated Improvements with Opicapone: From randomized trials to Phase IV studies in fluctuating Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 18	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Helena C Brigas
1141	Face Pareidolia in the East London Parkinson's Disease Project	Wednesday, October 7	12:00 - 13:00	Session 11	Station 18	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ellen Camboe
1142	Monopolar Sensing within the Globus Pallidus and the Relationship between Clinical Outcomes and Anatomy	Wednesday, October 7	12:00 - 13:00	Session 11	Station 18	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Michelle Case
1143	Clinical Characteristics of Gastric Motility Disorder in Early-Stage Parkinson's Disease and Its Longitudinal Predictive Value for Disease Progression	Wednesday, October 7	12:00 - 13:00	Session 11	Station 18	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Xiao-Yu Cheng
1144	Effectiveness and use of foscarnid in advanced Parkinson disease in real life setting in France (ENVOL study): interim analysis	Wednesday, October 7	12:00 - 13:00	Session 11	Station 18	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Olivier COLIN
1211	Endogenous reproductive factors and risk of Parkinson's disease in women: a systematic review and meta-analysis of observational studies	Wednesday, October 7	12:00 - 13:00	Session 11	Station 19	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Theodora Ntetsika
1212	Re-evaluating Olfactory Testing and Cardiac 123I-MIBG Scintigraphy in the MDS Clinical Diagnostic Criteria for Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 19	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Tomonori Nukariya

1213	Association Between the Side of Tremor Onset and Clinical Profiles of Patients with Parkinson's disease in Rural and Urban Tanzania	Wednesday, October 7	12:00 - 13:00	Session 11	Station 19	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Kigocha Okeng'o
1214	Performance of the functional staging of Parkinson's disease using the Neuronal aSynuclein Disease Integrated Staging System (NSD-ISS) in the Critical Path for Parkinson's (CPP) Integrated Parkinson's Database	Wednesday, October 7	12:00 - 13:00	Session 11	Station 19	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Diana Angelika Olszewska
1215	Neuronal aSynuclein Disease Integrated Staging System (NSD-ISS) Reveals Clinically Meaningful Functional Progression and Quality-of-Life Impact in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 19	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Diana Angelika Olszewska
1216	Long-term evolution of deep brain stimulation parameters in Parkinson's Disease: A 6-year analysis.	Wednesday, October 7	12:00 - 13:00	Session 11	Station 19	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Dante Oropeza-Velázquez
1283	Describing Factors Associated with Progression in Parkinson's Disease: A Retrospective Chart Review	Wednesday, October 7	12:00 - 13:00	Session 11	Station 20	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Shashika Rodrigo
1284	Pregnancy and Breastfeeding in Early-Onset Parkinson's Disease: Therapeutic Challenges of Levodopa Monotherapy. A case Report.	Wednesday, October 7	12:00 - 13:00	Session 11	Station 20	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Karla Salinas-Barboza
1285	Linking Motor and Non-Motor Fluctuations in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 20	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Alaa Shaaban
1286	Quantitative Analysis of the DESH in Normal Pressure Hydrocephalus and Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 20	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Natsumi Takemura

1287	Additive effect of Diabetes Mellitus and genetic risk variant in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 20	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Brendan Tan
1288	Feasibility study of a portable medical device, the Neuromotor pen, as a screening tool for Parkinson's disease in a rural northern Tanzania	Wednesday, October 7	12:00 - 13:00	Session 11	Station 20	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Isabelle Terry
1340	Chronic Vanadium Exposure Promotes Memory Impairment and Aggregation of Alpha-Synuclein, Tau and Amyloid Beta in Mouse Brain	Wednesday, October 7	12:00 - 13:00	Session 11	Station 21	1	Parkinson's Disease: Etiology (non-genetics)	oluwabusayo Folarin
1341	Relationships of serum & CSF Transcobalamin Receptor Antibodies to CSF vitamin B12, holotranscobalamin and clinical progression in Parkinson's disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 21	2	Parkinson's Disease: Etiology (non-genetics)	Chadwick Christine
1342	Brain-First and Body-First Model Translated to Individual-Level Characterization in Parkinson's Disease: Multimodal Imaging and Clinical Approach	Wednesday, October 7	12:00 - 13:00	Session 11	Station 21	3	Parkinson's Disease: Etiology (non-genetics)	Kaat Colman
1343	PEST-PD: Preliminary Findings from an Ongoing Longitudinal Observational Study for Prodromal Parkinson's disease in farmers exposed to pesticides.	Wednesday, October 7	12:00 - 13:00	Session 11	Station 21	4	Parkinson's Disease: Etiology (non-genetics)	Cubo Cubo
1344	Sleep Disorders and Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis	Wednesday, October 7	12:00 - 13:00	Session 11	Station 21	5	Parkinson's Disease: Etiology (non-genetics)	Rashad G. Mohamed
1345	The Association between Antiepileptic Drug Use, Epilepsy and the Risk of Parkinson's Disease: A Systematic Review and Meta-analysis	Wednesday, October 7	12:00 - 13:00	Session 11	Station 21	6	Parkinson's Disease: Etiology (non-genetics)	Rashad G. Mohamed
1427	Age-Related Hearing Loss in Idiopathic Parkinson's Disease and APOE E4 Carriers	Wednesday, October 7	12:00 - 13:00	Session 11	Station 22	1	Parkinson's Disease: Genetics	Matthew Kmiecik
1428	Characterisation of early onset Parkinson's disease in UK cohorts	Wednesday, October 7	12:00 - 13:00	Session 11	Station 22	2	Parkinson's Disease: Genetics	Erika Lam
1429	Clinico-radiological Phenotype of a Unique Family with Mutations in PRKN Over Three Decades	Wednesday, October 7	12:00 - 13:00	Session 11	Station 22	3	Parkinson's Disease: Genetics	Michael Li
1430	Adult-Onset Incomplete Kufor-Rakeb Syndrome Presenting with Parkinsonism: A Case Report	Wednesday, October 7	12:00 - 13:00	Session 11	Station 22	4	Parkinson's Disease: Genetics	Lorenzo Malfer
1431	Association of DAGLB Variants with Early-Onset Parkinson's Disease Across Populations	Wednesday, October 7	12:00 - 13:00	Session 11	Station 22	5	Parkinson's Disease: Genetics	Yasser Mecheri
1432	Expanding the Clinical Spectrum of 22q11.2 Duplication Syndrome: a 5-year Follow-up of Two Siblings with Young-onset Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 22	6	Parkinson's Disease: Genetics	Alexander Milovidov
1499	The Dual Functional Organization of the Substantia Nigra in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 23	1	Parkinson's disease: Neuroimaging	Massimiliano Passaretti

1500	Visualization of Small Brainstem Nuclei With the Ultra-High Performance NeuroEXPLORER PET Camera: a Comparison Study Using 18F-AV133	Wednesday, October 7	12:00 - 13:00	Session 11	Station 23	2	Parkinson's disease: Neuroimaging	Neha Prakash
1501	Clinical and brain morphological characteristics of patients with Parkinson's disease and co-occurring apathy and impulse control disorders	Wednesday, October 7	12:00 - 13:00	Session 11	Station 23	3	Parkinson's disease: Neuroimaging	Stephane Prange
1502	Comparison of Neuroimaging-Derived and Clinical Motor Subtypes in Early Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 23	4	Parkinson's disease: Neuroimaging	Leila Saadatpour
1503	Subtype-specific alterations of iron deposition and neuromelanin loss in the substantia nigra of Parkinson's disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 23	5	Parkinson's disease: Neuroimaging	Atsushi Shima
1504	Cortical-Subcortical Structural Signature of dementia with lewy bodies Reveals Cognitive Trajectories of Lewy Body Disease in REM Sleep Behavior Disorder	Wednesday, October 7	12:00 - 13:00	Session 11	Station 23	6	Parkinson's disease: Neuroimaging	Jung Hwan Shin
1571	The Relationship Between Neurobehavioral Profile and Cognitive Phenotype in Patients with Idiopathic Parkinson's Disease Without Dementia.	Wednesday, October 7	12:00 - 13:00	Session 11	Station 24	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Carlos Alberto Hurtado-González
1572	The Effect of Depression on the Cognitive Phenotype in a Group of Patients Diagnosed with Idiopathic Parkinson's Disease Without Dementia.	Wednesday, October 7	12:00 - 13:00	Session 11	Station 24	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Carlos Alberto Hurtado-González
1573	The Nature of autonomic dysfunction and its relationship with motor symptoms in Drug-Naive Parkinson's Disease Patients: Korean Cohort Data	Wednesday, October 7	12:00 - 13:00	Session 11	Station 24	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Yun Su Hwang
1574	Autonomic Coupling Patterns Differ by REM Sleep Behavior Disorder Status in De Novo Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 24	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Bora Jin
1575	Clinical Approach to Impulse Control-Related Behavioural Disorders in Parkinson's Disease: A Scoping Review	Wednesday, October 7	12:00 - 13:00	Session 11	Station 24	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Goh Jin Yi
1576	Sleep Disturbance and Sleep Fragmentation as Correlates of Gait Deterioration and Fall-Related Outcomes in Parkinson's Disease: A Systematic Review	Wednesday, October 7	12:00 - 13:00	Session 11	Station 24	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Shradha Kakde
1643	Bayesian Network Analysis of Directional Relationships Among Motor and Non-Motor Symptoms in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 25	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Alham Al-Sharman

1644	Spiritual Well-Being and Clinical Burden in Parkinson's Disease: A Case-Control Study	Wednesday, October 7	12:00 - 13:00	Session 11	Station 25	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Dasom Jeong
1645	Assessing Agreement of Self-Perception of Dysphagia in Individuals with Parkinson Disease and their Caregivers	Wednesday, October 7	12:00 - 13:00	Session 11	Station 25	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Alice Silbergleit
1708	Real-World Relationship Between Beta-Band LFP Activity and Motor States in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 25	4	Parkinson's Disease: Surgical Therapy	Isabel Martin
1709	Optogenetic mediated inhibition of the subthalamic nucleus alleviates motor symptoms in experimental hemi-parkinsonism mouse model	Wednesday, October 7	12:00 - 13:00	Session 11	Station 25	5	Parkinson's Disease: Surgical Therapy	Shani Sobol
1710	Dentatothalamic Projections Mediate Tremor Relief Across Deep Brain Stimulation Targets and Tremor Types	Wednesday, October 7	12:00 - 13:00	Session 11	Station 25	6	Parkinson's Disease: Surgical Therapy	Christina van-der-Linden
1696	Modeling the Genetic Complexity of Parkinson's Disease: Generation of Patient-Specific iPSCs with Co-occurring SNCA/GBA1 and PRKN/LRRK2 Variants	Wednesday, October 7	12:00 - 13:00	Session 11	Station 26	1	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Lucía Murillo-Hernández
1697	Investigating Subthalamic Neuronal Activity in Parkinsonian Patients with Hemidystonia	Wednesday, October 7	12:00 - 13:00	Session 11	Station 26	2	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Philip Pavlovsky
1698	Aggregation - Dependent Effects of Wild-Type and Mutant α -Synuclein on Synaptic Membrane Fusion	Wednesday, October 7	12:00 - 13:00	Session 11	Station 26	3	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Malavika Sriram
1699	Stage-Dependent Dysregulation of Peripheral TREM2, SOD1, and Neurofilament Light Chain Across the Parkinson's Disease Continuum	Wednesday, October 7	12:00 - 13:00	Session 11	Station 26	4	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Alessandra Calculi
1700	The Correlation Between Serum Uric Acid Levels And The Severity Of Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 26	5	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Dian Prihananti
1701	Cortical Disinhibition and Beta Hypersynchrony underlying Freezing of Gait in Parkinson's Disease: a TMS-EEG Study	Wednesday, October 7	12:00 - 13:00	Session 11	Station 26	6	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Huimin Sun
1787	Decoding Deep Brain Activity from Cortical Signals using Deep Learning across Movement Disorders	Wednesday, October 7	12:00 - 13:00	Session 11	Station 27	1	Parkinson's Disease: Surgical Therapy	Zixiao Yin
1788	Long-Term Instability of GPi Gamma Oscillations in Parkinson's Disease: A Case Study	Wednesday, October 7	12:00 - 13:00	Session 11	Station 27	2	Parkinson's Disease: Surgical Therapy	Qingqi Yuan

1789	Reasons and Factors Influencing Parkinson's Patients' Decision to Decline Deep Brain Stimulation	Wednesday, October 7	12:00 - 13:00	Session 11	Station 27	3	Parkinson's Disease: Surgical Therapy	Laura Cabrera
1790	Perioperative and Longitudinal Outcomes Following Deep Brain Stimulation in Patients with Movement Disorders: A Retrospective Review From a Movement Disorder Program	Wednesday, October 7	12:00 - 13:00	Session 11	Station 27	4	Parkinson's Disease: Surgical Therapy	Zahra Mohseni
1791	Non-Motor Symptom Improvement as a Driver of Quality of Life after Subthalamic Stimulation in Symmetric Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 27	5	Parkinson's Disease: Surgical Therapy	Stefanie Jost
1792	Dual-Node Neuromodulation of the Basal Ganglia Motor Circuit: Sequential STN-GPi Stimulation in Advanced Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 27	6	Parkinson's Disease: Surgical Therapy	Joao Paulo Brainer Lima
1070	Efficacy of Novel Antipsychotic Agents on Cognitive Functions in Parkinson's Disease: A Systematic Review and Meta-analysis of 2,533 Patients	Wednesday, October 7	12:00 - 13:00	Session 11	Station 28	1	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Ibrahim Serag
1071	Can digital Mobility Outcomes differentiate cognitive impairment in Parkinson's Disease?	Wednesday, October 7	12:00 - 13:00	Session 11	Station 28	2	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Pieter Ginis
1072	Diffusion MRI Markers of Neural Reserve: Interaction Between Callosal Integrity and Clinical Vulnerability After Functional Neurosurgery in Parkinson's Disease	Wednesday, October 7	12:00 - 13:00	Session 11	Station 28	3	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Joao Brainer Lima
1073	The Cats-and-Dogs Test Predicts Cognitive Impairment in Parkinson's Disease in a Diverse Population	Wednesday, October 7	12:00 - 13:00	Session 11	Station 28	4	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Kamalesh Dey
1074	Social Network Structure and Caregiving Experiences in South Asian Families Living with Dementia Associated with Parkinsonian Disorders	Wednesday, October 7	12:00 - 13:00	Session 11	Station 28	5	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	AKANKSHI OBEROI
1075	Episodic Memory Impairment in South Asian Individuals with Parkinson's Disease: A Pilot Comparative Study	Wednesday, October 7	12:00 - 13:00	Session 11	Station 28	6	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	AKANKSHI OBEROI
103	Factors Influencing Participation in Genetic Testing Among Prodromal and Family History Positive Controls in Parkinson's Disease Genetic Cohort in Thailand	Wednesday, October 7	13:00 - 14:00	Session 12	Station 1	1	Patient Perspectives	Kornake Horaruengdecha
104	American Parkinson Disease Association Outreach to Mandarin-Speaking Communities in the United States	Wednesday, October 7	13:00 - 14:00	Session 12	Station 1	2	Patient Perspectives	Elvin Yao
105	Transitional Life Events in Friedreich Ataxia: Differential Age at Onset Perspectives	Wednesday, October 7	13:00 - 14:00	Session 12	Station 1	3	Patient Perspectives	Audrey Iskandar

97	HOPFIT: proactive recognition of older in-patients with advanced Parkinson's disease improves palliative care outcomes and patient autonomy	Wednesday, October 7	13:00 - 14:00	Session 12	Station 1	4	Palliative Care	William Tai
98	Efficacy of Combining Outpatient Palliative Care with Standard Care on Quality of Life and Caregiver Burden in Atypical Parkinsonian Syndrome – A Randomised Controlled Trial	Wednesday, October 7	13:00 - 14:00	Session 12	Station 1	5	Palliative Care	Rajat Kamra
99	To Protect Life and Safeguard Autonomy: Ambiguous Expressions of the Will to Live	Wednesday, October 7	13:00 - 14:00	Session 12	Station 1	6	Palliative Care	Julia Braun
33	Towards Deep Learning for Personalized Parkinson's Disease Tremor Segmentation and Severity Classification Using Wearable Sensors	Wednesday, October 7	13:00 - 14:00	Session 12	Station 2	1	Artificial Intelligence (AI) and Machine Learning	Jonathan Jaegerman
34	Automated Facial Movement Analysis for Differentiating True Hemifacial Spasm from Mimicking Facial Movements: A Pilot Study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 2	2	Artificial Intelligence (AI) and Machine Learning	Suppata Maytharakheep
35	Accessible Assessment of Ataxia Severity Across Diverse Populations: Integrating Large Datasets, Machine-Learning, and Online Testing	Wednesday, October 7	13:00 - 14:00	Session 12	Station 2	3	Artificial Intelligence (AI) and Machine Learning	Tamar Gilad
36	Automatic Detection of Freezing of Gait from Simple, 2D Video Recordings in Complex Clinical Environments	Wednesday, October 7	13:00 - 14:00	Session 12	Station 2	4	Artificial Intelligence (AI) and Machine Learning	Arik Shakolnikov
37	Markerless Kinematic Analysis of Gait and Turning in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 2	5	Artificial Intelligence (AI) and Machine Learning	Ariany Tahara
38	Translating Real-World Parkinsonian Facial Kinematics onto Diverse Digital Avatars	Wednesday, October 7	13:00 - 14:00	Session 12	Station 2	6	Artificial Intelligence (AI) and Machine Learning	Christopher Gundler
255	Corticobasal Degeneration With Alien Limb Phenomenon and Severe Cognitive Decline: A Levodopa-Resistant Clinical Case	Wednesday, October 7	13:00 - 14:00	Session 12	Station 3	1	MSA, PSP, CBS (Other)	Naira Aripova
141	Degradation Mechanisms of PolyG	Wednesday, October 7	13:00 - 14:00	Session 12	Station 3	2	MSA, PSP, CBS: Disease Mechanisms	Yiling Chen
142	Multi-Modal Profiling of Peripheral and Central Nervous System T Cells Identifies Cytotoxic α -Synuclein-Reactive Immunity in Multiple System Atrophy	Wednesday, October 7	13:00 - 14:00	Session 12	Station 3	3	MSA, PSP, CBS: Disease Mechanisms	Jae-Seung Moon
143	Sex Differences in Vascular Burden, Neurodegeneration, and Clinical Progression in Progressive Supranuclear Palsy Richardson Syndrome	Wednesday, October 7	13:00 - 14:00	Session 12	Station 3	4	MSA, PSP, CBS: Disease Mechanisms	Indira Garcia Cordero
144	Interleukin 6 in the assessment of Parkinson's disease and Progressive Supranuclear Palsy	Wednesday, October 7	13:00 - 14:00	Session 12	Station 3	5	MSA, PSP, CBS: Disease Mechanisms	Natalia Madetko-Alster

145	Divergent Glymphatic Dysfunction and Free Water Pathology Underpin Distinct Mechanisms and Enable Differential Diagnosis in Parkinson's Disease and Multiple System Atrophy	Wednesday, October 7	13:00 - 14:00	Session 12	Station 3	6	MSA, PSP, CBS: Disease Mechanisms	Ruinan SHEN
188	Does CANVAS mimic MSA-C	Wednesday, October 7	13:00 - 14:00	Session 12	Station 4	1	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Irène Pei
189	Clinical and Multimodal Biomarker Profiles in Progressive Supranuclear Palsy: The PSPNI Cohort Study in China	Wednesday, October 7	13:00 - 14:00	Session 12	Station 4	2	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Qi Shen
190	Remotely Administered Reaction Time Correlates in Progressive Supranuclear Palsy	Wednesday, October 7	13:00 - 14:00	Session 12	Station 4	3	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Timothy Siejka
191	Multiple System Atrophy Without Dysautonomia	Wednesday, October 7	13:00 - 14:00	Session 12	Station 4	4	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ida Wilkens
192	Sex comparisons for co-pathologies and clinical phenotypes in autopsy-confirmed four-repeat tauopathies	Wednesday, October 7	13:00 - 14:00	Session 12	Station 4	5	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ece Bayram
193	Determinants of Re-diagnosis of Parkinson's Disease to Atypical Parkinsonism: Results from the Tracking Parkinson's Cohort (PRoBAND) and Oxford Parkinson's Discovery Cohort (OPDC) Cohorts	Wednesday, October 7	13:00 - 14:00	Session 12	Station 4	6	MSA, PSP, CBS: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Riona Fumi
313	Atypical Phenotype of SORL1-Associated Early-Onset Alzheimer's Disease With Oromandibular and Cervical Dystonia	Wednesday, October 7	13:00 - 14:00	Session 12	Station 5	1	Dystonia: Clinical Trials	Martin Danis
314	One day accelerated 10 Hz rTMS for Focal Hand Dystonia: A Phase II Clinical Trial	Wednesday, October 7	13:00 - 14:00	Session 12	Station 5	2	Dystonia: Clinical Trials	Ian Xu
315	Tardive Dystonia Case Series and Choreathetosis Case Report Secondary to Cocaine Use From a Specialized Movement Disorder Center in Santiago, Chile.	Wednesday, October 7	13:00 - 14:00	Session 12	Station 5	3	Dystonia: Clinical Trials	Matías Niedbalski

372	Hereditary Adult-Onset Generalized Dystonia Associated with Pathogenic IRF2BPL Mutation	Wednesday, October 7	13:00 - 14:00	Session 12	Station 6	1	Dystonia: Genetics	Jake Plagenz
373	Familial Myoclonus-Dystonia Associated with SGCE Variant in a Chinese Family: Clinical and Genetic Characterization of Two Siblings	Wednesday, October 7	13:00 - 14:00	Session 12	Station 6	2	Dystonia: Genetics	Gao Xing
374	SGCE Mutations in Chinese Dystonia Patients: A Dual-Center Sequencing Study and Literature Review	Wednesday, October 7	13:00 - 14:00	Session 12	Station 6	3	Dystonia: Genetics	Jun Ma
375	Audit of Diagnostic Standards in the Dystonia Clinic	Wednesday, October 7	13:00 - 14:00	Session 12	Station 6	4	Dystonia: Genetics	Emma Ryder
376	Globus Pallidus Internus Deep Brain Stimulation for Dystonia in COX20-Related Mitochondrial Complex IV Deficiency (MC4DN11): First Reported Case	Wednesday, October 7	13:00 - 14:00	Session 12	Station 6	5	Dystonia: Genetics	ümmü reyyan toklu çetinkaya
377	A Novel VAC14 Variant Associated With Levodopa-responsive Generalized Dystonia	Wednesday, October 7	13:00 - 14:00	Session 12	Station 6	6	Dystonia: Genetics	Giorgia Urciuolo
546	Partial Duplication of NBEA in a Patient Presenting Chorea with Incomplete Penetrance	Wednesday, October 7	13:00 - 14:00	Session 12	Station 8	1	Choreas (Non-Huntington's Disease)	Haoyu Wang
547	Immune-mediated Chorea in Antiphospholipid Syndrome: Normalization of FDG-PET and Neurofilament as Markers of Treatment Response.	Wednesday, October 7	13:00 - 14:00	Session 12	Station 8	2	Choreas (Non-Huntington's Disease)	Laia Peraferrer-Montesinos
548	Seronegative Autoimmune Encephalitis Presenting as Hemichorea: A Case Report	Wednesday, October 7	13:00 - 14:00	Session 12	Station 8	3	Choreas (Non-Huntington's Disease)	Fatemeh Sadeghifar
674	Unilateral Deep Brain Stimulation For Essential Tremor: Compromise or Long-term Effective Treatment?	Wednesday, October 7	13:00 - 14:00	Session 12	Station 9	1	Tremor	Sahar Hemeda Hemeda
675	Nocturnal Blood Pressure Non-Dipping as an Autonomic Biomarker of Psychosis and Movement Disorder Severity in Pediatric Epilepsy	Wednesday, October 7	13:00 - 14:00	Session 12	Station 9	2	Tremor	Siddhant Sharma
676	Vocal Tremor as the Initial Manifestation of Palatal Tremor with Response to Propranolol : A Case Report	Wednesday, October 7	13:00 - 14:00	Session 12	Station 9	3	Tremor	Amirah Sinum
677	When “Essential Tremor Plus” Is Not Enough: A Tremor-Dominant Presentation of Neuronal Intranuclear Inclusion Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 9	4	Tremor	Hwa Been Yang
678	Anti Tremorgenic Properties Of Eslicarbazepine Acetate in The Harmaline Induced Tremor Mouse Model	Wednesday, October 7	13:00 - 14:00	Session 12	Station 9	5	Tremor	Ana Coelho
679	Acute Microstructural Imaging of Focused Ultrasound Thalamotomy Lesions is Associated with Long-Term Tremor Relief in Essential Tremor	Wednesday, October 7	13:00 - 14:00	Session 12	Station 9	6	Tremor	Carlos Sanchez-Catusas
575	Clinical Profile and Key Correlates of Genetic Load, Motor Severity, and Caregiver Burden in an Iranian Huntington's Disease Cohort	Wednesday, October 7	13:00 - 14:00	Session 12	Station 10	1	Huntington's Disease	Mehri Salari
576	PET Imaging of Presynaptic Terminals with [18F]SynVesT-1 in Premanifest Huntington's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 10	2	Huntington's Disease	Jolien Van Opstal

577	Psychiatric manifestations in premanifest Huntington's disease as early indicators of motor onset: a systematic review	Wednesday, October 7	13:00 - 14:00	Session 12	Station 10	3	Huntington's Disease	Erick Pérez Rodríguez
578	Exploring the Relationship Between Circadian Disruption, Depression and Suicidal Ideation in People with Huntington's Disease (Mind & Clock Study)	Wednesday, October 7	13:00 - 14:00	Session 12	Station 10	4	Huntington's Disease	Alay Rangel Cristales
579	Huntington's Disease Genetic Testing Practices in the Lower North Island of New Zealand	Wednesday, October 7	13:00 - 14:00	Session 12	Station 10	5	Huntington's Disease	Dafydd Llewelyn
580	Efficacy of Rapid-Succession "Flash Song" Music Therapy on Cognitive and Behavioral Symptoms in Outpatients with Juvenile Huntington's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 10	6	Huntington's Disease	Anita Gangadhar
759	Slow-SPEED-US: Initiation of a Remote Exercise Trial in LRRK2 and GBA1 Carriers	Wednesday, October 7	13:00 - 14:00	Session 12	Station 12	1	Parkinson's Disease: Clinical Trials	Ruth Schneider
760	Evaluating Adaptive DBS Algorithm for Personalized Therapy in Parkinson's Disease in the Chinese Population (ADAPT-PD China Study)	Wednesday, October 7	13:00 - 14:00	Session 12	Station 12	2	Parkinson's Disease: Clinical Trials	Huifang Shang
761	Agreement Between Patient-Reported Experiences of Daily Living and Clinician-Rated Motor Exam Severity in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 12	3	Parkinson's Disease: Clinical Trials	Andres Silva
762	Join Parkinson's Research (JPR@Research+Me): A UK-wide registry to support clinical trial recruitment in Parkinson's disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 12	4	Parkinson's Disease: Clinical Trials	Charlotte Stewart
763	Opicapone as adjunct to levodopa in Chinese patients with Parkinson's disease and wearing-off: a randomized, double-blind, placebo-controlled phase 3 trial	Wednesday, October 7	13:00 - 14:00	Session 12	Station 12	5	Parkinson's Disease: Clinical Trials	Yuyan Tan
764	Impact of Hula on Balance Outcomes in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 12	6	Parkinson's Disease: Clinical Trials	Michael Yee
831	Multidisciplinary Care Preserves Function and Quality of Life After Nursing Home Placement in Late-Stage Parkinson's Disease: A Prospective Cohort Study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 13	1	Parkinson's Disease: Pharmacology and Medical Management	Yuta Kajiyama
832	Baseline Factors Associated with Sublingual Apomorphine Film Maintenance Dose	Wednesday, October 7	13:00 - 14:00	Session 12	Station 13	2	Parkinson's Disease: Pharmacology and Medical Management	Jan Kassubek
833	Sublingual Apomorphine Tolerability in Clinical Practice: 18-months Post launch experience in Europe	Wednesday, October 7	13:00 - 14:00	Session 12	Station 13	3	Parkinson's Disease: Pharmacology and Medical Management	Jan Kassubek
834	Early dopaminergic treatment patterns and 5-year survival in Parkinson's disease: a nationwide observational study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 13	4	Parkinson's Disease: Pharmacology and Medical Management	Seung Hyun Lee

835	A Cerner-based Electronic Prescribing and Medicines Administration (EPMA) Parkinson's Medicines Care Plan Reduces Time-Critical Medication (TCM) Errors.	Wednesday, October 7	13:00 - 14:00	Session 12	Station 13	5	Parkinson's Disease: Pharmacology and Medical Management	Thomas Lessware
836	Improvement of Wearing-Off Symptoms After Initiation of COMT Inhibitors in Parkinson's Disease patients with early motor fluctuations: Results from the 12 months interim analysis of REONPARK Study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 13	6	Parkinson's Disease: Pharmacology and Medical Management	Lydia López-Manzanares
1809	Low-Intensity Treadmill Training Preserves Motor Function and Muscle Mass Through Mitochondrial and Antioxidant Regulation in a Rat Model of Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 14	1	Parkinson's Disease (Other)	TU HSUEH YEH
1810	Effects of Personalized Visual and Auditory Cueing on Sit-to-Stand Biomechanics in Individuals with Parkinson's disease: A Subgroup Analysis	Wednesday, October 7	13:00 - 14:00	Session 12	Station 14	2	Parkinson's Disease (Other)	Natcha Charususin
1811	Postural Sway Frequencies in Isolated REM Sleep Behavior Disorder Might Indicate Subtle Motor Impairments as Prodromal Marker of Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 14	3	Parkinson's Disease (Other)	David Engel
1812	The Lived Experience of Parkinson's Disease in the Philippines: Challenges, Cultural Constructs, and Caregiving Impacts	Wednesday, October 7	13:00 - 14:00	Session 12	Station 14	4	Parkinson's Disease (Other)	Franzis Mari Lawas
1813	Understanding the Impact of the Small Scale Levodopa-Entacapone-Carbidopa-Intestinal-Gel Pump on Everyday Experiences of People Living with Parkinson's Disease: A Mixed-Methods Evaluation	Wednesday, October 7	13:00 - 14:00	Session 12	Station 14	5	Parkinson's Disease (Other)	Kenton O'Hara
1814	Anhedonia in Parkinson's Disease: Prevalence and Clinical Correlations	Wednesday, October 7	13:00 - 14:00	Session 12	Station 14	6	Parkinson's Disease (Other)	Zaynutdin Ikhuzha Sayfutdinkhuzhaev
1881	Effects of Phase-Specific Vibrotactile Cueing on Spatiotemporal Gait Parameters in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 15	1	Parkinson's Disease (Other)	Shanshika Maddumage Dona
1882	Automated Video-Based Assessment of Lip Articulation in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 15	2	Parkinson's Disease (Other)	Joshua Strelow
1883	Arm Swing and Early Gait Characteristics in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 15	3	Parkinson's Disease (Other)	Christian Aaen
1884	Levels of cytokines in the cerebrospinal fluid of patients depending on the stages of Parkinson's disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 15	4	Parkinson's Disease (Other)	Bakhrom Amonov
1885	Using Musical Groove to help People move in Parkinson's: A Participatory Action Research Study of Music and Movement.	Wednesday, October 7	13:00 - 14:00	Session 12	Station 15	5	Parkinson's Disease (Other)	George Arthur

1886	Multimodal Information Exploration for Automated Clinical Scale Prediction in Neurodegenerative Diseases	Wednesday, October 7	13:00 - 14:00	Session 12	Station 15	6	Parkinson's Disease (Other)	Nadia Bozetine
931	Developing non-invasive EEG biomarkers for Parkinson's disease using concurrent subthalamic nucleus/cortical recording as ground truth.	Wednesday, October 7	13:00 - 14:00	Session 12	Station 16	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Maria Ilenia De Bartolo
932	Investigating Plasma SIRT3 and SYT11 as Potential Indicators in Parkinson's Disease: A Preliminary Exploratory Study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 16	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	yongning deng
933	Digital Handwriting Analysis: A Useful Tool to Quantify Acute Dopaminergic Response in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 16	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Lola Díaz-Feliz
934	Peripheral Inflammatory Markers and Clinical Correlations in Parkinson's Disease Patients Carrying LRRK2 G2385R and R1628P Variants	Wednesday, October 7	13:00 - 14:00	Session 12	Station 16	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Hans Xing Ding
935	A Machine Learning-Based Approach to Identify Responders to Electrosonic Brain Stimulation in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 16	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Laura Dipietro
936	Volatile Organic Compound Signatures Differentiate Parkinson Disease from Parkinson Disease Mimic Syndromes and Controls	Wednesday, October 7	13:00 - 14:00	Session 12	Station 16	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Annika Dixon
1003	A Systematic Review and Meta-Analysis of the Diagnostic Accuracy of Fluid Biomarkers in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 17	1	Parkinson's disease: Biomarkers (non-Neuroimaging)	Sydney Thuy-Trang Nguyen
1004	Digital Speech Biomarkers Reveal Speech Changes in Physiological Aging and Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 17	2	Parkinson's disease: Biomarkers (non-Neuroimaging)	Lubomira Novakova
1005	Probabilistic Mapping of Subthalamic Beta and Theta Subcircuits Reveals Segregated Connectivity and Deep Brain Stimulation Outcomes in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 17	3	Parkinson's disease: Biomarkers (non-Neuroimaging)	Emily Schmehr
1006	Exploring the Impact of Parameter Selection on Digital Sleep Outcomes in Parkinson's Disease: Results from the IDEA-FAST Study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 17	4	Parkinson's disease: Biomarkers (non-Neuroimaging)	Mohammadreza Sedghi
1007	Tongue Shape Complexity in Cantonese Parkinsonian Speech	Wednesday, October 7	13:00 - 14:00	Session 12	Station 17	5	Parkinson's disease: Biomarkers (non-Neuroimaging)	Chris Shuying WANG
1008	Longitudinal α -synuclein Seed Amplification Assay Analysis of PPMI Participants	Wednesday, October 7	13:00 - 14:00	Session 12	Station 17	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Luis Concha-Marambio

1145	Association of Sarcopenia with Fear of Falling and Falls in patients with Parkinson's disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 18	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ioannis Dagklis
1146	Prevalence and Profile of Non-Motor Symptoms in Parkinson's Disease in the Uzbek Population Assessed with the MDS-NMS Scale	Wednesday, October 7	13:00 - 14:00	Session 12	Station 18	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Doniyorbek Daminov
1147	International validation of the Neuropsychiatric Fluctuations Scale in patients with Parkinson's disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 18	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Ines Debove
1148	Patient perspectives on meaningful symptoms and disease progression in Parkinson's Disease (PD): Interim findings from the Patient Endpoint Preference Project (PEPP)	Wednesday, October 7	13:00 - 14:00	Session 12	Station 18	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Valentina Di Foggia
1149	Tremor-onset Parkinson's Disease: Does Leg Tremor Portend a Poor Prognosis?	Wednesday, October 7	13:00 - 14:00	Session 12	Station 18	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Diego Diaz
1150	Ecological Momentary Assessment Monitoring Captures Motor Fluctuation Improvement after DBS in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 18	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Luisa Drescher
1217	Seeing the Full Picture: How Subjective and Objective Data Capture the Daily Impact of Fluctuations in Parkinson's disease.	Wednesday, October 7	13:00 - 14:00	Session 12	Station 19	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Javier Pagonabarraga
1218	Impact of Comorbidities on Clinical Outcomes and Socioeconomic Burden in Parkinson's Disease: A 10-Year Nationwide Cohort Study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 19	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Jinse Park

1219	Interest in Clinical Trial Participation in Parkinson's Disease: Insights from a Nationwide Registry	Wednesday, October 7	13:00 - 14:00	Session 12	Station 19	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Marina Peball
1220	Genomic Insights into Parkinson's Disease: LARGE-PD and PD GENERation Collaboration in El Salvador	Wednesday, October 7	13:00 - 14:00	Session 12	Station 19	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Susana Peña Martínez
1221	Immigration status and Parkinson's disease: a retrospective matched cohort study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 19	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Alejandro Peral Quirós
1222	High Step Marching Dyskinesia: A Case Series	Wednesday, October 7	13:00 - 14:00	Session 12	Station 19	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Nicole Pulley
1289	Optimizing Identification of Hyposmia for Parkinson's Disease Risk Screening: Results from the Healthy Brain Aging Study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 20	1	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Christoph Theyer
1290	Motor and Non-Motor Symptoms Across Psychiatric Profiles in Parkinson's: A Cluster Analysis	Wednesday, October 7	13:00 - 14:00	Session 12	Station 20	2	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Roberto Trejo-Ayala
1291	Correlation Between Daily Vitamin Intake and Clinical Severity of Parkinson's in Northeastern Mexico: An Exploratory Study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 20	3	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Roberto Trejo-Ayala
1292	Electrophysiological Tremor Analysis In Tremor-Dominant And Postural Instability And Gait Difficulty Phenotypes Of Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 20	4	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	LINH TRUONG

1293	Assessment of Demographic and Clinical Characteristics of Early- and Late-Onset Parkinson's Disease in Bangladesh.	Wednesday, October 7	13:00 - 14:00	Session 12	Station 20	5	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Tahira Zannat
1294	Correlational Study of the Clinical Impression of Severity Index for Parkinson's Disease (CISI-PD) with Functional Mobility Measures	Wednesday, October 7	13:00 - 14:00	Session 12	Station 20	6	Parkinson's Disease: Epidemiology, Phenomenology, Clinical Assessment, Rating Scales	Zuo-En Chan
1346	Real-World Mobility Measures Reveal Early Indicators of Parkinson's Disease Risk in Older Women	Wednesday, October 7	13:00 - 14:00	Session 12	Station 21	1	Parkinson's Disease: Etiology (non-genetics)	Yarin Udi
1347	Comprehensive large-scale analysis of gene-environment interactions in Parkinson's disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 21	2	Parkinson's Disease: Etiology (non-genetics)	Dehao Yang
1348	Environmental Determinants of Parkinson's Disease in Saudi Arabia: A Cross-Sectional Study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 21	3	Parkinson's Disease: Etiology (non-genetics)	Sohaila Alshimemeri
1349	Dopamine Receptor Blocking Drug Exposure is Associated with Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 21	4	Parkinson's Disease: Etiology (non-genetics)	Lee Neilson
1350	Toxic narratives: Farmers with Parkinson's Disease in the foothills of Kilimanjaro	Wednesday, October 7	13:00 - 14:00	Session 12	Station 21	5	Parkinson's Disease: Etiology (non-genetics)	Sarah Urasa
1366	Rare GBA c.1157T>G (p.F386C) Variant in Parkinson's Disease. Case study.	Wednesday, October 7	13:00 - 14:00	Session 12	Station 21	6	Parkinson's Disease: Genetics	Gulsana Mussagaliyeva
1433	Higher Dopaminergic Sensitivity Underlies Dyskinesia Occurrence in Indigenous Sabahan PRKN Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 22	1	Parkinson's Disease: Genetics	Joshua Ooi
1434	Assessing The Role Of Apg3l2 Pathogenic Variants In Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 22	2	Parkinson's Disease: Genetics	Valentina Quintana-Peña
1435	Early-Onset Parkinson Disease in 22q11.2 Deletion Syndrome: Diagnostic Challenges in a Patient With Schizophrenia. A Case Report	Wednesday, October 7	13:00 - 14:00	Session 12	Station 22	3	Parkinson's Disease: Genetics	Leonardo Salinas-Yañez
1436	Factors Influencing Participation in Genetic Testing in Parkinson's Disease Genetic Cohort in Thailand: Patients and Neurologists Perspective	Wednesday, October 7	13:00 - 14:00	Session 12	Station 22	4	Parkinson's Disease: Genetics	Rujdanai Seeluangsawat
1437	Predictors of Clinical Progression Over a Decade in GBA1 versus LRRK2 Non-Manifesting Carriers	Wednesday, October 7	13:00 - 14:00	Session 12	Station 22	5	Parkinson's Disease: Genetics	Melanie Stark
1438	GLP1R Expression and Parkinson's Disease and Related Disorders in GLP-1RA-Treated Type 2 Diabetes	Wednesday, October 7	13:00 - 14:00	Session 12	Station 22	6	Parkinson's Disease: Genetics	Kyung Ah Woo
1505	Neural Control of Real-Time Walking in people with Parkinson's disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 23	1	Parkinson's disease: Neuroimaging	Hilmar Sigurdsson

1506	FDG-PET-Based Machine Learning Differentiates Parkinson's Disease from Other Neurodegenerative Disorders	Wednesday, October 7	13:00 - 14:00	Session 12	Station 23	2	Parkinson's disease: Neuroimaging	Bowen Song
1507	Spatiotemporal Trajectories of Plasma Biomarkers and Diffusion MRI Metrics in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 23	3	Parkinson's disease: Neuroimaging	Shuntaro Ueno
1508	7 Tesla MRI with Quantitative Susceptibility Mapping: Quantitative focal measurements and qualitative grading of the substantia nigra as a biomarker for Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 23	4	Parkinson's disease: Neuroimaging	Runa Unsgård
1509	Subthalamic Nucleus Deep Brain Stimulation Modulates Cortical Activation During Kinesthetic Illusion in Parkinson's Disease: An fMRI Study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 23	5	Parkinson's disease: Neuroimaging	Anupa Vijayakumari
1510	Diffusion MRI Evidence of Cerebellar Involvement in Cognitive Dysfunction in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 23	6	Parkinson's disease: Neuroimaging	Anupa Vijayakumari
1577	Association Between Sleep Disturbance and Fatigue in Patients with Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 24	1	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Kanako Kurihara
1578	Association Between Esophageal Motility and Gait in Parkinson's Disease: Possible Differential Mechanisms by Esophageal Region	Wednesday, October 7	13:00 - 14:00	Session 12	Station 24	2	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Jungyeun Lee
1579	Distinct Non-Motor Symptom Progression Subtypes in Parkinson's Disease Identified Using a Data-Driven SuStaln Model	Wednesday, October 7	13:00 - 14:00	Session 12	Station 24	3	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Jingyue Liu
1580	Age of Onset as a Predictor of NonMotor Symptom Severity in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 24	4	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Prakash Manharlal
1581	Neural Network Reorganization Mediates the Analgesic Effects of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 24	5	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	Chengjie Mao
1582	Risk factors for dysautonomic fluctuations in Mexican PwP	Wednesday, October 7	13:00 - 14:00	Session 12	Station 24	6	Parkinson's Disease: Non-Motor Symptoms (non-Cognitive/ non-Psychiatric)	MARIA FERNANDA MEDINA-PÉREZ
1711	Experiences with Adaptive Deep Brain Stimulation for Parkinson's Disease in Routine Clinical Care	Wednesday, October 7	13:00 - 14:00	Session 12	Station 25	1	Parkinson's Disease: Surgical Therapy	Sanne Vegelin
1712	Implementing Adaptive Deep Brain Stimulation in Parkinson's Disease: A Multimodal Mixed-Methods Evaluation of a Pragmatic Clinical Workflow	Wednesday, October 7	13:00 - 14:00	Session 12	Station 25	2	Parkinson's Disease: Surgical Therapy	Alan Whone

1713	Automated Closed-Loop DBS Using AI Decoding in Parkinson's Disease: A Systematic Review and Meta-Analysis of UPDRS-III Improvements in tremor, bradykinesia and Motor Fluctuations.	Wednesday, October 7	13:00 - 14:00	Session 12	Station 25	3	Parkinson's Disease: Surgical Therapy	Arunagiri Gunasekar
1714	Incisionless versus Implantable: A Comparative Systematic Review of Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) Thalamotomy versus Deep Brain Stimulation in Tremor-Dominant Parkinson's Disease: Long-Term Durability and Safety Outcomes	Wednesday, October 7	13:00 - 14:00	Session 12	Station 25	4	Parkinson's Disease: Surgical Therapy	AYA AL-ZAIDI
1715	Motor and Quality-of-Life Outcomes After MR-Guided Focused Ultrasound Subthalamotomy for Parkinson's Disease: A Meta-analysis	Wednesday, October 7	13:00 - 14:00	Session 12	Station 25	5	Parkinson's Disease: Surgical Therapy	Ashwin Achuthaprasad
1716	Adaptive Deep Brain Stimulation Guided by Electrophysiological Mapping for Stimulation-Induced Gluteal Dystonia in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 25	6	Parkinson's Disease: Surgical Therapy	Kian Adabi
1702	Unravelling the neural correlates of visual cueing in Parkinson's disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 26	1	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Eileen Gülke
1703	Stimulation Amplitude Asymmetry in Subthalamic Deep Brain Stimulation Affects Freezing of Gait During Gait Adaptation in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 26	2	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Ibrahim Hanafi
1704	Assessment of α -Synuclein Seeding Activity in the Olfactory Mucosa after SARS-CoV-2: a Pilot Study	Wednesday, October 7	13:00 - 14:00	Session 12	Station 26	3	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Beatrice Heim
1705	Sex differences for clinical impact of APOE ϵ 4 mediated by Alzheimer's pathology in people with Lewy body pathology	Wednesday, October 7	13:00 - 14:00	Session 12	Station 26	4	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Ece Bayram
1706	Altered Diet-Microbiome Associations in Parkinson's Disease and Prodromal REM Sleep Behavior Disorder	Wednesday, October 7	13:00 - 14:00	Session 12	Station 26	5	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Sungyang Jo
1707	Dentate Glutamate as an OFF-State Biomarker of Levodopa-Resistant Postural Tremor in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 26	6	Parkinson's Disease: Pathophysiology / molecular mechanisms of disease	Shweta Prasad
1793	PLIC Fractional Anisotropy and Motor Outcome After Functional Neurosurgical Treatment in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 27	1	Parkinson's Disease: Surgical Therapy	João Paulo Brainer Lima

1794	A Retrospective Study Of Outcomes Of Deep Brain Stimulation In Juvenile Parkinson's Disease.	Wednesday, October 7	13:00 - 14:00	Session 12	Station 27	2	Parkinson's Disease: Surgical Therapy	Ishu Goyal
1795	Does Unilateral MR-Guided Focused Ultrasound Subthalamotomy Provide Bilateral Motor Benefit in Parkinson Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 27	3	Parkinson's Disease: Surgical Therapy	Elena Navarro-Mocholí
1796	Motor outcomes and safety of staged bilateral MR-guided focused ultrasound subthalamotomy in Parkinson disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 27	4	Parkinson's Disease: Surgical Therapy	Elena Navarro-Mocholí
1797	Functional neurosurgery in Parkinson's disease: Effects on quality of life.	Wednesday, October 7	13:00 - 14:00	Session 12	Station 27	5	Parkinson's Disease: Surgical Therapy	Paula Paez
1972	IMU Insole-Derived Gait Digital Biomarkers in idiopathic RBD and Parkinson Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 27	6	Parkinson's disease: Biomarkers (non-Neuroimaging)	Jin Ho Jung
1076	Prevalence and clinical predictors of depressive symptoms in Parkinson's Disease: an analysis from the Global Parkinson's Genetics Program	Wednesday, October 7	13:00 - 14:00	Session 12	Station 28	1	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Paula Reyes-Pérez
1077	Stakeholder Engagement to Inform Research on Suicidality and Assisted Dying in Parkinson's	Wednesday, October 7	13:00 - 14:00	Session 12	Station 28	2	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Lucy Wright
1078	Personality Dynamics and Cognitive Impairment and Related Neuropsychiatric Symptoms in Patience with Different Movement Disorders	Wednesday, October 7	13:00 - 14:00	Session 12	Station 28	3	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Marium Kulsum
1079	Development and preliminary results of a new self-assessment tool for neuropsychiatric syndromes in Parkinson's Disease	Wednesday, October 7	13:00 - 14:00	Session 12	Station 28	4	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Ulrike Lambotte
1080	Distinct Neurostructural, Cognitive, and Neuropsychiatric Associations of Plasma p-tau217, and Aβ42/40 in Parkinson's Disease and Aging Cohorts	Wednesday, October 7	13:00 - 14:00	Session 12	Station 28	5	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Eleonora Fiorenzato
1081	Plasma p-tau217 outperforms p-tau181 as a biomarker of Alzheimer's disease co-pathology in the Lewy Body Disorders spectrum	Wednesday, October 7	13:00 - 14:00	Session 12	Station 28	6	Parkinson's Disease: Cognition / Psychiatric Manifestations / Lewy Body Dementia	Eleonora Fiorenzato